Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 7, 2022, is named 121301_15103_SL.txt and is 316,713 bytes in size.

BACKGROUND OF THE INVENTION

Angiopoietin-like 3 (ANGPTL3) is a member of the angiopoietin-like family of secreted factors that regulates lipid metabolism and that is predominantly expressed in the liver (Koishi, R. et al., (2002) Nat. Genet. 30(2):151-157). ANGPTL3 dually inhibits the catalytic activities of lipoprotein lipase (LPL), which catalyzes the hydrolysis of triglycerides, and of endothelial lipase (EL), which hydrolyzes high density lipoprotein (HDL) phospholipids. In hypolipidemic, yet obese, KK/Snk mice, a reduction in ANGPTL3 expression has a protective effect against hyperlipidemia and artherosclerosis by promoting the clearance of triglycerides (Ando et al., (2003) J. Lipid Res., 44:1216-1223). Human ANGPTL3 plasma concentrations positively correlate with plasma HDL cholesterol and HDL phospholipid levels (Shimamura et al., (2007) Arterioscler. Thromb. Vasc. Biol., 27:366-372).

Disorders of lipid metabolism can lead to elevated levels of serum lipids, such as triglycerides and/or cholesterol. Elevated serum lipids are strongly associated with high blood pressure, cardiovascular disease, diabetes and other pathologic conditions. Hypertriglyceridemia is an example of a lipid metabolism disorder that is characterized by high blood levels of triglycerides. It has been associated with atherosclerosis, even in the absence of high cholesterol levels (hypercholesterolemia). When triglyceride concentrations are excessive (i.e., greater than 1000 mg/dl or 12 mmol/l), hypertriglyceridemia can also lead to pancreatitis. Hyperlipidemia is another example of a lipid metabolism disorder that is characterized by elevated levels of any one or all lipids and/or lipoproteins in the blood. Current treatments for disorders of lipid metabolism, including dieting, exercise and treatment with statins and other drugs, are not always effective. Accordingly, there is a need in the art for alternative treatments for subjects having disorders of lipid metabolism.

SUMMARY OF THE INVENTION

The present invention provides iRNA compositions which affect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a gene encoding Angiopoietin-like 3 (ANGPTL3). The ANGPTL3 gene may be within a cell, e.g., a cell within a subject, such as a human subject. The present invention also provides methods of using the iRNA compositions of the invention for inhibiting the expression of an ANGPL3 gene and/or for treating a subject who would benefit from inhibiting or reducing the expression of an ANGPL3 gene, e.g., a subject suffering or prone to suffering from a disorder of lipid metabolism, such as a subject suffering or prone to suffering from hyperlipidemia or hypertriglyceridemia.

Accordingly, in one aspect, the invention provides a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of Angiopoietin-like 3 (ANGPTL3) in a cell, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15, e.g., 15, 16, 17, 18, 19, 20, or 21, contiguous nucleotides differing by no more than 0, 1, 2, or 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and the antisense strand comprises at least 15, e.g., 15, 16, 17, 18, 19, 20, 21, 22, or 23, contiguous nucleotides differing by no more than 1, 2, or 3 nucleotides from the nucleotide sequence of SEQ ID NO:2. In one embodiment, the dsRNA agent comprises at least one thermally destabilizing nucleotide modification, e.g., an abasic modification; a mismatch with the opposing nucleotide in the duplex; a destabilizing sugar modification, a 2′-deoxy modification, an acyclic nucleotide, an unlocked nucleic acids (UNA), or a glycerol nucleic acid (GNA), e.g., the antisense strand comprises at least one thermally destabilizing nucleotide modification.

In one aspect, the present invention provides a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of Angiopoietin-like 3 (ANGPTL3) in a cell, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises a region of complementarity to an mRNA encoding ANGPTL3, and wherein the region of complementarity comprises at least 15, e.g., 15, 16, 17, 18, 19, 20, 21, 22, or 23, contiguous nucleotides differing by no more than 3, e.g., 3, 2, 1, or 0, nucleotides from any one of the antisense nucleotide sequences in any one of Tables 2-3 and 7-8.

In another aspect, the present invention provides a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of Angiopoietin-like 3 (ANGPTL3) in a cell, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15, e.g., 15, 16, 17, 18, 19, 20, or 21, contiguous nucleotides differing by no more than three, e.g., 3, 2, 1, or 0, nucleotides from any one of the nucleotide sequence of nucleotides 58-80, 73-102, 73-124, 80-114, 91-113, 92-114, 291-320, 291-342, 307-336, 540-567, 540-589 and 545-577 of SEQ ID NO: 1, and the antisense strand comprises at least 15, e.g., 15, 16, 17, 18, 19, 20, 21, 22, or 23, contiguous nucleotides differing by no more than 3, e.g., 3, 2, 1, or 0, nucleotides from the corresponding nucleotide sequence of SEQ ID NO:2.

In one aspect, the present invention provides a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of Angiopoietin-like 3 (ANGPTL3) in a cell, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15, e.g., 15, 16, 17, 18, 19, 20, or 21, contiguous nucleotides differing by no more than three, e.g., 3, 2, 1, or 0, nucleotides from any one of the nucleotide sequence of nucleotides 58-80, 80-102; 84-106; 87-109; 91-113; 92-114; 186-208; 307-329; 308-330; 310-332; 314-336; 545-567; 551-573; 553-575; 554-576; 555-577; 1133-1155; or 1140-1162 of SEQ ID NO: 1, and the antisense strand comprises at least 15, e.g., 15, 16, 17, 18, 19, 20, 21, 22, or 23, contiguous nucleotides differing by no more than 3, e.g., 3, 2, 1, or 0, nucleotides from the corresponding nucleotide sequence of SEQ ID NO:2.

In another aspect, the present invention provides a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of Angiopoietin-like 3 (ANGPTL3) in a cell, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15, e.g., 15, 16, 17, 18, 19, 20, or 21, contiguous nucleotides differing by no more than three, e.g., 3, 2, 1, or 0, nucleotides from any one of the nucleotide sequence of nucleotides 58-80, 91-113, or 92-114 of SEQ ID NO: 1, and the antisense strand comprises at least 15, e.g., 15, 16, 17, 18, 19, 20, 21, 22, or 23, contiguous nucleotides differing by no more than 3, e.g., 3, 2, 1, or 0, nucleotides from the corresponding nucleotide sequence of SEQ ID NO:2.

In one aspect, the present invention provides a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of Angiopoietin-like 3 (ANGPTL3) in a cell, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15, e.g., 15, 16, 17, 18, 19, 20, or 21, contiguous nucleotides differing by no more than three, e.g., 3, 2, 1, or 0, nucleotides from the nucleotide sequence of nucleotides 58-80 of SEQ ID NO: 1, and the antisense strand comprises at least 15, e.g., 15, 16, 17, 18, 19, 20, 21, 22, or 23, contiguous nucleotides differing by no more than 3, e.g., 3, 2, 1, or 0, nucleotides from the corresponding nucleotide sequence of SEQ ID NO:2.

In one embodiment, the antisense strand comprises at least 15, e.g., 15, 16, 17, 18, 19, 20, 21, 22, or 23, contiguous nucleotides differing by no more than three, e.g., 3, 2, 1, or 0, nucleotides from any one of the antisense strand nucleotide sequences of a duplex selected from the group consisting of AD-1331203.1; AD-1331206.1; AD-1331209.1; AD-1331212.1; AD-1331213.1; AD-1331329.1; AD-1331237.1; AD-1331238.1; AD-1331240.1; AD-1331244.1; AD-1331256.1; AD-1331262.1; AD-1331264.1; AD-1331265.1; AD-1331266.1; AD-1331316.1; AD-1331338.1; and AD-1479372.

In one embodiment, the antisense strand comprises at least 15, e.g., 15, 16, 17, 18, 19, 20, 21, 22, or 23, contiguous nucleotides differing by no more than three, e.g., 3, 2, 1, or 0, nucleotides from any one of the antisense strand nucleotide sequences of a duplex selected from the group consisting of AD-1331203.1; AD-1331206.1; AD-1331209.1; AD-1331212.1; AD-1331213.1; AD-1331329.1; AD-1331240.1; AD-1331262.1; AD-1331264.1; AD-1331265.1 AD-1331266.1; and AD-1479372.

In one embodiment, the dsRNA agent comprises at least one modified nucleotide.

In one embodiment, substantially all of the nucleotides of the sense strand; substantially all of the nucleotides of the antisense strand comprise a modification; or substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand comprise a modification.

In one embodiment, all of the nucleotides of the sense strand comprise a modification; all of the nucleotides of the antisense strand comprise a modification; or all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a modification.

In one embodiment, at least one of the modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3′-terminal deoxythymidine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, a nucleotide comprising a 5′-phosphate mimic, a thermally destabilizing nucleotide, a glycol modified nucleotide (GNA), a nucleotide comprising a 2′ phosphate, and a 2-O—(N-methylacetamide) modified nucleotide; and combinations thereof.

In one embodiment, the modifications on the nucleotides are selected from the group consisting of LNA, HNA, CeNA, 2′-methoxyethyl, 2′-O-alkyl, 2′-O-allyl, 2′-C-allyl, 2′-fluoro, 2′-deoxy, 2′-hydroxyl, and glycol; and combinations thereof.

In one embodiment, at least one of the modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a glycol modified nucleotide (GNA), e.g., Ggn, Cgn, Tgn, or Agn, a nucleotide with a 2′ phosphate, e.g., G2p, C2p, A2p or U2p, and, a vinyl-phosphonate nucleotide; and combinations thereof.

In another embodiment, at least one of the modifications on the nucleotides is a thermally destabilizing nucleotide modification.

In one embodiment, the thermally destabilizing nucleotide modification is selected from the group consisting of an abasic modification; a mismatch with the opposing nucleotide in the duplex; and destabilizing sugar modification, a 2′-deoxy modification, an acyclic nucleotide, an unlocked nucleic acids (UNA), and a glycerol nucleic acid (GNA).

In some embodiments, the modified nucleotide comprises a short sequence of 3′-terminal deoxythymidine nucleotides (dT).

In some embodiments, the dsRNA agent further comprises at least one phosphorothioate internucleotide linkage. In some embodiments, the dsRNA agent comprises 6-8 phosphorothioate internucleotide linkages. In one embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the 3′-terminus of one strand. Optionally, the strand is the antisense strand. In another embodiment, the strand is the sense strand. In a related embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the 5′-terminus of one strand. Optionally, the strand is the antisense strand. In another embodiment, the strand is the sense strand. In another embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the both the 5′- and 3′-terminus of one strand. Optionally, the strand is the antisense strand. In another embodiment, the strand is the sense strand.

The double stranded region may be 19-30 nucleotide pairs in length; 19-25 nucleotide pairs in length; 19-23 nucleotide pairs in length; 23-27 nucleotide pairs in length; or 21-23 nucleotide pairs in length.

In one embodiment, each strand is independently no more than 30 nucleotides in length.

In one embodiment, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

The region of complementarity may be at least 17 nucleotides in length; between 19 and 23 nucleotides in length; or 19 nucleotides in length.

In one embodiment, at least one strand comprises a 3′ overhang of at least 1 nucleotide. In another embodiment, at least one strand comprises a 3′ overhang of at least 2 nucleotides.

In one embodiment, the dsRNA agent further comprises a ligand.

In one embodiment, the ligand is conjugated to the 3′ end of the sense strand of the dsRNA agent.

In one embodiment, the ligand is an N-acetylgalactosamine (GalNAc) derivative.

In one embodiment, the ligand is one or more GalNAc derivatives attached through a monovalent, bivalent, or trivalent branched linker.

In one embodiment, the ligand is

embedded image

In one embodiment, the dsRNA agent is conjugated to the ligand as shown in the following schematic

embedded image

and, wherein X is O or S.

In one embodiment, the X is O.

In one embodiment, the dsRNA agent further comprises at least one phosphorothioate or methylphosphonate internucleotide linkage.

In one embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the 3′-terminus of one strand, e.g., the antisense strand or the sense strand.

In another embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the 5′-terminus of one strand, e.g., the antisense strand or the sense strand.

In one embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the both the 5′- and 3′-terminus of one strand. In one embodiment, the strand is the antisense strand.

In one embodiment, the base pair at the 1 position of the 5′-end of the antisense strand of the duplex is an AU base pair.

In one embodiment, the nucleotide sequence of the sense strand differs by no more than 4 bases from the nucleotide sequence 5′-asasgcuccuUfCfUfuuuuauuguu-3′ (SEQ ID NO: 18) and the nucleotide sequence of the antisense strand differs by no more than 4 bases from the nucleotide sequence 5′-asdAscadAudAaaaadGaAfggagcuusgsg-3′ (SEQ ID NO: 19), wherein a, g, c and u are 2′-O-methyl (2′-OMe) A, G, C, and U; dA and dG, are 2′-deoxy A and G; Cf and Uf are 2′-deoxy-2′-fluoro (2′-F) C and U; and s is a phosphorothioate linkage.

In one embodiment, the nucleotide sequence of the sense strand differs by no more than 3 bases from the nucleotide sequence 5′-asasgcuccuUfCfUfuuuuauuguu-3′ (SEQ ID NO: 18) and the nucleotide sequence of the antisense strand differs by no more than 3 bases from the nucleotide sequence 5′-asdAscadAudAaaaadGaAfggagcuusgsg-3′ (SEQ ID NO: 19), wherein a, g, c and u are 2′-O-methyl (2′-OMe) A, G, C, and U; dA and dG, are 2′-deoxy A and G; Cf and Uf are 2′-deoxy-2′-fluoro (2′-F) C and U; and s is a phosphorothioate linkage.

In one embodiment, the nucleotide sequence of the sense strand differs by no more than 2 bases from the nucleotide sequence 5′-asasgcuccuUfCfUfuuuuauuguu-3′ (SEQ ID NO: 18) and the nucleotide sequence of the antisense strand differs by no more than 2 bases from the nucleotide sequence 5′-asdAscadAudAaaaadGaAfggagcuusgsg-3′ (SEQ ID NO: 19), wherein a, g, c and u are 2′-O-methyl (2′-OMe) A, G, C, and U; dA and dG, are 2′-deoxy A and G; Cf and Uf are 2′-deoxy-2′-fluoro (2′-F) C and U; and s is a phosphorothioate linkage.

In one embodiment, the nucleotide sequence of the sense strand differs by no more than 1 base from the nucleotide sequence 5′-asasgcuccuUfCfUfuuuuauuguu-3′ (SEQ ID NO: 18) and the nucleotide sequence of the antisense strand differs by no more than 1 base from the nucleotide sequence 5′-asdAscadAudAaaaadGaAfggagcuusgsg-3′ (SEQ ID NO: 19), wherein a, g, c and u are 2′-O-methyl (2′-OMe) A, G, C, and U; dA and dG, are 2′-deoxy A and G; Cf and Uf are 2′-deoxy-2′-fluoro (2′-F) C and U; and s is a phosphorothioate linkage.

In one embodiment, the nucleotide sequence of the sense strand comprises the nucleotide sequence 5′-asasgcuccuUfCfUfuuuuauuguu-3′ (SEQ ID NO: 18) and the nucleotide sequence of the antisense strand comprises the nucleotide sequence 5′-asdAscadAudAaaaadGaAfggagcuusgsg-3′ (SEQ ID NO: 19), wherein a, g, c and u are 2′-O-methyl (2′-OMe) A, G, C, and U; dA and dG, are 2′-deoxy A and G; Cf and Uf are 2′-deoxy-2′-fluoro (2′-F) C and U; and s is a phosphorothioate linkage.

In one embodiment, the dsRNA agent further comprises a ligand.

In one embodiment, the ligand is conjugated to the 3′ end of the sense strand of the dsRNA agent.

In one embodiment, the ligand is an N-acetylgalactosamine (GalNAc) derivative.

In one embodiment, the ligand is one or more GalNAc derivatives attached through a monovalent, bivalent, or trivalent branched linker.

In one embodiment, the ligand is

embedded image

In one embodiment, the nucleotide sequence of the sense strand comprises the nucleotide sequence 5′-asasgcuccuUfCfUfuuuuauuguuL96-3′ (SEQ ID NO: 20) and the nucleotide sequence of the antisense strand comprises the nucleotide sequence 5′-asdAscadAudAaaaadGaAfggagcuusgsg-3′ (SEQ ID NO: 19), wherein a, g, c and u are 2′-O-methyl (2′-OMe) A, G, C, and U; dA and dG, are 2′-deoxy A and G; Cf and Uf are 2′-deoxy-2′-fluoro (2′-F) C and U; s is a phosphorothioate linkage, and L96 is N-[tris(GalNAc-alkyl)-amidodecanoyl)]-4-hydroxyprolinol.

embedded image

wherein X is O.

In one embodiment, the nucleotide sequence of the sense strand differs by no more than 4 bases from the nucleotide sequence 5′-asasgcucCfuUfCfUfuuuuauuguu-3′ (SEQ ID NO: 21) and the nucleotide sequence of the antisense strand differs by no more than 4 bases from the nucleotide sequence 5′-asAfscaaUfaaaaagaAfgGfagcuusasa-3′ (SEQ ID NO: 22); or wherein the nucleotide sequence of the sense strand differs by no more than 4 bases from the nucleotide sequence 5′-asgscuccUfuCfUfUfuuuauuguuu-3′ (SEQ ID NO: 23) and the nucleotide sequence of the antisense strand differs by no more than 4 bases from the nucleotide sequence 5′-asAfsacaAfuaaaaagAfaGfgagcususa-3′ (SEQ ID NO: 24), wherein a, g, c and u are 2′-O-methyl (2′-OMe) A, G, C, and U; Cf and Uf are 2′-deoxy-2′-fluoro (2′-F) C and U; and s is a phosphorothioate linkage.

In one embodiment, the nucleotide sequence of the sense strand differs by no more than 3 bases from the nucleotide sequence 5′-asasgcucCfuUfCfUfuuuuauuguu-3′ (SEQ ID NO: 21) and the nucleotide sequence of the antisense strand differs by no more than 3 bases from the nucleotide sequence 5′-asAfscaaUfaaaaagaAfgGfagcuusasa-3′ (SEQ ID NO: 22); or wherein the nucleotide sequence of the sense strand differs by no more than 3 bases from the nucleotide sequence 5′-asgscuccUfuCfUfUfuuuauuguuu-3′ (SEQ ID NO: 23) and the nucleotide sequence of the antisense strand differs by no more than 3 bases from the nucleotide sequence 5′-asAfsacaAfuaaaaagAfaGfgagcususa-3 (SEQ ID NO: 24), wherein a, g, c and u are 2′-O-methyl (2′-OMe) A, G, C, and U; Cf and Uf are 2′-deoxy-2′-fluoro (2′-F) C and U; and s is a phosphorothioate linkage.

In one embodiment, the nucleotide sequence of the sense strand differs by no more than 2 bases from the nucleotide sequence 5′-asasgcucCfuUfCfUfuuuuauuguu-3′ (SEQ ID NO: 21) and the nucleotide sequence of the antisense strand differs by no more than 2 bases from the nucleotide sequence 5′-asAfscaaUfaaaaagaAfgGfagcuusasa-3′ (SEQ ID NO: 22); or wherein the nucleotide sequence of the sense strand differs by no more than 2 bases from the nucleotide sequence 5′-asgscuccUfuCfUfUfuuuauuguuu-3′ (SEQ ID NO: 23) and the nucleotide sequence of the antisense strand differs by no more than 2 bases from the nucleotide sequence 5′-asAfsacaAfuaaaaagAfaGfgagcususa-3′ (SEQ ID NO: 24), wherein a, g, c and u are 2′-O-methyl (2′-OMe) A, G, C, and U; Cf and Uf are 2′-deoxy-2′-fluoro (2′-F) C and U; and s is a phosphorothioate linkage.

In one embodiment, the nucleotide sequence of the sense strand differs by no more than 1 base from the nucleotide sequence 5′-asasgcucCfuUfCfUfuuuuauuguu-3′ (SEQ ID NO: 21) and the nucleotide sequence of the antisense strand differs by no more than 1 base from the nucleotide sequence 5′-asAfscaaUfaaaaagaAfgGfagcuusasa-3′ (SEQ ID NO: 22); or wherein the nucleotide sequence of the sense strand differs by no more than 1 base from the nucleotide sequence 5′-asgscuccUfuCfUfUfuuuauuguuu-3′ (SEQ ID NO: 23) and the nucleotide sequence of the antisense strand differs by no more than 1 base from the nucleotide sequence 5′-asAfsacaAfuaaaaagAfaGfgagcususa-3 (SEQ ID NO: 24), wherein a, g, c and u are 2′-O-methyl (2′-OMe) A, G, C, and U; Cf and Uf are 2′-deoxy-2′-fluoro (2′-F) C and U; and s is a phosphorothioate linkage.

In one embodiment, the nucleotide sequence of the sense strand comprises the nucleotide sequence 5′-asasgcucCfuUfCfUfuuuuauuguu-3′ (SEQ ID NO: 21) and the nucleotide sequence of the antisense strand comprises the nucleotide sequence 5′-asAfscaaUfaaaaagaAfgGfagcuusasa-3′ (SEQ ID NO: 22); or wherein the nucleotide sequence of the sense strand comprises the nucleotide sequence 5′-asgscuccUfuCfUfUfuuuauuguuu-3′ (SEQ ID NO: 23) and the nucleotide sequence of the antisense strand comprises the nucleotide sequence 5′-asAfsacaAfuaaaaagAfaGfgagcususa-3 (SEQ ID NO: 24), wherein a, g, c and u are 2′-O-methyl (2′-OMe) A, G, C, and U; Cf and Uf are 2′-deoxy-2′-fluoro (2′-F) C and U; s is a phosphorothioate linkage.

In one embodiment, the dsRNA agent further comprises a ligand.

In one embodiment, the ligand is conjugated to the 3′ end of the sense strand of the dsRNA agent.

In one embodiment, the ligand is an N-acetylgalactosamine (GalNAc) derivative.

In one embodiment, the ligand is one or more GalNAc derivatives attached through a monovalent, bivalent, or trivalent branched linker.

In one embodiment, the ligand is

embedded image

In one embodiment, the nucleotide sequence of the sense strand comprises the nucleotide sequence 5′-asasgcucCfuUfCfUfuuuuauuguuL96-3′ (SEQ ID NO: 25) and the nucleotide sequence of the antisense strand comprises the nucleotide sequence 5′-asAfscaaUfaaaaagaAfgGfagcuusasa-3′ (SEQ ID NO: 22); or wherein the nucleotide sequence of the sense strand comprises the nucleotide sequence 5′-asgscuccUfuCfUfUfuuuauuguuuL96-3′ (SEQ ID NO: 281) and the nucleotide sequence of the antisense strand comprises the nucleotide sequence 5′-asAfsacaAfuaaaaagAfaGfgagcususa-3′ (SEQ ID NO: 24), wherein a, g, c and u are 2′-O-methyl (2′-OMe) A, G, C, and U; Cf and Uf are 2′-deoxy-2′-fluoro (2′-F) C and U; s is a phosphorothioate linkage, and L96 is N-[tris(GalNAc-alkyl)-amidodecanoyl)]-4-hydroxyprolinol.

In one embodiment, the nucleotide sequence of the sense strand comprises the nucleotide sequence 5′-asasgcucCfuUfCfUfuuuuauuguu-3′ (SEQ ID NO: 21) and the nucleotide sequence of the antisense strand comprises the nucleotide sequence 5′-asAfscaaUfaaaaagaAfgGfagcuusasa-3′ (SEQ ID NO: 22); wherein a, g, c and u are 2′-O-methyl (2′-OMe) A, G, C, and U; Cf and Uf are 2′-deoxy-2′-fluoro (2′-F) C and U; s is a phosphorothioate linkage, and wherein a ligand is conjugated to the 3′-end of the sense strand as shown in the following schematic

embedded image

wherein X is O.

In one embodiment, the nucleotide sequence of the sense strand comprises the nucleotide sequence 5′-asgscuccUfuCfUfUfuuuauuguuu-3′ (SEQ ID NO: 23) and the nucleotide sequence of the antisense strand comprises the nucleotide sequence 5′-asAfsacaAfuaaaaagAfaGfgagcususa-3 (SEQ ID NO: 24), wherein a, g, c and u are 2′-O-methyl (2′-OMe) A, G, C, and U; Cf and Uf are 2′-deoxy-2′-fluoro (2′-F) C and U; s is a phosphorothioate linkage and wherein a ligand is conjugated to the 3′-end of the sense strand as shown in the following schematic

embedded image

wherein X is O.

The present invention also provides cells containing any of the dsRNA agents of the invention and pharmaceutical compositions comprising any of the dsRNA agents of the invention.

The pharmaceutical composition of the invention may include dsRNA agent in an unbuffered solution, e.g., saline or water, or the pharmaceutical composition of the invention may include the dsRNA agent is in a buffer solution, e.g., a buffer solution comprising acetate, citrate, prolamine, carbonate, or phosphate or any combination thereof; or phosphate buffered saline (PBS).

In one aspect, the present invention provides a method of inhibiting expression of an Angiopoietin-like 3 (ANGPTL3) gene in a cell. The method includes contacting the cell with any of the dsRNAs of the invention or any of the pharmaceutical compositions of the invention, thereby inhibiting expression of the ANGPTL3 gene in the cell.

In one embodiment, the cell is within a subject, e.g., a human subject, e.g., a subject having an Angiopoietin-like 3 (ANGPTL3)-associated disorder, such as a disorder of lipid metabolism. In certain embodiments, the disorder of lipid metabolism is hyperlipidemia or hypertriglyceridemia.

In certain embodiments, the ANGPTL3 expression is inhibited by at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%. In one embodiment, inhibiting expression of ANGPTL3 decreases ANGPTL3 protein level in serum of the subject by at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%.

In one aspect, the present invention provides a method of treating a subject having a disorder that would benefit from reduction in Angiopoietin-like 3 (ANGPTL3) expression. The method includes administering to the subject a therapeutically effective amount of any of the dsRNAs of the invention or any of the pharmaceutical compositions of the invention, thereby treating the subject having the disorder that would benefit from reduction in ANGPTL3 expression.

In another aspect, the present invention provides a method of preventing at least one symptom in a subject having a disorder that would benefit from reduction in Angiopoietin-like 3 (ANGPTL3) expression. The method includes administering to the subject a prophylactically effective amount of any of the dsRNAs of the invention or any of the pharmaceutical compositions of the invention, thereby preventing at least one symptom in the subject having the disorder that would benefit from reduction in ANGPTL3 expression.

In certain embodiments, the disorder is an Angiopoietin-like 3 (ANGPTL3)-associated disorder, e.g., a disorder of lipid metabolism. In certain embodiments, the disorder of lipid metabolism is hyperlipidemia or hypertriglyceridemia. In certain embodiments, administration of the dsRNA to the subject causes a decrease in one or more serum lipid and/or a decrease in ANGPTL3 protein accumulation.

In a further aspect, the present invention also provides methods of inhibiting the expression of ANGPTL3 in a subject. The methods include administering to the subject a therapeutically effective amount of any of the dsRNAs provided herein, thereby inhibiting the expression of ANGPTL3 in the subject.

In one embodiment, the subject is human.

In one embodiment, the dsRNA agent is administered to the subject at a dose of about 0.01 mg/kg to about 50 mg/kg.

In one embodiment, the dsRNA agent is administered to the subject subcutaneously.

In one embodiment, the methods of the invention include further determining the level of ANGPTL3 in a sample(s) from the subject.

In one embodiment, the level of ANGPTL3 in the subject sample(s) is an ANGPTL3 protein level in a blood or serum sample(s).

In certain embodiments, the methods of the invention further comprise administering to the subject an additional therapeutic agent.

The present invention also provides kits comprising any of the dsRNAs of the invention or any of the pharmaceutical compositions of the invention, and optionally, instructions for use. In one embodiment, the invention provides a kit for performing a method of inhibiting expression of ANGPTL3 gene in a cell by contacting a cell with a double stranded RNAi agent of the invention in an amount effective to inhibit expression of the ANGPTL3 in the cell. The kit comprises an RNAi agent and instructions for use and, optionally, means for administering the RNAi agent to a subject.

In one embodiment, the RNAi agent is a pharmaceutically acceptable salt thereof. “Pharmaceutically acceptable salts” of each of RNAi agents herein include, but are not limited to, a sodium salt, a calcium salt, a lithium salt, a potassium salt, an ammonium salt, a magnesium salt, an mixtures thereof. One skilled in the art will appreciate that the RNAi agent, when provided as a polycationic salt having one cation per free acid group of the optionally modified phosphodiester backbone and/or any other acidic modifications (e.g., 5′-terminal phosphonate groups). For example, an oligonucleotide of “n” nucleotides in length contains n−1 optionally modified phosphodiesters, so that an oligonucleotide of 21 nt in length may be provided as a salt having up to 20 cations (e.g, 20 sodium cations). Similarly, an RNAi agents having a sense strand of 21 nt in length and an antisense strand of 23 nt in length may be provided as a salt having up to 42 cations (e.g, 42 sodium cations). In the preceding example, where the RNAi agent also includes a 5′-terminal phosphate or a 5′-terminal vinylphosphonate group, the RNAi agent may be provided as a salt having up to 44 cations (e.g, 44 sodium cations).

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B are graphs showing human ANGPTL3 protein levels in serum samples of mice (n=3 per group) subcutaneously administered with a single 3 mg/kg dose of the indicated dsRNA duplexes. The serum samples were collected on day 7 or day 14 post-dose. Human ANGPTL3 protein levels were determined by ELISA. FIG. 1A shows the group means with standard deviation. FIG. 1B shows the individual points with standard deviation.

FIG. 2 is a graph showing human ANGPTL3 mRNA levels in mice (n=3 per group) subcutaneously administered a single dose of the indicated dsRNA duplexes, on day 14 post-dose. Human ANGPTL3 mRNA levels are shown relative to control levels detected with PBS treatment.

FIG. 3 is a graph showing the level of ANGPTL3 protein in sera of cynomolgus monkeys (n=3 per group) subcutaneously administered a single dose 3 mg/kg or 10 mg/kg dose of AD-1331212, AD-1331213 or AD-1479372. The levels of ANGPTL3 are shown as percent change compared to Day 0 (dosing day).

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of an Angiopoietin-like 3 (ANGPTL3) gene. The gene may be within a cell, e.g., a cell within a subject, such as a human. The use of these iRNAs enables the targeted degradation of mRNAs of the corresponding gene (ANGPTL3) in mammals.

The iRNAs of the invention have been designed to target the human Angiopoietin-like 3 (ANGPTL3) gene, including portions of the gene that are conserved in the ANGPTL3 orthologs of other mammalian species. Without intending to be limited by theory, it is believed that a combination or sub-combination of the foregoing properties and the specific target sites or the specific modifications in these iRNAs confer to the iRNAs of the invention improved efficacy, stability, potency, durability, and safety.

Accordingly, the present invention provides methods for treating and preventing an Angiopoietin-like 3 (ANGPTL3)-associated disorder, e.g., a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of an ANGPTL3 gene.

The iRNAs of the invention include an RNA strand (the antisense strand) having a region which is up to about 30 nucleotides or less in length, e.g., 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length, which region is substantially complementary to at least part of an mRNA transcript of an ANGPTL3 gene.

In certain embodiments, one or both of the strands of the double stranded RNAi agents of the invention is up to 66 nucleotides in length, e.g., 36-66, 26-36, 25-36, 31-60, 22-43, 27-53 nucleotides in length, with a region of at least 19 contiguous nucleotides that is substantially complementary to at least a part of an mRNA transcript of an ANGPTL3 gene. In some embodiments, such iRNA agents having longer length antisense strands may, for example, include a second RNA strand (the sense strand) of 20-60 nucleotides in length wherein the sense and antisense strands form a duplex of 18-30 contiguous nucleotides.

The use of iRNAs of the invention enables the targeted degradation of mRNAs of the corresponding gene (ANGPTL3 gene) in mammals Using in vitro assays, the present inventors have demonstrated that iRNAs targeting an ANGPTL3 gene can potently mediate RNAi, resulting in significant inhibition of expression of an ANGPTL3 gene. Thus, methods and compositions including these iRNAs are useful for treating a subject having an ANGPTL3-associated disorder, e.g., a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia.

Accordingly, the present invention provides methods and combination therapies for treating a subject having a disorder that would benefit from inhibiting or reducing the expression of an ANGPTL3 gene, e.g., an Angiopoietin-like 3 (ANGPTL3)-associated disease, such as a disorder of lipid metabolism, e.g., hyperlipidemia or hypertriglyceridemia, using iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of an ANGPTL3 gene.

The present invention also provides methods for preventing at least one symptom in a subject having a disorder that would benefit from inhibiting or reducing the expression of a ANGPTL3 gene, e.g., a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia.

The following detailed description discloses how to make and use compositions containing iRNAs to inhibit the expression of an ANGPTL3 gene as well as compositions, uses, and methods for treating subjects that would benefit from inhibition and/or reduction of the expression of an ANGPTL3 gene, e.g., subjects susceptible to or diagnosed with an ANGPTL3-associated disorder.

I. Definitions

In order that the present invention may be more readily understood, certain terms are first defined. In addition, it should be noted that whenever a value or range of values of a parameter are recited, it is intended that values and ranges intermediate to the recited values are also intended to be part of this invention.

The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element, e.g., a plurality of elements.

The term “including” is used herein to mean, and is used interchangeably with, the phrase “including but not limited to”.

The term “or” is used herein to mean, and is used interchangeably with, the term “and/or,” unless context clearly indicates otherwise. For example, “sense strand or antisense strand” is understood as “sense strand or antisense strand or sense strand and antisense strand.”

The term “about” is used herein to mean within the typical ranges of tolerances in the art. For example, “about” can be understood as about 2 standard deviations from the mean. In certain embodiments, about means ±10%. In certain embodiments, about means ±5%. When about is present before a series of numbers or a range, it is understood that “about” can modify each of the numbers in the series or range.

The term “at least”, “no less than”, or “or more” prior to a number or series of numbers is understood to include the number adjacent to the term “at least”, and all subsequent numbers or integers that could logically be included, as clear from context. For example, the number of nucleotides in a nucleic acid molecule must be an integer. For example, “at least 19 nucleotides of a 21 nucleotide nucleic acid molecule” means that 19, 20, or 21 nucleotides have the indicated property. When at least is present before a series of numbers or a range, it is understood that “at least” can modify each of the numbers in the series or range.

As used herein, “no more than” or “or less” is understood as the value adjacent to the phrase and logical lower values or integers, as logical from context, to zero. For example, a duplex with an overhang of “no more than 2 nucleotides” has a 2, 1, or 0 nucleotide overhang. When “no more than” is present before a series of numbers or a range, it is understood that “no more than” can modify each of the numbers in the series or range. As used herein, ranges include both the upper and lower limit.

As used herein, methods of detection can include determination that the amount of analyte present is below the level of detection of the method.

In the event of a conflict between an indicated target site and the nucleotide sequence for a sense or antisense strand, the indicated sequence takes precedence.

In the event of a conflict between a sequence and its indicated site on a transcript or other sequence, the nucleotide sequence recited in the specification takes precedence. As used herein, “Angiopoietin-like 3,” used interchangeably with the term “ANGPTL3,” refers to the well-known gene that encodes a member of a family of secreted proteins that function in angiogenesis. The encoded protein, which is expressed predominantly in the liver, is further processed into an N-terminal coiled-coil domain-containing chain and a C-terminal fibrinogen chain. The N-terminal chain is important for lipid metabolism, while the C-terminal chain may be involved in angiogenesis. Mutations in this gene cause familial hypobetalipoproteinemia type 2.

The sequence of a human ANGPTL3 mRNA transcript can be found at, for example, GenBank Accession No. GI: 452408443 (NM_014495.3; SEQ ID NO:1; reverse complement, SEQ ID NO: 2) or GenBank Accession No. GI: 41327750 (NM_014495.2; SEQ ID NO: 3; reverse complement, SEQ ID NO: 4). The sequence of mouse ANGPTL3 mRNA can be found at, for example, GenBank Accession No. GI: 142388354 (NM_013913.3; SEQ ID NO:5; reverse complement, SEQ ID NO: 6). The sequence of rat ANGPTL3 mRNA can be found at, for example, GenBank Accession No. GI: 68163568 (NM_001025065.1; SEQ ID NO:7; reverse complement, SEQ ID NO: 8). The sequence of Macaca fascicularis ANGPTL3 mRNA can be found at, for example, GenBank Accession No. GI: 982227663 (XM_005543185.2; SEQ ID NO: 9; reverse complement, SEQ ID NO: 10). The sequence of Macaca mulatta ANGPTL3 mRNA can be found at, for example, GenBank Accession No. GI: 297278846 (XM_001086114.2; SEQ ID NO: 11; reverse complement, SEQ ID NO: 12).

Additional examples of ANGPTL3 mRNA sequences are readily available through publicly available databases, e.g., GenBank, UniProt, OMIM, and the Macaca genome project web site.

Further information on ANGPTL3 can be found, for example, at www.ncbi.nlm.nih.gov/gene/?term=ANGPTL3.

The entire contents of each of the foregoing GenBank Accession numbers and the Gene database numbers are incorporated herein by reference as of the date of filing this application.

The term ANGPTL3, as used herein, also refers to variations of the ANGPTL3 gene including variants provided in the SNP database. Numerous sequence variations within the ANGPTL3 gene have been identified and may be found at, for example, NCBI dbSNP and UniProt (see, e.g., www.ncbi.nlm.nih.gov/snp/?term=ANGPTL3, the entire contents of which is incorporated herein by reference as of the date of filing this application. Non-limiting examples of SNPs within the ANGPTL3 gene may be found at, NCBI dbSNP Accession Nos. rs193064039; rs192778191; rs192764027; rs192528948; rs191931953; rs191293319; rs191171206; rs191145608; rs191086880; rs191012841; or rs190255403.

As used herein, “target sequence” refers to a contiguous portion of the nucleotide sequence of an mRNA molecule formed during the transcription of an ANGPTL3 gene, including mRNA that is a product of RNA processing of a primary transcription product. In one embodiment, the target portion of the sequence will be at least long enough to serve as a substrate for iRNA-directed cleavage at or near that portion of the nucleotide sequence of an mRNA molecule formed during the transcription of an ANGPTL3gene.

The target sequence may be from about 19-36 nucleotides in length, e.g., about 19-30 nucleotides in length. For example, the target sequence can be about 19-30 nucleotides, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length. In certain embodiments, the target sequence is 19-23 nucleotides in length, optionally 21-23 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure.

As used herein, the term “strand comprising a sequence” refers to an oligonucleotide comprising a chain of nucleotides that is described by the sequence referred to using the standard nucleotide nomenclature.

“G,” “C,” “A,” “T,” and “U” each generally stand for a nucleotide that contains guanine, cytosine, adenine, thymidine, and uracil as a base, respectively. However, it will be understood that the term “ribonucleotide” or “nucleotide” can also refer to a modified nucleotide, as further detailed below, or a surrogate replacement moiety (see, e.g., Table 1). The skilled person is well aware that guanine, cytosine, adenine, and uracil can be replaced by other moieties without substantially altering the base pairing properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety. For example, without limitation, a nucleotide comprising inosine as its base can base pair with nucleotides containing adenine, cytosine, or uracil. Hence, nucleotides containing uracil, guanine, or adenine can be replaced in the nucleotide sequences of dsRNA featured in the invention by a nucleotide containing, for example, inosine. In another example, adenine and cytosine anywhere in the oligonucleotide can be replaced with guanine and uracil, respectively to form G-U Wobble base pairing with the target mRNA. Sequences containing such replacement moieties are suitable for the compositions and methods featured in the invention.

The terms “iRNA”, “RNAi agent,” “iRNA agent,”, “RNA interference agent” as used interchangeably herein, refer to an agent that contains RNA as that term is defined herein, and which mediates the targeted cleavage of an RNA transcript via an RNA-induced silencing complex (RISC) pathway. iRNA directs the sequence-specific degradation of mRNA through a process known as RNA interference (RNAi). The iRNA modulates, e.g., inhibits, the expression of an ANGPTL3 gene in a cell, e.g., a cell within a subject, such as a mammalian subject.

In one embodiment, an RNAi agent of the invention includes a single stranded RNA that interacts with a target RNA sequence, e.g., an ANGPTL3 target mRNA sequence, to direct the cleavage of the target RNA. Without wishing to be bound by theory it is believed that long double stranded RNA introduced into cells is broken down into siRNA by a Type III endonuclease known as Dicer (Sharp et al. (2001) Genes Dev. 15:485). Dicer, a ribonuclease-III-like enzyme, processes the dsRNA into 19-23 base pair short interfering RNAs with characteristic two base 3′ overhangs (Bernstein, et al., (2001) Nature 409:363). The siRNAs are then incorporated into an RNA-induced silencing complex (RISC) where one or more helicases unwind the siRNA duplex, enabling the complementary antisense strand to guide target recognition (Nykanen, et al., (2001) Cell 107:309). Upon binding to the appropriate target mRNA, one or more endonucleases within the RISC cleave the target to induce silencing (Elbashir, et al., (2001) Genes Dev. 15:188). Thus, in one aspect the invention relates to a single stranded RNA (siRNA) generated within a cell and which promotes the formation of a RISC complex to effect silencing of the target gene, i.e., an ANGPTL3 gene. Accordingly, the term “siRNA” is also used herein to refer to an iRNA as described above.

In certain embodiments, the RNAi agent may be a single-stranded siRNA (ssRNAi) that is introduced into a cell or organism to inhibit a target mRNA. Single-stranded RNAi agents bind to the RISC endonuclease, Argonaute 2, which then cleaves the target mRNA. The single-stranded siRNAs are generally 15-30 nucleotides and are chemically modified. The design and testing of single-stranded siRNAs are described in U.S. Pat. No. 8,101,348 and in Lima et al., (2012) Cell 150:883-894, the entire contents of each of which are hereby incorporated herein by reference. Any of the antisense nucleotide sequences described herein may be used as a single-stranded siRNA as described herein or as chemically modified by the methods described in Lima et al., (2012) Cell 150:883-894.

In certain embodiments, an “iRNA” for use in the compositions, uses, and methods of the invention is a double stranded RNA and is referred to herein as a “double stranded RNA agent,” “double stranded RNA (dsRNA) molecule,” “dsRNA agent,” or “dsRNA”. The term “dsRNA”, refers to a complex of ribonucleic acid molecules, having a duplex structure comprising two anti-parallel and substantially complementary nucleic acid strands, referred to as having “sense” and “antisense” orientations with respect to a target RNA, i.e., an ANGPTL3 gene. In some embodiments of the invention, a double stranded RNA (dsRNA) triggers the degradation of a target RNA, e.g., an mRNA, through a post-transcriptional gene-silencing mechanism referred to herein as RNA interference or RNAi.

In general, the majority of nucleotides of each strand of a dsRNA molecule are ribonucleotides, but as described in detail herein, each or both strands can also include one or more non-ribonucleotides, e.g., a deoxyribonucleotide or a modified nucleotide. In addition, as used in this specification, an “iRNA” may include ribonucleotides with chemical modifications; an iRNA may include substantial modifications at multiple nucleotides. As used herein, the term “modified nucleotide” refers to a nucleotide having, independently, a modified sugar moiety, a modified internucleotide linkage, or modified nucleobase, or any combination thereof. Thus, the term modified nucleotide encompasses substitutions, additions or removal of, e.g., a functional group or atom, to internucleoside linkages, sugar moieties, or nucleobases. The modifications suitable for use in the agents of the invention include all types of modifications disclosed herein or known in the art. Any such modifications, as used in a siRNA type molecule, are encompassed by “iRNA” or “RNAi agent” for the purposes of this specification and claims.

In certain embodiments of the instant disclosure, inclusion of a deoxy-nucleotide if present within an RNAi agent can be considered to constitute a modified nucleotide.

The duplex region may be of any length that permits specific degradation of a desired target RNA through a RISC pathway, and may range from about 19 to 36 base pairs in length, e.g., about 19-30 base pairs in length, for example, about 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 base pairs in length, such as about 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. In certain embodiments, the duplex region is 19-21 base pairs in length, e.g., 21 base pairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure.

The two strands forming the duplex structure may be different portions of one larger RNA molecule, or they may be separate RNA molecules. Where the two strands are part of one larger molecule, and therefore are connected by an uninterrupted chain of nucleotides between the 3′-end of one strand and the 5′-end of the respective other strand forming the duplex structure, the connecting RNA chain is referred to as a “hairpin loop.” A hairpin loop can comprise at least one unpaired nucleotide. In some embodiments, the hairpin loop can comprise at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 23 or more unpaired nucleotides. In some embodiments, the hairpin loop can be 10 or fewer nucleotides. In some embodiments, the hairpin loop can be 8 or fewer unpaired nucleotides. In some embodiments, the hairpin loop can be 4-10 unpaired nucleotides. In some embodiments, the hairpin loop can be 4-8 nucleotides.

Where the two substantially complementary strands of a dsRNA are comprised by separate RNA molecules, those molecules need not be, but can be covalently connected. Where the two strands are connected covalently by means other than an uninterrupted chain of nucleotides between the 3′-end of one strand and the 5′-end of the respective other strand forming the duplex structure, the connecting structure is referred to as a “linker.” The RNA strands may have the same or a different number of nucleotides. The maximum number of base pairs is the number of nucleotides in the shortest strand of the dsRNA minus any overhangs that are present in the duplex. In addition to the duplex structure, an RNAi may comprise one or more nucleotide overhangs. In one embodiment of the RNAi agent, at least one strand comprises a 3′ overhang of at least 1 nucleotide. In another embodiment, at least one strand comprises a 3′ overhang of at least 2 nucleotides, e.g., 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, or 15 nucleotides. In other embodiments, at least one strand of the RNAi agent comprises a 5′ overhang of at least 1 nucleotide. In certain embodiments, at least one strand comprises a 5′ overhang of at least 2 nucleotides, e.g., 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, or 15 nucleotides. In still other embodiments, both the 3′ and the 5′ end of one strand of the RNAi agent comprise an overhang of at least 1 nucleotide.

In certain embodiments, an iRNA agent of the invention is a dsRNA, each strand of which comprises 19-23 nucleotides, that interacts with a target RNA sequence, e.g., an ANGPTL3 gene, to direct cleavage of the target RNA.

In some embodiments, an iRNA of the invention is a dsRNA of 24-30 nucleotides that interacts with a target RNA sequence, e.g., an ANGPTL3 target mRNA sequence, to direct the cleavage of the target RNA.

As used herein, the term “nucleotide overhang” refers to at least one unpaired nucleotide that protrudes from the duplex structure of a double stranded iRNA. For example, when a 3′-end of one strand of a dsRNA extends beyond the 5′-end of the other strand, or vice versa, there is a nucleotide overhang. A dsRNA can comprise an overhang of at least one nucleotide; alternatively the overhang can comprise at least two nucleotides, at least three nucleotides, at least four nucleotides, at least five nucleotides or more. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) can be on the sense strand, the antisense strand, or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5′-end, 3′-end, or both ends of either an antisense or sense strand of a dsRNA.

In one embodiment, the antisense strand of a dsRNA has a 1-10 nucleotide, e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3′-end or the 5′-end. In one embodiment, the sense strand of a dsRNA has a 1-10 nucleotide, e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3′-end or the 5′-end. In another embodiment, one or more of the nucleotides in the overhang is replaced with a nucleoside thiophosphate.

In certain embodiments, the antisense strand of a dsRNA has a 1-10 nucleotide, e.g., 0-3, 1-3, 2-4, 2-5, 4-10, 5-10, e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3′-end or the 5′-end. In one embodiment, the sense strand of a dsRNA has a 1-10 nucleotide, e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3′-end or the 5′-end. In another embodiment, one or more of the nucleotides in the overhang is replaced with a nucleoside thiophosphate.

In certain embodiments, the antisense strand of a dsRNA has a 1-10 nucleotides, e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3′-end or the 5′-end. In certain embodiments, the overhang on the sense strand or the antisense strand, or both, can include extended lengths longer than 10 nucleotides, e.g., 1-30 nucleotides, 2-30 nucleotides, 10-30 nucleotides, 10-25 nucleotides, 10-20 nucleotides, or 10-15 nucleotides in length. In certain embodiments, an extended overhang is on the sense strand of the duplex. In certain embodiments, an extended overhang is present on the 3′ end of the sense strand of the duplex. In certain embodiments, an extended overhang is present on the 5′ end of the sense strand of the duplex. In certain embodiments, an extended overhang is on the antisense strand of the duplex. In certain embodiments, an extended overhang is present on the 3′end of the antisense strand of the duplex. In certain embodiments, an extended overhang is present on the 5′end of the antisense strand of the duplex. In certain embodiments, one or more of the nucleotides in the extended overhang is replaced with a nucleoside thiophosphate. In certain embodiments, the overhang includes a self-complementary portion such that the overhang is capable of forming a hairpin structure that is stable under physiological conditions.

“Blunt” or “blunt end” means that there are no unpaired nucleotides at that end of the double stranded RNA agent, i.e., no nucleotide overhang. A “blunt ended” double stranded RNA agent is double stranded over its entire length, i.e., no nucleotide overhang at either end of the molecule. The RNAi agents of the invention include RNAi agents with no nucleotide overhang at one end (i.e., agents with one overhang and one blunt end) or with no nucleotide overhangs at either end. Most often such a molecule will be double-stranded over its entire length.

The term “antisense strand” or “guide strand” refers to the strand of an iRNA, e.g., a dsRNA, which includes a region that is substantially complementary to a target sequence, e.g., an ANGPTL3 mRNA.

As used herein, the term “region of complementarity” refers to the region on the antisense strand that is substantially complementary to a sequence, for example a target sequence, e.g., an ANGPTL3 nucleotide sequence, as defined herein. Where the region of complementarity is not fully complementary to the target sequence, the mismatches can be in the internal or terminal regions of the molecule. Generally, the most tolerated mismatches are in the terminal regions, e.g., within 5, 4, or 3 nucleotides of the 5′- or 3′-end of the iRNA. In some embodiments, a double stranded RNA agent of the invention includes a nucleotide mismatch in the antisense strand. In some embodiments, the antisense strand of the double stranded RNA agent of the invention includes no more than 4 mismatches with the target mRNA, e.g., the antisense strand includes 4, 3, 2, 1, or 0 mismatches with the target mRNA. In some embodiments, the antisense strand double stranded RNA agent of the invention includes no more than 4 mismatches with the sense strand, e.g., the antisense strand includes 4, 3, 2, 1, or 0 mismatches with the sense strand. In some embodiments, a double stranded RNA agent of the invention includes a nucleotide mismatch in the sense strand. In some embodiments, the sense strand of the double stranded RNA agent of the invention includes no more than 4 mismatches with the antisense strand, e.g., the sense strand includes 4, 3, 2, 1, or 0 mismatches with the antisense strand. In some embodiments, the nucleotide mismatch is, for example, within 5, 4, 3 nucleotides from the 3′-end of the iRNA. In another embodiment, the nucleotide mismatch is, for example, in the 3′-terminal nucleotide of the iRNA agent. In some embodiments, the mismatch(s) is not in the seed region.

Thus, an RNAi agent as described herein can contain one or more mismatches to the target sequence. In one embodiment, an RNAi agent as described herein contains no more than 3 mismatches (i.e., 3, 2, 1, or 0 mismatches). In one embodiment, an RNAi agent as described herein contains no more than 2 mismatches. In one embodiment, an RNAi agent as described herein contains no more than 1 mismatch. In one embodiment, an RNAi agent as described herein contains 0 mismatches. In certain embodiments, if the antisense strand of the RNAi agent contains mismatches to the target sequence, the mismatch can optionally be restricted to be within the last 5 nucleotides from either the 5′- or 3′-end of the region of complementarity. For example, in such embodiments, for a 23 nucleotide RNAi agent, the strand which is complementary to a region of an ANGPTL3 gene, generally does not contain any mismatch within the central 13 nucleotides. The methods described herein or methods known in the art can be used to determine whether an RNAi agent containing a mismatch to a target sequence is effective in inhibiting the expression of an ANGPTL3 gene. Consideration of the efficacy of RNAi agents with mismatches in inhibiting expression of an ANGPTL3 gene is important, especially if the particular region of complementarity in an ANGPTL3 gene is known to have polymorphic sequence variation within the population.

The term “sense strand” or “passenger strand” as used herein, refers to the strand of an iRNA that includes a region that is substantially complementary to a region of the antisense strand as that term is defined herein.

As used herein, “substantially all of the nucleotides are modified” are largely but not wholly modified and can include not more than 5, 4, 3, 2, or 1 unmodified nucleotides.

As used herein, the term “cleavage region” refers to a region that is located immediately adjacent to the cleavage site. The cleavage site is the site on the target at which cleavage occurs. In some embodiments, the cleavage region comprises three bases on either end of, and immediately adjacent to, the cleavage site. In some embodiments, the cleavage region comprises two bases on either end of, and immediately adjacent to, the cleavage site. In some embodiments, the cleavage site specifically occurs at the site bound by nucleotides 10 and 11 of the antisense strand, and the cleavage region comprises nucleotides 11, 12 and 13.

As used herein, and unless otherwise indicated, the term “complementary,” when used to describe a first nucleotide sequence in relation to a second nucleotide sequence, refers to the ability of an oligonucleotide or polynucleotide comprising the first nucleotide sequence to hybridize and form a duplex structure under certain conditions with an oligonucleotide or polynucleotide comprising the second nucleotide sequence, as will be understood by the skilled person. Such conditions can, for example, be stringent conditions, where stringent conditions can include: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50° C. or 70° C. for 12-16 hours followed by washing (see, e.g., “Molecular Cloning: A Laboratory Manual, Sambrook, et al. (1989) Cold Spring Harbor Laboratory Press). Other conditions, such as physiologically relevant conditions as can be encountered inside an organism, can apply. The skilled person will be able to determine the set of conditions most appropriate for a test of complementarity of two sequences in accordance with the ultimate application of the hybridized nucleotides.

Complementary sequences within an iRNA, e.g., within a dsRNA as described herein, include base-pairing of the oligonucleotide or polynucleotide comprising a first nucleotide sequence to an oligonucleotide or polynucleotide comprising a second nucleotide sequence over the entire length of one or both nucleotide sequences. Such sequences can be referred to as “fully complementary” with respect to each other herein. However, where a first sequence is referred to as “substantially complementary” with respect to a second sequence herein, the two sequences can be fully complementary, or they can form one or more, but generally not more than 5, 4, 3, or 2 mismatched base pairs upon hybridization for a duplex up to 30 base pairs, while retaining the ability to hybridize under the conditions most relevant to their ultimate application, e.g., inhibition of gene expression, in vitro or in vivo. However, where two oligonucleotides are designed to form, upon hybridization, one or more single stranded overhangs, such overhangs shall not be regarded as mismatches with regard to the determination of complementarity. For example, a dsRNA comprising one oligonucleotide 21 nucleotides in length and another oligonucleotide 23 nucleotides in length, wherein the longer oligonucleotide comprises a sequence of 21 nucleotides that is fully complementary to the shorter oligonucleotide, can yet be referred to as “fully complementary” for the purposes described herein.

“Complementary” sequences, as used herein, can also include, or be formed entirely from, non-Watson-Crick base pairs or base pairs formed from non-natural and modified nucleotides, in so far as the above requirements with respect to their ability to hybridize are fulfilled. Such non-Watson-Crick base pairs include, but are not limited to, G:U Wobble or Hoogsteen base pairing.

The terms “complementary,” “fully complementary” and “substantially complementary” herein can be used with respect to the base matching between the sense strand and the antisense strand of a dsRNA, or between two oligonucleotides or polynucleotides, such as the antisense strand of a double stranded RNA agent and a target sequence, as will be understood from the context of their use.

As used herein, a polynucleotide that is “substantially complementary to at least part of” a messenger RNA (mRNA) refers to a polynucleotide that is substantially complementary to a contiguous portion of the mRNA of interest (e.g., an mRNA encoding an ANGPTL3 gene). For example, a polynucleotide is complementary to at least a part of an ANGPTL3 mRNA if the sequence is substantially complementary to a non-interrupted portion of an mRNA encoding an ANGPTL3 gene.

Accordingly, in some embodiments, the antisense polynucleotides disclosed herein are fully complementary to the target ANGPTL3 sequence. In other embodiments, the antisense polynucleotides disclosed herein are substantially complementary to the target ANGPTL3 sequence and comprise a contiguous nucleotide sequence which is at least 80% complementary over its entire length to the equivalent region of the nucleotide sequence of any one of SEQ ID NOs:1, 3, 5, 7, 9, or 11, or a fragment of any one of SEQ ID NOs:1, 3, 5, 7, 9, or 11, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary.

In some embodiments, the antisense polynucleotides disclosed herein are substantially complementary to a fragment of a target ANGPTL3 sequence and comprise a contiguous nucleotide sequence which is at least 80% complementary over its entire length to a fragment of SEQ ID NO: 1 selected from the group of nucleotides 73-102, 73-124, 80-114, 291-320, 291-342, 307-336, 540-567, 540-589 and 545-577 of SEQ ID NO: 1, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary.

In some embodiments, the antisense polynucleotides disclosed herein are substantially complementary to a fragment of a target ANGPTL3 sequence and comprise a contiguous nucleotide sequence which is at least 80% complementary over its entire length to a fragment of SEQ ID NO: 1 selected from the group of nucleotides 80-102; 84-106; 87-109; 91-113; 92-114; 186-208; 307-329; 308-330; 310-332; 314-336; 545-567; 551-573; 553-575; 554-576; 555-577; 1133-1155; or 1140-1162 of SEQ ID NO: 1, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary.

In other embodiments, the antisense polynucleotides disclosed herein are substantially complementary to the target ANGPTL3 sequence and comprise a contiguous nucleotide sequence which is at least about 80% complementary over its entire length to any one of the sense strand nucleotide sequences in any one of any one of Tables 2-3 and 7-8, or a fragment of any one of the sense strand nucleotide sequences in any one of Tables 2-3 and 7-8, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% complementary.

In one embodiment, an RNAi agent of the disclosure includes a sense strand that is substantially complementary to an antisense polynucleotide which, in turn, is the same as a target ANGPTL3 sequence, and wherein the sense strand polynucleotide comprises a contiguous nucleotide sequence which is at least about 80% complementary over its entire length to the equivalent region of the nucleotide sequence of SEQ ID NOs: 2, 4, 6, 8, 10, or 12, or a fragment of any one of SEQ ID NOs:2, 4, 6, 8, 10, or 12, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% complementary.

In some embodiments, an iRNA of the invention includes a sense strand that is substantially complementary to an antisense polynucleotide which, in turn, is complementary to a target ANGPTL3 sequence, and wherein the sense strand polynucleotide comprises a contiguous nucleotide sequence which is at least about 80% complementary over its entire length to any one of the antisense strand nucleotide sequences in any one of any one of Tables 2-3 and 7-8, or a fragment of any one of the antisense strand nucleotide sequences in any one of Tables 2-3 and 7-8, such as about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% complementary.

In one embodiment, the antisense strand comprises at least 15, e.g., 15, 16, 17, 18, 19, or 20, contiguous nucleotides differing by no more than 0, 1, 2, or 3 nucleotides from any one of the antisense strand nucleotide sequences of a duplex selected from the group consisting of AD-1331203.1; AD-1331206.1; AD-1331209.1; AD-1331212.1; AD-1331213.1; AD-1331329.1; AD-1331240.1; AD-1331262.1; AD-1331264.1; AD-1331265.1 and AD-1331266.1. In one embodiment, the antisense strand comprises at least 15, e.g., 15, 16, 17, 18, 19, or 20, contiguous nucleotides differing by no more than 0, 1, 2, or 3 nucleotides from any one of the antisense strand nucleotide sequences of a duplex selected from the group consisting of AD-1331203.1; AD-1331206.1; AD-1331209.1; AD-1331212.1; and AD-1331213.1.

In general, an “iRNA” includes ribonucleotides with chemical modifications. Such modifications may include all types of modifications disclosed herein or known in the art. Any such modifications, as used in a dsRNA molecule, are encompassed by “iRNA” for the purposes of this specification and claims.

In certain embodiments of the instant disclosure, inclusion of a deoxy-nucleotide if present within an RNAi agent can be considered to constitute a modified nucleotide.

In an aspect of the invention, an agent for use in the methods and compositions of the invention is a single-stranded antisense oligonucleotide molecule that inhibits a target mRNA via an antisense inhibition mechanism. The single-stranded antisense oligonucleotide molecule is complementary to a sequence within the target mRNA. The single-stranded antisense oligonucleotides can inhibit translation in a stoichiometric manner by base pairing to the mRNA and physically obstructing the translation machinery, see Dias, N. et al., (2002) Mol Cancer Ther 1:347-355. The single-stranded antisense oligonucleotide molecule may be about 14 to about 30 nucleotides in length and have a sequence that is complementary to a target sequence. For example, the single-stranded antisense oligonucleotide molecule may comprise a sequence that is at least about 14, 15, 16, 17, 18, 19, 20, or more contiguous nucleotides from any one of the antisense sequences described herein.

The phrase “contacting a cell with an iRNA,” such as a dsRNA, as used herein, includes contacting a cell by any possible means. Contacting a cell with an iRNA includes contacting a cell in vitro with the iRNA or contacting a cell in vivo with the iRNA. The contacting may be done directly or indirectly. Thus, for example, the iRNA may be put into physical contact with the cell by the individual performing the method, or alternatively, the iRNA may be put into a situation that will permit or cause it to subsequently come into contact with the cell.

Contacting a cell in vitro may be done, for example, by incubating the cell with the iRNA. Contacting a cell in vivo may be done, for example, by injecting the iRNA into or near the tissue where the cell is located, or by injecting the iRNA into another area, e.g., the bloodstream or the subcutaneous space, such that the agent will subsequently reach the tissue where the cell to be contacted is located. For example, the iRNA may contain or be coupled to a ligand, e.g., GalNAc, that directs the iRNA to a site of interest, e.g., the liver. Combinations of in vitro and in vivo methods of contacting are also possible. For example, a cell may also be contacted in vitro with an iRNA and subsequently transplanted into a subject.

In certain embodiments, contacting a cell with an iRNA includes “introducing” or “delivering the iRNA into the cell” by facilitating or effecting uptake or absorption into the cell. Absorption or uptake of an iRNA can occur through unaided diffusion or active cellular processes, or by auxiliary agents or devices. Introducing an iRNA into a cell may be in vitro or in vivo. For example, for in vivo introduction, iRNA can be injected into a tissue site or administered systemically. In vitro introduction into a cell includes methods known in the art such as electroporation and lipofection. Further approaches are described herein below or are known in the art.

The term “lipid nanoparticle” or “LNP” is a vesicle comprising a lipid layer encapsulating a pharmaceutically active molecule, such as a nucleic acid molecule, e.g., an iRNA or a plasmid from which an iRNA is transcribed. LNPs are described in, for example, U.S. Pat. Nos. 6,858,225, 6,815,432, 8,158,601, and 8,058,069, the entire contents of which are hereby incorporated herein by reference.

As used herein, a “subject” is an animal, such as a mammal, including a primate (such as a human, a non-human primate, e.g., a monkey, and a chimpanzee), a non-primate (such as a cow, a pig, a horse, a goat, a rabbit, a sheep, a hamster, a guinea pig, a cat, a dog, a rat, or a mouse), or a bird that expresses the target gene, either endogenously or heterologously. In an embodiment, the subject is a human, such as a human being treated or assessed for a disease or disorder that would benefit from reduction in ANGPTL3 expression; a human at risk for a disease or disorder that would benefit from reduction in ANGPTL3 expression; a human having a disease or disorder that would benefit from reduction in ANGPTL3 expression; or human being treated for a disease or disorder that would benefit from reduction in ANGPTL3 expression as described herein. In some embodiments, the subject is a female human. In other embodiments, the subject is a male human. In one embodiment, the subject is an adult subject. In another embodiment, the subject is a pediatric subject.

As used herein, the terms “treating” or “treatment” refer to a beneficial or desired result, such as reducing at least one sign or symptom of an ANGPTL3-associated disorder in a subject. Treatment also includes a reduction of one or more sign or symptoms associated with unwanted ANGPTL3 expression; diminishing the extent of unwanted ANGPTL3 activation or stabilization; amelioration or palliation of unwanted ANGPTL3 activation or stabilization. “Treatment” can also mean prolonging survival as compared to expected survival in the absence of treatment. The term “lower” in the context of the level of ANGPTL3 in a subject or a disease marker or symptom refers to a statistically significant decrease in such level. The decrease can be, for example, at least 10%, 15%, 20%, 25%, 30%, %, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more. In certain embodiments, a decrease is at least 20%. In certain embodiments, the decrease is at least 50% in a disease marker, e.g., protein or gene expression level. “Lower” in the context of the level of ANGPTL3 in a subject is a decrease to a level accepted as within the range of normal for an individual without such disorder. In certain embodiments, “lower” is the decrease in the difference between the level of a marker or symptom for a subject suffering from a disease and a level accepted within the range of normal for an individual, e.g., the level of decrease in bodyweight between an obese individual and an individual having a weight accepted within the range of normal.

As used herein, “prevention” or “preventing,” when used in reference to a disease, disorder or condition thereof, may be treated or ameliorated by a reduction in expression of an ANGPTL3 gene, refers to a reduction in the likelihood that a subject will develop a symptom associated with such a disease, disorder, or condition, e.g., a symptom of unwanted or excessive ANGPTL3 expression, such as high triglyceride levels or eruptive xanthoma. The likelihood of developing high triglyceride levels or eruptive xanthoma is reduced, for example, when an individual having one or more risk factors for high triglyceride levels or eruptive xanthoma either fails to develop high triglyceride levels or eruptive xanthoma, or develops high triglyceride levels or eruptive xanthoma with less severity relative to a population having the same risk factors and not receiving treatment as described herein.

The failure to develop a disease, disorder or condition, or the reduction in the development of a symptom associated with such a disease, disorder or condition (e.g., by at least about 10% on a clinically accepted scale for that disease or disorder), or the exhibition of delayed symptoms delayed (e.g., by days, weeks, months or years) is considered effective prevention.

As used herein, the term “serum lipid” refers to any major lipid present in the blood. Serum lipids may be present in the blood either in free form or as a part of a protein complex, e.g., a lipoprotein complex. Non-limiting examples of serum lipids may include triglycerides and cholesterol, such as total cholesterol (TG), low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), very low density lipoprotein cholesterol (VLDL-C) and intermediate-density lipoprotein cholesterol (IDL-C).

As used herein, the term “Angiopoietin-like 3-associated disease” or “ANGPTL3-associated disease,” is a disease or disorder that is caused by, or associated with ANGPTL3 gene expression or ANGPTL3 protein production. The term “ANGPTL3-associated disease” includes a disease, disorder or condition that would benefit from a decrease in ANGPTL3 gene expression, replication, or protein activity. In some embodiments, the ANGPTL3-associated disease is a disorder of lipid metabolism.

As used herein, a “disorder of lipid metabolism” refers to any disorder associated with or caused by a disturbance in lipid metabolism. For example, this term includes any disorder, disease or condition that can lead to hyperlipidemia, or condition characterized by abnormal elevation of levels of any or all lipids and/or lipoproteins in the blood. This term refers to an inherited disorder, such as familial hypertriglyceridemia, familial partial lipodystrophy type 1 (FPLD1), or an induced or acquired disorder, such as a disorder induced or acquired as a result of a disease, disorder or condition (e.g., renal failure), a diet, or intake of certain drugs (e.g., as a result of highly active antiretroviral therapy (HAART) used for treating, e.g., AIDS or HIV). Exemplary disorders of lipid metabolism include, but are not limited to, atherosclerosis, dyslipidemia, hypertriglyceridemia (including drug-induced hypertriglyceridemia, diuretic-induced hypertriglyceridemia, alcohol-induced hypertriglyceridemia, β-adrenergic blocking agent-induced hypertriglyceridemia, estrogen-induced hypertriglyceridemia, glucocorticoid-induced hypertriglyceridemia, retinoid-induced hypertriglyceridemia, cimetidine-induced hypertriglyceridemia, and familial hypertriglyceridemia), acute pancreatitis associated with hypertriglyceridemia, chylomicron syndrome, familial chylomicronemia, Apo-E deficiency or resistance, LPL deficiency or hypoactivity, hyperlipidemia (including familial combined hyperlipidemia), hypercholesterolemia, gout associated with hypercholesterolemia, xanthomatosis (subcutaneous cholesterol deposits), hyperlipidemia with heterogeneous LPL deficiency, and hyperlipidemia with high LDL and heterogeneous LPL deficiency.

Cardiovascular diseases associated with disorders of lipid metabolism are also considered “disorders of lipid metabolism”, as defined herein. These diseases may include coronary artery disease (also called ischemic heart disease), inflammation associated with coronary artery disease, restenosis, peripheral vascular diseases, and stroke.

Disorders related to body weight are also considered “disorders of lipid metabolism”, as defined herein. Such disorders may include obesity, metabolic syndrome including independent components of metabolic syndrome (e.g., central obesity, FBG/pre-diabetes/diabetes, hypercholesterolemia, hypertriglyceridemia, and hypertension), hypothyroidism, uremia, and other conditions associated with weight gain (including rapid weight gain), weight loss, maintenance of weight loss, or risk of weight regain following weight loss.

Blood sugar disorders are further considered “disorders of lipid metabolism”, as defined herein. Such disorders may include diabetes, hypertension, and polycystic ovarian syndrome related to insulin resistance. Other exemplary disorders of lipid metabolism may also include renal transplantation, nephrotic syndrome, Cushing's syndrome, acromegaly, systemic lupus erythematosus, dysglobulinemia, lipodystrophy, glycogenosis type I, and Addison's disease.

“Therapeutically effective amount,” as used herein, is intended to include the amount of an RNAi agent that, when administered to a subject having an ANGPTL3-associated disease, is sufficient to effect treatment of the disease (e.g., by diminishing, ameliorating, or maintaining the existing disease or one or more symptoms of disease). The “therapeutically effective amount” may vary depending on the RNAi agent, how the agent is administered, the disease and its severity and the history, age, weight, family history, genetic makeup, the types of preceding or concomitant treatments, if any, and other individual characteristics of the subject to be treated.

“Prophylactically effective amount,” as used herein, is intended to include the amount of an RNAi agent that, when administered to a subject having an ANGPTL3-associated disorder, is sufficient to prevent or ameliorate the disease or one or more symptoms of the disease. Ameliorating the disease includes slowing the course of the disease or reducing the severity of later-developing disease. The “prophylactically effective amount” may vary depending on the RNAi agent, how the agent is administered, the degree of risk of disease, and the history, age, weight, family history, genetic makeup, the types of preceding or concomitant treatments, if any, and other individual characteristics of the patient to be treated.

A “therapeutically-effective amount” or “prophylactically effective amount” also includes an amount of an RNAi agent that produces some desired effect at a reasonable benefit/risk ratio applicable to any treatment. The iRNA employed in the methods of the present invention may be administered in a sufficient amount to produce a reasonable benefit/risk ratio applicable to such treatment.

The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds (including salts), materials, compositions, or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human subjects and animal subjects without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The phrase “pharmaceutically-acceptable carrier” as used herein means a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject being treated. Such carriers are known in the art. Pharmaceutically acceptable carriers include carriers for administration by injection.

The term “sample,” as used herein, includes a collection of similar fluids, cells, or tissues isolated from a subject, as well as fluids, cells, or tissues present within a subject. Examples of biological fluids include blood, serum and serosal fluids, plasma, cerebrospinal fluid, ocular fluids, lymph, urine, saliva, and the like. Tissue samples may include samples from tissues, organs, or localized regions. For example, samples may be derived from particular organs, parts of organs, or fluids or cells within those organs. In certain embodiments, samples may be derived from the liver (e.g., whole liver or certain segments of liver or certain types of cells in the liver, such as, e.g., hepatocytes). In some embodiments, a “sample derived from a subject” refers to urine obtained from the subject. A “sample derived from a subject” can refer to blood or blood derived serum or plasma from the subject.

II. iRNAs of the Invention

The present invention provides iRNAs which inhibit the expression of an ANGPTL3 gene. In certain embodiments, the iRNA includes double stranded ribonucleic acid (dsRNA) molecules for inhibiting the expression of an ANGPTL3 gene in a cell, such as a cell within a subject, e.g., a mammal, such as a human susceptible to developing an ANGPTL3-associated disorder, e.g., a disorder of lipid metabolism, e.g., hyperlipidemia or hypertriglyceridemia. The dsRNAi agent includes an antisense strand having a region of complementarity which is complementary to at least a part of an mRNA formed in the expression of an ANGPTL3 gene. The region of complementarity is about 19-30 nucleotides in length (e.g., about 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, or 19 nucleotides in length).

Upon contact with a cell expressing the ANGPTL3 gene, the iRNA inhibits the expression of the ANGPTL3 gene (e.g., a human, a primate, a non-primate, or a rat ANGPTL3 gene) by at least about 50% as assayed by, for example, a PCR or branched DNA (bDNA)-based method, or by a protein-based method, such as by immunofluorescence analysis, using, for example, western blotting or flow cytometric techniques. In certain embodiments, inhibition of expression is determined by the qPCR method provided in the examples herein with the siRNA at, e.g., a 10 nM concentration, in an appropriate organism cell line provided therein. In certain embodiments, inhibition of expression in vivo is determined by knockdown of the human gene in a rodent expressing the human gene, e.g., a mouse or an AAV-infected mouse expressing the human target gene, e.g., when administered as single dose, e.g., at 3 mg/kg at the nadir of RNA expression.

A dsRNA includes two RNA strands that are complementary and hybridize to form a duplex structure under conditions in which the dsRNA will be used. One strand of a dsRNA (the antisense strand) includes a region of complementarity that is substantially complementary, and generally fully complementary, to a target sequence. The target sequence can be derived from the sequence of an mRNA formed during the expression of an ANGPTL3 gene. The other strand (the sense strand) includes a region that is complementary to the antisense strand, such that the two strands hybridize and form a duplex structure when combined under suitable conditions. As described elsewhere herein and as known in the art, the complementary sequences of a dsRNA can also be contained as self-complementary regions of a single nucleic acid molecule, as opposed to being on separate oligonucleotides.

Generally, the duplex structure is 15 to 30 base pairs in length, e.g., 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. In certain embodiments, the duplex structure is 18 to 25 base pairs in length, e.g., 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-25, 20-24, 20-23, 20-22, 20-21, 21-25, 21-24, 21-23, 21-22, 22-25, 22-24, 22-23, 23-25, 23-24 or 24-25 base pairs in length, for example, 19-21 basepairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure.

Similarly, the region of complementarity to the target sequence is 15 to 30 nucleotides in length, e.g., 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length, for example 19-23 nucleotides in length or 21-23 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure.

In some embodiments, the duplex structure is 19 to 30 base pairs in length. Similarly, the region of complementarity to the target sequence is 19 to 30 nucleotides in length.

In some embodiments, the dsRNA is about 19 to about 23 nucleotides in length, or about 25 to about 30 nucleotides in length. In general, the dsRNA is long enough to serve as a substrate for the Dicer enzyme. For example, it is well-known in the art that dsRNAs longer than about 21-23 nucleotides in length may serve as substrates for Dicer. As the ordinarily skilled person will also recognize, the region of an RNA targeted for cleavage will most often be part of a larger RNA molecule, often an mRNA molecule. Where relevant, a “part” of an mRNA target is a contiguous sequence of an mRNA target of sufficient length to allow it to be a substrate for RNAi-directed cleavage (i.e., cleavage through a RISC pathway).

One of skill in the art will also recognize that the duplex region is a primary functional portion of a dsRNA, e.g., a duplex region of about 19 to about 30 base pairs, e.g., about 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs. Thus, in one embodiment, to the extent that it becomes processed to a functional duplex, of e.g., 15-30 base pairs, that targets a desired RNA for cleavage, an RNA molecule or complex of RNA molecules having a duplex region greater than 30 base pairs is a dsRNA. Thus, an ordinarily skilled artisan will recognize that in one embodiment, a miRNA is a dsRNA. In another embodiment, a dsRNA is not a naturally occurring miRNA. In another embodiment, an iRNA agent useful to target ANGPTL3 gene expression is not generated in the target cell by cleavage of a larger dsRNA.

A dsRNA as described herein can further include one or more single-stranded nucleotide overhangs, e.g., 1-4, 2-4, 1-3, 2-3, 1, 2, 3, or 4 nucleotides. dsRNAs having at least one nucleotide overhang can have superior inhibitory properties relative to their blunt-ended counterparts. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) can be on the sense strand, the antisense strand, or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5′-end, 3′-end, or both ends of an antisense or sense strand of a dsRNA.

A dsRNA can be synthesized by standard methods known in the art. Double stranded RNAi compounds of the invention may be prepared using a two-step procedure. First, the individual strands of the double stranded RNA molecule are prepared separately. Then, the component strands are annealed. The individual strands of the siRNA compound can be prepared using solution-phase or solid-phase organic synthesis or both. Organic synthesis offers the advantage that the oligonucleotide strands comprising unnatural or modified nucleotides can be easily prepared. Similarly, single-stranded oligonucleotides of the invention can be prepared using solution-phase or solid-phase organic synthesis or both.

In an aspect, a dsRNA of the invention includes at least two nucleotide sequences, a sense sequence and an anti-sense sequence. The sense strand is selected from the group of sequences provided in any one of Tables 2-3 and 7-8, and the corresponding antisense strand of the sense strand is selected from the group of sequences of any one of Tables 2-3 and 7-8. In this aspect, one of the two sequences is complementary to the other of the two sequences, with one of the sequences being substantially complementary to a sequence of an mRNA generated in the expression of an ANGPTL3 gene. As such, in this aspect, a dsRNA will include two oligonucleotides, where one oligonucleotide is described as the sense strand in any one of Tables 2-3 and 7-8, and the second oligonucleotide is described as the corresponding antisense strand of the sense strand in any one of Tables 2-3 and 7-8.

In certain embodiments, the substantially complementary sequences of the dsRNA are contained on separate oligonucleotides. In other embodiments, the substantially complementary sequences of the dsRNA are contained on a single oligonucleotide.

It will be understood that, although the sequences in, for example, Table 3, are not described as modified or conjugated sequences, the RNA of the iRNA of the invention e.g., a dsRNA of the invention, may comprise any one of the sequences set forth in any one of Tables 2-3 and 7-8 that is un-modified, un-conjugated, or modified or conjugated differently than described therein. In other words, the invention encompasses dsRNA of Tables 2-3 and 7-8 which are un-modified, un-conjugated, modified, or conjugated, as described herein.

The skilled person is well aware that dsRNAs having a duplex structure of about 20 to 23 base pairs, e.g., 21, base pairs have been hailed as particularly effective in inducing RNA interference (Elbashir et al., EMBO 2001, 20:6877-6888). However, others have found that shorter or longer RNA duplex structures can also be effective (Chu and Rana (2007) RNA 14:1714-1719; Kim et al. (2005) Nat Biotech 23:222-226). In the embodiments described above, by virtue of the nature of the oligonucleotide sequences provided in any one of Tables 2-3 and 7-8. dsRNAs described herein can include at least one strand of a length of minimally 21 nucleotides. It can be reasonably expected that shorter duplexes having any one of the sequences in any one of Tables 2-3 and 7-8 minus only a few nucleotides on one or both ends can be similarly effective as compared to the dsRNAs described above. Hence, dsRNAs having a sequence of at least 19, 20, or more contiguous nucleotides derived from any one of the sequences of any one of Tables 2-3 and 7-8, and differing in their ability to inhibit the expression of an ANGPTL3 gene by not more than about 5, 10, 15, 20, 25, or 30% inhibition from a dsRNA comprising the full sequence, are contemplated to be within the scope of the present invention.

In addition, the RNAs provided in Tables 2-3 and 7-8 identify a site(s) in an ANGPTL3 transcript that is susceptible to RISC-mediated cleavage. As such, the present invention further features iRNAs that target within one of these sites. As used herein, an iRNA is said to target within a particular site of an RNA transcript if the iRNA promotes cleavage of the transcript anywhere within that particular site. Such an iRNA will generally include at least about 19 contiguous nucleotides from any one of the sequences provided in any one of Tables 2-3 and 7-8 coupled to additional nucleotide sequences taken from the region contiguous to the selected sequence in an ANGPTL3 gene.

III. Modified iRNAs of the Invention

In certain embodiments, the RNA of the iRNA of the invention e.g., a dsRNA, is un-modified, and does not comprise, e.g., chemical modifications or conjugations known in the art and described herein. In other embodiments, the RNA of an iRNA of the invention, e.g., a dsRNA, is chemically modified to enhance stability or other beneficial characteristics. In certain embodiments of the invention, substantially all of the nucleotides of an iRNA of the invention are modified. In other embodiments of the invention, all of the nucleotides of an iRNA or substantially all of the nucleotides of an iRNA are modified, i.e., not more than 5, 4, 3, 2, or 1 unmodified nucleotides are present in a strand of the iRNA.

The nucleic acids featured in the invention can be synthesized or modified by methods well established in the art, such as those described in “Current protocols in nucleic acid chemistry,” Beaucage, S. L. et al. (Edrs.), John Wiley & Sons, Inc., New York, N.Y., USA, which is hereby incorporated herein by reference. Modifications include, for example, end modifications, e.g., 5′-end modifications (phosphorylation, conjugation, inverted linkages) or 3′-end modifications (conjugation, DNA nucleotides, inverted linkages, etc.); base modifications, e.g., replacement with stabilizing bases, destabilizing bases, or bases that base pair with an expanded repertoire of partners, removal of bases (abasic nucleotides), or conjugated bases; sugar modifications (e.g., at the 2′-position or 4′-position) or replacement of the sugar; or backbone modifications, including modification or replacement of the phosphodiester linkages. Specific examples of iRNA compounds useful in the embodiments described herein include, but are not limited to RNAs containing modified backbones or no natural internucleoside linkages. RNAs having modified backbones include, among others, those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified RNAs that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides. In some embodiments, a modified iRNA will have a phosphorus atom in its internucleoside backbone.

Modified RNA backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′-linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Various salts, mixed salts and free acid forms are also included. In some embodiments of the invention, the dsRNA agents of the invention are in a free acid form. In other embodiments of the invention, the dsRNA agents of the invention are in a salt form. In one embodiment, the dsRNA agents of the invention are in a sodium salt form. In certain embodiments, when the dsRNA agents of the invention are in the sodium salt form, sodium ions are present in the agent as counterions for substantially all of the phosphodiester and/or phosphorothioate groups present in the agent. Agents in which substantially all of the phosphodiester and/or phosphorothioate linkages have a sodium counterion include not more than 5, 4, 3, 2, or 1 phosphodiester and/or phosphorothioate linkages without a sodium counterion. In some embodiments, when the dsRNA agents of the invention are in the sodium salt form, sodium ions are present in the agent as counterions for all of the phosphodiester and/or phosphorothioate groups present in the agent.

Representative U.S. patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,195; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,316; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,625,050; 6,028,188; 6,124,445; 6,160,109; 6,169,170; 6,172,209; 6,239,265; 6,277,603; 6,326,199; 6,346,614; 6,444,423; 6,531,590; 6,534,639; 6,608,035; 6,683,167; 6,858,715; 6,867,294; 6,878,805; 7,015,315; 7,041,816; 7,273,933; 7,321,029; and U.S. Pat. RE39464, the entire contents of each of which are hereby incorporated herein by reference.

Modified RNA backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatoms and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S, and CH₂component parts.

Representative U.S. patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,641,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, the entire contents of each of which are hereby incorporated herein by reference.

Suitable RNA mimetics are contemplated for use in iRNAs provided herein, in which both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound in which an RNA mimetic that has been shown to have excellent hybridization properties is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of an RNA is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative US patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, the entire contents of each of which are hereby incorporated herein by reference. Additional PNA compounds suitable for use in the iRNAs of the invention are described in, for example, in Nielsen et al., Science, 1991, 254, 1497-1500.

Some embodiments featured in the invention include RNAs with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular —CH₂—NH—CH₂—, —CH₂—N(CH₃)—O—CH₂— [known as a methylene (methylimino) or MMI backbone], —CH₂—O—N(CH₃)—CH₂—, —CH₂—N(CH₃)—N(CH₃)—CH₂— and —N(CH₃)—CH₂—CH₂— of the above-referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above-referenced U.S. Pat. No. 5,602,240. In some embodiments, the RNAs featured herein have morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506. The native phosphodiester backbone can be represented as O—P(O)(OH)—OCH2-.

Modified RNAs can also contain one or more substituted sugar moieties. The iRNAs, e.g., dsRNAs, featured herein can include one of the following at the 2′-position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl can be substituted or unsubstituted C₁to C₁₀alkyl or C₂to C₁₀alkenyl and alkynyl. Exemplary suitable modifications include O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂, and O(CH₂)_nON[(CH₂)_nCH₃)]₂, where n and m are from 1 to about 10. In other embodiments, dsRNAs include one of the following at the 2′ position: C₁to C₁₀lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an iRNA, or a group for improving the pharmacodynamic properties of an iRNA, and other substituents having similar properties. In some embodiments, the modification includes a 2′-methoxyethoxy (2′-O—CH₂CH₂OCH₃, also known as 2′-O-(2-methoxyethyl) or 2′-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78:486-504) i.e., an alkoxy-alkoxy group. Another exemplary modification is 2′-dimethylaminooxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂group, also known as 2′-DMAOE, as described in examples herein below, and 2′-dimethylaminoethoxyethoxy (also known in the art as 2′-O-dimethylaminoethoxyethyl or 2′-DMAEOE), i.e., 2′-O—CH₂—O—CH₂—N(CH₃)₂. Further exemplary modifications include: 5′-Me-2′-F nucleotides, 5′-Me-2′-OMe nucleotides, 5′-Me-2′-deoxynucleotides, (both R and S isomers in these three families); 2′-alkoxyalkyl; and 2′-NMA (N-methylacetamide).

Other modifications include 2′-methoxy (2′-OCH₃), 2′-aminopropoxy (2′-OCH₂CH₂CH₂NH₂) and 2′-fluoro (2′-F). Similar modifications can also be made at other positions on the RNA of an iRNA, particularly the 3′ position of the sugar on the 3′ terminal nucleotide or in 2′-5′ linked dsRNAs and the 5′ position of 5′ terminal nucleotide. iRNAs can also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative US patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the instant application. The entire contents of each of the foregoing are hereby incorporated herein by reference.

An iRNA can also include nucleobase (often referred to in the art simply as “base”) modifications or substitutions. As used herein, “unmodified” or “natural” nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C), and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as deoxythymidine (dT), 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl anal other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P. ed. Wiley-VCH, 2008; those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. L, ed. John Wiley & Sons, 1990, these disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y S., Chapter 15, dsRNA Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B., Ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds featured in the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., Eds., dsRNA Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are exemplary base substitutions, even more particularly when combined with 2′-O-methoxyethyl sugar modifications.

Representative U.S. patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Pat. Nos. 3,687,808, 4,845,205; 5,130,30; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,681,941; 5,750,692; 6,015,886; 6,147,200; 6,166,197; 6,222,025; 6,235,887; 6,380,368; 6,528,640; 6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088, the entire contents of each of which are hereby incorporated herein by reference.

In some embodiments, an RNAi agent of the disclosure can also be modified to include one or more bicyclic sugar moieties. A “bicyclic sugar” is a furanosyl ring modified by a ring formed by the bridging of two carbons, whether adjacent or non-adjacent. A “bicyclic nucleoside” (“BNA”) is a nucleoside having a sugar moiety comprising a ring formed by bridging two carbons, whether adjacent or non-adjacent, of the sugar ring, thereby forming a bicyclic ring system. In certain embodiments, the bridge connects the 4′-carbon and the 2′-carbon of the sugar ring, optionally, via the 2′-acyclic oxygen atom. Thus, in some embodiments an agent of the invention may include one or more locked nucleic acids (LNA). A locked nucleic acid is a nucleotide having a modified ribose moiety in which the ribose moiety comprises an extra bridge connecting the 2′ and 4′ carbons. In other words, an LNA is a nucleotide comprising a bicyclic sugar moiety comprising a 4′-CH₂—O-2′ bridge. This structure effectively “locks” the ribose in the 3′-endo structural conformation. The addition of locked nucleic acids to siRNAs has been shown to increase siRNA stability in serum, and to reduce off-target effects (Elmen, J. et al., (2005) Nucleic Acids Research 33(1):439-447; Mook, O R. et al., (2007) Mol Canc Ther 6(3):833-843; Grunweller, A. et al., (2003) Nucleic Acids Research 31(12):3185-3193). Examples of bicyclic nucleosides for use in the polynucleotides of the invention include without limitation nucleosides comprising a bridge between the 4′ and the 2′ ribosyl ring atoms. In certain embodiments, the antisense polynucleotide agents of the invention include one or more bicyclic nucleosides comprising a 4′ to 2′ bridge.

A locked nucleoside can be represented by the structure (omitting stereochemistry),

embedded image

wherein B is a nucleobase or modified nucleobase and L is the linking group that joins the 2′-carbon to the 4′-carbon of the ribose ring. Examples of such 4′ to 2′ bridged bicyclic nucleosides, include but are not limited to 4′-(CH₂)—O-2′ (LNA); 4′-(CH₂)—S-2′; 4′-(CH₂)₂—O-2′ (ENA); 4′-CH(CH₃)—O-2′ (also referred to as “constrained ethyl” or “cEt”) and 4′-CH(CH₂OCH₃)—O-2′ (and analogs thereof; see, e.g., U.S. Pat. No. 7,399,845); 4′-C(CH₃)(CH₃)—O-2′ (and analogs thereof; see e.g., U.S. Pat. No. 8,278,283); 4′-CH₂—N(OCH₃)-2′ (and analogs thereof; see e.g., U.S. Pat. No. 8,278,425); 4′-CH₂—O—N(CH₃)-2′ (see, e.g., U.S. Patent Publication No. 2004/0171570); 4′-CH₂—N(R)—O-2′, wherein R is H, C1-C12 alkyl, or a nitrogen protecting group (see, e.g., U.S. Pat. No. 7,427,672); 4′-CH₂—C(H)(CH₃)-2′ (see, e.g., Chattopadhyaya et al., J. Org. Chem., 2009, 74, 118-134); and 4′-CH₂—C(═CH₂)-2′ (and analogs thereof; see, e.g., U.S. Pat. No. 8,278,426). The entire contents of each of the foregoing are hereby incorporated herein by reference.

Additional representative U.S. patents and U.S. Patent Publications that teach the preparation of locked nucleic acid nucleotides include, but are not limited to, the following: U.S. Pat. Nos. 6,268,490; 6,525,191; 6,670,461; 6,770,748; 6,794,499; 6,998,484; 7,053,207; 7,034,133; 7,084,125; 7,399,845; 7,427,672; 7,569,686; 7,741,457; 8,022,193; 8,030,467; 8,278,425; 8,278,426; 8,278,283; US 2008/0039618; and US 2009/0012281, the entire contents of each of which are hereby incorporated herein by reference.

Any of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including for example α-L-ribofuranose and β-D-ribofuranose (see WO 99/14226).

The RNA of an iRNA can also be modified to include one or more constrained ethyl nucleotides. As used herein, a “constrained ethyl nucleotide” or “cEt” is a locked nucleic acid comprising a bicyclic sugar moiety comprising a 4′-CH(CH₃)—O-2′ bridge (i.e., L in the preceding structure). In one embodiment, a constrained ethyl nucleotide is in the S conformation referred to herein as “S-cEt.”

An iRNA of the invention may also include one or more “conformationally restricted nucleotides” (“CRN”). CRN are nucleotide analogs with a linker connecting the C2′ and C4′ carbons of ribose or the C3 and —C5′ carbons of ribose. CRN lock the ribose ring into a stable conformation and increase the hybridization affinity to mRNA. The linker is of sufficient length to place the oxygen in an optimal position for stability and affinity resulting in less ribose ring puckering.

Representative publications that teach the preparation of certain of the above noted CRN include, but are not limited to, U.S. Patent Publication No. 2013/0190383; and PCT publication WO 2013/036868, the entire contents of each of which are hereby incorporated herein by reference.

In some embodiments, an iRNA of the invention comprises one or more monomers that are UNA (unlocked nucleic acid) nucleotides. UNA is unlocked acyclic nucleic acid, wherein any of the bonds of the sugar has been removed, forming an unlocked “sugar” residue. In one example, UNA also encompasses monomer with bonds between C1′-C4′ have been removed (i.e. the covalent carbon-oxygen-carbon bond between the C1′ and C4′ carbons). In another example, the C2′-C3′ bond (i.e. the covalent carbon-carbon bond between the C2′ and C3′ carbons) of the sugar has been removed (see Nuc. Acids Symp. Series, 52, 133-134 (2008) and Fluiter et al., Mol. Biosyst., 2009, 10, 1039 hereby incorporated by reference).

Representative U.S. publications that teach the preparation of UNA include, but are not limited to, U.S. Pat. No. 8,314,227; and U.S. Patent Publication Nos. 2013/0096289; 2013/0011922; and 2011/0313020, the entire contents of each of which are hereby incorporated herein by reference.

Potentially stabilizing modifications to the ends of RNA molecules can include N-(acetylaminocaproyl)-4-hydroxyprolinol (Hyp-C6-NHAc), N-(caproyl-4-hydroxyprolinol (Hyp-C6), N-(acetyl-4-hydroxyprolinol (Hyp-NHAc), thymidine-2′-O-deoxythymidine (ether), N-(aminocaproyl)-4-hydroxyprolinol (Hyp-C6-amino), 2-docosanoyl-uridine-3′-phosphate, inverted 2′-deoxy-modified ribonucleotide, such as inverted dT (idT), inverted dA (idA), and inverted abasic 2′-deoxyribonucleotide (iAb) and others. Disclosure of this modification can be found in WO 2011/005861.

In one example, the 3′ or 5′ terminal end of a oligonucleotide is linked to an inverted 2′-deoxy-modified ribonucleotide, such as inverted dT (idT), inverted dA (idA), or a inverted abasic 2′-deoxyribonucleotide (iAb). In one particular example, the inverted 2′-deoxy-modified ribonucleotide is linked to the 3′end of an oligonucleotide, such as the 3′-end of a sense strand described herein, where the linking is via a 3′-3′ phosphodiester linkage or a 3′-3′-phosphorothioate linkage.

In another example, the 3′-end of a sense strand is linked via a 3′-3′-phosphorothioate linkage to an inverted abasic ribonucleotide (iAb). In another example, the 3′-end of a sense strand is linked via a 3′-3′-phosphorothioate linkage to an inverted dA (idA).

In one particular example, the inverted 2′-deoxy-modified ribonucleotide is linked to the 3′end of an oligonucleotide, such as the 3′-end of a sense strand described herein, where the linking is via a 3′-3′ phosphodiester linkage or a 3′-3′-phosphorothioate linkage.

In another example, the 3′-terminal nucleotides of a sense strand is an inverted dA (idA) and is linked to the preceding nucleotide via a 3′-3′-linkage (e.g., 3′-3′-phosphorothioate linkage).

Other modifications of the nucleotides of an iRNA of the invention include a 5′ phosphate or 5′ phosphate mimic, e.g., a 5′-terminal phosphate or phosphate mimic on the antisense strand of an iRNA. Suitable phosphate mimics are disclosed in, for example U.S. Patent Publication No. 2012/0157511, the entire contents of which are incorporated herein by reference.

A. Modified iRNAs Comprising Motifs of the Invention

In certain aspects of the invention, the double stranded RNA agents of the invention include agents with chemical modifications as disclosed, for example, in WO2013/075035, the entire contents of each of which are incorporated herein by reference. As shown herein and in WO2013/075035, one or more motifs of three identical modifications on three consecutive nucleotides may be introduced into a sense strand or antisense strand of a dsRNAi agent, particularly at or near the cleavage site. In some embodiments, the sense strand and antisense strand of the dsRNAi agent may otherwise be completely modified. The introduction of these motifs interrupts the modification pattern, if present, of the sense or antisense strand. The dsRNAi agent may be optionally conjugated with a GalNAc derivative ligand, for instance on the sense strand.

More specifically, when the sense strand and antisense strand of the double stranded RNA agent are completely modified to have one or more motifs of three identical modifications on three consecutive nucleotides at or near the cleavage site of at least one strand of a dsRNAi agent, the gene silencing activity of the dsRNAi agent was observed.

Accordingly, the invention provides double stranded RNA agents capable of inhibiting the expression of a target gene (i.e., ANGPTL3 gene) in vivo. The RNAi agent comprises a sense strand and an antisense strand. Each strand of the RNAi agent may be, for example, 17-30 nucleotides in length, 25-30 nucleotides in length, 27-30 nucleotides in length, 19-25 nucleotides in length, 19-23 nucleotides in length, 19-21 nucleotides in length, 21-25 nucleotides in length, or 21-23 nucleotides in length.

The sense strand and antisense strand typically form a duplex double stranded RNA (“dsRNA”), also referred to herein as “dsRNAi agent.” The duplex region of a dsRNAi agent may be, for example, the duplex region can be 27-30 nucleotide pairs in length, 19-25 nucleotide pairs in length, 19-23 nucleotide pairs in length, 19-21 nucleotide pairs in length, 21-25 nucleotide pairs in length, or 21-23 nucleotide pairs in length. In another example, the duplex region is selected from 19, 20, 21, 22, 23, 24, 25, 26, and 27 nucleotides in length.

In certain embodiments, the dsRNAi agent may contain one or more overhang regions or capping groups at the 3′-end, 5′-end, or both ends of one or both strands. The overhang can be, independently, 1-6 nucleotides in length, for instance 2-6 nucleotides in length, 1-5 nucleotides in length, 2-5 nucleotides in length, 1-4 nucleotides in length, 2-4 nucleotides in length, 1-3 nucleotides in length, 2-3 nucleotides in length, or 1-2 nucleotides in length. In certain embodiments, the overhang regions can include extended overhang regions as provided above. The overhangs can be the result of one strand being longer than the other, or the result of two strands of the same length being staggered. The overhang can form a mismatch with the target mRNA or it can be complementary to the gene sequences being targeted or can be another sequence. The first and second strands can also be joined, e.g., by additional bases to form a hairpin, or by other non-base linkers.

In certain embodiments, the nucleotides in the overhang region of the dsRNAi agent can each independently be a modified or unmodified nucleotide including, but no limited to 2′-sugar modified, such as, 2′-F, 2′-O-methyl, thymidine (T), 2′-O-methoxyethyl-5-methyluridine (Teo), 2′-O-methoxyethyladenosine (Aeo), 2′-O-methoxyethyl-5-methylcytidine (m5Ceo), and any combinations thereof.

For example, TT can be an overhang sequence for either end on either strand. The overhang can form a mismatch with the target mRNA or it can be complementary to the gene sequences being targeted or can be another sequence.

The 5′- or 3′-overhangs at the sense strand, antisense strand, or both strands of the dsRNAi agent may be phosphorylated. In some embodiments, the overhang region(s) contains two nucleotides having a phosphorothioate between the two nucleotides, where the two nucleotides can be the same or different. In some embodiments, the overhang is present at the 3′-end of the sense strand, antisense strand, or both strands. In some embodiments, this 3′-overhang is present in the antisense strand. In some embodiments, this 3′-overhang is present in the sense strand.

The dsRNAi agent may contain only a single overhang, which can strengthen the interference activity of the RNAi, without affecting its overall stability. For example, the single-stranded overhang may be located at the 3′-end of the sense strand or, alternatively, at the 3′-end of the antisense strand. The RNAi may also have a blunt end, located at the 5′-end of the antisense strand (i.e., the 3′-end of the sense strand) or vice versa. Generally, the antisense strand of the dsRNAi agent has a nucleotide overhang at the 3′-end, and the 5′-end is blunt. While not wishing to be bound by theory, the asymmetric blunt end at the 5′-end of the antisense strand and 3′-end overhang of the antisense strand favor the guide strand loading into RISC process.

In certain embodiments, the dsRNAi agent is a double blunt-ended of 19 nucleotides in length, wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides at positions 7, 8, 9 from the 5′end. The antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at positions 11, 12, and 13 from the 5′end.

In other embodiments, the dsRNAi agent is a double blunt-ended of 20 nucleotides in length, wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides at positions 8, 9, and 10 from the 5′end. The antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at positions 11, 12, and 13 from the 5′end.

In yet other embodiments, the dsRNAi agent is a double blunt-ended of 21 nucleotides in length, wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides at positions 9, 10, and 11 from the 5′end. The antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at positions 11, 12, and 13 from the 5′end.

In certain embodiments, the dsRNAi agent comprises a 21 nucleotide sense strand and a 23 nucleotide antisense strand, wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides at positions 9, 10, and 11 from the 5′end; the antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at positions 11, 12, and 13 from the 5′end, wherein one end of the RNAi agent is blunt, while the other end comprises a 2 nucleotide overhang. In one embodiment, the 2 nucleotide overhang is at the 3′-end of the antisense strand.

When the 2 nucleotide overhang is at the 3′-end of the antisense strand, there may be two phosphorothioate internucleotide linkages between the terminal three nucleotides, wherein two of the three nucleotides are the overhang nucleotides, and the third nucleotide is a paired nucleotide next to the overhang nucleotide. In one embodiment, the RNAi agent additionally has two phosphorothioate internucleotide linkages between the terminal three nucleotides at both the 5′-end of the sense strand and at the 5′-end of the antisense strand. In certain embodiments, every nucleotide in the sense strand and the antisense strand of the dsRNAi agent, including the nucleotides that are part of the motifs are modified nucleotides. In certain embodiments each residue is independently modified with a 2′-O-methyl or 3′-fluoro, e.g., in an alternating motif. Optionally, the dsRNAi agent further comprises a ligand (such as, GalNAc₃).

In certain embodiments, the dsRNAi agent comprises a sense and an antisense strand, wherein the sense strand is 25-30 nucleotide residues in length, wherein starting from the 5′ terminal nucleotide (position 1) positions 1 to 23 of the first strand comprise at least 8 ribonucleotides; the antisense strand is 36-66 nucleotide residues in length and, starting from the 3′ terminal nucleotide, comprises at least 8 ribonucleotides in the positions paired with positions 1-23 of sense strand to form a duplex; wherein at least the 3 ‘ terminal nucleotide of antisense strand is unpaired with sense strand, and up to 6 consecutive 3’ terminal nucleotides are unpaired with sense strand, thereby forming a 3′ single stranded overhang of 1-6 nucleotides; wherein the 5′ terminus of antisense strand comprises from 10-30 consecutive nucleotides which are unpaired with sense strand, thereby forming a 10-30 nucleotide single stranded 5′ overhang; wherein at least the sense strand 5′ terminal and 3′ terminal nucleotides are base paired with nucleotides of antisense strand when sense and antisense strands are aligned for maximum complementarity, thereby forming a substantially duplexed region between sense and antisense strands; and antisense strand is sufficiently complementary to a target RNA along at least 19 ribonucleotides of antisense strand length to reduce target gene expression when the double stranded nucleic acid is introduced into a mammalian cell; and wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides, where at least one of the motifs occurs at or near the cleavage site. The antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at or near the cleavage site.

In certain embodiments, the dsRNAi agent comprises sense and antisense strands, wherein the dsRNAi agent comprises a first strand having a length which is at least 25 and at most 29 nucleotides and a second strand having a length which is at most 30 nucleotides with at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at position 11, 12, 13 from the 5′ end; wherein the 3′ end of the first strand and the 5′ end of the second strand form a blunt end and the second strand is 1˜4 nucleotides longer at its 3′ end than the first strand, wherein the duplex region which is at least 25 nucleotides in length, and the second strand is sufficiently complementary to a target mRNA along at least 19 nucleotide of the second strand length to reduce target gene expression when the RNAi agent is introduced into a mammalian cell, and wherein Dicer cleavage of the dsRNAi agent results in an siRNA comprising the 3′-end of the second strand, thereby reducing expression of the target gene in the mammal. Optionally, the dsRNAi agent further comprises a ligand.

In certain embodiments, the sense strand of the dsRNAi agent contains at least one motif of three identical modifications on three consecutive nucleotides, where one of the motifs occurs at the cleavage site in the sense strand.

In certain embodiments, the antisense strand of the dsRNAi agent can also contain at least one motif of three identical modifications on three consecutive nucleotides, where one of the motifs occurs at or near the cleavage site in the antisense strand.

For a dsRNAi agent having a duplex region of 19-23 nucleotides in length, the cleavage site of the antisense strand is typically around the 10, 11, and 12 positions from the 5′-end. Thus the motifs of three identical modifications may occur at the 9, 10, 11 positions; the 10, 11, 12 positions; the 11, 12, 13 positions; the 12, 13, 14 positions; or the 13, 14, 15 positions of the antisense strand, the count starting from the first nucleotide from the 5′-end of the antisense strand, or, the count starting from the first paired nucleotide within the duplex region from the 5′-end of the antisense strand. The cleavage site in the antisense strand may also change according to the length of the duplex region of the dsRNAi agent from the 5′-end.

The sense strand of the dsRNAi agent may contain at least one motif of three identical modifications on three consecutive nucleotides at the cleavage site of the strand; and the antisense strand may have at least one motif of three identical modifications on three consecutive nucleotides at or near the cleavage site of the strand. When the sense strand and the antisense strand form a dsRNA duplex, the sense strand and the antisense strand can be so aligned that one motif of the three nucleotides on the sense strand and one motif of the three nucleotides on the antisense strand have at least one nucleotide overlap, i.e., at least one of the three nucleotides of the motif in the sense strand forms a base pair with at least one of the three nucleotides of the motif in the antisense strand. Alternatively, at least two nucleotides may overlap, or all three nucleotides may overlap.

In some embodiments, the sense strand of the dsRNAi agent may contain more than one motif of three identical modifications on three consecutive nucleotides. The first motif may occur at or near the cleavage site of the strand and the other motifs may be a wing modification. The term “wing modification” herein refers to a motif occurring at another portion of the strand that is separated from the motif at or near the cleavage site of the same strand. The wing modification is either adjacent to the first motif or is separated by at least one or more nucleotides. When the motifs are immediately adjacent to each other then the chemistries of the motifs are distinct from each other, and when the motifs are separated by one or more nucleotide than the chemistries can be the same or different. Two or more wing modifications may be present. For instance, when two wing modifications are present, each wing modification may occur at one end relative to the first motif which is at or near cleavage site or on either side of the lead motif.

Like the sense strand, the antisense strand of the dsRNAi agent may contain more than one motif of three identical modifications on three consecutive nucleotides, with at least one of the motifs occurring at or near the cleavage site of the strand. This antisense strand may also contain one or more wing modifications in an alignment similar to the wing modifications that may be present on the sense strand.

In some embodiments, the wing modification on the sense strand or antisense strand of the dsRNAi agent typically does not include the first one or two terminal nucleotides at the 3′-end, 5′-end, or both ends of the strand.

In other embodiments, the wing modification on the sense strand or antisense strand of the dsRNAi agent typically does not include the first one or two paired nucleotides within the duplex region at the 3′-end, 5′-end, or both ends of the strand.

When the sense strand and the antisense strand of the dsRNAi agent each contain at least one wing modification, the wing modifications may fall on the same end of the duplex region, and have an overlap of one, two, or three nucleotides.

When the sense strand and the antisense strand of the dsRNAi agent each contain at least two wing modifications, the sense strand and the antisense strand can be so aligned that two modifications each from one strand fall on one end of the duplex region, having an overlap of one, two, or three nucleotides; two modifications each from one strand fall on the other end of the duplex region, having an overlap of one, two or three nucleotides; two modifications one strand fall on each side of the lead motif, having an overlap of one, two or three nucleotides in the duplex region.

In some embodiments, every nucleotide in the sense strand and antisense strand of the dsRNAi agent, including the nucleotides that are part of the motifs, may be modified. Each nucleotide may be modified with the same or different modification which can include one or more alteration of one or both of the non-linking phosphate oxygens or of one or more of the linking phosphate oxygens; alteration of a constituent of the ribose sugar, e.g., of the 2′-hydroxyl on the ribose sugar; wholesale replacement of the phosphate moiety with “diphospho” linkers; modification or replacement of a naturally occurring base; and replacement or modification of the ribose-phosphate backbone.

As nucleic acids are polymers of subunits, many of the modifications occur at a position which is repeated within a nucleic acid, e.g., a modification of a base, or a phosphate moiety, or a non-linking O of a phosphate moiety. In some cases the modification will occur at all of the subject positions in the nucleic acid but in many cases it will not. By way of example, a modification may only occur at a 3′- or 5′ terminal position, may only occur in a terminal region, e.g., at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand. A modification may occur in a double strand region, a single strand region, or in both. A modification may occur only in the double strand region of an RNA or may only occur in a single strand region of a RNA. For example, a phosphorothioate modification at a non-linking O position may only occur at one or both termini, may only occur in a terminal region, e.g., at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand, or may occur in double strand and single strand regions, particularly at termini. The 5′-end or ends can be phosphorylated.

It may be possible, e.g., to enhance stability, to include particular bases in overhangs, or to include modified nucleotides or nucleotide surrogates, in single strand overhangs, e.g., in a 5′- or 3′-overhang, or in both. For example, it can be desirable to include purine nucleotides in overhangs. In some embodiments all or some of the bases in a 3′- or 5′-overhang may be modified, e.g., with a modification described herein. Modifications can include, e.g., the use of modifications at the 2′ position of the ribose sugar with modifications that are known in the art, e.g., the use of deoxyribonucleotides, 2′-deoxy-2′-fluoro (2′-F) or 2′-O-methyl modified instead of the ribosugar of the nucleobase, and modifications in the phosphate group, e.g., phosphorothioate modifications. Overhangs need not be homologous with the target sequence.

In some embodiments, each residue of the sense strand and antisense strand is independently modified with LNA, CRN, cET, UNA, HNA, CeNA, 2′-methoxyethyl, 2′-O-methyl, 2′-O-allyl, 2′-C-allyl, 2′-deoxy, 2′-hydroxyl, or 2′-fluoro. The strands can contain more than one modification. In one embodiment, each residue of the sense strand and antisense strand is independently modified with 2′-O-methyl or 2′-fluoro.

At least two different modifications are typically present on the sense strand and antisense strand. Those two modifications may be the 2′-O-methyl or 2′-fluoro modifications, or others.

In certain embodiments, the N_aor N_bcomprise modifications of an alternating pattern. The term “alternating motif” as used herein refers to a motif having one or more modifications, each modification occurring on alternating nucleotides of one strand. The alternating nucleotide may refer to one per every other nucleotide or one per every three nucleotides, or a similar pattern. For example, if A, B and C each represent one type of modification to the nucleotide, the alternating motif can be “ABABABABABAB . . . ,” “AABBAABBAABB . . . ,” “AABAABAABAAB . . . ,” “AAABAAABAAAB . . . ,” “AAABBBAAABBB . . . ,” or “ABCABCABCABC . . . ,” etc.

The type of modifications contained in the alternating motif may be the same or different. For example, if A, B, C, D each represent one type of modification on the nucleotide, the alternating pattern, i.e., modifications on every other nucleotide, may be the same, but each of the sense strand or antisense strand can be selected from several possibilities of modifications within the alternating motif such as “ABABAB . . . ”, “ACACAC . . . ” “BDBDBD . . . ” or “CDCDCD . . . ,” etc.

In some embodiments, the dsRNAi agent of the invention comprises the modification pattern for the alternating motif on the sense strand relative to the modification pattern for the alternating motif on the antisense strand is shifted. The shift may be such that the modified group of nucleotides of the sense strand corresponds to a differently modified group of nucleotides of the antisense strand and vice versa. For example, the sense strand when paired with the antisense strand in the dsRNA duplex, the alternating motif in the sense strand may start with “ABABAB” from 5′ to 3′ of the strand and the alternating motif in the antisense strand may start with “BABABA” from 5′ to 3′ of the strand within the duplex region. As another example, the alternating motif in the sense strand may start with “AABBAABB” from 5′ to 3′ of the strand and the alternating motif in the antisense strand may start with “BBAABBAA” from 5′ to 3′ of the strand within the duplex region, so that there is a complete or partial shift of the modification patterns between the sense strand and the antisense strand.

In one particular example, the alternating motif in the sense strand is “ABABAB” from 5′ 3′ of the strand, where each A is an unmodified ribonucleotide and each B is a 2′-Omethyl modified nucleotide.

In one particular example, the alternating motif in the sense strand is “ABABAB” from 5′ 3′ of the strand, where each A is an 2′-deoxy-2′-fluoro modified nucleotide and each B is a 2′-Omethyl modified nucleotide.

In another particular example, the alternating motif in the antisense strand is “BABABA” from 3′-5′ of the strand, where each A is a 2′-deoxy-2′-fluoro modified nucleotide and each B is a 2′-Omethyl modified nucleotide.

In one particular example, the alternating motif in the sense strand is “ABABAB” from 5′ 3′ of the strand and the alternating motif in the antisense strand is “BABABA” from 3′-5′ of the strand, where each A is an unmodified ribonucleotide and each B is a 2′-Omethyl modified nucleotide.

In one particular example, the alternating motif in the sense strand is “ABABAB” from 5′ 3′ of the strand and the alternating motif in the antisense strand is “BABABA” from 3′-5′ of the strand, where each A is a 2′-deoxy-2′-fluoro modified nucleotide and each B is a 2′-Omethyl modified nucleotide.

In some embodiments, the dsRNAi agent comprises the pattern of the alternating motif of 2′-O-methyl modification and 2′-F modification on the sense strand initially has a shift relative to the pattern of the alternating motif of 2′-O-methyl modification and 2′-F modification on the antisense strand initially, i.e., the 2′-O-methyl modified nucleotide on the sense strand base pairs with a 2′-F modified nucleotide on the antisense strand and vice versa. The 1 position of the sense strand may start with the 2′-F modification, and the 1 position of the antisense strand may start with the 2′-O-methyl modification.

The introduction of one or more motifs of three identical modifications on three consecutive nucleotides to the sense strand or antisense strand interrupts the initial modification pattern present in the sense strand or antisense strand. This interruption of the modification pattern of the sense or antisense strand by introducing one or more motifs of three identical modifications on three consecutive nucleotides to the sense or antisense strand may enhance the gene silencing activity against the target gene.

In some embodiments, when the motif of three identical modifications on three consecutive nucleotides is introduced to any of the strands, the modification of the nucleotide next to the motif is a different modification than the modification of the motif. For example, the portion of the sequence containing the motif is “ . . . N_aYYYN_b. . . ,” where “Y” represents the modification of the motif of three identical modifications on three consecutive nucleotide, and “N_a” and “N_b” represent a modification to the nucleotide next to the motif “YYY” that is different than the modification of Y, and where N_aand N_bcan be the same or different modifications. Alternatively, N_aor N_bmay be present or absent when there is a wing modification present.

The iRNA may further comprise at least one phosphorothioate or methylphosphonate internucleotide linkage. The phosphorothioate or methylphosphonate internucleotide linkage modification may occur on any nucleotide of the sense strand, antisense strand, or both strands in any position of the strand. For instance, the internucleotide linkage modification may occur on every nucleotide on the sense strand or antisense strand; each internucleotide linkage modification may occur in an alternating pattern on the sense strand or antisense strand; or the sense strand or antisense strand may contain both internucleotide linkage modifications in an alternating pattern. The alternating pattern of the internucleotide linkage modification on the sense strand may be the same or different from the antisense strand, and the alternating pattern of the internucleotide linkage modification on the sense strand may have a shift relative to the alternating pattern of the internucleotide linkage modification on the antisense strand. In one embodiment, a double-stranded RNAi agent comprises 6-8 phosphorothioate internucleotide linkages. In some embodiments, the antisense strand comprises two phosphorothioate internucleotide linkages at the 5′-end and two phosphorothioate internucleotide linkages at the 3′-end, and the sense strand comprises at least two phosphorothioate internucleotide linkages at either the 5′-end or the 3′-end.

In some embodiments, the dsRNAi agent comprises a phosphorothioate or methylphosphonate internucleotide linkage modification in the overhang region. For example, the overhang region may contain two nucleotides having a phosphorothioate or methylphosphonate internucleotide linkage between the two nucleotides. Internucleotide linkage modifications also may be made to link the overhang nucleotides with the terminal paired nucleotides within the duplex region. For example, at least 2, 3, 4, or all the overhang nucleotides may be linked through phosphorothioate or methylphosphonate internucleotide linkage, and optionally, there may be additional phosphorothioate or methylphosphonate internucleotide linkages linking the overhang nucleotide with a paired nucleotide that is next to the overhang nucleotide. For instance, there may be at least two phosphorothioate internucleotide linkages between the terminal three nucleotides, in which two of the three nucleotides are overhang nucleotides, and the third is a paired nucleotide next to the overhang nucleotide. These terminal three nucleotides may be at the 3′-end of the antisense strand, the 3′-end of the sense strand, the 5′-end of the antisense strand, or the 5′ end of the antisense strand.

In some embodiments, the 2-nucleotide overhang is at the 3′-end of the antisense strand, and there are two phosphorothioate internucleotide linkages between the terminal three nucleotides, wherein two of the three nucleotides are the overhang nucleotides, and the third nucleotide is a paired nucleotide next to the overhang nucleotide. Optionally, the dsRNAi agent may additionally have two phosphorothioate internucleotide linkages between the terminal three nucleotides at both the 5′-end of the sense strand and at the 5′-end of the antisense strand.

In one embodiment, the dsRNAi agent comprises mismatch(es) with the target, within the duplex, or combinations thereof. The mismatch may occur in the overhang region or the duplex region. The base pair may be ranked on the basis of their propensity to promote dissociation or melting (e.g., on the free energy of association or dissociation of a particular pairing, the simplest approach is to examine the pairs on an individual pair basis, though next neighbor or similar analysis can also be used). In terms of promoting dissociation: A:U is preferred over G:C; G:U is preferred over G:C; and I:C is preferred over G:C (I=inosine). Mismatches, e.g., non-canonical or other than canonical pairings (as described elsewhere herein) are preferred over canonical (A:T, A:U, G:C) pairings; and pairings which include a universal base are preferred over canonical pairings.

In certain embodiments, the dsRNAi agent comprises at least one of the first 1, 2, 3, 4, or 5 base pairs within the duplex regions from the 5′-end of the antisense strand independently selected from the group of: A:U, G:U, I:C, and mismatched pairs, e.g., non-canonical or other than canonical pairings or pairings which include a universal base, to promote the dissociation of the antisense strand at the 5′-end of the duplex.

In certain embodiments, the nucleotide at the 1 position within the duplex region from the 5′-end in the antisense strand is selected from A, dA, dU, U, and dT. Alternatively, at least one of the first 1, 2, or 3 base pair within the duplex region from the 5′-end of the antisense strand is an AU base pair. For example, the first base pair within the duplex region from the 5′-end of the antisense strand is an AU base pair.

In other embodiments, the nucleotide at the 3′-end of the sense strand is deoxythymidine (dT) or the nucleotide at the 3′-end of the antisense strand is deoxythymidine (dT). For example, there is a short sequence of deoxythymidine nucleotides, for example, two dT nucleotides on the 3′-end of the sense, antisense strand, or both strands.

In certain embodiments, the sense strand sequence may be represented by formula (I):

5′n_p-N_a-(XXX)_i—N_b-YYY-N_b-(ZZZ)_j-N_a-n_q3′ (I)

wherein:

i and j are each independently 0 or 1;

p and q are each independently 0-6;

each N_aindependently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;

each N_bindependently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;

each n_pand n_qindependently represent an overhang nucleotide;

wherein Nb and Y do not have the same modification; and

XXX, YYY, and ZZZ each independently represent one motif of three identical modifications on three consecutive nucleotides. In one embodiment, YYY is all 2′-F modified nucleotides.

In some embodiments, the N_aor N_bcomprises modifications of alternating pattern.

In some embodiments, the YYY motif occurs at or near the cleavage site of the sense strand. For example, when the dsRNAi agent has a duplex region of 17-23 nucleotides in length, the YYY motif can occur at or the vicinity of the cleavage site (e.g.: can occur at positions 6, 7, 8; 7, 8, 9; 8, 9, 10; 9, 10, 11; 10, 11, 12; or 11, 12, 13) of the sense strand, the count starting from the first nucleotide, from the 5′-end; or optionally, the count starting at the first paired nucleotide within the duplex region, from the 5′-end.

In one embodiment, i is 1 and j is 0, or i is 0 and j is 1, or both i and j are 1. The sense strand can therefore be represented by the following formulas:

5′n_p-N_a-YYY-N_b-ZZZ-N_a-n_q3′ (Ib);
5′n_p-N_a-XXX-N_b-YYY-N_a-n_q3′ (Ic); or
5′n_p-N_a-XXX-N_b-YYY-N_b-ZZZ-N_a-n_q3′ (Id).

When the sense strand is represented by formula (Ib), N_brepresents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N_aindependently can represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the sense strand is represented as formula (Ic), N_brepresents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N_acan independently represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the sense strand is represented as formula (Id), each N_bindependently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. In one embodiment, N_bis 0, 1, 2, 3, 4, 5, or 6 Each N_acan independently represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

Each of X, Y and Z may be the same or different from each other.

In other embodiments, i is 0 and j is 0, and the sense strand may be represented by the formula:

5′n_p-N_a-YYY-N_a-n_q3′ (Ia).

When the sense strand is represented by formula (Ia), each N_aindependently can represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

In one embodiment, the antisense strand sequence of the RNAi may be represented by formula (II):

5′n_q′-N_a′-(Z′Z′Z′)_k-N_b′-Y′Y′Y′-N_b′-(X′X′X′)_l-N′_a-n_p′3′ (II)

wherein:

k and l are each independently 0 or 1;

p′ and q′ are each independently 0-6;

each N_a′ independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;

each N_b′ independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;

each n_p′ and n_q′ independently represent an overhang nucleotide;

wherein N_b′ and Y′ do not have the same modification; and

X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides.

In some embodiments, the N_a′ or N_b′ comprises modifications of alternating pattern.

The Y′Y′Y′ motif occurs at or near the cleavage site of the antisense strand. For example, when the dsRNAi agent has a duplex region of 17-23 nucleotides in length, the Y′Y′Y′ motif can occur at positions 9, 10, 11; 10, 11, 12; 11, 12, 13; 12, 13, 14; or 13, 14, 15 of the antisense strand, with the count starting from the first nucleotide, from the 5′-end; or optionally, the count starting at the first paired nucleotide within the duplex region, from the 5′-end. In one embodiment, the Y′Y′Y′ motif occurs at positions 11, 12, 13.

In certain embodiments, Y′Y′Y′ motif is all 2′-OMe modified nucleotides.

In certain embodiments, k is 1 and l is 0, or k is 0 and l is 1, or both k and l are 1.

The antisense strand can therefore be represented by the following formulas:

5′n_q′-N_a′-Z′Z′Z′-N_b′-Y′Y′Y′-N_a′-n_p′3′ (IIb);
5′n_q′-N_a′-Y′Y′Y′-N_b′-X′X′X′-n_p′3′ (IIc); or
5′n_q′-N_a′-Z′Z′Z′-N_b′-Y′Y′Y′-N_b′-X′X′X′-N_a′-n_p′3′ (IId).

When the antisense strand is represented by formula (IIb), N_b′ represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N_a′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the antisense strand is represented as formula (IIC), N_b′ represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N_a′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the antisense strand is represented as formula (IId), each N_b′ independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N_a′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. In one embodiment, N_bis 0, 1, 2, 3, 4, 5, or 6.

In other embodiments, k is 0 and l is 0 and the antisense strand may be represented by the formula:

5′n_p′-N_a′-Y′Y′Y′-N_a′-n_q′3′ (Ia).

When the antisense strand is represented as formula (IIa), each N_a′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. Each of X′, Y′ and Z′ may be the same or different from each other.

Each nucleotide of the sense strand and antisense strand may be independently modified with LNA, CRN, UNA, cEt, HNA, CeNA, 2′-methoxyethyl, 2′-O-methyl, 2′-O-allyl, 2′-C-allyl, 2′-hydroxyl, or 2′-fluoro. For example, each nucleotide of the sense strand and antisense strand is independently modified with 2′-O-methyl or 2′-fluoro. Each X, Y, Z, X′, Y′, and Z′, in particular, may represent a 2′-O-methyl modification or a 2′-fluoro modification.

In some embodiments, the sense strand of the dsRNAi agent may contain YYY motif occurring at 9, 10, and 11 positions of the strand when the duplex region is 21 nt, the count starting from the first nucleotide from the 5′-end, or optionally, the count starting at the first paired nucleotide within the duplex region, from the 5′-end; and Y represents 2′-F modification. The sense strand may additionally contain XXX motif or ZZZ motifs as wing modifications at the opposite end of the duplex region; and XXX and ZZZ each independently represents a 2′-OMe modification or 2′-F modification.

In some embodiments the antisense strand may contain Y′Y′Y′ motif occurring at positions 11, 12, 13 of the strand, the count starting from the first nucleotide from the 5′-end, or optionally, the count starting at the first paired nucleotide within the duplex region, from the 5′-end; and Y′ represents 2′-O-methyl modification. The antisense strand may additionally contain X′X′X′ motif or Z′Z′Z′ motifs as wing modifications at the opposite end of the duplex region; and X′X′X′ and Z′Z′Z′ each independently represents a 2′-OMe modification or 2′-F modification.

The sense strand represented by any one of the above formulas (Ia), (Ib), (Ic), and (Id) forms a duplex with an antisense strand being represented by any one of formulas (IIa), (IIb), (IIc), and (IId), respectively.

Accordingly, the dsRNAi agents for use in the methods of the invention may comprise a sense strand and an antisense strand, each strand having 14 to 30 nucleotides, the iRNA duplex represented by formula (III):

sense: 5′n_p-N_a-(XXX)_i-N_b-YYY-N_b-(ZZZ)_j-N_a-n_q3′
antisense: 3′n_p′-N_a′-(X′X′X′)_k-N_b′-Y′Y′Y′-N_b′-(Z′Z′Z′)_l-N_a′-n_q′5′ (III)

wherein:

j, k, and l are each independently 0 or 1;

p, p′, q, and q′ are each independently 0-6;

each N_aand N_a′ independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;

each N_band N_b′ independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;

wherein each n_p′, n_p, n_q′, and n_q, each of which may or may not be present, independently represents an overhang nucleotide; and

XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides.

In one embodiment, i is 0 and j is 0; or i is 1 and j is 0; or i is 0 and j is 1; or both i and j are 0; or both i and j are 1. In another embodiment, k is 0 and l is 0; or k is 1 and l is 0; k is 0 and l is 1; or both k and l are 0; or both k and l are 1.

Exemplary combinations of the sense strand and antisense strand forming an iRNA duplex include the formulas below:

5′n_p-N_a-YYY-N_a-n_q3′
3′n_p′-N_a′-Y′Y′Y′-N_a′n_q′5′ (IIIa)
5′n_p-N_a-YYY-N_b-ZZZ-N_a-n_q3′
3′n_p′-N_a′-Y′Y′Y′-N_b′-Z′Z′Z′-N_a′n_q′5′ (IIIb)
5′n_p-N_a-XXX-N_b-YYY-N_a-n_q3′
3′n_p′-N_a′-X′X′X′-N_b′-Y′Y′Y′-N_a′-n_q′5′ (IIIc)
5′n_p-N_a-XXX-N_b-YYY-N_b-ZZZ-N_a-n_q3′
3′n_p′-N_a′-X′X′X′-N_b′-Y′Y′Y′-N_b′-Z′Z′Z′-N_a-n_q′5′ (IIId)

When the dsRNAi agent is represented by formula (IIIa), each N_aindependently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the dsRNAi agent is represented by formula (IIIb), each N_bindependently represents an oligonucleotide sequence comprising 1-10, 1-7, 1-5, or 1-4 modified nucleotides. Each N_aindependently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the dsRNAi agent is represented as formula (IIIc), each N_b, N_b′ independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N_aindependently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the dsRNAi agent is represented as formula (IIId), each N_b, N_b′ independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2, or 0 modified nucleotides. Each N_a, N_a′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. Each of N_a, N_a′, N_b, and N_b′ independently comprises modifications of alternating pattern.

Each of X, Y, and Z in formulas (III), (IIIa), (IIIb), (IIIc), and (IIId) may be the same or different from each other.

When the dsRNAi agent is represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), at least one of the Y nucleotides may form a base pair with one of the Y′ nucleotides. Alternatively, at least two of the Y nucleotides form base pairs with the corresponding Y′ nucleotides; or all three of the Y nucleotides all form base pairs with the corresponding Y′ nucleotides.

When the dsRNAi agent is represented by formula (IIIb) or (IIId), at least one of the Z nucleotides may form a base pair with one of the Z′ nucleotides. Alternatively, at least two of the Z nucleotides form base pairs with the corresponding Z′ nucleotides; or all three of the Z nucleotides all form base pairs with the corresponding Z′ nucleotides.

When the dsRNAi agent is represented as formula (IIIc) or (IIId), at least one of the X nucleotides may form a base pair with one of the X′ nucleotides. Alternatively, at least two of the X nucleotides form base pairs with the corresponding X′ nucleotides; or all three of the X nucleotides all form base pairs with the corresponding X′ nucleotides.

In certain embodiments, the modification on the Y nucleotide is different than the modification on the Y′ nucleotide, the modification on the Z nucleotide is different than the modification on the Z′ nucleotide, or the modification on the X nucleotide is different than the modification on the X′ nucleotide.

In certain embodiments, when the dsRNAi agent is represented by formula (IIId), the N_amodifications are 2′-O-methyl or 2′-fluoro modifications. In other embodiments, when the RNAi agent is represented by formula (IIId), the N_amodifications are 2′-O-methyl or 2′-fluoro modifications and n_p′>0 and at least one n_p′ is linked to a neighboring nucleotide a via phosphorothioate linkage. In yet other embodiments, when the RNAi agent is represented by formula (IIId), the N_amodifications are 2′-O-methyl or 2′-fluoro modifications, n_p′>0 and at least one n_p′ is linked to a neighboring nucleotide via phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker (described below). In other embodiments, when the RNAi agent is represented by formula (IIId), the N_amodifications are 2′-O-methyl or 2′-fluoro modifications, n_p′>0 and at least one n_p′ is linked to a neighboring nucleotide via phosphorothioate linkage, the sense strand comprises at least one phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.

In some embodiments, when the dsRNAi agent is represented by formula (IIIa), the N_amodifications are 2′-O-methyl or 2′-fluoro modifications, n_p′>0 and at least one n_p′ is linked to a neighboring nucleotide via phosphorothioate linkage, the sense strand comprises at least one phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.

In some embodiments, the dsRNAi agent is a multimer containing at least two duplexes represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the multimer further comprises a ligand. Each of the duplexes can target the same gene or two different genes; or each of the duplexes can target same gene at two different target sites.

In some embodiments, the dsRNAi agent is a multimer containing three, four, five, six, or more duplexes represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the multimer further comprises a ligand. Each of the duplexes can target the same gene or two different genes; or each of the duplexes can target same gene at two different target sites.

In one embodiment, two dsRNAi agents represented by at least one of formulas (III), (IIIa), (IIIb), (IIIc), and (IIId) are linked to each other at the 5′ end, and one or both of the 3′ ends, and are optionally conjugated to a ligand. Each of the agents can target the same gene or two different genes; or each of the agents can target same gene at two different target sites.

In certain embodiments, an RNAi agent of the invention may contain a low number of nucleotides containing a 2′-fluoro modification, e.g., 10 or fewer nucleotides with 2′-fluoro modification. For example, the RNAi agent may contain 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 nucleotides with a 2′-fluoro modification. In a specific embodiment, the RNAi agent of the invention contains 10 nucleotides with a 2′-fluoro modification, e.g., 4 nucleotides with a 2′-fluoro modification in the sense strand and 6 nucleotides with a 2′-fluoro modification in the antisense strand. In another specific embodiment, the RNAi agent of the invention contains 6 nucleotides with a 2′-fluoro modification, e.g., 4 nucleotides with a 2′-fluoro modification in the sense strand and 2 nucleotides with a 2′-fluoro modification in the antisense strand.

In other embodiments, an RNAi agent of the invention may contain an ultra low number of nucleotides containing a 2′-fluoro modification, e.g., 2 or fewer nucleotides containing a 2′-fluoro modification. For example, the RNAi agent may contain 2, 1 of 0 nucleotides with a 2′-fluoro modification. In a specific embodiment, the RNAi agent may contain 2 nucleotides with a 2′-fluoro modification, e.g., 0 nucleotides with a 2-fluoro modification in the sense strand and 2 nucleotides with a 2′-fluoro modification in the antisense strand.

Various publications describe multimeric iRNAs that can be used in the methods of the invention. Such publications include WO2007/091269, U.S. Pat. No. 7,858,769, WO2010/141511, WO2007/117686, WO2009/014887, and WO2011/031520 the entire contents of each of which are hereby incorporated herein by reference.

In certain embodiments, the compositions and methods of the disclosure include a vinyl phosphonate (VP) modification of an RNAi agent as described herein. In exemplary embodiments, a 5′ vinyl phosphonate modified nucleotide of the disclosure has the structure:

embedded image

wherein X is O or S;

R is hydrogen, hydroxy, fluoro, or C_1-20alkoxy (e.g., methoxy or n-hexadecyloxy);

R^5′ is ═C(H)—P(O)(OH)₂and the double bond between the C5′ carbon and R^5′ is in the E or Z orientation (e.g., E orientation); and

B is a nucleobase or a modified nucleobase, optionally where B is adenine, guanine, cytosine, thymine, or uracil.

A vinyl phosphonate of the instant disclosure may be attached to either the antisense or the sense strand of a dsRNA of the disclosure. In certain embodiments, a vinyl phosphonate of the instant disclosure is attached to the antisense strand of a dsRNA, optionally at the 5′ end of the antisense strand of the dsRNA.

Vinyl phosphate modifications are also contemplated for the compositions and methods of the instant disclosure. An exemplary vinyl phosphate structure includes the preceding structure, where R5′ is ═C(H)—OP(O)(OH)2 and the double bond between the C5′ carbon and R5′ is in the E or Z orientation (e.g., E orientation).

As described in more detail below, the iRNA that contains conjugations of one or more carbohydrate moieties to an iRNA can optimize one or more properties of the iRNA. In many cases, the carbohydrate moiety will be attached to a modified subunit of the iRNA. For example, the ribose sugar of one or more ribonucleotide subunits of a iRNA can be replaced with another moiety, e.g., a non-carbohydrate (such as, cyclic) carrier to which is attached a carbohydrate ligand. A ribonucleotide subunit in which the ribose sugar of the subunit has been so replaced is referred to herein as a ribose replacement modification subunit (RRMS). A cyclic carrier may be a carbocyclic ring system, i.e., all ring atoms are carbon atoms, or a heterocyclic ring system, i.e., one or more ring atoms may be a heteroatom, e.g., nitrogen, oxygen, sulfur. The cyclic carrier may be a monocyclic ring system, or may contain two or more rings, e.g. fused rings. The cyclic carrier may be a fully saturated ring system, or it may contain one or more double bonds.

The ligand may be attached to the polynucleotide via a carrier. The carriers include (i) at least one “backbone attachment point,” such as, two “backbone attachment points” and (ii) at least one “tethering attachment point.” A “backbone attachment point” as used herein refers to a functional group, e.g. a hydroxyl group, or generally, a bond available for, and that is suitable for incorporation of the carrier into the backbone, e.g., the phosphate, or modified phosphate, e.g., sulfur containing, backbone, of a ribonucleic acid. A “tethering attachment point” (TAP) in some embodiments refers to a constituent ring atom of the cyclic carrier, e.g., a carbon atom or a heteroatom (distinct from an atom which provides a backbone attachment point), that connects a selected moiety. The moiety can be, e.g., a carbohydrate, e.g. monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide. Optionally, the selected moiety is connected by an intervening tether to the cyclic carrier. Thus, the cyclic carrier will often include a functional group, e.g., an amino group, or generally, provide a bond, that is suitable for incorporation or tethering of another chemical entity, e.g., a ligand to the constituent ring.

The iRNA may be conjugated to a ligand via a carrier, wherein the carrier can be cyclic group or acyclic group. In one embodiment, the cyclic group is selected from pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolane, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuryl, and decalin. In one embodiment, the acyclic group is a serinol backbone or diethanolamine backbone.

i. Thermally Destabilizing Modifications

In certain embodiments, a dsRNA molecule can be optimized for RNA interference by incorporating thermally destabilizing modifications in the seed region of the antisense strand. As used herein “seed region” means at positions 2-9 of the 5′-end of the referenced strand. For example, thermally destabilizing modifications can be incorporated in the seed region of the antisense strand to reduce or inhibit off-target gene silencing.

The term “thermally destabilizing modification(s)” includes modification(s) that would result with a dsRNA with a lower overall melting temperature (T_m) than the T_mof the dsRNA without having such modification(s). For example, the thermally destabilizing modification(s) can decrease the T_mof the dsRNA by 1-4° C., such as one, two, three or four degrees Celcius. And, the term “thermally destabilizing nucleotide” refers to a nucleotide containing one or more thermally destabilizing modifications.

It has been discovered that dsRNAs with an antisense strand comprising at least one thermally destabilizing modification of the duplex within the first 9 nucleotide positions, counting from the 5′ end, of the antisense strand have reduced off-target gene silencing activity. Accordingly, in some embodiments, the antisense strand comprises at least one (e.g., one, two, three, four, five or more) thermally destabilizing modification of the duplex within the first 9 nucleotide positions of the 5′ region of the antisense strand. In some embodiments, one or more thermally destabilizing modification(s) of the duplex is/are located in positions 2-9, such as, positions 4-8, from the 5′-end of the antisense strand. In some further embodiments, the thermally destabilizing modification(s) of the duplex is/are located at position 6, 7 or 8 from the 5′-end of the antisense strand. In still some further embodiments, the thermally destabilizing modification of the duplex is located at position 7 from the 5′-end of the antisense strand. In some embodiments, the thermally destabilizing modification of the duplex is located at position 2, 3, 4, 5 or 9 from the 5′-end of the antisense strand.

An iRNA agent comprises a sense strand and an antisense strand, each strand having 14 to 40 nucleotides. The RNAi agent may be represented by formula (L):

embedded image

In formula (L), B1, B2, B3, B1′, B2′, B3′, and B4′ each are independently a nucleotide containing a modification selected from the group consisting of 2′-O-alkyl, 2′-substituted alkoxy, 2′-substituted alkyl, 2′-halo, ENA, and BNA/LNA. In one embodiment, B1, B2, B3, B1′, B2′, B3′, and B4′ each contain 2′-OMe modifications. In one embodiment, B1, B2, B3, B1′, B2′, B3′, and B4′ each contain 2′-OMe or 2′-F modifications. In one embodiment, at least one of B1, B2, B3, B1′, B2′, B3′, and B4′ contain 2′-O—N-methylacetamido (2′-O-NMA, 2′O—CH2C(O)N(Me)H) modification.

C1 is a thermally destabilizing nucleotide placed at a site opposite to the seed region of the antisense strand (i.e., at positions 2-8 of the 5′-end of the antisense strand). For example, C1 is at a position of the sense strand that pairs with a nucleotide at positions 2-8 of the 5′-end of the antisense strand. In one example, C1 is at position 15 from the 5′-end of the sense strand. C1 nucleotide bears the thermally destabilizing modification which can include abasic modification; mismatch with the opposing nucleotide in the duplex; and sugar modification such as 2′-deoxy modification or acyclic nucleotide e.g., unlocked nucleic acids (UNA) or glycerol nucleic acid (GNA) or 2′-5′-linked ribonucleotides (“3′-RNA”). In one embodiment, C1 has thermally destabilizing modification selected from the group consisting of: i) mismatch with the opposing nucleotide in the antisense strand; ii) abasic modification selected from the group consisting of:

embedded image

iii) sugar modification selected from the group consisting of:

embedded image

wherein B is a modified or unmodified nucleobase, R¹and R²independently are H, halogen, OR₃, or alkyl; and R₃is H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar. In one embodiment, the thermally destabilizing modification in C1 is a mismatch selected from the group consisting of G:G, G:A, G:U, G:T, A:A, A:C, C:C, C:U, C:T, U:U, T:T, and U:T; and optionally, at least one nucleobase in the mismatch pair is a 2′-deoxy nucleobase. In one example, the thermally destabilizing modification in C1 is GNA or

embedded image

T1, T1′, T2′, and T3′ each independently represent a nucleotide comprising a modification providing the nucleotide a steric bulk that is less or equal to the steric bulk of a 2′-OMe modification. A steric bulk refers to the sum of steric effects of a modification. Methods for determining steric effects of a modification of a nucleotide are known to one skilled in the art. The modification can be at the 2′ position of a ribose sugar of the nucleotide, or a modification to a non-ribose nucleotide, acyclic nucleotide, or the backbone of the nucleotide that is similar or equivalent to the 2′ position of the ribose sugar, and provides the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2′-OMe modification. For example, T1, T1′, T2′, and T3′ are each independently selected from DNA, RNA, LNA, 2′-F, and 2′-F-5′-methyl. In one embodiment, T1 is DNA. In one embodiment, T1′ is DNA, RNA or LNA. In one embodiment, T2′ is DNA or RNA. In one embodiment, T3′ is DNA or RNA.

n¹, n³, and q¹are independently 4 to 15 nucleotides in length.

n⁵, q³, and q⁷are independently 1-6 nucleotide(s) in length.

n⁴, q², and q⁶are independently 1-3 nucleotide(s) in length; alternatively, n⁴is 0.

q⁵is independently 0-10 nucleotide(s) in length.

n²and q⁴are independently 0-3 nucleotide(s) in length.

Alternatively, n⁴is 0-3 nucleotide(s) in length.

In one embodiment, n⁴can be 0. In one example, n⁴is 0, and q²and q⁶are 1. In another example, n⁴is 0, and q²and q⁶are 1, with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand).

In one embodiment, n⁴, q², and q⁶are each 1.

In one embodiment, n², n⁴, q², q⁴, and q⁶are each 1.

In one embodiment, C1 is at position 14-17 of the 5′-end of the sense strand, when the sense strand is 19-22 nucleotides in length, and n⁴is 1. In one embodiment, C1 is at position 15 of the 5′-end of the sense strand

In one embodiment, T3′ starts at position 2 from the 5′ end of the antisense strand. In one example, T3′ is at position 2 from the 5′ end of the antisense strand and q⁶is equal to 1.

In one embodiment, T1′ starts at position 14 from the 5′ end of the antisense strand. In one example, T1′ is at position 14 from the 5′ end of the antisense strand and q²is equal to 1.

In an exemplary embodiment, T3′ starts from position 2 from the 5′ end of the antisense strand and T1′ starts from position 14 from the 5′ end of the antisense strand. In one example, T3′ starts from position 2 from the 5′ end of the antisense strand and q⁶is equal to 1 and T1′ starts from position 14 from the 5′ end of the antisense strand and q²is equal to 1.

In one embodiment, T1′ and T3′ are separated by 11 nucleotides in length (i.e. not counting the T1′ and T3′ nucleotides).

In one embodiment, T1′ is at position 14 from the 5′ end of the antisense strand. In one example, T1′ is at position 14 from the 5′ end of the antisense strand and q²is equal to 1, and the modification at the 2′ position or positions in a non-ribose, acyclic or backbone that provide less steric bulk than a 2′-OMe ribose.

In one embodiment, T3′ is at position 2 from the 5′ end of the antisense strand. In one example, T3′ is at position 2 from the 5′ end of the antisense strand and q⁶is equal to 1, and the modification at the 2′ position or positions in a non-ribose, acyclic or backbone that provide less than or equal to steric bulk than a 2′-OMe ribose.

In one embodiment, T1 is at the cleavage site of the sense strand. In one example, T1 is at position 11 from the 5′ end of the sense strand, when the sense strand is 19-22 nucleotides in length, and n²is 1. In an exemplary embodiment, T1 is at the cleavage site of the sense strand at position 11 from the 5′ end of the sense strand, when the sense strand is 19-22 nucleotides in length, and n²is 1,

In one embodiment, T2′ starts at position 6 from the 5′ end of the antisense strand. In one example, T2′ is at positions 6-10 from the 5′ end of the antisense strand, and q⁴is 1.

In an exemplary embodiment, T1 is at the cleavage site of the sense strand, for instance, at position 11 from the 5′ end of the sense strand, when the sense strand is 19-22 nucleotides in length, and n²is 1; T1′ is at position 14 from the 5′ end of the antisense strand, and q²is equal to 1, and the modification to T1′ is at the 2′ position of a ribose sugar or at positions in a non-ribose, acyclic or backbone that provide less steric bulk than a 2′-OMe ribose; T2′ is at positions 6-10 from the 5′ end of the antisense strand, and q⁴is 1; and T3′ is at position 2 from the 5′ end of the antisense strand, and q⁶is equal to 1, and the modification to T3′ is at the 2′ position or at positions in a non-ribose, acyclic or backbone that provide less than or equal to steric bulk than a 2′-OMe ribose.

In one embodiment, T2′ starts at position 8 from the 5′ end of the antisense strand. In one example, T2′ starts at position 8 from the 5′ end of the antisense strand, and q⁴is 2.

In one embodiment, T2′ starts at position 9 from the 5′ end of the antisense strand. In one example, T2′ is at position 9 from the 5′ end of the antisense strand, and q⁴is 1.

In one embodiment, B1′ is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, T2′ is 2′-F, q⁴is 1, B3′ is 2′-OMe or 2′-F, q⁵is 6, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand).

In one embodiment, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, T2′ is 2′-F, q⁴is 1, B3′ is 2′-OMe or 2′-F, q⁵is 6, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand).

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, B1′ is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand).

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 6, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 7, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 6, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 7, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand).

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 1, B3′ is 2′-OMe or 2′-F, q⁵is 6, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 1, B3′ is 2′-OMe or 2′-F, q⁵is 6, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand).

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 5, T2′ is 2′-F, q⁴is 1, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; optionally with at least 2 additional TT at the 3′-end of the antisense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 5, T2′ is 2′-F, q⁴is 1, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; optionally with at least 2 additional TT at the 3′-end of the antisense strand; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand).

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand).

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within positions 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand).

The RNAi agent can comprise a phosphorus-containing group at the 5′-end of the sense strand or antisense strand. The 5′-end phosphorus-containing group can be 5′-end phosphate (5′-P), 5′-end phosphorothioate (5′-PS), 5′-end phosphorodithioate (5′-PS₂), 5′-end vinylphosphonate (5′-VP), 5′-end methylphosphonate (MePhos), or 5′-deoxy-5′-C-malonyl (

embedded image

When the 5′-end phosphorus-containing group is 5′-end vinylphosphonate (5′-VP), the 5′-VP can be either 5′-E-VP isomer (i.e., trans-vinylphosphate,

embedded image

5′-Z-VP isomer (i.e., cis-vinylphosphate

embedded image

or mixtures thereof.

In one embodiment, the RNAi agent comprises a phosphorus-containing group at the 5′-end of the sense strand. In one embodiment, the RNAi agent comprises a phosphorus-containing group at the 5′-end of the antisense strand.

In one embodiment, the RNAi agent comprises a 5′-P. In one embodiment, the RNAi agent comprises a 5′-P in the antisense strand.

In one embodiment, the RNAi agent comprises a 5′-PS. In one embodiment, the RNAi agent comprises a 5′-PS in the antisense strand.

In one embodiment, the RNAi agent comprises a 5′-VP. In one embodiment, the RNAi agent comprises a 5′-VP in the antisense strand. In one embodiment, the RNAi agent comprises a 5′-E-VP in the antisense strand. In one embodiment, the RNAi agent comprises a 5′-Z-VP in the antisense strand.

In one embodiment, the RNAi agent comprises a 5′-PS₂. In one embodiment, the RNAi agent comprises a 5′-PS₂in the antisense strand.

In one embodiment, the RNAi agent comprises a 5′-PS₂. In one embodiment, the RNAi agent comprises a 5′-deoxy-5′-C-malonyl in the antisense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1. The RNAi agent also comprises a 5′-PS.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-P.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-PS.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-VP. The 5′-VP may be 5′-E-VP, 5′-Z-VP, or combination thereof.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-PS₂.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-deoxy-5′-C-malonyl.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1. The RNAi agent also comprises a 5′-VP. The 5′-VP may be 5′-E-VP, 5′-Z-VP, or combination thereof.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end). The RNAi agent also comprises a 5′-P.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end). The RNAi agent also comprises a 5′-PS.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end). The RNAi agent also comprises a 5′-VP. The 5′-VP may be 5′-E-VP, 5′-Z-VP, or combination thereof.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end). The RNAi agent also comprises a 5′-PS₂.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end). The RNAi agent also comprises a 5′-deoxy-5′-C-malonyl.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1. The dsRNAi RNA agent also comprises a 5′-PS₂.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-P.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-PS.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-VP. The 5′-VP may be 5′-E-VP, 5′-Z-VP, or combination thereof.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-PS₂.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-deoxy-5′-C-malonyl.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1. The RNAi agent also comprises a 5′-VP. The 5′-VP may be 5′-E-VP, 5′-Z-VP, or combination thereof.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-P.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-PS.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-VP. The 5′-VP may be 5′-E-VP, 5′-Z-VP, or combination thereof.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-PS₂.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-deoxy-5′-C-malonyl.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-P and a targeting ligand. In one embodiment, the 5′-P is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-PS and a targeting ligand. In one embodiment, the 5′-PS is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, B1′ is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-VP (e.g., a 5′-E-VP, 5′-Z-VP, or combination thereof), and a targeting ligand.

In one embodiment, the 5′-VP is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, B1′ is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-PS₂and a targeting ligand. In one embodiment, the 5′-PS₂is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, B1′ is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-deoxy-5′-C-malonyl and a targeting ligand. In one embodiment, the 5′-deoxy-5′-C-malonyl is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, B1′ is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end). The RNAi agent also comprises a 5′-P and a targeting ligand. In one embodiment, the 5′-P is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, B1′ is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end). The RNAi agent also comprises a 5′-PS and a targeting ligand. In one embodiment, the 5′-PS is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, B1′ is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end). The RNAi agent also comprises a 5′-VP (e.g., a 5′-E-VP, 5′-Z-VP, or combination thereof) and a targeting ligand. In one embodiment, the 5′-VP is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, B1′ is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end). The RNAi agent also comprises a 5′-PS₂and a targeting ligand. In one embodiment, the 5′-PS₂is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, B1′ is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-OMe, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end). The RNAi agent also comprises a 5′-deoxy-5′-C-malonyl and a targeting ligand. In one embodiment, the 5′-deoxy-5′-C-malonyl is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-P and a targeting ligand. In one embodiment, the 5′-P is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-PS and a targeting ligand. In one embodiment, the 5′-PS is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-VP (e.g., a 5′-E-VP, 5′-Z-VP, or combination thereof) and a targeting ligand. In one embodiment, the 5′-VP is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-PS₂and a targeting ligand. In one embodiment, the 5′-PS₂is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, BF is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′- F, q³is 4, T2′ is 2′-F, q⁴is 2, B3′ is 2′-OMe or 2′-F, q⁵is 5, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-deoxy-5′-C-malonyl and a targeting ligand. In one embodiment, the 5′-deoxy-5′-C-malonyl is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, B1′ is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-P and a targeting ligand. In one embodiment, the 5′-P is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, B1′ is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-PS and a targeting ligand. In one embodiment, the 5′-PS is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, B1′ is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-VP (e.g., a 5′-E-VP, 5′-Z-VP, or combination thereof) and a targeting ligand. In one embodiment, the 5′-VP is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, B1′ is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-PS₂and a targeting ligand. In one embodiment, the 5′-PS₂is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In one embodiment, B1 is 2′-OMe or 2′-F, n¹is 8, T1 is 2′F, n²is 3, B2 is 2′-OMe, n³is 7, n⁴is 0, B3 is 2′-OMe, n⁵is 3, B1′ is 2′-OMe or 2′-F, q¹is 9, T1′ is 2′-F, q²is 1, B2′ is 2′-OMe or 2′-F, q³is 4, q⁴is 0, B3′ is 2′-OMe or 2′-F, q⁵is 7, T3′ is 2′-F, q⁶is 1, B4′ is 2′-F, and q⁷is 1; with two phosphorothioate internucleotide linkage modifications within position 1-5 of the sense strand (counting from the 5′-end of the sense strand), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end of the antisense strand). The RNAi agent also comprises a 5′-deoxy-5′-C-malonyl and a targeting ligand. In one embodiment, the 5′-deoxy-5′-C-malonyl is at the 5′-end of the antisense strand, and the targeting ligand is at the 3′-end of the sense strand.

In a particular embodiment, an RNAi agent of the present invention comprises:

(a) a sense strand having:

- (i) a length of 21 nucleotides;
- (ii) an ASGPR ligand attached to the 3′-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker; and
- (iii) 2′-F modifications at positions 1, 3, 5, 7, 9 to 11, 13, 17, 19, and 21, and 2′-OMe modifications at positions 2, 4, 6, 8, 12, 14 to 16, 18, and 20 (counting from the 5′ end);

and

(b) an antisense strand having:

- (i) a length of 23 nucleotides;
- (ii) 2′-OMe modifications at positions 1, 3, 5, 9, 11 to 13, 15, 17, 19, 21, and 23, and 2′F modifications at positions 2, 4, 6 to 8, 10, 14, 16, 18, 20, and 22 (counting from the 5′ end); and
- (iii) phosphorothioate internucleotide linkages between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5′ end);

wherein the dsRNA agents have a two nucleotide overhang at the 3′-end of the antisense strand, and a blunt end at the 5′-end of the antisense strand.

In another particular embodiment, an RNAi agent of the present invention comprises:

(a) a sense strand having:

- (i) a length of 21 nucleotides;
- (ii) an ASGPR ligand attached to the 3′-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;
- (iii) 2′-F modifications at positions 1, 3, 5, 7, 9 to 11, 13, 15, 17, 19, and 21, and 2′-OMe modifications at positions 2, 4, 6, 8, 12, 14, 16, 18, and 20 (counting from the 5′ end); and
- (iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5′ end);

and

(b) an antisense strand having:

- (i) a length of 23 nucleotides;
- (ii) 2′-OMe modifications at positions 1, 3, 5, 7, 9, 11 to 13, 15, 17, 19, and 21 to 23, and 2′F modifications at positions 2, 4, 6, 8, 10, 14, 16, 18, and 20 (counting from the 5′ end); and
- (iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5′ end);
  
  wherein the RNAi agents have a two nucleotide overhang at the 3′-end of the antisense strand, and a blunt end at the 5′-end of the antisense strand.

In another particular embodiment, a RNAi agent of the present invention comprises:

(a) a sense strand having:

- (i) a length of 21 nucleotides;
- (ii) an ASGPR ligand attached to the 3′-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;
- (iii) 2′-OMe modifications at positions 1 to 6, 8, 10, and 12 to 21, 2′-F modifications at positions 7, and 9, and a deoxy-nucleotide (e.g. dT) at position 11 (counting from the 5′ end); and
- (iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5′ end);

and

(b) an antisense strand having:

- (i) a length of 23 nucleotides;
- (ii) 2′-OMe modifications at positions 1, 3, 7, 9, 11, 13, 15, 17, and 19 to 23, and 2′-F modifications at positions 2, 4 to 6, 8, 10, 12, 14, 16, and 18 (counting from the 5′ end); and
- (iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5′ end);
  
  wherein the RNAi agents have a two nucleotide overhang at the 3′-end of the antisense strand, and a blunt end at the 5′-end of the antisense strand.

In another particular embodiment, a RNAi agent of the present invention comprises:

(a) a sense strand having:

- (i) a length of 21 nucleotides;
- (ii) an ASGPR ligand attached to the 3′-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;
- (iii) 2′-OMe modifications at positions 1 to 6, 8, 10, 12, 14, and 16 to 21, and 2′-F modifications at positions 7, 9, 11, 13, and 15; and
- (iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5′ end);

and

(b) an antisense strand having:

- (i) a length of 23 nucleotides;
- (ii) 2′-OMe modifications at positions 1, 5, 7, 9, 11, 13, 15, 17, 19, and 21 to 23, and 2′-F modifications at positions 2 to 4, 6, 8, 10, 12, 14, 16, 18, and 20 (counting from the 5′ end); and
- (iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5′ end);
  
  wherein the RNAi agents have a two nucleotide overhang at the 3′-end of the antisense strand, and a blunt end at the 5′-end of the antisense strand.

In another particular embodiment, a RNAi agent of the present invention comprises:

(a) a sense strand having:

- (i) a length of 21 nucleotides;
- (ii) an ASGPR ligand attached to the 3′-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;
- (iii) 2′-OMe modifications at positions 1 to 9, and 12 to 21, and 2′-F modifications at positions 10, and 11; and
- (iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5′ end);

and

(b) an antisense strand having:

- (i) a length of 23 nucleotides;
- (ii) 2′-OMe modifications at positions 1, 3, 5, 7, 9, 11 to 13, 15, 17, 19, and 21 to 23, and 2′-F modifications at positions 2, 4, 6, 8, 10, 14, 16, 18, and 20 (counting from the 5′ end); and
- (iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5′ end);
  
  wherein the RNAi agents have a two nucleotide overhang at the 3′-end of the antisense strand, and a blunt end at the 5′-end of the antisense strand.

In another particular embodiment, a RNAi agent of the present invention comprises:

(a) a sense strand having:

- (i) a length of 21 nucleotides;
- (ii) an ASGPR ligand attached to the 3′-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;
- (iii) 2′-F modifications at positions 1, 3, 5, 7, 9 to 11, and 13, and 2′-OMe modifications at positions 2, 4, 6, 8, 12, and 14 to 21; and
- (iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5′ end);

and

(b) an antisense strand having:

- (i) a length of 23 nucleotides;
- (ii) 2′-OMe modifications at positions 1, 3, 5 to 7, 9, 11 to 13, 15, 17 to 19, and 21 to 23, and 2′-F modifications at positions 2, 4, 8, 10, 14, 16, and 20 (counting from the 5′ end); and
- (iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5′ end);
  
  wherein the RNAi agents have a two nucleotide overhang at the 3′-end of the antisense strand, and a blunt end at the 5′-end of the antisense strand.

In another particular embodiment, a RNAi agent of the present invention comprises:

(a) a sense strand having:

- (i) a length of 21 nucleotides;
- (ii) an ASGPR ligand attached to the 3′-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;
- (iii) 2′-OMe modifications at positions 1, 2, 4, 6, 8, 12, 14, 15, 17, and 19 to 21, and 2′-F modifications at positions 3, 5, 7, 9 to 11, 13, 16, and 18; and
- (iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5′ end);

and

(b) an antisense strand having:

- (i) a length of 25 nucleotides;
- (ii) 2′-OMe modifications at positions 1, 4, 6, 7, 9, 11 to 13, 15, 17, and 19 to 23, 2′-F modifications at positions 2, 3, 5, 8, 10, 14, 16, and 18, and deoxy-nucleotides (e.g. dT) at positions 24 and 25 (counting from the 5′ end); and
- (iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5′ end);
  
  wherein the RNAi agents have a four nucleotide overhang at the 3′-end of the antisense strand, and a blunt end at the 5′-end of the antisense strand.

In another particular embodiment, a RNAi agent of the present invention comprises:

(a) a sense strand having:

- (i) a length of 21 nucleotides;
- (ii) an ASGPR ligand attached to the 3′-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;
- (iii) 2′-OMe modifications at positions 1 to 6, 8, and 12 to 21, and 2′-F modifications at positions 7, and 9 to 11; and
- (iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5′ end);

and

(b) an antisense strand having:

- (i) a length of 23 nucleotides;
- (ii) 2′-OMe modifications at positions 1, 3 to 5, 7, 8, 10 to 13, 15, and 17 to 23, and 2′-F modifications at positions 2, 6, 9, 14, and 16 (counting from the 5′ end); and
- (iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5′ end);
  
  wherein the RNAi agents have a two nucleotide overhang at the 3′-end of the antisense strand, and a blunt end at the 5′-end of the antisense strand.

In another particular embodiment, a RNAi agent of the present invention comprises:

(a) a sense strand having:

- (i) a length of 21 nucleotides;
- (ii) an ASGPR ligand attached to the 3′-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;
- (iii) 2′-OMe modifications at positions 1 to 6, 8, and 12 to 21, and 2′-F modifications at positions 7, and 9 to 11; and
- (iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5′ end);

and

(b) an antisense strand having:

- (i) a length of 23 nucleotides;
- (ii) 2′-OMe modifications at positions 1, 3 to 5, 7, 10 to 13, 15, and 17 to 23, and 2′-F modifications at positions 2, 6, 8, 9, 14, and 16 (counting from the 5′ end); and
- (iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23 (counting from the 5′ end);
  
  wherein the RNAi agents have a two nucleotide overhang at the 3′-end of the antisense strand, and a blunt end at the 5′-end of the antisense strand.

In another particular embodiment, a RNAi agent of the present invention comprises:

(a) a sense strand having:

- (i) a length of 19 nucleotides;
- (ii) an ASGPR ligand attached to the 3′-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;
- (iii) 2′-OMe modifications at positions 1 to 4, 6, and 10 to 19, and 2′-F modifications at positions 5, and 7 to 9; and
- (iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3 (counting from the 5′ end);

and

(b) an antisense strand having:

- (i) a length of 21 nucleotides;
- (ii) 2′-OMe modifications at positions 1, 3 to 5, 7, 10 to 13, 15, and 17 to 21, and 2′-F modifications at positions 2, 6, 8, 9, 14, and 16 (counting from the 5′ end); and
- (iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5′ end);
  
  wherein the RNAi agents have a two nucleotide overhang at the 3′-end of the antisense strand, and a blunt end at the 5′-end of the antisense strand.

In certain embodiments, the iRNA for use in the methods of the invention is an agent selected from agents listed in any one of Tables 2-3 and 7-8. These agents may further comprise a ligand.

III. iRNAs Conjugated to Ligands

Another modification of the RNA of an iRNA of the invention involves chemically linking to the iRNA one or more ligands, moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the iRNA e.g., into a cell. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acid. Sci. USA, 1989, 86: 6553-6556). In other embodiments, the ligand is cholic acid (Manoharan et al., Biorg. Med. Chem. Let., 1994, 4:1053-1060), a thioether, e.g., beryl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660:306-309; Manoharan et al., Biorg. Med. Chem. Let., 1993, 3:2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J, 1991, 10:1111-1118; Kabanov et al., FEBS Lett., 1990, 259:327-330; Svinarchuk et al., Biochimie, 1993, 75:49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651-3654; Shea et al., Nucl. Acids Res., 1990, 18:3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36:3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229-237), or an octadecylamine or hexylamino-carbonyloxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923-937).

In certain embodiments, a ligand alters the distribution, targeting, or lifetime of an iRNA agent into which it is incorporated. In some embodiments a ligand provides an enhanced affinity for a selected target, e.g., molecule, cell or cell type, compartment, e.g., a cellular or organ compartment, tissue, organ or region of the body, as, e.g., compared to a species absent such a ligand. In some embodiments, ligands do not take part in duplex pairing in a duplexed nucleic acid.

Ligands can include a naturally occurring substance, such as a protein (e.g., human serum albumin (HSA), low-density lipoprotein (LDL), or globulin); carbohydrate (e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin, N-acetylglucosamine, N-acetylgalactosamine, or hyaluronic acid); or a lipid. The ligand can also be a recombinant or synthetic molecule, such as a synthetic polymer, e.g., a synthetic polyamino acid. Examples of polyamino acids include polyamino acid is a polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolide) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacrylic acid), N-isopropylacrylamide polymers, or polyphosphazene. Example of polyamines include: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an alpha helical peptide.

Ligands can also include targeting groups, e.g., a cell or tissue targeting agent, e.g., a lectin, glycoprotein, lipid or protein, e.g., an antibody, that binds to a specified cell type such as a kidney cell. A targeting group can be a thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, Mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine multivalent mannose, multivalent fucose, glycosylated polyaminoacids, multivalent galactose, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, vitamin A, biotin, or an RGD peptide or RGD peptide mimetic. In certain embodiments, the ligand is a multivalent galactose, e.g., an N-acetyl-galactosamine.

Other examples of ligands include dyes, intercalating agents (e.g. acridines), cross-linkers (e.g. psoralen, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g. EDTA), lipophilic molecules, e.g., cholesterol, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenoic acid, dimethoxytrityl, or phenoxazine) and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (e.g., PEG-40K), MPEG, [MPEG]₂, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (e.g. biotin), transport/absorption facilitators (e.g., aspirin, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocycles), dinitrophenyl, HRP, or AP.

Ligands can be proteins, e.g., glycoproteins, or peptides, e.g., molecules having a specific affinity for a co-ligand, or antibodies e.g., an antibody, that binds to a specified cell type such as a hepatic cell. Ligands can also include hormones and hormone receptors. They can also include non-peptidic species, such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine multivalent mannose, or multivalent fucose. The ligand can be, for example, a lipopolysaccharide, an activator of p38 MAP kinase, or an activator of NF-κB.

The ligand can be a substance, e.g., a drug, which can increase the uptake of the iRNA agent into the cell, for example, by disrupting the cell's cytoskeleton, e.g., by disrupting the cell's microtubules, microfilaments, or intermediate filaments. The drug can be, for example, taxol, vincristine, vinblastine, cytochalasin, nocodazole, jasplakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin.

In some embodiments, a ligand attached to an iRNA as described herein acts as a pharmacokinetic modulator (PK modulator). PK modulators include lipophiles, bile acids, steroids, phospholipid analogues, peptides, protein binding agents, PEG, vitamins, etc. Exemplary PK modulators include, but are not limited to, cholesterol, fatty acids, cholic acid, lithocholic acid, dialkylglycerides, diacylglyceride, phospholipids, sphingolipids, naproxen, ibuprofen, vitamin E, biotin. Oligonucleotides that comprise a number of phosphorothioate linkages are also known to bind to serum protein, thus short oligonucleotides, e.g., oligonucleotides of about 5 bases, 10 bases, 15 bases, or 20 bases, comprising multiple of phosphorothioate linkages in the backbone are also amenable to the present invention as ligands (e.g. as PK modulating ligands). In addition, aptamers that bind serum components (e.g. serum proteins) are also suitable for use as PK modulating ligands in the embodiments described herein.

Ligand-conjugated iRNAs of the invention may be synthesized by the use of an oligonucleotide that bears a pendant reactive functionality, such as that derived from the attachment of a linking molecule onto the oligonucleotide (described below). This reactive oligonucleotide may be reacted directly with commercially-available ligands, ligands that are synthesized bearing any of a variety of protecting groups, or ligands that have a linking moiety attached thereto.

The oligonucleotides used in the conjugates of the present invention may be conveniently and routinely made through the well-known technique of solid-phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems® (Foster City, Calif.). Any other methods for such synthesis known in the art may additionally or alternatively be employed. It is also known to use similar techniques to prepare other oligonucleotides, such as the phosphorothioates and alkylated derivatives.

In the ligand-conjugated iRNAs and ligand-molecule bearing sequence-specific linked nucleosides of the present invention, the oligonucleotides and oligonucleosides may be assembled on a suitable DNA synthesizer utilizing standard nucleotide or nucleoside precursors, or nucleotide or nucleoside conjugate precursors that already bear the linking moiety, ligand-nucleotide or nucleoside-conjugate precursors that already bear the ligand molecule, or non-nucleoside ligand-bearing building blocks.

When using nucleotide-conjugate precursors that already bear a linking moiety, the synthesis of the sequence-specific linked nucleosides is typically completed, and the ligand molecule is then reacted with the linking moiety to form the ligand-conjugated oligonucleotide. In some embodiments, the oligonucleotides or linked nucleosides of the present invention are synthesized by an automated synthesizer using phosphoramidites derived from ligand-nucleoside conjugates in addition to the standard phosphoramidites and non-standard phosphoramidites that are commercially available and routinely used in oligonucleotide synthesis.

A. Lipid Conjugates

In certain embodiments, the ligand or conjugate is a lipid or lipid-based molecule. In one embodiment, such a lipid or lipid-based molecule binds a serum protein, e.g., human serum albumin (HSA). An HSA binding ligand allows for distribution of the conjugate to a target tissue, e.g., a non-kidney target tissue of the body. For example, the target tissue can be the liver, including parenchymal cells of the liver. Other molecules that can bind HSA can also be used as ligands. For example, naproxen or aspirin can be used. A lipid or lipid-based ligand can (a) increase resistance to degradation of the conjugate, (b) increase targeting or transport into a target cell or cell membrane, or (c) can be used to adjust binding to a serum protein, e.g., HSA.

A lipid based ligand can be used to inhibit, e.g., control the binding of the conjugate to a target tissue. For example, a lipid or lipid-based ligand that binds to HSA more strongly will be less likely to be targeted to the kidney and therefore less likely to be cleared from the body. A lipid or lipid-based ligand that binds to HSA less strongly can be used to target the conjugate to the kidney.

In certain embodiments, the lipid based ligand binds HSA. In one embodiment, it binds HSA with a sufficient affinity such that the conjugate will be distributed to a non-kidney tissue. However, it is preferred that the affinity not be so strong that the HSA-ligand binding cannot be reversed.

In other embodiments, the lipid based ligand binds HSA weakly or not at all. In one embodiment, the conjugate will be distributed to the kidney. Other moieties that target to kidney cells can also be used in place of, or in addition to, the lipid based ligand.

In another aspect, the ligand is a moiety, e.g., a vitamin, which is taken up by a target cell, e.g., a proliferating cell. These are particularly useful for treating disorders characterized by unwanted cell proliferation, e.g., of the malignant or non-malignant type, e.g., cancer cells. Exemplary vitamins include vitamin A, E, and K. Other exemplary vitamins include are B vitamin, e.g., folic acid, B12, riboflavin, biotin, pyridoxal or other vitamins or nutrients taken up by target cells such as liver cells. Also included are HSA and low density lipoprotein (LDL).

B. Cell Permeation Agents

In another aspect, the ligand is a cell-permeation agent, such as, a helical cell-permeation agent. In one embodiment, the agent is amphipathic. An exemplary agent is a peptide such as tat or antennapedia. If the agent is a peptide, it can be modified, including a peptidylmimetic, invertomers, non-peptide or pseudo-peptide linkages, and use of D-amino acids. In one embodiment, the helical agent is an alpha-helical agent, which has a lipophilic and a lipophobic phase.

The ligand can be a peptide or peptidomimetic. A peptidomimetic (also referred to herein as an oligopeptidomimetic) is a molecule capable of folding into a defined three-dimensional structure similar to a natural peptide. The attachment of peptide and peptidomimetics to iRNA agents can affect pharmacokinetic distribution of the iRNA, such as by enhancing cellular recognition and absorption. The peptide or peptidomimetic moiety can be about 5-50 amino acids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long.

A peptide or peptidomimetic can be, for example, a cell permeation peptide, cationic peptide, amphipathic peptide, or hydrophobic peptide (e.g., consisting primarily of Tyr, Trp, or Phe). The peptide moiety can be a dendrimer peptide, constrained peptide or crosslinked peptide. In another alternative, the peptide moiety can include a hydrophobic membrane translocation sequence (MTS). An exemplary hydrophobic MTS-containing peptide is RFGF having the amino acid sequence AAVALLPAVLLALLAP (SEQ ID NO: 14). An RFGF analogue (e g, amino acid sequence AALLPVLLAAP (SEQ ID NO:15) containing a hydrophobic MTS can also be a targeting moiety. The peptide moiety can be a “delivery” peptide, which can carry large polar molecules including peptides, oligonucleotides, and protein across cell membranes. For example, sequences from the HIV Tat protein (GRKKRRQRRRPPQ (SEQ ID NO:16) and the Drosophila Antennapedia protein (RQIKIWFQNRRMKWKK (SEQ ID NO:17) have been found to be capable of functioning as delivery peptides. A peptide or peptidomimetic can be encoded by a random sequence of DNA, such as a peptide identified from a phage-display library, or one-bead-one-compound (OBOC) combinatorial library (Lam et al., Nature, 354:82-84, 1991). Examples of a peptide or peptidomimetic tethered to a dsRNA agent via an incorporated monomer unit for cell targeting purposes is an arginine-glycine-aspartic acid (RGD)-peptide, or RGD mimic. A peptide moiety can range in length from about 5 amino acids to about 40 amino acids. The peptide moieties can have a structural modification, such as to increase stability or direct conformational properties. Any of the structural modifications described below can be utilized.

An RGD peptide for use in the compositions and methods of the invention may be linear or cyclic, and may be modified, e.g., glycosylated or methylated, to facilitate targeting to a specific tissue(s). RGD-containing peptides and peptidomimetics may include D-amino acids, as well as synthetic RGD mimics. In addition to RGD, one can use other moieties that target the integrin ligand, e.g., PECAM-1 or VEGF.

A “cell permeation peptide” is capable of permeating a cell, e.g., a microbial cell, such as a bacterial or fungal cell, or a mammalian cell, such as a human cell. A microbial cell-permeating peptide can be, for example, an α-helical linear peptide (e.g., LL-37 or Ceropin P1), a disulfide bond-containing peptide (e.g., α-defensin, β-defensin or bactenecin), or a peptide containing only one or two dominating amino acids (e.g., PR-39 or indolicidin). A cell permeation peptide can also include a nuclear localization signal (NLS). For example, a cell permeation peptide can be a bipartite amphipathic peptide, such as MPG, which is derived from the fusion peptide domain of HIV-1 gp41 and the NLS of SV40 large T antigen (Simeoni et al., Nucl. Acids Res. 31:2717-2724, 2003).

C. Carbohydrate Conjugates

In some embodiments of the compositions and methods of the invention, an iRNA further comprises a carbohydrate. The carbohydrate conjugated iRNA is advantageous for the in vivo delivery of nucleic acids, as well as compositions suitable for in vivo therapeutic use, as described herein. As used herein, “carbohydrate” refers to a compound which is either a carbohydrate per se made up of one or more monosaccharide units having at least 6 carbon atoms (which can be linear, branched or cyclic) with an oxygen, nitrogen or sulfur atom bonded to each carbon atom; or a compound having as a part thereof a carbohydrate moiety made up of one or more monosaccharide units each having at least six carbon atoms (which can be linear, branched or cyclic), with an oxygen, nitrogen or sulfur atom bonded to each carbon atom. Representative carbohydrates include the sugars (mono-, di-, tri-, and oligosaccharides containing from about 4, 5, 6, 7, 8, or 9 monosaccharide units), and polysaccharides such as starches, glycogen, cellulose and polysaccharide gums. Specific monosaccharides include C5 and above (e.g., C5, C6, C7, or C8) sugars; di- and trisaccharides include sugars having two or three monosaccharide units (e.g., C5, C6, C7, or C8).

In certain embodiments, a carbohydrate conjugate for use in the compositions and methods of the invention is a monosaccharide.

In certain embodiments, the monosaccharide is an N-acetylgalactosamine (GalNAc). GalNAc conjugates, which comprise one or more N-acetylgalactosamine (GalNAc) derivatives, are described, for example, in U.S. Pat. No. 8,106,022, the entire content of which is hereby incorporated herein by reference. In some embodiments, the GalNAc conjugate serves as a ligand that targets the iRNA to particular cells. In some embodiments, the GalNAc conjugate targets the iRNA to liver cells, e.g., by serving as a ligand for the asialoglycoprotein receptor of liver cells (e.g., hepatocytes).

In some embodiments, the carbohydrate conjugate comprises one or more GalNAc derivatives. The GalNAc derivatives may be attached via a linker, e.g., a bivalent or trivalent branched linker. In some embodiments the GalNAc conjugate is conjugated to the 3′ end of the sense strand. In some embodiments, the GalNAc conjugate is conjugated to the iRNA agent (e.g., to the 3′ end of the sense strand) via a linker, e.g., a linker as described herein. In some embodiments the GalNAc conjugate is conjugated to the 5′ end of the sense strand. In some embodiments, the GalNAc conjugate is conjugated to the iRNA agent (e.g., to the 5′ end of the sense strand) via a linker, e.g., a linker as described herein.

In certain embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a monovalent linker. In some embodiments, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a bivalent linker. In yet other embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a trivalent linker. In other embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a tetravalent linker.

In certain embodiments, the double stranded RNAi agents of the invention comprise one GalNAc or GalNAc derivative attached to the iRNA agent. In certain embodiments, the double stranded RNAi agents of the invention comprise a plurality (e.g., 2, 3, 4, 5, or 6) GalNAc or GalNAc derivatives, each independently attached to a plurality of nucleotides of the double stranded RNAi agent through a plurality of monovalent linkers.

In some embodiments, for example, when the two strands of an iRNA agent of the invention are part of one larger molecule connected by an uninterrupted chain of nucleotides between the 3′-end of one strand and the 5′-end of the respective other strand forming a hairpin loop comprising, a plurality of unpaired nucleotides, each unpaired nucleotide within the hairpin loop may independently comprise a GalNAc or GalNAc derivative attached via a monovalent linker. The hairpin loop may also be formed by an extended overhang in one strand of the duplex.

In one embodiment, a carbohydrate conjugate for use in the compositions and methods of the invention is selected from the group consisting of:

embedded image

embedded image

wherein Y is O or S and n is 3-6 (Formula XXIV);

embedded image

wherein Y is O or S and n is 3-6 (Formula XXV);

embedded image

embedded image

wherein X is O or S (Formula XXVII);

embedded image

In another embodiment, a carbohydrate conjugate for use in the compositions and methods of the invention is a monosaccharide. In one embodiment, the monosaccharide is an N-acetylgalactosamine, such as

embedded image

In some embodiments, the RNAi agent is attached to the carbohydrate conjugate via a linker as shown in the following schematic, wherein X is O or S

embedded image

In some embodiments, the RNAi agent is conjugated to L96 as defined in Table 1 and shown below:

embedded image

Another representative carbohydrate conjugate for use in the embodiments described herein includes, but is not limited to,

embedded image

when one of X or Y is an oligonucleotide, the other is a hydrogen.

In some embodiments, a suitable ligand is a ligand disclosed in WO 2019/055633, the entire contents of which are incorporated herein by reference. In one embodiment the ligand comprises the structure below:

embedded image

In one embodiment, the double stranded RNAi agents of the invention comprise one or more GalNAc or GalNAc derivative attached to the iRNA agent. The GalNAc may be attached to any nucleotide via a linker on the sense strand or antisense strand. The GalNac may be attached to the 5′-end of the sense strand, the 3′ end of the sense strand, the 5′-end of the antisense strand, or the 3′-end of the antisense strand. In one embodiment, the GalNAc is attached to the 3′ end of the sense strand, e.g., via a trivalent linker.

In other embodiments, the double stranded RNAi agents of the invention comprise a plurality (e.g., 2, 3, 4, 5, or 6) GalNAc or GalNAc derivatives, each independently attached to a plurality of nucleotides of the double stranded RNAi agent through a plurality of linkers, e.g., monovalent linkers.

In some embodiments, for example, when the two strands of an iRNA agent of the invention is part of one larger molecule connected by an uninterrupted chain of nucleotides between the 3′-end of one strand and the 5′-end of the respective other strand forming a hairpin loop comprising, a plurality of unpaired nucleotides, each unpaired nucleotide within the hairpin loop may independently comprise a GalNAc or GalNAc derivative attached via a monovalent linker.

In some embodiments, the carbohydrate conjugate further comprises one or more additional ligands as described above, such as, but not limited to, a PK modulator or a cell permeation peptide.

Additional carbohydrate conjugates and linkers suitable for use in the present invention include those described in PCT Publication Nos. WO 2014/179620 and WO 2014/179627, the entire contents of each of which are incorporated herein by reference.

D. Linkers

In some embodiments, the conjugate or ligand described herein can be attached to an iRNA oligonucleotide with various linkers that can be cleavable or non-cleavable.

The term “linker” or “linking group” means an organic moiety that connects two parts of a compound, e.g., covalently attaches two parts of a compound. Linkers typically comprise a direct bond or an atom such as oxygen or sulfur, a unit such as NRB, C(O), C(O)NH, SO, SO₂, SO₂NH or a chain of atoms, such as, but not limited to, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclylalkyl, alkylheterocyclylalkenyl, alkylhererocyclylalkynyl, alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl, alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl, alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, alkynylhereroaryl, which one or more methylenes can be interrupted or terminated by O, S, S(O), SO₂, N(R8), C(O), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclic; where R8 is hydrogen, acyl, aliphatic, or substituted aliphatic. In one embodiment, the linker is about 1-24 atoms, 2-24, 3-24, 4-24, 5-24, 6-24, 6-18, 7-18, 8-18, 7-17, 8-17, 6-16, 7-17, or 8-16 atoms.

A cleavable linking group is one which is sufficiently stable outside the cell, but which upon entry into a target cell is cleaved to release the two parts the linker is holding together. In an exemplary embodiment, the cleavable linking group is cleaved at least about 10 times, 20, times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, or more, or at least 100 times faster in a target cell or under a first reference condition (which can, e.g., be selected to mimic or represent intracellular conditions) than in the blood of a subject, or under a second reference condition (which can, e.g., be selected to mimic or represent conditions found in the blood or serum).

Cleavable linking groups are susceptible to cleavage agents, e.g., pH, redox potential, or the presence of degradative molecules. Generally, cleavage agents are more prevalent or found at higher levels or activities inside cells than in serum or blood. Examples of such degradative agents include: redox agents which are selected for particular substrates or which have no substrate specificity, including, e.g., oxidative or reductive enzymes or reductive agents such as mercaptans, present in cells, that can degrade a redox cleavable linking group by reduction; esterases; endosomes or agents that can create an acidic environment, e.g., those that result in a pH of five or lower; enzymes that can hydrolyze or degrade an acid cleavable linking group by acting as a general acid, peptidases (which can be substrate specific), and phosphatases.

A cleavable linkage group, such as a disulfide bond can be susceptible to pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3. Endosomes have a more acidic pH, in the range of 5.5-6.0, and lysosomes have an even more acidic pH at around 5.0. Some linkers will have a cleavable linking group that is cleaved at a selected pH, thereby releasing a cationic lipid from the ligand inside the cell, or into the desired compartment of the cell.

A linker can include a cleavable linking group that is cleavable by a particular enzyme. The type of cleavable linking group incorporated into a linker can depend on the cell to be targeted. For example, a liver-targeting ligand can be linked to a cationic lipid through a linker that includes an ester group. Liver cells are rich in esterases, and therefore the linker will be cleaved more efficiently in liver cells than in cell types that are not esterase-rich. Other cell-types rich in esterases include cells of the lung, renal cortex, and testis.

Linkers that contain peptide bonds can be used when targeting cell types rich in peptidases, such as liver cells and synoviocytes.

In general, the suitability of a candidate cleavable linking group can be evaluated by testing the ability of a degradative agent (or condition) to cleave the candidate linking group. It will also be desirable to also test the candidate cleavable linking group for the ability to resist cleavage in the blood or when in contact with other non-target tissue. Thus, one can determine the relative susceptibility to cleavage between a first and a second condition, where the first is selected to be indicative of cleavage in a target cell and the second is selected to be indicative of cleavage in other tissues or biological fluids, e.g., blood or serum. The evaluations can be carried out in cell free systems, in cells, in cell culture, in organ or tissue culture, or in whole animals. It can be useful to make initial evaluations in cell-free or culture conditions and to confirm by further evaluations in whole animals. In certain embodiments, useful candidate compounds are cleaved at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood or serum (or under in vitro conditions selected to mimic extracellular conditions).

i. Redox Cleavable Linking Groups

In certain embodiments, a cleavable linking group is a redox cleavable linking group that is cleaved upon reduction or oxidation. An example of reductively cleavable linking group is a disulphide linking group (—S—S—). To determine if a candidate cleavable linking group is a suitable “reductively cleavable linking group,” or for example is suitable for use with a particular iRNA moiety and particular targeting agent one can look to methods described herein. For example, a candidate can be evaluated by incubation with dithiothreitol (DTT), or other reducing agent using reagents know in the art, which mimic the rate of cleavage which would be observed in a cell, e.g., a target cell. The candidates can also be evaluated under conditions which are selected to mimic blood or serum conditions. In one, candidate compounds are cleaved by at most about 10% in the blood. In other embodiments, useful candidate compounds are degraded at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood (or under in vitro conditions selected to mimic extracellular conditions). The rate of cleavage of candidate compounds can be determined using standard enzyme kinetics assays under conditions chosen to mimic intracellular media and compared to conditions chosen to mimic extracellular media.

ii. Phosphate-Based Cleavable Linking Groups

In other embodiments, a cleavable linker comprises a phosphate-based cleavable linking group. A phosphate-based cleavable linking group is cleaved by agents that degrade or hydrolyze the phosphate group. An example of an agent that cleaves phosphate groups in cells are enzymes such as phosphatases in cells. Examples of phosphate-based linking groups are —O—P(O)(ORk)-O—, —O—P(S)(ORk)-O—, —O—P(S)(SRk)-O—, —S—P(O)(ORk)-O—, —O—P(O)(ORk)-S—, —S—P(O)(ORk)-S—, —O—P(S)(ORk)-S—, —S—P(S)(ORk)-O—, —O—P(O)(Rk)-O—, —O—P(S)(Rk)-O—, —S—P(O)(Rk)-O—, —S—P(S)(Rk)-O—, —S—P(O)(Rk)-S—, —O—P(S)(Rk)-S—, wherein Rk at each occurrence can be, independently, C1-C20 alkyl, C1-C20 haloalkyl, C6-C10 aryl, or C7-C12 aralkyl. Exemplary embodiments include —O—P(O)(OH)—O—, —O—P(S)(OH)—O—, —O—P(S)(SH)—O—, —S—P(O)(OH)—O—, —O—P(O)(OH)—S—, —S—P(O)(OH)—S—, —O—P(S)(OH)—S—, —S—P(S)(OH)—O—, —O—P(O)(H)—O—, —O—P(S)(H)—O—, —S—P(O)(H)—O, —S—P(S)(H)—O—, —S—P(O)(H)—S—, and —O—P(S)(H)—S—. In certain embodiments a phosphate-based linking group is —O—P(O)(OH)—O—. These candidates can be evaluated using methods analogous to those described above.

iii. Acid Cleavable Linking Groups

In other embodiments, a cleavable linker comprises an acid cleavable linking group. An acid cleavable linking group is a linking group that is cleaved under acidic conditions. In certain embodiments acid cleavable linking groups are cleaved in an acidic environment with a pH of about 6.5 or lower (e.g., about 6.0, 5.5, 5.0, or lower), or by agents such as enzymes that can act as a general acid. In a cell, specific low pH organelles, such as endosomes and lysosomes can provide a cleaving environment for acid cleavable linking groups. Examples of acid cleavable linking groups include but are not limited to hydrazones, esters, and esters of amino acids. Acid cleavable groups can have the general formula —C═NN—, C(O)O, or —OC(O). An exemplary embodiment is when the carbon attached to the oxygen of the ester (the alkoxy group) is an aryl group, substituted alkyl group, or tertiary alkyl group such as dimethyl pentyl or t-butyl. These candidates can be evaluated using methods analogous to those described above.

iv. Ester-Based Linking Groups

In other embodiments, a cleavable linker comprises an ester-based cleavable linking group. An ester-based cleavable linking group is cleaved by enzymes such as esterases and amidases in cells. Examples of ester-based cleavable linking groups include, but are not limited to, esters of alkylene, alkenylene and alkynylene groups. Ester cleavable linking groups have the general formula —C(O)O—, or —OC(O)—. These candidates can be evaluated using methods analogous to those described above.

v. Peptide-Based Cleaving Groups

In yet other embodiments, a cleavable linker comprises a peptide-based cleavable linking group. A peptide-based cleavable linking group is cleaved by enzymes such as peptidases and proteases in cells. Peptide-based cleavable linking groups are peptide bonds formed between amino acids to yield oligopeptides (e.g., dipeptides, tripeptides etc.) and polypeptides. Peptide-based cleavable groups do not include the amide group (—C(O)NH—). The amide group can be formed between any alkylene, alkenylene or alkynylene. A peptide bond is a special type of amide bond formed between amino acids to yield peptides and proteins. The peptide based cleavage group is generally limited to the peptide bond (i.e., the amide bond) formed between amino acids yielding peptides and proteins and does not include the entire amide functional group. Peptide-based cleavable linking groups have the general formula —NHCHRAC(O)NHCHRBC(O)—, where RA and RB are the R groups of the two adjacent amino acids. These candidates can be evaluated using methods analogous to those described above.

In some embodiments, an iRNA of the invention is conjugated to a carbohydrate through a linker. Non-limiting examples of iRNA carbohydrate conjugates with linkers of the compositions and methods of the invention include, but are not limited to,

embedded image

when one of X or Y is an oligonucleotide, the other is a hydrogen.

In certain embodiments of the compositions and methods of the invention, a ligand is one or more “GalNAc” (N-acetylgalactosamine) derivatives attached through a bivalent or trivalent branched linker.

In one embodiment, a dsRNA of the invention is conjugated to a bivalent or trivalent branched linker selected from the group of structures shown in any of formula (XLV)-(XLVI):

embedded image

wherein:

q2A, q2B, q3A, q3B, q4A, q4B, q5A, q5B and q5C represent independently for each occurrence 0-20 and wherein the repeating unit can be the same or different;

P^2A, P^2B, P^3A, P^3B, P^4A, P^4B, P^5A, P^5B, P^5C, T^2A, T^2B, T^3A, T^3B, T^4A, T^4B, T^4A, T^5B, T^5Care each independently for each occurrence absent, CO, NH, O, S, OC(O), NHC(O), CH₂, CH₂NH or CH₂O;

Q^2A, Q^2B, Q^3A, Q^3B, Q^4A, Q^4B, Q^5A, Q^5Care independently for each occurrence absent, alkylene, substituted alkylene wherein one or more methylenes can be interrupted or terminated by one or more of O, S, S(O), SO₂, N(R^N), C(R′)═C(R″), C≡C or C(O);

R^2A, R^2B, R^3A, R^3B, R^4A, R^4B, R^5A, R^5B, R^5Care each independently for each occurrence absent, NH, O, S, CH₂, C(O)O, C(O)NH, NHCH(R^a)C(O), —C(O)—CH(R^a)—NH—, CO, CH═N—O,

embedded image

or heterocyclyl;

L^2A, L^2B, L^3A, L^3B, L^4A, L^5A, L^5B, L^5Crepresent the ligand; i.e. each independently for each occurrence a monosaccharide (such as GalNAc), disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide; and R^ais H or amino acid side chain. Trivalent conjugating GalNAc derivatives are particularly useful for use with RNAi agents for inhibiting the expression of a target gene, such as those of formula (XLIX):

embedded image

wherein L^5A, L^5Band L^5Crepresent a monosaccharide, such as GalNAc derivative.

Examples of suitable bivalent and trivalent branched linker groups conjugating GalNAc derivatives include, but are not limited to, the structures recited above as formulas II, VII, XI, X, and XIII.

Representative U.S. patents that teach the preparation of RNA conjugates include, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928; 5,688,941; 6,294,664; 6,320,017; 6,576,752; 6,783,931; 6,900,297; 7,037,646; and 8,106,022, the entire contents of each of which are hereby incorporated herein by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications can be incorporated in a single compound or even at a single nucleoside within an iRNA. The present invention also includes iRNA compounds that are chimeric compounds.

“Chimeric” iRNA compounds or “chimeras,” in the context of this invention, are iRNA compounds, such as, dsRNAi agents, that contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of a dsRNA compound. These iRNAs typically contain at least one region wherein the RNA is modified so as to confer upon the iRNA increased resistance to nuclease degradation, increased cellular uptake, or increased binding affinity for the target nucleic acid. An additional region of the iRNA can serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of iRNA inhibition of gene expression. Consequently, comparable results can often be obtained with shorter iRNAs when chimeric dsRNAs are used, compared to phosphorothioate deoxy dsRNAs hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

In certain instances, the RNA of an iRNA can be modified by a non-ligand group. A number of non-ligand molecules have been conjugated to iRNAs in order to enhance the activity, cellular distribution or cellular uptake of the iRNA, and procedures for performing such conjugations are available in the scientific literature. Such non-ligand moieties have included lipid moieties, such as cholesterol (Kubo, T. et al., Biochem. Biophys. Res. Comm., 2007, 365(1):54-61; Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86:6553), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4:1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660:306; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3:2765), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10:111; Kabanov et al., FEBS Lett., 1990, 259:327; Svinarchuk et al., Biochimie, 1993, 75:49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651; Shea et al., Nucl. Acids Res., 1990, 18:3777), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36:3651), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923). Representative United States patents that teach the preparation of such RNA conjugates have been listed above. Typical conjugation protocols involve the synthesis of RNAs bearing an aminolinker at one or more positions of the sequence. The amino group is then reacted with the molecule being conjugated using appropriate coupling or activating reagents. The conjugation reaction can be performed either with the RNA still bound to the solid support or following cleavage of the RNA, in solution phase. Purification of the RNA conjugate by HPLC typically affords the pure conjugate.

IV. Delivery of an iRNA of the Invention

The delivery of an iRNA of the invention to a cell e.g., a cell within a subject, such as a human subject (e.g., a subject in need thereof, such as a subject susceptible to or diagnosed with an ANGPTL3-associated disorder, e.g., a disorder of lipid metabolism) can be achieved in a number of different ways. For example, delivery may be performed by contacting a cell with an iRNA of the invention either in vitro or in vivo. In vivo delivery may also be performed directly by administering a composition comprising an iRNA, e.g., a dsRNA, to a subject. Alternatively, in vivo delivery may be performed indirectly by administering one or more vectors that encode and direct the expression of the iRNA. These alternatives are discussed further below.

In general, any method of delivering a nucleic acid molecule (in vitro or in vivo) can be adapted for use with an iRNA of the invention (see e.g., Akhtar S. and Julian R L. (1992) Trends Cell. Biol. 2(5):139-144 and WO94/02595, which are incorporated herein by reference in their entireties). For in vivo delivery, factors to consider in order to deliver an iRNA molecule include, for example, biological stability of the delivered molecule, prevention of non-specific effects, and accumulation of the delivered molecule in the target tissue. RNA interference has also shown success with local delivery to the CNS by direct injection (Dorn, G., et al. (2004) Nucleic Acids 32:e49; Tan, P H., et al (2005) Gene Ther. 12:59-66; Makimura, H., et al (2002) BMC Neurosci. 3:18; Shishkina, G T., et al (2004) Neuroscience 129:521-528; Thakker, E R., et al (2004) Proc. Natl. Acad. Sci. U.S.A. 101:17270-17275; Akaneya, Y., et al (2005) J. Neurophysiol. 93:594-602). Modification of the RNA or the pharmaceutical carrier can also permit targeting of the iRNA to the target tissue and avoid undesirable off-target effects. iRNA molecules can be modified by chemical conjugation to lipophilic groups such as cholesterol to enhance cellular uptake and prevent degradation. For example, an iRNA directed against ApoB conjugated to a lipophilic cholesterol moiety was injected systemically into mice and resulted in knockdown of apoB mRNA in both the liver and jejunum (Soutschek, J., et al (2004) Nature 432:173-178).

In an alternative embodiment, the iRNA can be delivered using drug delivery systems such as a nanoparticle, a dendrimer, a polymer, liposomes, or a cationic delivery system. Positively charged cationic delivery systems facilitate binding of an iRNA molecule (negatively charged) and also enhance interactions at the negatively charged cell membrane to permit efficient uptake of an iRNA by the cell. Cationic lipids, dendrimers, or polymers can either be bound to an iRNA, or induced to form a vesicle or micelle (see e.g., Kim S H, et al (2008) Journal of Controlled Release 129(2):107-116) that encases an iRNA. The formation of vesicles or micelles further prevents degradation of the iRNA when administered systemically. Methods for making and administering cationic-iRNA complexes are well within the abilities of one skilled in the art (see e.g., Sorensen, D R, et al (2003) J. Mol. Biol 327:761-766; Verma, U N, et al (2003) Clin. Cancer Res. 9:1291-1300; Arnold, A S et al (2007) J. Hypertens. 25:197-205, which are incorporated herein by reference in their entirety). Some non-limiting examples of drug delivery systems useful for systemic delivery of iRNAs include DOTAP (Sorensen, D R., et al (2003), supra; Verma, U N, et al (2003), supra), “solid nucleic acid lipid particles” (Zimmermann, T S, et al (2006) Nature 441:111-114), cardiolipin (Chien, P Y, et al (2005) Cancer Gene Ther. 12:321-328; Pal, A, et al (2005) Int J. Oncol. 26:1087-1091), polyethyleneimine (Bonnet M E, et al (2008) Pharm. Res. August 16 Epub ahead of print; Aigner, A. (2006) J. Biomed. Biotechnol. 71659), Arg-Gly-Asp (RGD) peptides (Liu, S. (2006) Mol. Pharm. 3:472-487), and polyamidoamines (Tomalia, D A, et al (2007) Biochem. Soc. Trans. 35:61-67; Yoo, H., et al (1999) Pharm. Res. 16:1799-1804). In some embodiments, an iRNA forms a complex with cyclodextrin for systemic administration. Methods for administration and pharmaceutical compositions of iRNAs and cyclodextrins can be found in U.S. Pat. No. 7,427,605, which is herein incorporated by reference in its entirety.

A. Vector encoded iRNAs of the Invention

iRNA targeting the ANGPTL3 gene can be expressed from transcription units inserted into DNA or RNA vectors (see, e.g., Couture, A, et al., TIG. (1996), 12:5-10; Skillern, A, et al., International PCT Publication No. WO 00/22113, Conrad, International PCT Publication No. WO 00/22114, and Conrad, U.S. Pat. No. 6,054,299). Expression can be transient (on the order of hours to weeks) or sustained (weeks to months or longer), depending upon the specific construct used and the target tissue or cell type. These transgenes can be introduced as a linear construct, a circular plasmid, or a viral vector, which can be an integrating or non-integrating vector. The transgene can also be constructed to permit it to be inherited as an extrachromosomal plasmid (Gassmann, et al., Proc. Natl. Acad. Sci. USA (1995) 92:1292).

Viral vector systems which can be utilized with the methods and compositions described herein include, but are not limited to, (a) adenovirus vectors; (b) retrovirus vectors, including but not limited to lentiviral vectors, moloney murine leukemia virus, etc.; (c) adeno-associated virus vectors; (d) herpes simplex virus vectors; (e) SV 40 vectors; (f) polyoma virus vectors; (g) papilloma virus vectors; (h) picornavirus vectors; (i) pox virus vectors such as an orthopox, e.g., vaccinia virus vectors or avipox, e.g. canary pox or fowl pox; and (j) a helper-dependent or gutless adenovirus. Replication-defective viruses can also be advantageous. Different vectors will or will not become incorporated into the cells' genome. The constructs can include viral sequences for transfection, if desired. Alternatively, the construct can be incorporated into vectors capable of episomal replication, e.g. EPV and EBV vectors. Constructs for the recombinant expression of an iRNA will generally require regulatory elements, e.g., promoters, enhancers, etc., to ensure the expression of the iRNA in target cells. Other aspects to consider for vectors and constructs are known in the art.

V. Pharmaceutical Compositions of the Invention

The present invention also includes pharmaceutical compositions and formulations which include the iRNAs of the invention. In one embodiment, provided herein are pharmaceutical compositions containing an iRNA, as described herein, and a pharmaceutically acceptable carrier. The pharmaceutical compositions containing the iRNA are useful for preventing or treating an ANGPTL3-associated disorder, e.g., a disorder of lipid metabolism. Such pharmaceutical compositions are formulated based on the mode of delivery. One example is compositions that are formulated for systemic administration via parenteral delivery, e.g., by subcutaneous (SC), intramuscular (IM), or intravenous (IV) delivery. The pharmaceutical compositions of the invention may be administered in dosages sufficient to inhibit expression of an ANGPTL3 gene.

In some embodiments, the pharmaceutical compositions of the invention are sterile. In another embodiment, the pharmaceutical compositions of the invention are pyrogen free.

The pharmaceutical compositions of the invention may be administered in dosages sufficient to inhibit expression of an ANGPTL3 gene. In general, a suitable dose of an iRNA of the invention will be in the range of about 0.001 to about 200.0 milligrams per kilogram body weight of the recipient per day, generally in the range of about 1 to 50 mg per kilogram body weight per day. Typically, a suitable dose of an iRNA of the invention will be in the range of about 0.1 mg/kg to about 5.0 mg/kg, such as, about 0.3 mg/kg and about 3.0 mg/kg. A repeat-dose regimen may include administration of a therapeutic amount of iRNA on a regular basis, such as every month, once every 3-6 months, or once a year. In certain embodiments, the iRNA is administered about once per month to about once per six months.

After an initial treatment regimen, the treatments can be administered on a less frequent basis. Duration of treatment can be determined based on the severity of disease.

In other embodiments, a single dose of the pharmaceutical compositions can be long lasting, such that doses are administered at not more than 1, 2, 3, or 4 month intervals. In some embodiments of the invention, a single dose of the pharmaceutical compositions of the invention is administered about once per month. In other embodiments of the invention, a single dose of the pharmaceutical compositions of the invention is administered quarterly (i.e., about every three months). In other embodiments of the invention, a single dose of the pharmaceutical compositions of the invention is administered twice per year (i.e., about once every six months).

The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to mutations present in the subject, previous treatments, the general health or age of the subject, and other diseases present. Moreover, treatment of a subject with a prophylactically or therapeutically effective amount, as appropriate, of a composition can include a single treatment or a series of treatments.

The iRNA can be delivered in a manner to target a particular tissue (e.g., hepatocytes).

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions can be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids, and self-emulsifying semisolids. Formulations include those that target the liver.

The pharmaceutical formulations of the present invention, which can conveniently be presented in unit dosage form, can be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers.

A. Additional Formulations

i. Emulsions

The compositions of the present invention can be prepared and formulated as emulsions. Emulsions are typically heterogeneous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 301). Emulsions are often biphasic systems comprising two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions can be of either the water-in-oil (w/o) or the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase, the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase, the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions can contain additional components in addition to the dispersed phases, and the active drug which can be present as a solution either in the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants can also be present in emulsions as needed. Pharmaceutical emulsions can also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous phase provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Other means of stabilizing emulsions entail the use of emulsifiers that can be incorporated into either phase of the emulsion. Emulsifiers can broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants can be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic, and amphoteric (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y. Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives, and antioxidants (Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

The application of emulsion formulations via dermatological, oral, and parenteral routes, and methods for their manufacture have been reviewed in the literature (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

ii. Microemulsions

In one embodiment of the present invention, the compositions of iRNAs and nucleic acids are formulated as microemulsions. A microemulsion can be defined as a system of water, oil, and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: Controlled Release of Drugs: Polymers and Aggregate Systems, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215).

iii. Microparticles

An iRNA of the invention may be incorporated into a particle, e.g., a microparticle. Microparticles can be produced by spray-drying, but may also be produced by other methods including lyophilization, evaporation, fluid bed drying, vacuum drying, or a combination of these techniques.

iv. Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly iRNAs, to the skin of animals Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs can cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers can be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (see e.g., Malmsten, M. Surfactants and polymers in drug delivery, Informa Health Care, New York, N.Y., 2002; Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92). Each of the above mentioned classes of penetration enhancers and their use in manufacture of pharmaceutical compositions and delivery of pharmaceutical agents are well known in the art.

v. Excipients

In contrast to a carrier compound, a “pharmaceutical carrier” or “excipient” is a pharmaceutically acceptable solvent, suspending agent, or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient can be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Such agent are well known in the art.

vi. Other Components

The compositions of the present invention can additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions can contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or can contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings, or aromatic substances, and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions can contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol, or dextran. The suspension can also contain stabilizers.

In some embodiments, pharmaceutical compositions featured in the invention include (a) one or more iRNA and (b) one or more agents which function by a non-iRNA mechanism and which are useful in treating an ANGPTL33-associated disorder, e.g., a disorder of lipid metabolism.

Toxicity and prophylactic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose prophylactically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds that exhibit high therapeutic indices are preferred.

The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of compositions featured herein in the invention lies generally within a range of circulating concentrations that include the ED50, such as, an ED80 or ED90, with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods featured in the invention, the prophylactically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range of the compound or, when appropriate, of the polypeptide product of a target sequence (e.g., achieving a decreased concentration of the polypeptide) that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) or higher levels of inhibition as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.

In addition to their administration, as discussed above, the iRNAs featured in the invention can be administered in combination with other known agents used for the prevention or treatment of an ANGPTL3-associated disorder, e.g., a disorder of lipid metabolism. In any event, the administering physician can adjust the amount and timing of iRNA administration on the basis of results observed using standard measures of efficacy known in the art or described herein.

VI. Methods For Inhibiting ANGPTL3 Expression

The present invention also provides methods of inhibiting expression of an ANGPTL3 gene in a cell. The methods include contacting a cell with an RNAi agent, e.g., double stranded RNA agent, in an amount effective to inhibit expression of ANGPTL3 in the cell, thereby inhibiting expression of ANGPTL3 in the cell.

Contacting of a cell with an iRNA, e.g., a double stranded RNA agent, may be done in vitro or in vivo. Contacting a cell in vivo with the iRNA includes contacting a cell or group of cells within a subject, e.g., a human subject, with the iRNA. Combinations of in vitro and in vivo methods of contacting a cell are also possible. Contacting a cell may be direct or indirect, as discussed above. Furthermore, contacting a cell may be accomplished via a targeting ligand, including any ligand described herein or known in the art. In some embodiments, the targeting ligand is a carbohydrate moiety, e.g., a GalNAc₃ligand, or any other ligand that directs the RNAi agent to a site of interest.

The term “inhibiting,” as used herein, is used interchangeably with “reducing,” “silencing,” “downregulating”, “suppressing”, and other similar terms, and includes any level of inhibition.

The phrase “inhibiting expression of a ANGPTL3” is intended to refer to inhibition of expression of any ANGPTL3 gene (such as, e.g., a mouse ANGPTL3 3 gene, a rat ANGPTL3 gene, a monkey ANGPTL3 gene, or a human ANGPTL3 gene) as well as variants or mutants of a ANGPTL3 gene. Thus, the ANGPTL3 gene may be a wild-type ANGPTL3 gene, a mutant ANGPTL3 gene, or a transgenic ANGPTL3 gene in the context of a genetically manipulated cell, group of cells, or organism.

“Inhibiting expression of an ANGPTL3 gene” includes any level of inhibition of an ANGPTL3 gene, e.g., at least partial suppression of the expression of an ANGPTL3 gene. The expression of the ANGPTL3 gene may be assessed based on the level, or the change in the level, of any variable associated with ANGPTL3 gene expression, e.g., ANGPTL3 mRNA level or ANGPTL3 protein level. The expression of an ANGPTL3 may also be assessed indirectly based on the levels of a serum lipid, a triglyceride, cholesterol (including LDL-C, HDL-C, VLDL-C, IDL-C and total cholesterol), or free fatty acids. This level may be assessed in an individual cell or in a group of cells, including, for example, a sample derived from a subject. It is understood that ANGPTL3 is expressed predominantly in the liver.

Inhibition may be assessed by a decrease in an absolute or relative level of one or more variables that are associated with ANGPTL3 expression compared with a control level. The control level may be any type of control level that is utilized in the art, e.g., a pre-dose baseline level, or a level determined from a similar subject, cell, or sample that is untreated or treated with a control (such as, e.g., buffer only control or inactive agent control).

In some embodiments of the methods of the invention, expression of an ANGPTL3 gene is inhibited by at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or to below the level of detection of the assay. In some embodiments, expression of an ANGPTL3 gene is inhibited by at least 70%. It is further understood that inhibition of ANGPTL3 expression in certain tissues, e.g., in liver, without a significant inhibition of expression in other tissues, e.g., brain, may be desirable. In some embodiments, expression level is determined using the assay method provided in Example 2 with a 10 nM siRNA concentration in the appropriate species matched cell line.

In certain embodiments, inhibition of expression in vivo is determined by knockdown of the human gene in a rodent expressing the human gene, e.g., an AAV-infected mouse expressing the human target gene (i.e., ANGPTL3), e.g., when administered as a single dose, e.g., at 3 mg/kg at the nadir of RNA expression. Knockdown of expression of an endogenous gene in a model animal system can also be determined, e.g., after administration of a single dose at, e.g., 3 mg/kg at the nadir of RNA expression. Such systems are useful when the nucleic acid sequence of the human gene and the model animal gene are sufficiently close such that the human iRNA provides effective knockdown of the model animal gene. RNA expression in liver is determined using the PCR methods provided in Example 2.

Inhibition of the expression of an ANGPTL3 gene may be manifested by a reduction of the amount of mRNA expressed by a first cell or group of cells (such cells may be present, for example, in a sample derived from a subject) in which an ANGPTL3 gene is transcribed and which has or have been treated (e.g., by contacting the cell or cells with an iRNA of the invention, or by administering an iRNA of the invention to a subject in which the cells are or were present) such that the expression of an ANGPTL3 gene is inhibited, as compared to a second cell or group of cells substantially identical to the first cell or group of cells but which has not or have not been so treated (control cell(s) not treated with an iRNA or not treated with an iRNA targeted to the gene of interest). In some embodiments, the inhibition is assessed by the method provided in Example 2 using a 10 nM siRNA concentration in the species matched cell line and expressing the level of mRNA in treated cells as a percentage of the level of mRNA in control cells, using the following formula:

$\frac{(mRNA in control cells) - (mRNA in treated cells)}{(mRNA in control cells)} •100 %$

In other embodiments, inhibition of the expression of an ANGPTL3 gene may be assessed in terms of a reduction of a parameter that is functionally linked to ANGPTL3 gene expression, e.g., ANGPTL3 protein level in blood or serum from a subject. ANGPTL3 gene silencing may be determined in any cell expressing ANGPTL3, either endogenous or heterologous from an expression construct, and by any assay known in the art.

Inhibition of the expression of an ANGPTL3 protein may be manifested by a reduction in the level of the ANGPTL3 protein that is expressed by a cell or group of cells or in a subject sample (e.g., the level of protein in a blood sample derived from a subject). As explained above, for the assessment of mRNA suppression, the inhibition of protein expression levels in a treated cell or group of cells may similarly be expressed as a percentage of the level of protein in a control cell or group of cells, or the change in the level of protein in a subject sample, e.g., blood or serum derived therefrom.

A control cell, a group of cells, or subject sample that may be used to assess the inhibition of the expression of an ANGPTL3 gene includes a cell, group of cells, or subject sample that has not yet been contacted with an RNAi agent of the invention. For example, the control cell, group of cells, or subject sample may be derived from an individual subject (e.g., a human or animal subject) prior to treatment of the subject with an RNAi agent or an appropriately matched population control.

The level of ANGPTL3 mRNA that is expressed by a cell or group of cells may be determined using any method known in the art for assessing mRNA expression. In one embodiment, the level of expression of ANGPTL3 in a sample is determined by detecting a transcribed polynucleotide, or portion thereof, e.g., mRNA of the ANGPTL3 gene. RNA may be extracted from cells using RNA extraction techniques including, for example, using acid phenol/guanidine isothiocyanate extraction (RNAzol B; Biogenesis), RNeasy™ RNA preparation kits (Qiagen®) or PAXgene™ (PreAnalytix™, Switzerland). Typical assay formats utilizing ribonucleic acid hybridization include nuclear run-on assays, RT-PCR, RNase protection assays, northern blotting, in situ hybridization, and microarray analysis.

In some embodiments, the level of expression of ANGPTL3 is determined using a nucleic acid probe. The term “probe”, as used herein, refers to any molecule that is capable of selectively binding to a specific ANGPTL3. Probes can be synthesized by one of skill in the art, or derived from appropriate biological preparations. Probes may be specifically designed to be labeled. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.

Isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or northern analyses, polymerase chain reaction (PCR) analyses and probe arrays. One method for the determination of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to ANGPTL3 mRNA. In one embodiment, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative embodiment, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix® gene chip array. A skilled artisan can readily adapt known mRNA detection methods for use in determining the level of ANGPTL3 mRNA.

An alternative method for determining the level of expression of ANGPTL3 in a sample involves the process of nucleic acid amplification or reverse transcriptase (to prepare cDNA) of for example mRNA in the sample, e.g., by RT-PCR (the experimental embodiment set forth in Mullis, 1987, U.S. Pat. No. 4,683,202), ligase chain reaction (Barany (1991) Proc. Natl. Acad. Sci. USA 88:189-193), self sustained sequence replication (Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh et al. (1989) Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-Beta Replicase (Lizardi et al. (1988) Bio/Technology 6:1197), rolling circle replication (Lizardi et al., U.S. Pat. No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. In particular aspects of the invention, the level of expression of ANGPTL3 is determined by quantitative fluorogenic RT-PCR (i.e., the TaqMan™ System). In some embodiments, expression level is determined by the method provided in Example 2 using, e.g., a 10 nM siRNA concentration, in the species matched cell line.

The expression levels of ANGPTL3 mRNA may be monitored using a membrane blot (such as used in hybridization analysis such as northern, Southern, dot, and the like), or microwells, sample tubes, gels, beads or fibers (or any solid support comprising bound nucleic acids). See U.S. Pat. Nos. 5,770,722, 5,874,219, 5,744,305, 5,677,195 and 5,445,934, which are incorporated herein by reference. The determination of ANGPTL3 expression level may also comprise using nucleic acid probes in solution.

In some embodiments, the level of mRNA expression is assessed using branched DNA (bDNA) assays or real time PCR (qPCR). The use of these methods is described and exemplified in the Examples presented herein. In some embodiments, expression level is determined by the method provided in Example 2 using a 10 nM siRNA concentration in the species matched cell line.

The level of ANGPTL3 protein expression may be determined using any method known in the art for the measurement of protein levels. Such methods include, for example, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, fluid or gel precipitin reactions, absorption spectroscopy, a colorimetric assays, spectrophotometric assays, flow cytometry, immunodiffusion (single or double), immunoelectrophoresis, western blotting, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, electrochemiluminescence assays, and the like.

In some embodiments, the efficacy of the methods of the invention are assessed by a decrease in ANGPTL3 mRNA or protein level (e.g., in a liver biopsy).

In some embodiments of the methods of the invention, the iRNA is administered to a subject such that the iRNA is delivered to a specific site within the subject. The inhibition of expression of ANGPTL3 may be assessed using measurements of the level or change in the level of ANGPTL3 mRNA or ANGPTL3 protein in a sample derived from fluid or tissue from the specific site within the subject (e.g., liver or blood).

As used herein, the terms detecting or determining a level of an analyte are understood to mean performing the steps to determine if a material, e.g., protein, RNA, is present. As used herein, methods of detecting or determining include detection or determination of an analyte level that is below the level of detection for the method used.

VII. Prophylactic and Treatment Methods of the Invention

The present invention also provides methods of using an iRNA of the invention or a composition containing an iRNA of the invention to inhibit expression of ANGPTL3, thereby preventing or treating an ANGPTL3-associated disorder, e.g., a disorder of lipid metabolism. In the methods of the invention the cell may be contacted with the siRNA in vitro or in vivo, i.e., the cell may be within a subject.

A cell suitable for treatment using the methods of the invention may be any cell that expresses an ANGPTL3 gene, e.g., a liver cell. A cell suitable for use in the methods of the invention may be a mammalian cell, e.g., a primate cell (such as a human cell, including human cell in a chimeric non-human animal, or a non-human primate cell, e.g., a monkey cell or a chimpanzee cell), or a non-primate cell. In certain embodiments, the cell is a human cell, e.g., a human liver cell. In the methods of the invention, ANGPTL3 expression is inhibited in the cell by at least 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95, or to a level below the level of detection of the assay.

The in vivo methods of the invention may include administering to a subject a composition containing an iRNA, where the iRNA includes a nucleotide sequence that is complementary to at least a part of an RNA transcript of the ANGPTL3 gene of the mammal to which the RNAi agent is to be administered. The composition can be administered by any means known in the art including, but not limited to oral, intraperitoneal, or parenteral routes, including intracranial (e.g., intraventricular, intraparenchymal, and intrathecal), intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), nasal, rectal, and topical (including buccal and sublingual) administration. In certain embodiments, the compositions are administered by intravenous infusion or injection. In certain embodiments, the compositions are administered by subcutaneous injection. In certain embodiments, the compositions are administered by intramuscular injection.

In one aspect, the present invention also provides methods for inhibiting the expression of an ANGPTL3 gene in a mammal. The methods include administering to the mammal a composition comprising a dsRNA that targets an ANGPTL3 gene in a cell of the mammal and maintaining the mammal for a time sufficient to obtain degradation of the mRNA transcript of the ANGPTL3 gene, thereby inhibiting expression of the ANGPTL3 gene in the cell. Reduction in gene expression can be assessed by any methods known in the art and by methods, e.g. qRT-PCR, described herein, e.g., in Example 2. Reduction in protein production can be assessed by any methods known it the art, e.g. ELISA. In certain embodiments, a puncture liver biopsy sample serves as the tissue material for monitoring the reduction in the ANGPTL3 gene or protein expression. In other embodiments, a blood sample serves as the subject sample for monitoring the reduction in the ANGPTL3 protein expression.

The present invention further provides methods of treatment in a subject in need thereof, e.g., a subject diagnosed with an ANGPTL3-associated disorder, such as a disorder of lipid metabolism. In one embodiment, a subject having a disorder of lipid metabolism has hyperlipidemia. In another embodiment, a subject having a disorder of lipid metabolism has hypertriglyceridemia.

The present invention further provides methods of prophylaxis in a subject in need thereof. The treatment methods of the invention include administering an iRNA of the invention to a subject, e.g., a subject that would benefit from a reduction of ANGPTL3 expression, in a prophylactically effective amount of a dsRNA targeting an ANGPTL3 gene or a pharmaceutical composition comprising a dsRNA targeting an ANGPTL3 gene.

In one aspect, the present invention provides methods of treating a subject having a disorder that would benefit from reduction in ANGPTL3 expression, e.g., an ANGPTL3-associated disease, such as a disorder of lipid metabolism, e.g., hyperlipidemia or hypertriglyceridemia. Treatment of a subject that would benefit from a reduction and/or inhibition of ANGPTL3 gene expression includes therapeutic treatment (e.g., a subject is having eruptive xanthomas) and prophylactic treatment (e.g., the subject is not having eruptive xanthomas or a subject may be at risk of developing eruptive xanthomas).

An iRNA of the invention may be administered as a “free iRNA.” A free iRNA is administered in the absence of a pharmaceutical composition. The naked iRNA may be in a suitable buffer solution. The buffer solution may comprise acetate, citrate, prolamine, carbonate, or phosphate, or any combination thereof. In one embodiment, the buffer solution is phosphate buffered saline (PBS). The pH and osmolarity of the buffer solution containing the iRNA can be adjusted such that it is suitable for administering to a subject.

Alternatively, an iRNA of the invention may be administered as a pharmaceutical composition, such as a dsRNA liposomal formulation.

Subjects that would benefit from an inhibition of ANGPTL3 gene expression are subjects susceptible to or diagnosed with an ANGPTL3-associated disorder, such as a disorder of lipid metabolism, e.g., hyperlipidemia or hypertriglyceridemia. In an embodiment, the method includes administering a composition featured herein such that expression of the target an ANGPTL3 gene is decreased, such as for about 1, 2, 3, 4, 5, 6, 1-6, 1-3, or 3-6 months per dose. In certain embodiments, the composition is administered once every 3-6 months.

In one embodiment, the iRNAs useful for the methods and compositions featured herein specifically target RNAs (primary or processed) of the target ANGPTL3 gene. Compositions and methods for inhibiting the expression of these genes using iRNAs can be prepared and performed as described herein.

Administration of the iRNA according to the methods of the invention may result prevention or treatment of an ANGPTL3-associated disorder, e.g., a disorder of lipid metabolism, e.g., hyperlipidemia or hypertriglyceridemia. Subjects can be administered a therapeutic amount of iRNA, such as about 0.01 mg/kg to about 200 mg/kg.

In one embodiment, the iRNA is administered subcutaneously, i.e., by subcutaneous injection. One or more injections may be used to deliver the desired dose of iRNA to a subject. The injections may be repeated over a period of time.

The administration may be repeated on a regular basis. In certain embodiments, after an initial treatment regimen, the treatments can be administered on a less frequent basis. A repeat-dose regimen may include administration of a therapeutic amount of iRNA on a regular basis, such as once per month to once a year. In certain embodiments, the iRNA is administered about once per month to about once every three months, or about once every three months to about once every six months.

The invention further provides methods and uses of an iRNA agent or a pharmaceutical composition thereof for treating a subject that would benefit from reduction and/or inhibition of ANGPTL3 gene expression, e.g., a subject having an ANGPTL3-associated disease, in combination with other pharmaceuticals and/or other therapeutic methods, e.g., with known pharmaceuticals and/or known therapeutic methods, such as, for example, those which are currently employed for treating these disorders.

Accordingly, in some aspects of the invention, the methods which include either a single iRNA agent of the invention, further include administering to the subject one or more additional therapeutic agents.

For example, in certain embodiments, an iRNA targeting ANGPTL3 is administered in combination with, e.g., an agent useful in treating a disorder of lipid metabolism. For example, additional agents suitable for treating a subject that would benefit from reducton in ANGPTL3 expression, e.g., a subject having a disorder of lipid metabolism, may include agents that lower one or more serum lipids. Non-limiting examples of such agents may include cholesterol synthesis inhibitors, such as HMG-CoA reductase inhibitors, e.g., statins. Statins may include atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Mevacor), lovastatin extended-release (Altoprev), pitavastatin (Livalo), pravastatin (Pravachol), rosuvastatin (Crestor), and simvastatin (Zocor). Other agents useful in treating a disorder of lipid metabolism may include bile sequestering agents, such as cholestyramine and other resins; VLDL secretion inhibitors, such as niacin; lipophilic antioxidants, such as Probucol; acyl-CoA cholesterol acyl transferase inhibitors; farnesoid X receptor antagonists; sterol regulatory binding protein cleavage activating protein (SCAP) activators; microsomal triglyceride transfer protein (MTP) inhibitors; ApoE-related peptide; and therapeutic antibodies against ANGPTL3. The additional therapeutic agents may also include agents that raise high density lipoprotein (HDL), such as cholesteryl ester transfer protein (CETP) inhibitors. Furthermore, the additional therapeutic agents may also include dietary supplements, e.g., fish oil. The iRNA and additional therapeutic agents may be administered at the same time and/or in the same combination, e.g., parenterally, or the additional therapeutic agent can be administered as part of a separate composition or at separate times and/or by another method known in the art or described herein.

The iRNA agent and an additional therapeutic agent and/or treatment may be administered at the same time and/or in the same combination, e.g., parenterally, or the additional therapeutic agent can be administered as part of a separate composition or at separate times and/or by another method known in the art or described herein.

VIII. Kits

In certain aspects, the instant disclosure provides kits that include a suitable container containing a pharmaceutical formulation of a siRNA compound, e.g., a double-stranded siRNA compound, or siRNA compound, (e.g., a precursor, e.g., a larger siRNA compound which can be processed into a siRNA compound, or a DNA which encodes an siRNA compound, e.g., a double-stranded siRNA compound, or ssiRNA compound, or precursor thereof).

Such kits include one or more dsRNA agent(s) and instructions for use, e.g., instructions for administering a prophylactically or therapeutically effective amount of a dsRNA agent(s). The dsRNA agent may be in a vial or a pre-filled syringe. The kits may optionally further comprise means for administering the dsRNA agent (e.g., an injection device, such as a pre-filled syringe), or means for measuring the inhibition of ANGPTL3 (e.g., means for measuring the inhibition of ANGPTL3 mRNA, ANGPTL3 protein, and/or ANGPTL3 activity). Such means for measuring the inhibition of ANGPTL3 may comprise a means for obtaining a sample from a subject, such as, e.g., a plasma sample. The kits of the invention may optionally further comprise means for determining the therapeutically effective or prophylactically effective amount.

In certain embodiments the individual components of the pharmaceutical formulation may be provided in one container, e.g., a vial or a pre-filled syringe. Alternatively, it may be desirable to provide the components of the pharmaceutical formulation separately in two or more containers, e.g., one container for a siRNA compound preparation, and at least another for a carrier compound. The kit may be packaged in a number of different configurations such as one or more containers in a single box. The different components can be combined, e.g., according to instructions provided with the kit. The components can be combined according to a method described herein, e.g., to prepare and administer a pharmaceutical composition. The kit can also include a delivery device.

This invention is further illustrated by the following examples which should not be construed as limiting. The entire contents of all references, patents and published patent applications cited throughout this application, as well as the informal Sequence Listing and Figures, are hereby incorporated herein by reference.

EXAMPLES
Example 1. iRNA Synthesis

Source of Reagents

Where the source of a reagent is not specifically given herein, such reagent can be obtained from any supplier of reagents for molecular biology at a quality/purity standard for application in molecular biology.

siRNA Design

siRNAs targeting the human Angiopoietin-like 3 (ANGPTL3) gene (human: NCBI refseqID NM_014995.3 and NM_014995.2, NCBI GeneID: 27329) were designed using custom R and Python scripts. The human NM_014995.3 REFSEQ mRNA, has a length of 2951 bases. The human NM_014995.2 REFSEQ mRNA, has a length of 2126 bases.

Detailed lists of the unmodified ANGPTL3 sense and antisense strand nucleotide sequences are shown in Table 2. Detailed lists of the modified ANGPTL3 sense and antisense strand nucleotide sequences are shown in Table 3.

It is to be understood that, throughout the application, a duplex name without a decimal is equivalent to a duplex name with a decimal which merely references the batch number of the duplex. For example, AD-959917 is equivalent to AD-959917.1.

siRNA Synthesis

siRNAs were designed, synthesized, and prepared using methods known in the art.

Briefly, siRNA sequences were synthesized on a 1 μmol scale using a Mermade 192 synthesizer (BioAutomation) with phosphoramidite chemistry on solid supports. The solid support was controlled pore glass (500-1000 Å) loaded with a custom GalNAc ligand (3′-GalNAc conjugates), universal solid support (AM Chemicals), or the first nucleotide of interest. Ancillary synthesis reagents and standard 2-cyanoethyl phosphoramidite monomers (2′-deoxy-2′-fluoro, 2′-O-methyl, RNA, DNA) were obtained from Thermo-Fisher (Milwaukee, Wis.), Hongene (China), or Chemgenes (Wilmington, Mass., USA). Additional phosphoramidite monomers were procured from commercial suppliers, prepared in-house, or procured using custom synthesis from various CMOs. Phosphoramidites were prepared at a concentration of 100 mM in either acetonitrile or 9:1 acetonitrile:DMF and were coupled using 5-Ethylthio-1H-tetrazole (ETT, 0.25 M in acetonitrile) with a reaction time of 400 s. Phosphorothioate linkages were generated using a 100 mM solution of 3-((Dimethylamino-methylidene) amino)-3H-1,2,4-dithiazole-3-thione (DDTT, obtained from Chemgenes (Wilmington, Mass., USA)) in anhydrous acetonitrile/pyridine (9:1 v/v). Oxidation time was 5 minutes. All sequences were synthesized with final removal of the DMT group (“DMT-Off”).

Upon completion of the solid phase synthesis, solid-supported oligoribonucleotides were treated with 300 μL of Methylamine (40% aqueous) at room temperature in 96 well plates for approximately 2 hours to afford cleavage from the solid support and subsequent removal of all additional base-labile protecting groups. For sequences containing any natural ribonucleotide linkages (2′-OH) protected with a tert-butyl dimethyl silyl (TBDMS) group, a second deprotection step was performed using TEA.3HF (triethylamine trihydrofluoride). To each oligonucleotide solution in aqueous methylamine was added 200 μL of dimethyl sulfoxide (DMSO) and 300 μL TEA.3HF and the solution was incubated for approximately 30 mins at 60° C. After incubation, the plate was allowed to come to room temperature and crude oligonucleotides were precipitated by the addition of 1 mL of 9:1 acetontrile:ethanol or 1:1 ethanol:isopropanol. The plates were then centrifuged at 4° C. for 45 mins and the supernatant carefully decanted with the aid of a multichannel pipette. The oligonucleotide pellet was resuspended in 20 mM NaOAc and subsequently desalted using a HiTrap size exclusion column (5 mL, GE Healthcare) on an Agilent LC system equipped with an autosampler, UV detector, conductivity meter, and fraction collector. Desalted samples were collected in 96 well plates and then analyzed by LC-MS and UV spectrometry to confirm identity and quantify the amount of material, respectively.

Duplexing of single strands was performed on a Tecan liquid handling robot. Sense and antisense single strands were combined in an equimolar ratio to a final concentration of 10 μM in 1×PBS in 96 well plates, the plate sealed, incubated at 100° C. for 10 minutes, and subsequently allowed to return slowly to room temperature over a period of 2-3 hours. The concentration and identity of each duplex was confirmed and then subsequently utilized for in vitro screening assays.

Example 2. In Vitro Screening Methods

Cell Culture and 384-Well Transfections

For transfections, primary cynomolgus hepatocytes (PCH) cells or Hep3B cells (ATCC, Manassas, Va.) were grown to near confluence at 37° C. in an atmosphere of 5% CO₂in Eagle's Minimum Essential Medium (Gibco) supplemented with 10% FBS (ATCC) before being released from the plate by trypsinization. Transfection was carried out by adding 7.5 μl of Opti-MEM plus 0.1 μl of Lipofectamine RNAiMax per well (Invitrogen, Carlsbad Calif. cat #13778-150) to 2.5 μl of each siRNA duplex to an individual well in a 384-well plate. The mixture was then incubated at room temperature for 15 minutes. Forty μl of complete growth media without antibiotic containing ˜1.5×10⁴cells were then added to the siRNA mixture. Cells were incubated for 24 hours prior to RNA purification. Single dose experiments were performed at 10 nM, 1 nM, and 0.1 nM final duplex concentration.

Total RNA Isolation Using DYNABEADS mRNA Isolation Kit (Invitrogen™, Part #: 610-12)

Cells were lysed in 75 μl of Lysis/Binding Buffer containing 3 μL of beads per well and mixed for 10 minutes on an electrostatic shaker. The washing steps were automated on a Biotek EL406, using a magnetic plate support. Beads were washed (in 90 μL) once in Buffer A, once in Buffer B, and twice in Buffer E, with aspiration steps in between. Following a final aspiration, complete 10 μL RT mixture was added to each well, as described below.

cDNA Synthesis Using ABI High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, Calif., Cat #4368813)

A master mix of 1 μl 10× Buffer, 0.4 μl 25× dNTPs, 1 μl Random primers, 0.5 μl Reverse Transcriptase, 0.5 μl RNase inhibitor and 6.6 μl of H₂O per reaction were added per well. Plates were sealed, agitated for 10 minutes on an electrostatic shaker, and then incubated at 37 degrees C. for 2 hours. Following this, the plates were agitated at 80 degrees C. for 8 minutes.

Real time PCR

Two microlitre (μl) of cDNA were added to a master mix containing 0.5 μl of human GAPDH TaqMan Probe (4326317E), 0.5 μl human ANGPTL3, 2 μl nuclease-free water and 5 μl Lightcycler 480 probe master mix (Roche Cat #04887301001) per well in a 384 well plates (Roche cat #04887301001). Real time PCR was done in a LightCycler480 Real Time PCR system (Roche).

To calculate relative fold change, data were analyzed using the ΔΔCt method and normalized to assays performed with cells transfected with 10 nM AD-1955, or mock transfected cells. IC₅₀s were calculated using a 4 parameter fit model using XLFit and normalized to cells transfected with AD-1955 or mock-transfected. The sense and antisense sequences of AD-1955 are: sense: cuuAcGcuGAGuAcuucGAdTsdT (SEQ ID NO: 27) and antisense UCGAAGuACUcAGCGuAAGdTsdT (SEQ ID NO: 28).

The results of the single dose screens of the dsRNA agents listed in Tables 2 and 3 in primary cynomolgus hepatocytes (PCH) are shown in Table 4.

Table 1. Abbreviations of nucleotide monomers used in nucleic acid sequence representation. It will be understood that these monomers, when present in an oligonucleotide, are mutually linked by 5′-3′-phosphodiester bonds; and it is understood that when the nucleotide contains a 2′-fluoro modification, then the fluoro replaces the hydroxy at that position in the parent nucleotide (i.e., it is a 2′-deoxy-2′-fluoronucleotide).

TABLE 1

Abbreviations of nucleotide monomers used in nucleic acid sequence representation. It will be understood that these monomers, when present

in an oligonucleotide, are mutually linked by 5′-3′-phosphodiester bonds; and it is understood that when the nucleotide contains a 2′-fluoro

modification, then the fluoro replaces the hydroxy at that position in the parent nucleotide (i.e., it is a 2′-deoxy-2′-fluoronucleotide).

Abbre-

viation
Nucleotide(s)

A
Adenosine-3′-phosphate

Ab
beta-L-adenosine-3′-phosphate

Abs
beta-L-adenosine-3′-phosphorothioate

Af
2′-fluoroadenosine-3′-phosphate

Afs
2′-fluoroadenosine-3′-phosphorothioate

As
adenosine-3′-phosphorothioate

C
cytidine-3′-phosphate

Cb
beta-L-cytidine-3′-phosphate

Cbs
beta-L-cytidine-3′-phosphorothioate

Cf
2′-fluorocytidine-3′-phosphate

Cfs
2′-fluorocytidine-3′-phosphorothioate

Cs
cytidine-3′-phosphorothioate

G
guanosine-3′-phosphate

Gb
beta-L-guanosine-3′-phosphate

Gbs
beta-L-guanosine-3′-phosphorothioate

Gf
2′-fluoroguanosine-3′-phosphate

Gfs
2′-fluoroguanosine-3′-phosphorothioate

Gs
guanosine-3′-phosphorothioate

T
5′-methyluridine-3′-phosphate

Tf
2′-fluoro-5-methyluridine-3′-phosphate

Tfs
2′-fluoro-5-methyluridine-3′-phosphorothioate

Ts
5-methyluridine-3′-phosphorothioate

U
Uridine-3′-phosphate

Uf
2′-fluorouridine-3′-phosphate

Ufs
2′-fluorouridine-3′-phosphorothioate

Us
uridine-3′-phosphorothioate

N
any nucleotide, modified or unmodified

a
2′-O-methyladenosine-3′-phosphate

as
2′-O-methyladenosine-3′-phosphorothioate

c
2′-O-methylcytidine-3′-phosphate

cs
2′-O-methylcytidine-3′-phosphorothioate

g
2′-O-methylguanosine-3′-phosphate

gs
2′-O-methylguanosine-3′-phosphorothioate

t
2′-O-methyl-5-methyluridine-3′-phosphate

ts
2′-O-methyl-5-methyluridine-3′-phosphorothioate

u
2′-O-methyluridine-3′-phosphate

us
2′-O-methyluridine-3′-phosphorothioate

s
phosphorothioate linkage

L10
N-(cholesterylcarboxamidocaproyl)-4-hydroxyprolinol (Hyp-C6-Chol)

L96
N-[tris(GalNAc-alkyl)-amidodecanoyl)]-4-hydroxyprolinol (Hyp-(GalNAc-alkyl)3)

embedded image

Y34
2-hydroxymethyl-tetrahydrofurane-4-methoxy-3-phosphate (abasic 2′-OMe furanose)

Y44
inverted abasic DNA (2-hydroxymethyl-tetrahydrofurane-5-phosphate)

(Agn)
Adenosine-glycol nucleic acid (GNA) S-Isomer

(Cgn)
Cytidine-glycol nucleic acid (GNA) S-Isomer

(Ggn)
Guanosine-glycol nucleic acid (GNA) S-Isomer

(Tgn)
Thymidine-glycol nucleic acid (GNA) S-Isomer

P
Phosphate

VP
Vinyl-phosphonate

dA
2′-deoxyadenosine-3′-phosphate

dAs
2′-deoxyadenosine-3′-phosphorothioate

dC
2′-deoxycytidine-3′-phosphate

dCs
2′-deoxycytidine-3′-phosphorothioate

dG
2′-deoxyguanosine-3′-phosphate

dGs
2′-deoxyguanosine-3′-phosphorothioate

dT
2′-deoxythimidine-3′-phosphate

dTs
2′-deoxythimidine-3′-phosphorothioate

dU
2′-deoxyuridine

dUs
2′-deoxyuridine-3′-phosphorothioate

(C2p)
cytidine-2′-phosphate

(G2p)
guanosine-2′-phosphate

(U2p)
uridine-2′-phosphate

(A2p)
adenosine-2′-phosphate

(Chd)
2′-O-hexadecyl-cytidine-3′-phosphate

(Ahd)
2′-O-hexadecyl-adenosine-3′-phosphate

(Ghd)
2′-O-hexadecyl-guanosine-3′-phosphate

(Uhd)
2′-O-hexadecyl-uridine-3′-phosphate

s
phosphorothioate

TABLE 2

Unmodified Sense and Antisense Strand Sequences of ANGPTL3 dsRNA Agents

SEQ

Range in

SEQ

Range in

Duplex Name
Sense Sequence 5′ to 3′
ID NO:
Source Name
NM_014495.3
Antisense Sequence 5′ to 3′
ID NO:
Source Name
NM_014495.3

AD-1331197.1
AUAAAAAUGUUCACAAUUAAU
29
NM_014495.3_75-
75-95
AUUAAUUGUGAACAUUUUUAUCU
138

73-95

95_G21U_s

AD-1331198.1
UAAAAAUGUUCACAAUUAAGU
30
NM_014495.3_76-
76-96
ACUUAAUUGUGAACAUUUUUAUC
139

74-96

96_C21U_s

AD-1331199.1
AAAAAUGUUCACAAUUAAGCU
31
NM_014495.3_77-
77-97
AGCUUAAUUGUGAACAUUUUUAU
140

75-97

97_s

AD-1331200.1
AAAAUGUUCACAAUUAAGCUU
32
NM_014495.3_78-
78-98
AAGCUUAAUUGUGAACAUUUUUA
141

76-98

98_C21U_s

AD-1331201.1
AAAUGUUCACAAUUAAGCUCU
33
NM_014495.3_79-
79-99
AGAGCUTAAUUGUGAACAUUUUU
142

77-99

99_C21U_s

AD-1331202.1
AUGUUCACAAUUAAGCUCCUU
34
NM_014495.3_81-
81-101
AAGGAGCUUAAUUGUGAACAUUU
143

79-101

101_s

AD-1331203.1
UGUUCACAAUUAAGCUCCUUU
35
NM_014495.3_82-
82-102
AAAGGAGCUUAAUUGUGAACAUU
144

80-102

102_C21U_s

AD-1331204.1
GUUCACAAUUAAGCUCCUUCU
36
NM_014495.3_83-
83-103
AGAAGGAGCUUAAUUGUGAACAU
145

81-103

103_s

AD-1331205.1
UUCACAAUUAAGCUCCUUCUU
37
NM_014495.3_84-
84-104
AAGAAGGAGCUUAAUUGUGAACA
146

82-104

104_s

AD-66977.2
UCACAAUUAAGCUCCUUCUUU
38

85-105
AAAGAAGGAGCUUAAUUGUGAAC
147
NM_014495.2_54-76_as
83-105

AD-1331206.1
CACAAUUAAGCUCCUUCUUUU
39
NM_014495.3_86-
86-106
AAAAGAAGGAGCUUAAUUGUGAA
148

84-106

106_s

AD-1331207.1
ACAAUUAAGCUCCUUCUUUUU
40
NM_014495.3_87-
87-107
AAAAAGAAGGAGCUUAAUUGUGA
149

85-107

107_s

AD-1331208.1
CAAUUAAGCUCCUUCUUUUUU
41

88-108
AAAAAAGAAGGAGCUUAAUUGUG
150

86-108

AD-1331209.1
AAUUAAGCUCCUUCUUUUUAU
42
NM_014495.3_89-
89-109
AUAAAAAGAAGGAGCUUAAUUGU
151

87-109

109_s

AD-67003.3
AUUAAGCUCCUUCUUUUUAUU
43

90-110
AAUAAAAAGAAGGAGCUUAAUUG
152
NM_014495.2_59-81_as
88-110

AD-1331210.1
UUAAGCUCCUUCUUUUUAUUU
44
NM_014495.3_91-
91-111
AAAUAAAAAGAAGGAGCUUAAUU
153

89-111

111_G21U_s

AD-1331211.1
UAAGCUCCUUCUUUUUAUUGU
45
NM_014495.3_92-
92-112
ACAAUAAAAAGAAGGAGCUUAAU
154

90-112

112_s

AD-1331212.1
AAGCUCCUUCUUUUUAUUGUU
46
NM_014495.3_93-
93-113
AACAAUAAAAAGAAGGAGCUUAA
155

91-113

113_s

AD-1331213.1
AGCUCCUUCUUUUUAUUGUUU
47

94-114
AAACAAUAAAAAGAAGGAGCUUA
156

92-114

AD-1331214.1
GCUCCUUCUUUUUAUUGUUCU
48

95-115
AGAACAAUAAAAAGAAGGAGCUU
157

93-115

AD-1331215.1
CUCCUUCUUUUUAUUGUUCCU
49
NM_014495.3_96-
96-116
AGGAACAAUAAAAAGAAGGAGCU
158

94-116

116_s

AD-1331216.1
UCCUUCUUUUUAUUGUUCCUU
50

97-117
AAGGAACAAUAAAAAGAAGGAGC
159

95-117

AD-1331217.1
CCUUCUUUUUAUUGUUCCUCU
51

98-118
AGAGGAACAAUAAAAAGAAGGAG
160

96-118

AD-1331218.1
CUUCUUUUUAUUGUUCCUCUA
52

99-119
UAGAGGAACAAUAAAAAGAAGGA
161

97-119

AD-1331220.1
UCUUUUUAUUGUUCCUCUAGU
53
NM_014495.3_101-
101-121
ACUAGAGGAACAAUAAAAAGAAG
162

99-121

121_s

AD-1331221.1
CUUUUUAUUGUUCCUCUAGUU
54
NM_014495.3_102-
102-122
AACUAGAGGAACAAUAAAAAGAA
163

100-122

122_s

AD-1331222.1
UUUUUAUUGUUCCUCUAGUUU
55

103-123
AAACUAGAGGAACAAUAAAAAGA
164

101-123

AD-1331223.1
UUUUAUUGUUCCUCUAGUUAU
56
NM_014495.3_104-
104-124
AUAACUAGAGGAACAAUAAAAAG
165

102-124

124_s

AD-1331224.1
AUUUCAAAAACUCAACAUAUU
57
NM_014495.3_293-
293-313
AAUATGTUGAGUUUUUGAAAUAU
166

291-313

313_s

AD-1331225.1
UUUCAAAAACUCAACAUAUUU
58
NM_014495.3_294-
294-314
AAAUAUGUUGAGUUUUUGAAAUA
167

292-314

314_s

AD-1331226.1
UUCAAAAACUCAACAUAUUUU
59

295-315
AAAAUAUGUUGAGUUUUUGAAAU
168

293-315

AD-1331227.1
UCAAAAACUCAACAUAUUUGU
60

296-316
ACAAAUAUGUUGAGUUUUUGAAA
169

294-316

AD-1331228.1
CAAAAACUCAACAUAUUUGAU
61
NM_014495.3_297-
297-317
AUCAAAUAUGUUGAGUUUUUGAA
170

295-317

317_s

AD-1331229.1
AAAAACUCAACAUAUUUGAUU
62
NM_014495.3_298-
298-318
AAUCAAAUAUGUUGAGUUUUUGA
171

296-318

318_C21U_s

AD-1331230.1
AAAACUCAACAUAUUUGAUCU
63

299-319
AGAUCAAAUAUGUUGAGUUUUUG
172

297-319

AD-1331231.1
AAACUCAACAUAUUUGAUCAU
64
NM_014495.3_300-
300-320
AUGATCAAAUAUGUUGAGUUUUU
173

298-320

320_G21U_s

AD-1331232.1
AACUCAACAUAUUUGAUCAGU
65
NM_014495.3_301-
301-321
ACUGAUCAAAUAUGUUGAGUUUU
174

299-321

321_s

AD-1331233.1
ACUCAACAUAUUUGAUCAGUU
66
NM_014495.3_302-
302-322
AACUGATCAAAUAUGUUGAGUUU
175

300-322

322_C21U_s

AD-1331234.1
UCAACAUAUUUGAUCAGUCUU
67
NM_014495.3_304-
304-324
AAGACUGAUCAAAUAUGUUGAGU
176

302-324

324_s

AD-67031.2
CAACAUAUUUGAUCAGUCUUU
68

305-325
AAAGACUGAUCAAAUAUGUUGAG
177
NM_014495.2_274-296_as
303-325

AD-1331235.1
AACAUAUUUGAUCAGUCUUUU
69
NM_014495.3_306-
306-326
AAAAGACUGAUCAAAUAUGUUGA
178

304-326

326_s

AD-65695.22
ACAUAUUUGAUCAGUCUUUUU
70

307-327
AAAAAGACUGAUCAAAUAUGUUG
179
NM_014495.2_276-298_as
305-327

AD-1331236.1
CAUAUUUGAUCAGUCUUUUUU
71

308-328
AAAAAAGACUGAUCAAAUAUGUU
180

306-328

AD-1331237.1
AUAUUUGAUCAGUCUUUUUAU
72
NM_014495.3_309-
309-329
AUAAAAAGACUGAUCAAAUAUGU
181

307-329

329_s

AD-1331238.1
UAUUUGAUCAGUCUUUUUAUU
73
NM_014495.3_310-
310-330
AAUAAAAAGACUGAUCAAAUAUG
182

308-330

330_G21U_s

AD-1331239.1
AUUUGAUCAGUCUUUUUAUGU
74

311-331
ACAUAAAAAGACUGAUCAAAUAU
183

309-331

AD-1331240.1
UUUGAUCAGUCUUUUUAUGAU
75
NM_014495.3_312-
312-332
AUCAUAAAAAGACUGAUCAAAUA
184

310-332

332_s

AD-1331241.1
UUGAUCAGUCUUUUUAUGAUU
76
NM_014495.3_313-
313-333
AAUCAUAAAAAGACUGAUCAAAU
185

311-333

333_C21U_s

AD-1331242.1
UGAUCAGUCUUUUUAUGAUCU
77
NM_014495.3_314-
314-334
AGAUCATAAAAAGACUGAUCAAA
186

312-334

334_s

AD-1331243.1
GAUCAGUCUUUUUAUGAUCUA
78
NM_014495.3_315-
315-335
UAGATCAUAAAAAGACUGAUCAA
187

313-335

335_s

AD-1331244.1
AUCAGUCUUUUUAUGAUCUAU
79
NM_014495.3_316-
316-336
AUAGAUCAUAAAAAGACUGAUCA
188

314-336

336_s

AD-1331245.1
UCAGUCUUUUUAUGAUCUAUU
80
NM_014495.3_317-
317-337
AAUAGATCAUAAAAAGACUGAUC
189

315-337

337_C21U_s

AD-1331246.1
CAGUCUUUUUAUGAUCUAUCU
81
NM_014495.3_318-
318-338
AGAUAGAUCAUAAAAAGACUGAU
190

316-338

338_G21U_s

AD-1331247.1
AGUCUUUUUAUGAUCUAUCGU
82
NM_014495.3_319-
319-339
ACGAUAGAUCAUAAAAAGACUGA
191

317-339

339_C21U_s

AD-1331248.1
GUCUUUUUAUGAUCUAUCGCU
83
NM_014495.3_320-
320-340
AGCGAUAGAUCAUAAAAAGACUG
192

318-340

340_s

AD-1331249.1
UCUUUUUAUGAUCUAUCGCUU
84
NM_014495.3_321-
321-341
AAGCGAUAGAUCAUAAAAAGACU
193

319-341

341_G21U_s

AD-1331250.1
CUUUUUAUGAUCUAUCGCUGU
85
NM_014495.3_322-
322-342
ACAGCGAUAGAUCAUAAAAAGAC
194

320-342

342_C21U_s

AD-1331251.1
AACUCCAGAACACCCAGAAGU
86
NM_014495.3_542-
542-562
ACUUCUGGGUGUUCUGGAGUUUC
195

540-562

562_s

AD-1331252.1
ACUCCAGAACACCCAGAAGUA
87
NM_014495.3_543-
543-563
UACUTCTGGGUGUUCUGGAGUUU
196

541-563

563_s

AD-1331253.1
CUCCAGAACACCCAGAAGUAA
88
NM_014495.3_544-
544-564
UUACTUCUGGGUGUUCUGGAGUU
197

542-564

564_s

AD-1331254.1
UCCAGAACACCCAGAAGUAAU
89
NM_014495.3_545-
545-565
AUUACUTCUGGGUGUUCUGGAGU
198

543-565

565_C21U_s

AD-1331255.1
CCAGAACACCCAGAAGUAACU
90
NM_014495.3_546-
546-566
AGUUACTUCUGGGUGUUCUGGAG
199

544-566

566_s

AD-1331256.1
CAGAACACCCAGAAGUAACUU
91
NM_014495.3_547-
547-567
AAGUTACUUCUGGGUGUUCUGGA
200

545-567

567_s

AD-1331257.1
AGAACACCCAGAAGUAACUUU
92
NM_014495.3_548-
548-568
AAAGUUACUUCUGGGUGUUCUGG
201

546-568

568_C21U_s

AD-1331258.1
GAACACCCAGAAGUAACUUCA
93
NM_014495.3_549-
549-569
UGAAGUTACUUCUGGGUGUUCUG
202

547-569

569_s

AD-1331259.1
AACACCCAGAAGUAACUUCAU
94
NM_014495.3_550-
550-570
AUGAAGTUACUUCUGGGUGUUCU
203

548-570

570_C21U_s

AD-1331260.1
ACACCCAGAAGUAACUUCACU
95
NM_014495.3_551-
551-571
AGUGAAGUUACUUCUGGGUGUUC
204

549-571

571_s

AD-1331261.1
CACCCAGAAGUAACUUCACUU
96
NM_014495.3_552-
552-572
AAGUGAAGUUACUUCUGGGUGUU
205

550-572

572_s

AD-1331262.1
ACCCAGAAGUAACUUCACUUU
97

553-573
AAAGUGAAGUUACUUCUGGGUGU
206

551-573

AD-1331263.1
CCCAGAAGUAACUUCACUUAA
98
NM_014495.3_554-
554-574
UUAAGUGAAGUUACUUCUGGGUG
207

552-574

574_s

AD-1331264.1
CCAGAAGUAACUUCACUUAAA
99
NM_014495.3_557-
555-575
UUUAAGTGAAGUUACUUCUGGGU
208

553-575

576_s

AD-1331265.1
CAGAAGUAACUUCACUUAAAA
100
NM_014495.3_556-
556-576
UUUUAAGUGAAGUUACUUCUGGG
209

554-576

576_s

AD-1331266.1
AGAAGUAACUUCACUUAAAAU
101
NM_014495.3_557-
557-577
AUUUUAAGUGAAGUUACUUCUGG
210

555-577

577_C21U_s

AD-1331267.1
GAAGUAACUUCACUUAAAACU
102
NM_014495.3_558-
558-578
AGUUUUAAGUGAAGUUACUUCUG
211

556-578

578_s

AD-1331268.1
AAGUAACUUCACUUAAAACUU
103
NM_014495.3_559-
559-579
AAGUUUUAAGUGAAGUUACUUCU
212

557-579

579_s

AD-1331269.1
AGUAACUUCACUUAAAACUUU
104
NM_014495.3_560-
560-580
AAAGUUUUAAGUGAAGUUACUUC
213

558-580

580_s

AD-1331270.1
GUAACUUCACUUAAAACUUUU
105
NM_014495.3_561-
561-581
AAAAGUUUUAAGUGAAGUUACUU
214

559-581

581_s

AD-1331271.1
UAACUUCACUUAAAACUUUUU
106

562-582
AAAAAGUUUUAAGUGAAGUUACU
215

560-582

AD-1331272.1
AACUUCACUUAAAACUUUUGU
107
NM_014495.3_563-
563-583
ACAAAAGUUUUAAGUGAAGUUAC
216

561-583

583_s

AD-1331273.1
ACUUCACUUAAAACUUUUGUU
108

564-584
AACAAAAGUUUUAAGUGAAGUUA
217

562-584

AD-1331274.1
CUUCACUUAAAACUUUUGUAU
109
NM_014495.3_565-
565-585
AUACAAAAGUUUUAAGUGAAGUU
218

563-585

585_G21U_s

AD-1331275.1
UUCACUUAAAACUUUUGUAGU
110

566-586
ACUACAAAAGUUUUAAGUGAAGU
219

564-586

AD-1331276.1
UCACUUAAAACUUUUGUAGAU
111

567-587
AUCUACAAAAGUUUUAAGUGAAG
220

565-587

AD-1331277.1
CACUUAAAACUUUUGUAGAAA
112
NM_014495.3_570-
568-588
UUUCTACAAAAGUUUUAAGUGAA
221

566-588

589_s

AD-1331278.1
ACUUAAAACUUUUGUAGAAAA
113
NM_014495.3_569-
569-589
UUUUCUACAAAAGUUUUAAGUGA
222

567-589

589_s

AD-1331279.1
AAUGUUCACAAUUAAGCUCCU
114

80-100
AGGAGCTUAAUTGUGAACAUUUU
223

78-100

AD-1331280.1
AUUUGCUAUGUUAGACGAUGU
115

188-208
ACAUCGTCUAACAUAGCAAAUCU
224

186-208

AD-1331281.1
UUGCUAUGUUAGACGAUGUAA
116

190-210
UTACAUCGUCUAACAUAGCAAAU
225

188-210

AD-1331282.1
UGCUAUGUUAGACGAUGUAAA
117

191-211
UTUACATCGUCTAACAUAGCAAA
226

189-211

AD-1331283.1
AACUGAGAAGAACUACAUAUA
118

373-393
UAUATGTAGUUCUUCUCAGUUCC
227

371-393

AD-1331284.1
AACCAACAGCAUAGUCAAAUA
119

648-668
UAUUTGACUAUGCUGUUGGUUUA
228

646-668

AD-1331285.1
CCCACAGAAAUUUCUCUAUCU
120

711-731
AGAUAGAGAAATUUCUGUGGGUU
229

709-731

AD-1331286.1
CAGGUAGUCCAUGGACAUUAA
121

913-933
UTAATGTCCAUGGACUACCUGAU
230

911-933

AD-1331287.1
GGUAGUCCAUGGACAUUAAUU
122

915-935
AAUUAATGUCCAUGGACUACCUG
231

913-935

AD-1331288.1
AGUUGGAAGACUGGAAAGACA
123

1081-1101
UGUCTUTCCAGTCUUCCAACUCA
232

1079-1101

AD-1331289.1
UGGAAAGACAACAAACAUUAU
124

1092-1112
ATAATGTUUGUTGUCUUUCCAGU
233

1090-1112

AD-1331290.1
UUUACUUGGGAAAUCACGAAA
125

1126-1146
UTUCGUGAUUUCCCAAGUAAAAA
234

1124-1146

AD-1331291.1
GGGAAAUCACGAAACCAACUA
126

1133-1153
UAGUTGGUUUCGUGAUUUCCCAA
235

1131-1153

AD-1331292.1
GAAAUCACGAAACCAACUAUA
127

1135-1155
UAUAGUTGGUUTCGUGAUUUCCC
236

1133-1155

AD-1331293.1
CGAAACCAACUAUACGCUACA
128

1142-1162
UGUAGCGUAUAGUUGGUUUCGUG
237

1140-1162

AD-1331294.1
AUCAACCAAAAUGUUGAUCCA
129

1415-1435
UGGATCAACAUTUUGGUUGAUUU
238

1413-1435

AD-1331295.1
UUAAAACUCUAAACUUGACUA
130

1850-1870
UAGUCAAGUUUTGAGUUUUAACA
239

1848-1870

AD-1331296.1
CAAAACUUGAAAGCCUCCUAU
131

445-465
ATAGGAGGCUUTCAAGUUUUGAG
240

443-465

AD-1331297.1
UCAACAUCGAAUAGAUGGAUU
132

935-955
AAUCCATCUAUTCGAUGUUGAAU
241

933-955

AD-1331298.1
CAAAACUUCAAUGAAACGUGU
133

957-977
ACACGUTUCAUTGAAGUUUUGUG
242

955-977

AD-1331299.1
AAUCACGAAACCAACUAUACU
134

1137-1157
AGUATAGUUGGTUUCGUGAUUUC
243

1135-1157

AD-1331300.1
GGGAAUCAAUUUUAGAUGGUU
135

1695-1715
AACCAUCUAAAAUUGAUUCCCAC
244

1693-1715

AD-1331301.1
CAAAAUGUUGAUCCAUCCAAU
136

1421-1441
ATUGGATGGAUCAACAUUUUGGU
245

1419-1441

AD-1331302.1
UGGACAUUAAUUCAACAUCGA
137

924-944
UCGATGTUGAATUAAUGUCCAUG
246

922-944

AD-1331328.1
AAUGUUCACAAUUAAGCUCCU
114

80-100
AGGAGCTUAAUTGTGAACAUUUU
247

78-100

AD-1331329.1
AUUUGCUAUGUUAGACGAUGU
115

188-208
ACAUCGTCUAACATAGCAAAUCU
248

186-208

AD-1331330.1
UUGCUAUGUUAGACGAUGUAA
116

190-210
UTACAUCGUCUAACATAGCAAAU
249

188-210

AD-1331306.1
UGCUAUGUUAGACGAUGUAAA
117

191-211
UTUACATCGUCTAACAUAGCAAA
226

189-211

AD-1331331.1
AACUGAGAAGAACUACAUAUA
118

373-393
UAUATGTAGUUCUTCTCAGUUCC
250

371-393

AD-1331332.1
AACCAACAGCAUAGUCAAAUA
119

648-668
UAUUTGACUAUGCTGTUGGUUUA
251

646-668

AD-1331333.1
CCCACAGAAAUUUCUCUAUCU
120

711-731
AGAUAGAGAAATUTCTGUGGGUU
252

709-731

AD-1331334.1
CAGGUAGUCCAUGGACAUUAA
121

913-933
UTAATGTCCAUGGACTACCUGAU
253

911-933

AD-1331311.1
GGUAGUCCAUGGACAUUAAUU
122

915-935
AAUUAATGUCCAUGGACUACCUG
231

913-935

AD-1331335.1
AGUUGGAAGACUGGAAAGACA
123

1081-1101
UGUCTUTCCAGTCTUCCAACUCA
254

1079-1101

AD-1331336.1
UGGAAAGACAACAAACAUUAU
124

1092-1112
ATAATGTUUGUTGTCTUUCCAGU
255

1090-1112

AD-1331314.1
UUUACUUGGGAAAUCACGAAA
125

1126-1146
UTUCGUGAUUUCCCAAGUAAAAA
234

1124-1146

AD-1331337.1
GGGAAAUCACGAAACCAACUA
126

1133-1153
UAGUTGGUUUCGUGATUUCCCAA
256

1131-1153

AD-1331316.1
GAAAUCACGAAACCAACUAUA
127

1135-1155
UAUAGUTGGUUTCGUGAUUUCCC
236

1133-1155

AD-1331338.1
CGAAACCAACUAUACGCUACA
128

1142-1162
UGUAGCGUAUAGUTGGUUUCGUG
257

1140-1162

AD-1331339.1
AUCAACCAAAAUGUUGAUCCA
129

1415-1435
UGGATCAACAUTUTGGUUGAUUU
258

1413-1435

AD-1331340.1
UUAAAACUCUAAACUUGACUA
130

1850-1870
UAGUCAAGUUUTGAGTUUUAACA
259

1848-1870

AD-1331320.1
CAAAACUUGAAAGCCUCCUAU
131

445-465
ATAGGAGGCUUTCAAGUUUUGAG
240

443-465

AD-1331341.1
UCAACAUCGAAUAGAUGGAUU
132

935-955
AAUCCATCUAUTCGATGUUGAAU
260

933-955

AD-1331322.1
CAAAACUUCAAUGAAACGUGU
133

957-977
ACACGUTUCAUTGAAGUUUUGUG
242

955-977

AD-1331342.1
AAUCACGAAACCAACUAUACU
134

1137-1157
AGUATAGUUGGTUTCGUGAUUUC
261

1135-1157

AD-1331343.1
GGGAAUCAAUUUUAGAUGGUU
135

1695-1715
AACCAUCUAAAAUTGAUUCCCAC
262

1693-1715

AD-1331325.1
CAAAAUGUUGAUCCAUCCAAU
136

1421-1441
ATUGGATGGAUCAACAUUUUGGU
245

1419-1441

AD-1331344.1
UGGACAUUAAUUCAACAUCGA
137

924-944
UCGATGTUGAATUAATGUCCAUG
263

922-944

TABLE 3

Modified Sense and Antisense Strand Sequences of ANGPTL3 dsRNA Agents

SEQ

SEQ

SEQ

ID
Antisense
ID
mRNA Target
ID

Duplex Name
Sense Sequence 5′ to 3′
NO:
Sequence 5′ to 3′
NO:
Sequence 5′ to 3′
NO:

AD-1331197.1
asusaaaaAfuGfUfUfcacaauuaauL96
264
asUfsuaaUfugugaacAfu
372
AGAUAAAAAUGUUCACAAU
503

Ufuuuauscsu

UAAG

AD-1331198.1
usasaaaaUfgUfUfCfacaauuaaguL96
265
asCfsuuaAfuugugaaCfa
373
GAUAAAAAUGUUCACAAUU
504

Ufuuuuasusc

AAGC

AD-1331199.1
asasaaauGfuUfCfAfcaauuaagcuL96
266
asGfscuuAfauugugaAfc
374
AUAAAAAUGUUCACAAUUA
505

Afuuuuusasu

AGCU

AD-1331200.1
asasaaugUfuCfAfCfaauuaagcuuL96
267
asAfsgcuUfaauugugAfa
375
UAAAAAUGUUCACAAUUAA
506

Cfauuuususa

GCUC

AD-1331201.1
asasauguUfcAfCfAfauuaagcucuL96
268
asGfsagdCu(Tgn)aauug
376
AAAAAUGUUCACAAUUAAG
507

uGfaAfcauuususu

CUCC

AD-1331202.1
asusguucAfcAfAfUfuaagcuccuuL96
269
asAfsggdAg(C2p)uuaau
377
AAAUGUUCACAAUUAAGCU
508

uGfuGfaacaususu

CCUU

AD-1331203.1
usgsuucaCfaAfUfUfaagcuccuuuL96
270
asAfsagdGa(G2p)cuuaa
378
AAUGUUCACAAUUAAGCUC
509

uUfgUfgaacasusu

CUUC

AD-1331204.1
gsusucacAfaUfUfAfagcuccuucuL96
271
asGfsaadGg(Agn)gcuua
379
AUGUUCACAAUUAAGCUCC
510

aUfuGfugaacsasu

UUCU

AD-1331205.1
ususcacaAfuUfAfAfgcuccuucuuL96
272
asAfsgadAg(G2p)agcuu
380
UGUUCACAAUUAAGCUCCU
511

aAfuUfgugaascsa

UCUU

AD-66977.2
uscsacaaUfuAfAfGfcuccuucuuuL96
273
asAfsagaAfggagcuuAfa
381
GUUCACAAUUAAGCUCCUU
512

Ufugugasasc

CUUU

AD-1331206.1
csascaauUfaAfGfCfuccuucuuuuL96
274
asAfsaagAfaggagcuUfa
382
UUCACAAUUAAGCUCCUUC
513

Afuugugsasa

UUUU

AD-1331207.1
ascsaauuAfaGfCfUfccuucuuuuuL96
275
asAfsaaaGfaaggagcUfu
383
UCACAAUUAAGCUCCUUCU
514

Afauugusgsa

UUUU

AD-1331208.1
csasauuaAfgCfUfCfcuucuuuuuuL96
276
asAfsaaaAfgaaggagCfu
384
CACAAUUAAGCUCCUUCUU
515

Ufaauugsusg

UUUA

AD-1331209.1
asasuuaaGfcUfCfCfuucuuuuuauL96
277
asUfsaaaAfagaaggaGfc
385
ACAAUUAAGCUCCUUCUUU
516

Ufuaauusgsu

UUAU

AD-67003.3
asusuaagCfuCfCfUfucuuuuuauuL96
278
asAfsuaaAfaagaaggAfg
386
CAAUUAAGCUCCUUCUUUU
517

Cfuuaaususg

UAUU

AD-1331210.1
ususaagcUfcCfUfUfcimuuuauuuL96
279
asAfsauaAfaaagaagGfa
387
AAUUAAGCUCCUUCUUUUU
518

Gfcuuaasusu

AUUG

AD-1331211.1
usasagcuCfcUfUfCfuuuuuauuguL96
280
asCfsaauAfaaaagaaGfg
388
AUUAAGCUCCUUCUUUUUA
519

Afgcuuasasu

UUGU

AD-1331212.1
asasgcucCfuUfCfUfuuuuauuguuL96
25
asAfscaaUfaaaaagaAfg
22
UUAAGCUCCUUCUUUUUAU
520

Gfagcuusasa

UGUU

AD-1331213.1
asgscuccUfuCfUfUfuuuauuguuuL96
281
asAfsacaAfuaaaaagAfa
24
UAAGCUCCUUCUUUUUAUU
521

Gfgagcususa

GUUC

AD-1331214.1
gscsuccuUfcUfUfUfuuauuguucuL96
282
asGfsaacAfauaaaaaGfa
389
AAGCUCCUUCUUUUUAUUG
522

Afggagcsusu

UUCC

AD-1331215.1
csusccuuCfuUfUfUfuauuguuccuL96
283
asGfsguaCfaauaaaaAfg
390
AGCUCCUUCUUUUUAUUGU
523

Afaggagscsu

UCCU

AD-1331216.1
uscscuucUfuUfUfUfauuguuccuuL96
284
asAfsggaAfcaauaaaAfa
391
GCUCCUUCUUUUUAUUGUU
524

Gfaaggasgsc

CCUC

AD-1331217.1
cscsuucuUfuUfUfAfuuguuccucuL96
285
asGfsaggAfacaauaaAfaA
392
CUCCUUCUUUUUAUUGUUC
525

fgaaggsasg

CUCU

AD-1331218.1
csusucuuUfuUfAfUfuguuccucuaL96
286
usAfsgadGg(Agn)acaaua
393
UCCUUCUUUUUAUUGUUCC
526

AfaAfagaagsgsa

UCUA

AD-1331220.1
uscsuuuuUfaUfUfGfuuccucuaguL96
287
asCfsuadGa(G2p)gaacaa
394
CUUCUUUUUAUUGUUCCUC
527

UfaAfaaagasasg

UAGU

AD-1331221.1
csusuuuuAfuUfGfUfuccucuaguuL96
288
asAfscudAg(Agn)ggaaca
395
UUCUUUUUAUUGUUCCUCU
528

AfuAfaaaagsasa

AGUU

AD-1331222.1
ususuuuaUfuGfUfUfccucuaguuuL96
289
asAfsacuAfgaggaacAfaU
396
UCUUUUUAUUGUUCCUCUA
529

faaaaasgsa

GUUA

AD-1331223.1
ususuuauUfgUfUfCfcucuaguuauL96
290
asUfsaacUfagaggaaCfaA
397
CUUUUUAUUGUUCCUCUAG
530

fuaaaasasg

UUAU

AD-1331224.1
asusuucaAfaAfAfCfucaacauauuL96
291
asAfsuadTg(Tgn)ugaguu
398
AUAUUUCAAAAACUCAACA
531

UfuUfgaaausasu

UAUU

AD-1331225.1
ususucaaAfaAfCfUfcaacauauuuL96
292
asAfsaudAu(G2p)uugagu
399
UAUUUCAAAAACUCAACAU
532

UfuUfugaaasusa

AUUU

AD-1331226.1
ususcaaaAfaCfUfCfaacauauuuuL96
293
asAfsaauAfuguugagUfuU
400
AUUUCAAAAACUCAACAUA
533

fuugaasasu

UUUG

AD-1331227.1
uscsaaaaAfcUfCfAfacauauuuguL96
294
asCfsaaaUfauguugaGfuU
401
UUUCAAAAACUCAACAUAU
534

fuuugasasa

UUGA

AD-1331228.1
csasaaaaCfuCfAfAfcauauuugauL96
295
asUfscaaAfuauguugAfgU
402
UUCAAAAACUCAACAUAUU
535

fuuuugsasa

UGAU

AD-1331229.1
asasaaacUfcAfAfCfauauuugauuL96
296
asAfsucaAfauauguuGfaG
403
UCAAAAACUCAACAUAUUU
536

fuuuuusgsa

GAUC

AD-1331230.1
asasaacuCfaAfCfAfuauuugaucuL96
297
asGfsaucAfaauauguUfgA
404
CAAAAACUCAACAUAUUUG
537

fguuuususg

AUCA

AD-1331231.1
asasacucAfaCfAfUfauuugaucauL96
298
asUfsgadTc(Agn)aauaug
405
AAAAACUCAACAUAUUUGA
538

UfuGfaguuususu

UCAG

AD-1331232.1
asascucaAfcAfUfAfuuugaucaguL96
299
asCfsugaUfcaaauauGfuU
406
AAAACUCAACAUAUUUGAU
539

fgaguususu

CAGU

AD-1331233.1
ascsucaaCfaUfAfUfuugaucaguuL96
300
asAfscudGa(Tgn)caaaua
407
AAACUCAACAUAUUUGAUC
540

UfgUfugagususu

AGUC

AD-1331234.1
uscsaacaUfaUfUfUfgaucagucuuL96
301
asAfsgadCu(G2p)aucaaa
408
ACUCAACAUAUUUGAUCAG
541

UfaUfguugasgsu

UCUU

AD-67031.2
csasacauAfuUfUfGfaucagucuuuL96
302
asAfsagaCfugaucaaAfuA
409
CUCAACAUAUUUGAUCAGU
542

fuguugsasg

CUUU

AD-1331235.1
asascauaUfuUfGfAfucagucuuuuL96
303
asAfsaadGa(C2p)ugauca
410
UCAACAUAUUUGAUCAGUC
543

AfaUfauguusgsa

UUUU

AD-65695.22
ascsauauUfuGfAfUfcagucuuuuuL96
304
asAfsaaaGfacugaucAfaA
411
AAAAAGACUGAUCAAAUAU
544

fuaugususg

GUUG

AD-1331236.1
csasuauuUfgAfUfCfagucuuuuuuL96
305
asAfsaaaAfgacugauCfaA
412
AACAUAUUUGAUCAGUCUU
545

fauaugsusu

UUUA

AD-1331237.1
asusauuuGfaUfCfAfgucuuuuuauL96
306
asUfsaaaAfagacugaUfcA
413
ACAUAUUUGAUCAGUCUUU
546

faauausgsu

UUAU

AD-1331238.1
usasuuugAfuCfAfGfucuuuuuauuL96
307
asAfsuaaAfaagacugAfuC
414
CAUAUUUGAUCAGUCUUUU
547

faaauasusg

UAUG

AD-1331239.1
asusuugaUfcAfGfUfcuuuuuauguL96
308
asCfsauaAfaaagacuGfaU
415
AUAUUUGAUCAGUCUUUUU
548

fcaaausasu

AUGA

AD-1331240.1
ususugauCfaGfUfCfuuuuuaugauL96
309
asUfscauAfaaaagacUfgA
416
UAUUUGAUCAGUCUUUUUA
549

fucaaasusa

UGAU

AD-1331241.1
ususgaucAfgUfCfUfuuuuaugauuL96
310
asAfsucaUfaaaaagaCfuG
417
AUUUGAUCAGUCUUUUUAU
550

faucaasasu

GAUC

AD-1331242.1
usgsaucaGfuCfUfUfuuuaugaucuL96
311
asGfsaudCa(Tgn)aaaaag
418
UUUGAUCAGUCUUUUUAUG
551

AfcUfgaucasasa

AUCU

AD-1331243.1
gsasucagUfcUfUfUfuuaugaucuaL96
312
usAfsgadTc(Agn)uaaaaa
419
UUGAUCAGUCUUUUUAUGA
552

GfaCfugaucsasa

UCUA

AD-1331244.1
asuscaguCfuUfUfUfuaugaucuauL96
313
asUfsagdAu(C2p)auaaaa
420
UGAUCAGUCUUUUUAUGAU
553

AfgAfcugauscsa

CUAU

AD-1331245.1
uscsagucUfuUfUfUfaugaucuauuL96
314
asAfsuadGa(Tgn)cauaaa
421
GAUCAGUCUUUUUAUGAUC
554

AfaGfacugasusc

UAUC

AD-1331246.1
csasgucuUfuUfUfAfugaucuaucuL96
315
asGfsaudAg(Agn)ucauaa
422
AUCAGUCUUUUUAUGAUCU
555

AfaAfgacugsasu

AUCG

AD-1331247.1
asgsucuuUfuUfAfUfgaucuaucguL96
316
asCfsgauAfgaucauaAfaA
423
UCAGUCUUUUUAUGAUCUA
556

fagacusgsa

UCGC

AD-1331248.1
gsuscuuuUfuAfUfGfaucuaucgcuL96
317
asGfscgaUfagaucauAfaA
424
CAGUCUUUUUAUGAUCUAU
557

faagacsusg

CGCU

AD-1331249.1
uscsuuuuUfaUfGfAfucuaucgcuuL96
318
asAfsgcgAfuagaucaUfaA
425
AGUCUUUUUAUGAUCUAUC
558

faaagascsu

GCUG

AD-1331250.1
csusuuuuAfuGfAfUfcuaucgcuguL96
319
asCfsagcGfauagaucAfnA
426
GUCUUUUUAUGAUCUAUCG
559

faaaagsasc

CUGC

AD-1331251.1
asascuccAfgAfAfCfacccagaaguL96
320
asCfsuudCu(G2p)gguguu
427
GAAACUCCAGAACACCCAG
560

CfuGfgaguususc

AAGU

AD-1331252.1
ascsuccaGfaAfCfAfcccagaaguaL96
321
usAfscudTc(Tgn)gggugu
428
AAACUCCAGAACACCCAGA
561

UfcUfggagususu

AGUA

AD-1331253.1
csusccagAfaCfAfCfccagaaguaaL96
322
usUfsacdTu(C2p)ugggug
429
AACUCCAGAACACCCAGAA
562

UfuCfuggagsusu

GUAA

AD-1331254.1
uscscagaAfcAfCfCfcagaaguaauL96
323
asUfsuadCu(Tgn)cugggu
430
ACUCCAGAACACCCAGAAG
563

GfuUfcuggasgsu

UAAC

AD-1331255.1
cscsagaaCfaCfCfCfagaaguaacuL96
324
asGfsuudAc(Tgn)ucuggg
431
CUCCAGAACACCCAGAAGU
564

UfgUfucuggsasg

AACU

AD-1331256.1
csasgaacAfcCfCfAfgaaguaacuuL96
325
asAfsgudTa(C2p)uucugg
432
UCCAGAACACCCAGAAGUA
565

GfuGfuucugsgsa

ACUU

AD-1331257.1
asgsaacaCfcCfAfGfaaguaacuuuL96
326
asAfsaguUfacuucugGfgU
433
CCAGAACACCCAGAAGUAA
566

fguucusgsg

CUUC

AD-1331258.1
gsasacacCfcAfGfAfaguaacuucaL96
327
usGfsaadGu(Tgn)acuucu
434
CAGAACACCCAGAAGUAAC
567

GfgGfuguucsusg

UUCA

AD-1331259.1
asascaccCfaGfAfAfguaacuucauL96
328
asUfsgadAg(Tgn)uacuuc
435
AGAACACCCAGAAGUAACU
568

UfgGfguguuscsu

UCAC

AD-1331260.1
ascsacccAfgAfAfGfuaacuucacuL96
329
asGfsugdAa(G2p)uuacuu
436
GAACACCCAGAAGUAACUU
569

CfuGfggugususc

CACU

AD-1331261.1
csascccaGfaAfGfUfaacuucacuuL96
330
asAfsgudGa(Agn)guuacu
437
AACACCCAGAAGUAACUUC
570

UfcUfgggugsusu

ACUU

AD-1331262.1
ascsccagAfaGfUfAfacuucacuuuL96
331
asAfsaguGfaaguuacUfuC
438
ACACCCAGAAGUAACUUCA
571

fugggusgsu

CUUA

AD-1331263.1
cscscagaAfgUfAfAfcuucacuuaaL96
332
usUfsaadGu(G2p)aaguua
439
CACCCAGAAGUAACUUCAC
572

CfuUfcugggsusg

UUAA

AD-1331264.1
cscsagaaGfuAfAfCfuucacuuaaaL96
333
usUfsuadAg(Tgn)gaaguu
440
ACCCAGAAGUAACUUCACU
573

AfcUfucuggsgsu

UAAA

AD-1331265.1
csasgaagUfaAfCfUfucacuuaaaaL96
334
usUfsuudAa(G2p)ugaagu
441
CCCAGAAGUAACUUCACUU
574

UfaCfuucugsgsg

AAAA

AD-1331266.1
asgsaaguAfaCfUfUfcacuuaaaauL96
335
asUfsuuuAfagugaagUfuA
442
CCAGAAGUAACUUCACUUA
575

fcuucusgsg

AAAC

AD-1331267.1
gsasaguaAfcUfUfCfacuuaaaacuL96
336
asGfsuuuUfaagugaaGfuU
443
CAGAAGUAACUUCACUUAA
576

facuucsusg

AACU

AD-1331268.1
asasguaaCfuUfCfAfcuuaaaacuuL96
337
asAfsguuUfuaagugaAfgU
444
AGAAGUAACUUCACUUAAA
577

fuacuuscsu

ACUU

AD-1331269.1
asgsuaacUfuCfAfCfuuaaaacuuuL96
338
asAfsaguUfuuaagugAfaG
445
GAAGUAACUUCACUUAAAA
578

fuuacususc

CUUU

AD-1331270.1
gsusaacuUfcAfCfUfuaaaacuuuuL96
339
asAfsaagUfuuuaaguGfaA
446
AAGUAACUUCACUUAAAAC
579

fguuacsusu

UUUU

AD-1331271.1
usasacuuCfa€fUfUfaaaacuuuuuL96
340
asAfsaaaGfuuuuaagUfgA
447
AGUAACUUCACUUAAAACU
580

faguuascsu

UUUG

AD-1331272.1
asascuucAfcUfUfAfaaacuuuuguL96
341
asCfsaaaAfguuuuaaGfuG
448
GUAACUUCACUUAAAACUU
581

faaguusasc

UUGU

AD-1331273.1
ascsuucaCfuUfAfAfaacuuuuguuL96
342
asAfscaaAfaguuuuaAfgU
449
UAACUUCACUUAAAACUUU
582

fgaagususa

UGUA

AD-1331274.1
csusucacUfuAfAfAfacuuuuguauL96
343
asUfsacaAfaaguuuuAfaG
450
AACUUCACUUAAAACUUUU
583

fugaagsusu

GUAG

AD-1331275.1
ususcacuUfaAfAfAfcuuuuguaguL96
344
asCfsuacAfaaaguuuUfaA
451
ACUUCACUUAAAACUUUUG
584

fgugaasgsu

UAGA

AD-1331276.1
uscsacuuAfaAfAfCfuuuuguagauL96
345
asUfscuaCfaaaaguuUfUA
452
CUUCACUUAAAACUUUUGU
585

fagugasasg

AGAA

AD-1331277.1
csascuuaAfaAfCfUfuuuguagaaaL96
346
usUfsucdTa(C2p)aaaagu
453
UUCACUUAAAACUUUUGUA
586

UfuUfaagugsasa

GAAA

AD-1331278.1
ascsuuaaAfaCfUfUfuuguagaaaaL96
347
usUfsuudCu(Agn)caaaag
454
UCACUUAAAACUUUUGUAG
587

UfuUfuaagusgsa

AAAA

AD-1331279.1
asasuguucaCfAfAfuuaagcuccuL96
348
asdGsgadGcdTuaaudTgU
455
AAAAUGUUCACAAUUAAGC
588

fgaacauususu

UCCU

AD-1331280.1
asusuugcuaUfGfUfuagacgauguL96
349
asdCsaudCgdTcuaadCaU
456
AGAUUUGCUAUGUUAGACG
589

fagcaaauscsu

AUGU

AD-1331281.1
ususgcuaugUfUfAfgacgauguaaL96
350
usdTsacdAudCgucudAaC
457
AUUUGCUAUGUUAGACGAU
590

fauagcaasasu

GUAA

AD-1331282.1
usgscuauguUfAfGfacgauguaaaL96
351
usdTsuadCadTcgucdTaA
458
UUUGCUAUGUUAGACGAUG
591

fcauagcasasa

UAAA

AD-1331283.1
asascugagaAfGfAfacuacauauaL96
352
usdAsuadTgdTaguudCuU
459
GGAACUGAGAAGAACUACA
592

fcucaguuscsc

UAUA

AD-1331284.1
asasccaacaGfCfAfuagucaaauaL96
353
usdAsuudTgdAcuaudGcU
460
UAAACCAACAGCAUAGUCA
593

fguugguususa

AAUA

AD-1331285.1
cscscacagaAfAfUfuucucuaucuL96
354
asdGsaudAgdAgaaadTuU
461
AACCCACAGAAAUUUCUCU
594

fcugugggsusu

AUCU

AD-1331286.1
csasgguaguCfCfAfuggacauuaaL96
355
usdTsaadTgdTccaudGgA
462
AUCAGGUAGUCCAUGGACA
595

fcuaccugsasu

UUAA

AD-1331287.1
gsgsuaguccAfUfGfgacauuaauuL96
356
asdAsuudAadTguccdAuG
463
CAGGUAGUCCAUGGACAUU
596

fgacuaccsusg

AAUU

AD-1331288.1
asgsuuggaaGfAfCfuggaaagacaL96
357
usdGsucdTudTccagdTcU
464
UGAGUUGGAAGACUGGAAA
597

fuccaacuscsa

GACA

AD-1331289.1
usgsgaaagaCfAfAfcaaacauuauL96
358
asdTsaadTgdTuugudTgU
465
ACUGGAAAGACAACAAACA
598

fcuuuccasgsu

UUAU

AD-1331290.1
ususuacuugGfGfAfaaucacgaaaL96
359
usdTsucdGudGauuudCcC
466
UUUUUACUUGGGAAAUCAC
599

faaguaaasasa

GAAA

AD-1331291.1
gsgsgaaaucAfCfGfaaaccaacuaL96
360
usdAsgudTgdGuuucdGuG
467
UUGGGAAAUCACGAAACCA
600

fauuucccsasa

ACUA

AD-1331292.1
gsasaaucacGfAfAfaccaacuauaL96
361
usdAsuadGudIgguudTcG
468
GGGAAAUCACGAAACCAAC
601

fugauuucscsc

UAUA

AD-1331293.1
csgsaaaccaAfCfUfauacgcuacaL96
362
usdGsuadGcdGuauadGuU
469
CACGAAACCAACUAUACGC
602

fgguuucgsusg

UACA

AD-1331294.1
asuscaaccaAfAfAfuguugauccaL96
363
usdGsgadTcdAacaudTuU
470
AAAUCAACCAAAAUGUUGA
603

fgguugaususu

UCCA

AD-1331295.1
ususaaaacuCfUfAfaacuugacuaL96
364
usdAsgudCadAguuudTgA
471
UGUUAAAACUCUAAACUUG
604

fguuuuaascsa

ACUA

AD-1331296.1
csasaaacuuGfAfAfagccuccuauL96
365
asdTsagdGadGgcuudTcA
472
CUCAAAACUUGAAAGCCUC
605

faguuuugsasg

CUAG

AD-1331297.1
uscsaacaucGfAfAfuagauggauuL96
366
asdAsucdCadTcuaudTcG
473
AUUCAACAUCGAAUAGAUG
606

fauguugasasu

GAUC

AD-1331298.1
csasaaacuuCfAfAfugaaacguguL96
367
asdCsacdGudTucandTgA
474
CACAAAACUUCAAUGAAAC
607

faguuuugsusg

GUGG

AD-1331299.1
asasucacgaAfAfCfcaacuauacuL96
368
asdGsuadTadGuuggdTuU
475
GAAAUCACGAAACCAACUA
608

fcgugauususc

UACG

AD-1331300.1
gsgsgaaucaAfUfUfuuagaugguuL96
369
asdAsccdAudCuaaadAuU
476
GUGGGAAUCAAUUUUAGAU
609

fgauucccsasc

GGUC

AD-1331301.1
csasaaauguUfGfAfuccauccaauL96
370
asdTsugdGadTggaudCaA
477
ACCAAAAUGUUGAUCCAUC
610

fcauuuugsgsu

CAAC

AD-1331302.1
usgsgacauuAfAfUfucaacaucgaL96
371
usdCsgadTgdTugaadTuA
478
CAUGGACAUUAAUUCAACA
611

fauguccasusg

UCGA

AD-1331328.1
asasuguucaCfAfAfuuaagcuccuL96
348
asdGsgadGcdTuaaudTgdT
479
AAAAUGUUCACAAUUAAGC
588

gdAacauususu

UCCU

AD-1331329.1
asusuugcuaUfGfUfuagacgauguL96
349
asdCsaudCgdTcuaadCadT
480
AGAUUUGCUAUGUUAGACG
589

adGcaaauscsu

AUGU

AD-1331330.1
ususgcuaugUfUfAfgacgauguaaL96
350
usdTsacdAudCgucudAadC
481
AUUUGCUAUGUUAGACGAU
590

adTagcaasasu

GUAA

AD-1331306.1
usgscuauguUfAfGfacgauguaaaL96
351
usdTsuadCadTcgucdTadA
482
UUUGCUAUGUUAGACGAUG
591

cdAuagcasasa

UAAA

AD-1331331.1
asascugagaAfGfAfacuacauauaL96
352
usdAsuadTgdTaguudCudT
483
GGAACUGAGAAGAACUACA
592

cdTcaguuscsc

UAUA

AD-1331332.1
asasccaacaGfCfAfuagucaaauaL96
353
usdAsuudTgdAcuaudGcdT
484
UAAACCAACAGCAUAGUCA
593

gdTugguususa

AAUA

AD-1331333.1
cscscacagaAfAfUfuucucuaucuL96
354
asdGsaudAgdAgaaadTudT
485
AACCCACAGAAAUUUCUCU
594

cdTgugggsusu

AUCU

AD-1331334.1
csasgguaguCfCfAfuggacauuaaL96
355
usdTsaadTgdTccaudGgdA
486
AUCAGGUAGUCCAUGGACA
595

cdTaccugsasu

UUAA

AD-1331311.1
gsgsuaguccAfUfGfgacauuaauuL96
356
asdAsuudAadTguccdAudG
487
CAGGUAGUCCAUGGACAUU
596

gdAcuaccsusg

AAUU

AD-1331335.1
asgsuuggaaGfAfCfuggaaagacaL96
357
usdGsucdTudTccagdTcdT
488
UGAGUUGGAAGACUGGAAA
597

udCcaacuscsa

GACA

AD-1331336.1
usgsgaaagaCfAfAfcaaacauuauL96
358
asdTsaadTgdTuugudTgdT
489
ACUGGAAAGACAACAAACA
598

cdTuuccasgsu

UUAU

AD-1331314.1
ususuacuugGfGfAfaaucacgaaaL96
359
usdTsucdGudGauuudCcdC
490
UUUUUACUUGGGAAAUCAC
599

adAguaaasasa

GAAA

AD-1331337.1
gsgsgaaaucAfCfGfaaaccaacuaL96
360
usdAsgudTgdGuuucdGudG
491
UUGGGAAAUCACGAAACCA
600

adTuucccsasa

ACUA

AD-1331316.1
gsasaaucacGfAfAfaccaacuauaL96
361
usdAsuadGudTgguudTcdG
492
GGGAAAUCACGAAACCAAC
601

udGauuucscsc

UAUA

AD-1331338.1
csgsaaaecaAfCfUfauacgcuacaL96
362
usdGsuadGcdGuauadGudT
493
CACGAAACCAACUAUACGC
602

gdGuuucgsusg

UACA

AD-1331339.1
asuscaaccaAfAfAfuguugauccaL96
363
usdGsgadTcdAacaudTudT
494
AAAUCAACCAAAAUGUUGA
603

gdGuugaususu

UCCA

AD-1331340.1
ususaaaacuCfUfAfaacuugacuaL96
364
usdAsgudCadAguuudTgdA
495
UGUUAAAACUCUAAACUUG
604

gdTuuuaascsa

ACUA

AD-1331320.1
csasaaacuuGfAfAfagccuccuauL96
365
asdTsagdGadGgcuudTcdA
496
CUCAAAACUUGAAAGCCUC
605

adGuuuugsasg

CUAG

AD-1331341.1
uscsaacaucGfAfAfuagauggauuL96
366
asdAsucdCadTcuaudTcdG
497
AUUCAACAUCGAAUAGAUG
606

adTguugasasu

GAUC

AD-1331322.1
csasaaacuuCfAfAfugaaacguguL96
367
asdCsacdGudTucaudTgdA
498
CACAAAACUUCAAUGAAAC
607

adGuuuugsusg

GUGG

AD-1331342.1
asasucacgaAfAfCfcaacuauacuL96
368
asdGsuadTadGuuggdTudT
499
GAAAUCACGAAACCAACUA
608

cdGugauususc

UACG

AD-1331343.1
gsgsgaaucaAfUfUfuuagaugguuL96
369
asdAsccdAudCuaaadAudT
500
GUGGGAAUCAAUUUUAGAU
609

gdAuucccsasc

GGUC

AD-1331325.1
csasaaauguUfGfAfuccauccaauL96
370
asdTsugdGadTggaudCadA
501
ACCAAAAUGUUGAUCCAUC
610

cdAuuuugsgsu

CAAC

AD-1331344.1
usgsgacauuAfAfUfucaacaucgaL96
371
usdCsgadTgdTugaadTudA
502
CAUGGACAUUAAUUCAACA
611

adTguccasusg

UCGA

TABLE 4

ANGPTL3 Dose Screen in Primary Cynomolgus Hepatocytes (PCH)

10 nM
1 nM
0.1 nM

% Avg Cyno

% Avg Cyno

% Avg Cyno

Message

Message

Message

DuplexID
Remaining
STDEV
Remaining
STDEV
Remaining
STDEV

AD-1331197.1
17.2
4.9
17.2
3.1
42.1
16.6

AD-1331198.1
18.7
3.3
15.6
9.8
117.6
10.7

AD-1331199.1
22.5
3.2
20.6
1.2
79.0
20.6

AD-1331200.1
16.0
2.3
10.7
6.4
47.0
14.5

AD-1331201.1
33.2
1.5
22.1
13.9
95.6
3.0

AD-1331202.1
15.4
5.8
12.2
1.2
34.2
11.8

AD-1331203.1
14.2
1.6
10.3
3.7
32.6
5.9

AD-1331204.1
21.4
1.5
15.2
0.9
73.1
4.2

AD-1331205.1
21.7
5.5
15.6
0.2
40.1
11.3

AD-66977.2
19.3
2.6
17.4
2.6
39.2
4.8

AD-1331206.1
16.0
9.0
11.2
1.1
18.6
4.9

AD-1331207.1
17.9
6.0
10.2
3.2
24.2
8.9

AD-1331208.1
19.4
4.5
11.8
0.9
29.1
12.6

AD-1331209.1
10.9
2.8
11.9
2.9
27.6
3.9

AD-67003.3
13.7
3.3
11.8
1.3
27.0
5.0

AD-1331210.1
23.2
5.8
24.6
1.8
58.4
15.3

AD-1331211.1
25.9
8.3
22.5
0.3
68.1
11.4

AD-1331212.1
13.0
5.2
12.5
0.8
33.4
10.7

AD-1331213.1
23.1
9.0
8.5
0.5
22.1
3.1

AD-1331214.1
25.9
13.0
27.5
6.1
69.5
13.3

AD-1331215.1
16.6
4.3
18.2
3.7
53.0
9.2

AD-1331216.1
18.3
4.1
17.8
4.0
44.0
6.5

AD-1331217.1
27.5
8.6
29.8
5.2
81.8
21.5

AD-1331218.1
21.2
2.2
26.7
6.2
63.5
9.7

AD-1331220.1
36.0
7.5
26.5
4.0
59.7
6.7

AD-1331221.1
34.7
0.3
55.1
5.0
89.3
12.3

AD-1331222.1
17.4
2.6
17.3
4.2
43.6
12.2

AD-1331223.1
13.6
1.5
16.0
2.8
39.7
10.0

AD-1331224.1
23.3
4.0
28.5
5.4
60.3
15.5

AD-1331225.1
20.3
7.8
18.8
1.4
50.5
9.5

AD-1331226.1
14.6
3.0
13.3
4.7
46.2
11.3

AD-1331227.1
23.7
11.6
26.2
6.6
65.2
6.1

AD-1331228.1
14.8
1.9
10.3
0.7
25.9
2.4

AD-1331229.1
16.6
5.2
13.0
1.8
38.6
17.3

AD-1331230.1
14.3
4.1
13.2
1.9
44.4
12.4

AD-1331231.1
27.2
6.0
29.9
6.4
68.0
13.1

AD-1331232.1
32.7
7.9
64.6
4.1
110.0
6.3

AD-1331233.1
26.5
4.1
23.9
1.2
70.0
16.6

AD-1331234.1
15.4
3.2
11.8
3.3
37.2
13.6

AD-67031.2
12.3
1.3
9.6
3.3
31.4
5.3

AD-1331235.1
19.7
12.5
10.2
0.5
21.3
6.7

AD-65695.22
23.2
13.7
9.3
0.3
16.9
3.4

AD-1331236.1
26.1
15.3
21.7
3.1
51.8
3.1

AD-1331237.1
10.9
3.2
11.8
1.9
26.2
6.2

AD-1331238.1
48.2
21.0
13.1
0.8
18.3
4.3

AD-1331239.1
26.4
8.5
38.7
26.4
88.0
4.2

AD-1331240.1
12.6
3.6
8.3
0.5
26.6
2.9

AD-1331241.1
18.4
5.1
13.2
0.7
37.5
5.7

AD-1331242.1
82.5
18.7
77.3
5.4
87.9
5.6

AD-1331243.1
48.8
6.0
48.6
9.9
86.4
3.3

AD-1331244.1
9.6
1.2
9.5
1.0
23.2
4.2

AD-1331245.1
16.5
3.8
25.5
1.1
70.2
9.9

AD-1331246.1
24.7
10.8
25.1
2.9
68.7
9.7

AD-1331247.1
23.2
3.1
43.3
3.9
84.2
1.5

AD-1331248.1
42.1
4.4
65.4
5.8
90.0
5.2

AD-1331249.1
17.5
4.6
19.7
4.0
44.9
6.0

AD-1331250.1
20.1
4.3
35.1
2.1
70.0
8.0

AD-1331251.1
27.7
2.8
48.0
3.7
72.7
5.0

AD-1331252.1
14.1
2.7
17.2
1.1
45.6
6.2

AD-1331253.1
13.8
2.1
19.8
6.9
71.7
11.1

AD-1331254.1
39.4
4.8
61.7
6.8
87.1
7.7

AD-1331255.1
10.5
2.5
12.3
2.2
53.7
4.9

AD-1331256.1
10.1
4.1
7.9
1.6
19.0
5.3

AD-1331257.1
11.8
2.0
12.3
1.0
30.7
6.8

AD-1331258.1
34.1
3.7
52.2
7.0
74.3
7.6

AD-1331259.1
9.8
0.8
11.8
3.1
28.9
3.2

AD-1331260.1
12.3
1.5
15.2
2.3
47.9
8.8

AD-1331261.1
7.2
0.4
13.0
0.6
54.6
5.6

AD-1331262.1
9.3
5.8
9.1
1.4
22.3
0.8

AD-1331263.1
8.2
2.2
8.2
0.9
28.4
3.3

AD-1331264.1
7.9
1.6
7.4
1.2
15.4
4.4

AD-1331265.1
10.4
3.0
8.0
1.1
18.4
7.3

AD-1331266.1
11.4
6.2
9.7
0.5
21.0
10.2

AD-1331267.1
21.0
6.6
28.6
7.1
94.6
15.5

AD-1331268.1
20.1
6.0
32.5
3.3
96.7
12.2

AD-1331269.1
9.8
1.6
10.2
1.5
34.0
13.0

AD-1331270.1
10.0
1.4
18.3
4.2
47.6
6.0

AD-1331271.1
22.1
3.8
26.2
3.3
72.0
13.6

AD-1331272.1
72.2
21.7
93.0
10.8
77.7
12.6

AD-1331273.1
20.2
4.7
44.8
3.2
75.7
14.3

AD-1331274.1
18.1
5.0
42.6
9.2
75.5
17.7

AD-1331275.1
99.2
9.6
113.2
15.1
123.9
20.7

AD-1331276.1
69.0
8.5
110.6
19.8
118.4
13.9

AD-1331277.1
50.8
3.5
82.7
16.1
125.9
14.9

AD-1331278.1
98.0
19.7
109.0
6.2
106.9
13.3

AD-1331279.1
7.8
2.0
6.6
0.7
16.1
2.5

AD-1331280.1
6.7
3.3
9.0
1.5
30.0
6.2

AD-1331281.1
10.5
0.8
16.9
4.9
54.5
12.8

AD-1331282.1
9.2
1.6
20.6
8.1
34.1
10.3

AD-1331283.1
7.1
2.4
10.5
N/A
41.3
13.7

AD-1331284.1
13.0
3.2
10.9
N/A
28.2
8.3

AD-1331285.1
9.1
1.8
22.5
1.6
42.9
13.8

AD-1331286.1
7.9
0.6
15.6
3.9
25.3
9.0

AD-1331287.1
54.2
6.7
74.6
12.2
112.7
19.8

AD-1331288.1
13.0
3.6
22.6
2.8
56.2
10.4

AD-1331289.1
10.1
1.8
12.3
3.4
26.7
8.8

AD-1331290.1
33.2
4.8
68.6
10.9
118.9
21.4

AD-1331291.1
10.0
0.9
26.6
18.1
64.9
20.3

AD-1331292.1
10.1
2.6
14.1
2.9
23.7
2.7

AD-1331293.1
8.5
2.3
11.2
3.8
19.5
5.8

AD-1331294.1
11.6
2.1
15.9
3.7
27.5
6.3

AD-1331295.1
110.5
23.3
80.1
7.6
85.5
4.1

AD-1331296.1
15.4
3.0
18.6
5.6
29.2
5.3

AD-1331297.1
14.2
4.2
21.1
1.4
45.5
15.2

AD-1331298.1
13.1
1.3
24.8
5.7
79.2
26.9

AD-1331299.1
7.0
2.1
19.6
13.3
34.9
6.3

AD-1331300.1
127.0
19.3
113.5
14.8
112.9
15.2

AD-1331301.1
10.0
2.9
12.6
3.6
19.7
3.3

AD-1331302.1
8.8
1.0
14.1
3.0
33.2
12.3

AD-1331328.1
9.6
2.0
19.8
4.6
23.0
1.9

AD-1331329.1
9.7
1.8
16.3
1.1
28.4
8.6

AD-1331330.1
26.3
4.3
58.4
12.1
109.3
9.6

AD-1331306.1
11.5
1.6
19.3
8.2
39.7
6.5

AD-1331331.1
9.9
1.9
11.1
2.8
20.6
5.4

AD-1331332.1
13.1
2.3
22.4
2.0
15.6
2.7

AD-1331333.1
9.0
1.0
19.0
5.8
34.3
4.1

AD-1331334.1
7.8
1.3
10.5
1.0
17.5
3.9

AD-1331311.1
67.9
13.4
89.8
11.0
94.8
6.0

AD-1331335.1
9.6
1.6
27.4
6.8
52.8
13.5

AD-1331336.1
7.1
2.1
13.5
4.5
29.8
7.1

AD-1331314.1
56.4
6.5
64.3
5.5
90.2
15.7

AD-1331337.1
7.6
1.9
20.9
3.2
48.2
3.6

AD-1331316.1
5.8
0.8
12.4
1.7
22.4
3.5

AD-1331338.1
5.1
1.5
10.3
2.4
20.6
5.8

AD-1331339.1
7.6
1.6
13.9
3.2
36.3
6.2

AD-1331340.1
119.3
11.9
113.7
8.5
105.6
8.0

AD-1331320.1
7.5
0.5
17.5
4.2
37.1
6.7

AD-1331341.1
12.2
2.3
44.4
5.4
68.3
7.2

AD-1331322.1
7.6
1.8
15.0
4.8
48.7
18.1

AD-1331342.1
4.8
1.4
15.3
6.8
26.4
6.4

AD-1331343.1
89.2
4.2
103.3
7.2
92.8
5.6

AD-1331325.1
7.4
3.1
12.2
2.3
28.3
10.3

AD-1331344.1
9.0
2.4
23.2
9.0
33.0
4.0

Example 3. In Vivo Screening of dsRNA Duplexes in Mice

Duplexes of interest, identified from the above in vitro studies, were evaluated in vivo. In particular, at pre-dose day −14 wild-type mice (C57BL/6) were transduced by intravenous administration of 2×10¹¹viral particles of an adeno-associated virus 8 (AAV8) vector encoding human ANGPTL3. In particular, mice were administered an AAV8 encoding the open reading frame and 3′ UTR of human ANGPTL3 mRNA referenced as NM_014495.3.

At day 0, groups of three mice were subcutaneously administered a single 3 mg/kg dose of the agents of interest (see Table 5) or PBS control. At day 7 or day 14 post-dose, serum samples were collected and the level of ANGPTL3 in the serum samples was measured by an ELISA assay. Results are shown with group means and standard deviation (SD) (FIG. 1A), and individual points plotted with SD (FIG. 1B). Treatment with the positive control, AD-74757, at 3 mg/kg resulted in 3 ng/mL or lower at Day 7 and Day 14 as expected. A cluster of several compounds resulted in levels of ANGPTL3 similar to or below the benchmark group (dotted line). Specifically, most of the compounds targeting the region of nucleotides 80-114 in human ANGPTL3 transcript, e.g., AD-1331203.1, AD-1331206.1, AD-1331209.1, AD-1331212.1 and AD-1331213.1, showed KD similar to AD-74757.

At day 14 post-dose, animals were sacrificed, liver samples were collected and snap-frozen in liquid nitrogen. Tissue mRNA was extracted and analyzed by the RT-QPCR method. Human ANGPTL3 mRNA levels were compared to housekeeping gene GAPDH. The values were then normalized to the average of PBS vehicle control group. The data were expressed as percent of baseline value, and presented as mean plus standard deviation. The results, shown in FIG. 2, demonstrate that the exemplary duplex agents tested effectively reduce the level of the human ANGPTL3 messenger RNA in vivo.

TABLE 5

Duplexes of Interest for In Vivo Screening

Duplex Name
Range

AD-1331203.1
80-102

AD-1331206.1
84-106

AD-1331209.1
87-109

AD-1331212.1
91-113

AD-1331213.1
92-114

AD-1331329.1
186-208

AD-1331237.1
307-329

AD-1331238.1
308-330

AD-1331240.1
310-332

AD-1331244.1
314-336

AD-1331256.1
545-567

AD-1331262.1
551-573

AD-1331264.1
553-575

AD-1331265.1
554-576

AD-1331266.1
555-577

AD-1331316.1
1133-1155

AD-1331338.1
1140-1162

AD-74757
553-575

Example 4. Structure-Activity Relationship (SAR) Analyses

Based on the in vitro and the in vivo analyses in Examples 2 and 3, structure-active relationship (SAR) analyses were performed on selected duplexes (see Table 6). In particular, additional duplexes were designed, synthesized, and assayed in vitro and in vivo.

siRNAs were synthesized and annealed using routine methods known in the art and described above. In vitro screening assays in PCH cells and Hep3B cells with these siRNAs were performed as described above.

Detailed lists of the unmodified ANGPTL3 sense and antisense strand nucleotide sequences are shown in Table 7. Detailed lists of the modified ANGPTL3 sense and antisense strand nucleotide sequences are shown in Table 8.

The results of the single dose screens of the dsRNA agents listed in Tables 7-8 in primary cynomolgus hepatocytes (PCH) are shown in Table 9.

The results of the single dose screens of the dsRNA agents listed in Tables 7-8 in Hep3B cells are shown in Table 10.

TABLE 6

Duplexes of Interest for SAR Analysis

Duplex Name
Range

AD-1331203.1
80-102

AD-1331206.1
84-106

AD-1331209.1
87-109

AD-1331212.1
91-113

AD-1331213.1
92-114

AD-1331329.1
186-208

AD-1331240.1
310-332

AD-1331262.1
551-573

AD-1331264.1
553-575

AD-1331265.1
554-576

AD-1331266.1
555-577

TABLE 7

Unmodified Sense and Antisense Strand Sequences of ANGPTL3 dsRNA Agents

Duplex
Sense
SEQ
Range in
Antisense Sequence
SEQ
Range in

Name
Sequence 5′ to 3′
ID NO:
NM_014495.3
5′ to 3′
ID NO:
NM_014495.3

AD-
UGUUCACAAUUAAGCUCCUUU
35
82-102
AAAGGAGCUUAAUUGUGAACAUU
144
80-102

1331203.3

AD-
CACAAUUAAGCUCCUUCUUUU
39
86-106
AAAAGAAGGAGCUUAAUUGUGAA
148
84-106

1331206.3

AD-
AAUUAAGCUCCUUCUUUUUAU
42
89-109
AUAAAAAGAAGGAGCUUAAUUGU
151
87-109

1331209.3

AD-
AAGCUCCUUCUUUUUAUUGUU
46
93-113
AACAAUAAAAAGAAGGAGCUUAA
155
91-113

1331212.3

AD-
AGCUCCUUCUUUUUAUUGUUU
47
61-81
AAACAAUAAAAAGAAGGAGCUUA
156
59-81

1331213.3

AD-
UUUGAUCAGUCUUUUUAUGAU
75
312-332
AUCAUAAAAAGACUGAUCAAAUA
184
310-332

1331240.3

AD-
ACCCAGAAGUAACUUCACUUU
97
520-540
AAAGUGAAGUUACUUCUGGGUGU
206
518-540

1331262.3

AD-
CCAGAAGUAACUUCACUUAAA
99
555-575
UUUAAGTGAAGUUACUUCUGGGU
208
553-575

1331264.3

AD-
CAGAAGUAACUUCACUUAAAA
100
556-576
UUUUAAGUGAAGUUACUUCUGGG
209
554-576

1331265.3

AD-
AGAAGUAACUUCACUUAAAAU
101
557-577
AUUUUAAGUGAAGUUACUUCUGG
210
555-577

1331266.3

AD-
AUUUGCUAUGUUAGACGAUGU
115
155-175
ACAUCGTCUAACATAGCAAAUCU
248
153-175

1331329.3

AD-
AAGCUCCUUCUUUUUAUUGUU
46
60-80
AACAAUAAAAAGAAGGAGCUUAA
155
58-80

1479370.1

AD-
AAGCUCCUUCUUUUUAUUGUU
46
60-80
AACAAUAAAAAGAAGGAGCUUAA
155
58-80

1479371.1

AD-
AAGCUCCUUCUUUUUAUUGUU
46
60-80
AACAAUAAAAAGAAGGAGCUUGG
661
58-80

1479372.1

AD-
AAGCUCCUUCUUUUUAUUGUU
46
60-80
AACAAUAAAAAGAAGGAGCUUGG
661
58-80

1479373.1

AD-
AAGCUCCUUCUUUUUAUUGUA
612
60-80
UACAAUAAAAAGAAGGAGCUUGG
662
58-80

1479374.1

AD-
AAGCUCCUUCUUUUUAUUGUA
612
60-80
UACAAUAAAAAGAAGGAGCUUGG
662
58-80

1479375.1

AD-
AAGCUCCUUCUUUUUAUUGUU
46
60-80
AACAAUAAAAAGAAGGAGCUUCU
663
58-80

1479376.1

AD-
AAGCUCCUUCUUUUUAUUGUU
46
60-80
AACAAUAAAAAGAAGGAGCUUCU
663
58-80

1479377.1

AD-
GCUCCUUCUUUUUAUUGUU
613
62-80
AACAAUAAAAAGAAGGAGCUU
664
60-80

1479378.1

AD-
GCUCCUUCUUUUUAUUGUU
613
62-80
AACAAUAAAAAGAAGGAGCUU
664
60-80

1479379.1

AD-
AAGCACCUUCUUUUUAUUGUU
614
60-80
AACAAUAAAAAGAAGGUGCUUCU
665
58-80

1479380.1

AD-
AAGGUCCUUCUUUUUAUUGUU
615
60-80
AACAAUAAAAAGAAGGACCUUCU
666
58-80

1479381.1

AD-
AACCUCCUUCUUUUUAUUGUU
616
60-80
AACAAUAAAAAGAAGGAGGUUCU
667
58-80

1479382.1

AD-
AGCUCCUUCUUUUUAUUGUUU
47
61-81
AAACAATAAAAAGAAGGAGCUUA
668
59-81

1479383.1

AD-
AGCUCCUUCUUUUUAUUGUUU
47
61-81
AAACAATAAAAAGAAGGAGCUUA
668
59-81

1479384.1

AD-
AGCUCCUUCUUUUUAUUGUUU
47
61-81
AAACAATAAAAAGAAGGAGCUUG
669
59-81

1479385.1

AD-
AGCUCCUUCUUUUUAUUGUUU
47
61-81
AAACAATAAAAAGAAGGAGCUUG
669
59-81

1479386.1

AD-
AGCUCCUUCUUUUUAUUGUUA
617
61-81
UAACAATAAAAAGAAGGAGCUUG
670
59-81

1479387.1

AD-
AGCUCCUUCUUUUUAUUGUUA
617
61-81
UAACAATAAAAAGAAGGAGCUUG
670
59-81

1479388.1

AD-
AGCUCCUUCUUUUUAUUGUUU
47
61-81
AAACAATAAAAAGAAGGAGCUCU
671
59-81

1479389.1

AD-
AGCUCCUUCUUUUUAUUGUUU
47
61-81
AAACAATAAAAAGAAGGAGCUCU
671
59-81

1479390.1

AD-
CUCCUUCUUUUUAUUGUUU
618
63-81
AAACAATAAAAAGAAGGAGCU
672
61-81

1479391.1

AD-
CUCCUUCUUUUUAUUGUUU
618
63-81
AAACAATAAAAAGAAGGAGCU
672
61-81

1479392.1

AD-
AGCUGCUUCUUUUUAUUGUUU
619
61-81
AAACAATAAAAAGAAGCAGCUCU
673
59-81

1479393.1

AD-
AGCACCUUCUUUUUAUUGUUU
620
61-81
AAACAATAAAAAGAAGGUGCUCU
674
59-81

1479394.1

AD-
AGGUCCUUCUUUUUAUUGUUU
621
61-81
AAACAATAAAAAGAAGGUCCUCU
675
59-81

1479395.1

AD-
CCAGAAGUAACUUCACUUAAA
99
522-542
UUUAAGTGAAGUUACUUCUGGGU
208
520-542

1479396.1

AD-
CCAGAAGUAACUUCACUUAAA
99
522-542
UTUAAGTGAAGUUACUUCUGGGU
676
520-542

1479397.1

AD-
CCAGAAGUAACUUCACUUAAA
99
522-542
UUUAAGTGAAGTUACUUCUGGGU
677
520-542

1479398.1

AD-
CCAGAAGUAACUUCACUUAAA
99
522-542
UUUAAGTGAAGTUACTUCUGGGU
678
520-542

1479399.1

AD-
CCAGAAGUAACUUCACUUAAA
99
522-542
UTUAAGTGAAGUUACUUCUGGCU
679
520-542

1479400.1

AD-
CCAGAAGUAACUUCACUUAAA
99
522-542
UUUAAGTGAAGTUACUUCUGGCU
680
520-542

1479401.1

AD-
AGAAGUAACUUCACUUAAA
622
524-542
UTUAAGTGAAGUUACUUCUGG
681
522-542

1479402.1

AD-
AGAAGUAACUUCACUUAAA
622
524-542
UUUAAGTGAAGTUACUUCUGG
682
522-542

1479403.1

AD-
CCAGAAGUAACUUCACUUAAA
99
522-542
UTUAAGTGAAGTUACUUCUGGGU
683
520-542

1479404.1

AD-
AGAAGUAACUUCACUUAAA
622
524-542
UTUAAGTGAAGTUACUUCUGG
684
522-542

1479405.1

AD-
CCAGAAGUAACUUCACUUAAA
99
522-542
UUUAAGTGAAGUUACUUCUGGGU
208
520-542

1479406.1

AD-
CCAGAAGUAACUUCACUUAAA
99
522-542
UUUAAGTGAAGUUACUUCUGGGU
208
520-542

1479407.1

AD-
CCAGAAGUAACUUCACUUAAA
99
522-542
UTUAAGTGAAGTUACUUCUGGGU
683
520-542

1479408.1

AD-
CCAGAAGUAACUUCACUUAAA
99
522-542
UTUAAGTGAAGTUACUUCUGGGU
683
520-542

1479409.1

AD-
CCAGAAGUAACUUCACUUAAA
99
522-542
UTUAAGUGAAGTUACUUCUGGCU
685
520-542

1479410.1

AD-
CCAGAAGUAACUUCACUUAAA
99
522-542
UTUAAGUGAAGTUACUUCUGGCU
685
520-542

1479411.1

AD-
CCAGUAGUAACUUCACUUAAA
623
522-542
UUUAAGTGAAGUUACUACUGGGU
686
520-542

1479412.1

AD-
CCACAAGUAACUUCACUUAAA
624
522-542
UUUAAGTGAAGUUACUUGUGGGU
687
520-542

1479413.1

AD-
CCUGAAGUAACUUCACUUAAA
625
522-542
UUUAAGTGAAGUUACUUCAGGGU
688
520-542

1479414.1

AD-
UGUUCACAAUUAAGCUCCUUU
35
82-102
AAAGGAGCUUAAUUGUGAACAUU
144
80-102

1479415.1

AD-
UGUUCACAAUUAAGCUCCUUU
35
49-69
AAAGGAGCUUAAUUGUGAACAUU
144
47-69

1479416.1

AD-
UGUUCACAAUUAAGCUCCUUU
35
49-69
AAAGGAGCUUAAUUGUGAACAUU
144
47-69

1479417.1

AD-
UGUUCACAAUUAAGCUCCUUU
35
49-69
AAAGGAGCUUAAUTGTGAACAUU
689
47-69

1479418.1

AD-
UGUUCACAAUUAAGCUCCUUU
35
49-69
AAAGGAGCUUAAUTGTGAACACU
690
47-69

1479419.1

AD-
UGUUCACAAUUAAGCUCCUUU
35
82-102
AAAGGAGCUUAAUUGUGAACAGG
691
80-102

1479420.1

AD-
UGUUCACAAUUAAGCUCCUUU
35
82-102
AAAGGAGCUUAAUUGUGAACAGG
691
80-102

1479421.1

AD-
UGUUCACAAUUAAGCUCCUUU
35
49-69
AAAGGAGCUUAAUUGUGAACAGG
691
47-69

1479422.1

AD-
UGUUCACAAUUAAGCUCCUUU
35
82-102
AAAGGAGCUUAAUUGUGAACG
692
82-102

1479423.1

AD-
UGUUCACAAUUAAGCUCCUUU
35
82-102
AAAGGAGCUUAAUUGUGAACG
692
82-102

1479424.1

AD-
UGUUCACAAUUAAGCUCCUUU
35
49-69
AAAGGAGCUUAAUUGUGAACG
692
49-69

1479425.1

AD-
UGUUGACAAUUAAGCUCCUUU
626
49-69
AAAGGAGCUUAAUUGUCAACAUU
693
47-69

1479426.1

AD-
UGUACACAAUUAAGCUCCUUU
627
49-69
AAAGGAGCUUAAUUGUGUACAUU
694
47-69

1479427.1

AD-
UGAUCACAAUUAAGCUCCUUU
628
49-69
AAAGGAGCUUAAUUGUGAUCAUU
695
47-69

1479428.1

AD-
CACAAUUAAGCUCCUUCUUUU
39
53-73
AAAAGAAGGAGCUUAAUUGUGAA
148
51-73

1479429.1

AD-
CACAAUUAAGCUCCUUCUUUU
39
53-73
AAAAGAAGGAGCUTAAUUGUGAA
696
51-73

1479430.1

AD-
CACAAUUAAGCUCCUUCUUUU
39
53-73
AAAAGAAGGAGCUUAAUUGUGGG
697
51-73

1479431.1

AD-
CACAAUUAAGCUCCUUCUUUA
629
53-73
UAAAGAAGGAGCUUAAUUGUGGG
698
51-73

1479432.1

AD-
CACAAUUAAGCUCCUUCUUUU
39
53-73
AAAAGAAGGAGCUTAAUUGUGGG
699
51-73

1479433.1

AD-
CACAAUUAAGCUCCUUCUUUU
39
53-73
AAAAGAAGGAGCUUAAUUGUGCU
700
51-73

1479434.1

AD-
CACAAUUAAGCUCCUUCUUUA
629
53-73
UAAAGAAGGAGCUUAAUUGUGCU
701
51-73

1479435.1

AD-
CACAAUUAAGCUCCUUCUUUU
39
53-73
AAAAGAAGGAGCUTAAUUGUGCU
702
51-73

1479436.1

AD-
CAAUUAAGCUCCUUCUUUU
630
55-73
AAAAGAAGGAGCUUAAUUGUG
703
53-73

1479437.1

AD-
CAAUUAAGCUCCUUCUUUU
630
55-73
AAAAGAAGGAGCUTAAUUGUG
704
53-73

1479438.1

AD-
CACAUUUAAGCUCCUUCUUUU
631
53-73
AAAAGAAGGAGCUUAAAUGUGCU
705
51-73

1479439.1

AD-
CACUAUUAAGCUCCUUCUUUU
632
53-73
AAAAGAAGGAGCUUAAUAGUGCU
706
51-73

1479440.1

AD-
CAGAAUUAAGCUCCUUCUUUU
633
53-73
AAAAGAAGGAGCUUAAUUCUGCU
707
51-73

1479441.1

AD-
CACAAUUAAGCUCCUUCUUUU
39
53-73
AAAAGAAGGAGCUUAAUUGUGCU
700
51-73

1479442.1

AD-
CACAAUUAAGCUCCUUCUUUU
39
53-73
AAAAGAAGGAGCUUAAUUGUGCU
700
51-73

1479443.1

AD-
CACAAUUAAGCUCCUUCUUUU
39
53-73
AAAAGAAGGAGCUUAAUUGUGCU
700
51-73

1479444.1

AD-
AAUUAAGCUCCUUCUUUUUAU
42
56-76
ATAAAAAGAAGGAGCUUAAUUGU
708
54-76

1479445.1

AD-
AAUUAAGCUCCUUCUUUUUAA
634
56-76
UTAAAAAGAAGGAGCUUAAUUGU
709
54-76

1479446.1

AD-
AAUUAAGCUCCUUCUUUUUAU
42
56-76
ATAAAAAGAAGGAGCTUAAUUGU
710
54-76

1479447.1

AD-
AAUUAAGCUCCUUCUUUUUAA
634
56-76
UTAAAAAGAAGGAGCTUAAUUGU
711
54-76

1479448.1

AD-
AAUUAAGCUCCUUCUUUUUAU
42
56-76
ATAAAAAGAAGGAGCUUAAUUGU
708
54-76

1479449.1

AD-
AAUUAAGCUCCUUCUUUUUAU
42
56-76
ATAAAAAGAAGGAGCUUAAUUGU
708
54-76

1479450.1

AD-
UUAAGCUCCUUCUUUUUAU
635
58-76
ATAAAAAGAAGGAGCUUAAUU
712
56-76

1479451.1

AD-
UUAAGCUCCUUCUUUUUAU
635
58-76
ATAAAAAGAAGGAGCTUAAUU
713
56-76

1479452.1

AD-
UUAAGCUCCUUCUUUUUAU
635
58-76
ATAAAAAGAAGGAGCUUAAUU
712
56-76

1479453.1

AD-
UUAAGCUCCUUCUUUUUAU
635
58-76
ATAAAAAGAAGGAGCTUAAUU
713
56-76

1479454.1

AD-
AAUUUAGCUCCUUCUUUUUAU
636
56-76
ATAAAAAGAAGGAGCUAAAUUGU
714
54-76

1479455.1

AD-
AAUAAAGCUCCUUCUUUUUAU
637
56-76
ATAAAAAGAAGGAGCUUUAUUGU
715
54-76

1479456.1

AD-
AAAUAAGCUCCUUCUUUUUAU
638
56-76
ATAAAAAGAAGGAGCUUAUUUGU
716
54-76

1479457.1

AD-
UUUGAUCAGUCUUUUUAUGAU
75
312-332
AUCATAAAAAGACUGAUCAAAUG
717
310-332

1479458.1

AD-
UUUGAUCAGUCUUUUUAUGAA
639
279-299
UUCATAAAAAGACUGAUCAAAUG
718
277-299

1479459.1

AD-
UUUGAUCAGUCUUUUUAUGAU
75
312-332
ATCATAAAAAGACUGAUCAAAUG
719
310-332

1479460.1

AD-
UUUGAUCAGUCUUUUUAUGAU
75
312-332
ATCAUAAAAAGACUGAUCAAAUG
720
310-332

1479461.1

AD-
UUUGAUCAGUCUUUUUAUGAU
75
312-332
ATCATAAAAAGACUGAUCAAAUG
719
310-332

1479462.1

AD-
UUUGAUCAGUCUUUUUAUGAA
639
279-299
UTCATAAAAAGACUGAUCAAAUG
721
277-299

1479463.1

AD-
UUUGAUCAGUCUUUUUAUGAU
75
312-332
ATCAUAAAAAGACUGAUCAAAUG
720
310-332

1479464.1

AD-
UUUGAUCAGUCUUUUUAUGAU
75
312-332
ATCAUAAAAAGACTGAUCAAAUG
722
310-332

1479465.1

AD-
UUUGAUCAGUCUUUUUAUGAU
75
312-332
ATCATAAAAAGACUGAUCAAAUG
719
310-332

1479466.1

AD-
UUGAUCAGUCUUUUUAUGAU
640
280-299
ATCAUAAAAAGACUGAUCAACU
723
278-299

1479467.1

AD-
UUUGAUCAGUCUUUUUAUGAU
75
279-299
ATCATAAAAAGACUGAUCAAACU
724
277-299

1479468.1

AD-
UUUGAUCAGUCUUUUUAUGAU
75
279-299
ATCATAAAAAGACUGAUCAAACU
724
277-299

1479469.1

AD-
UUUGUUCAGUCUUUUUAUGAU
641
279-299
ATCATAAAAAGACUGAACAAAUG
725
277-299

1479470.1

AD-
UUUCAUCAGUCUUUUUAUGAU
642
279-299
ATCATAAAAAGACUGAUGAAAUG
726
277-299

1479471.1

AD-
UUAGAUCAGUCUUUUUAUGAU
643
279-299
ATCATAAAAAGACUGAUCUAAUG
727
277-299

1479472.1

AD-
UUUGAUCAGUCUUUUUAUGAU
75
279-299
ATCATAAAAAGACUGAUCAAACU
724
277-299

1479473.1

AD-
CAGAAGUAACUUCACUUAAAA
100
556-576
UTUUAAGUGAAGUUACUUCUGGG
728
554-576

1479474.1

AD-
CAGAAGUAACUUCACUUAAAA
100
556-576
UTUUAAGUGAAGUUACUUCUGGG
728
554-576

1479475.1

AD-
CAGAAGUAACUUCACUUAAAA
100
556-576
UTUUAAGUGAAGUUACUUCUGGG
728
554-576

1479476.1

AD-
CAGAAGUAACUUCACUUAAAA
100
556-576
UTUUAAGUGAAGUTACUUCUGGG
729
554-576

1479477.1

AD-
GAAGUAACUUCACUUAAAA
644
525-543
UTUUAAGUGAAGUUACUUCUG
730
523-543

1479478.1

AD-
CAGAAGUAACUUCACUUAAAA
100
523-543
UTUUAAGUGAAGUUACUUCUGGG
728
521-543

1479479.1

AD-
CAGAAGUAACUUCACUUAAAA
100
523-543
UTUUAAGUGAAGUUACUUCUGGG
728
521-543

1479480.1

AD-
CAGAAGUAACUUCACUUAAAA
100
523-543
UTUUAAGUGAAGUUACUUCUGGG
728
521-543

1479481.1

AD-
CAGAAGUAACUUCACUUAAAA
100
523-543
UTUUAAGUGAAGUUACUUCUGGG
728
521-543

1479482.1

AD-
CAGAAGUAACUUCACUUAAAA
100
523-543
UTUUAAGUGAAGUUACUUCUGGG
728
521-543

1479483.1

AD-
CAGAAGUAACUUCACUUAAAA
100
556-576
UTUUAAGUGAAGUUACUUCUGGG
728
554-576

1479484.1

AD-
CAGAAGUAACUUCACUUAAAA
100
556-576
UTUUAAGUGAAGUUACUUCUGGG
728
554-576

1479485.1

AD-
CAGAAGUAACUUCACUUAAAA
100
556-576
UTUUAAGUGAAGUUACUUCUGGG
728
554-576

1479486.1

AD-
CAGAAGUAACUUCACUUAAAA
100
556-576
UTUUAAGUGAAGUUACUUCUGGG
728
554-576

1479487.1

AD-
CAGAAGUAACUUCACUUAAAA
100
523-543
UTUUAAGUGAAGUUACUUCUGGG
728
521-543

1479488.1

AD-
ACCCAGAAGUAACUUCACUUU
97
520-540
AAAGTGAAGUUACUUCUGGGUGU
731
518-540

1479489.1

AD-
ACCCAGAAGUAACUUCACUUU
97
520-540
AAAGTGAAGUUACUUCUGGGUGU
731
518-540

1479490.1

AD-
ACCCAGAAGUAACUUCACUUA
645
520-540
UAAGTGAAGUUACUUCUGGGUGU
732
518-540

1479491.1

AD-
ACCCAGAAGUAACUUCACUUA
645
520-540
UAAGTGAAGUUACUUCUGGGUGU
732
518-540

1479492.1

AD-
ACCCAGAAGUAACUUUACUUU
646
520-540
AAAGTAAAGUUACUUCUGGGUGU
733
518-540

1479493.1

AD-
ACCCAGAAGUAACUUCACUUU
97
520-540
AAAGTGAAGUUACUUCUGGGUGU
731
518-540

1479494.1

AD-
ACCCAGAAGUAACUUCACUUU
97
520-540
AAAGTGAAGUUACUUCUGGGUGU
731
518-540

1479495.1

AD-
ACCCAGAAGUAACUUCACUUU
97
520-540
AAAGTGAAGUUACUUCUGGGUCU
734
518-540

1479496.1

AD-
ACCCAGAAGUAACUUCACUUU
97
520-540
AAAGTGAAGUUACUUCUGGGUCU
734
518-540

1479497.1

AD-
ACCCAGAAGUAACUUCACUUU
97
520-540
AAAGTGAAGUUACUUCUGGGUCU
734
518-540

1479498.1

AD-
ACCCAGAAGUAACUUCACUUU
97
520-540
AAAGTGAAGUUACUUCUGGGUCU
734
518-540

1479499.1

AD-
CCAGAAGUAACUUCACUUU
647
522-540
AAAGTGAAGUUACUUCUGGGU
735
520-540

1479500.1

AD-
CCAGAAGUAACUUCACUUU
647
522-540
AAAGTGAAGUUACUUCUGGGU
735
520-540

1479501.1

AD-
CCAGAAGUAACUUCACUUU
647
522-540
AAAGTGAAGUUACUUCUGGGU
735
520-540

1479502.1

AD-
CCAGAAGUAACUUCACUUU
647
522-540
AAAGTGAAGUUACUUCUGGGU
735
520-540

1479503.1

AD-
ACCCUGAAGUAACUUCACUUU
648
520-540
AAAGTGAAGUUACUUCAGGGUGU
736
518-540

1479504.1

AD-
ACCGAGAAGUAACUUCACUUU
649
520-540
AAAGTGAAGUUACUUCUCGGUGU
737
518-540

1479505.1

AD-
ACGCAGAAGUAACUUCACUUU
650
520-540
AAAGTGAAGUUACUUCUGCGUGU
738
518-540

1479506.1

AD-
ACCCAGAAGUAACUUCACUUU
97
520-540
AAAGTGAAGUUACUUCUGGGUGU
731
518-540

1479507.1

AD-
ACCCAGAAGUAACUUCACUUU
97
520-540
AAAGTGAAGUUACUUCUGGGUGU
731
518-540

1479508.1

AD-
AGAAGUAACUUCACUUAAAAU
101
524-544
AUUUTAAGUGAAGUUACUUCUGG
739
522-544

1479509.1

AD-
AGAAGUAACUUCACUUAAAAU
101
524-544
AUUUTAAGUGAAGUUACUUCUGG
739
522-544

1479510.1

AD-
AGAAGUAACUUCACUUAAAAU
101
524-544
AUUUTAAGUGAAGUUACUUCUGG
739
522-544

1479511.1

AD-
AGAAGUAACUUCACUUAAAAU
101
524-544
AUUUTAAGUGAAGUUACUUCUGG
739
522-544

1479512.1

AD-
AGAAGUAACUUCACUUAAAAA
651
524-544
UUUUTAAGUGAAGUUACUUCUGG
740
522-544

1479513.1

AD-
AGAAGUAACUUCACUUAAAAA
651
524-544
UUUUTAAGUGAAGUUACUUCUGG
740
522-544

1479514.1

AD-
AGAAGUAACUUCACUUAAAAU
101
524-544
AUUUTAAGUGAAGUUACUUCUGG
739
522-544

1479515.1

AD-
AGAAGUAACUUCACUUAAAAU
101
524-544
AUUUTAAGUGAAGUUACUUCUGG
739
522-544

1479516.1

AD-
AGAAGUAACUUCACUUAAAAU
101
524-544
ATUUTAAGUGAAGUUACUUCUGG
741
522-544

1479517.1

AD-
AGAAGUAACUUCACUUAAAAU
101
524-544
ATUUTAAGUGAAGUUACUUCUGG
741
522-544

1479518.1

AD-
AGAAGUAACUUCACUUAAAAU
101
524-544
ATUUTAAGUGAAGUUACUUCUGG
741
522-544

1479519.1

AD-
AGAAGUAACUUCACUUAAAAU
101
524-544
ATUUTAAGUGAAGUUACUUCUGG
741
522-544

1479520.1

AD-
AGAAGUAACUUCACUUAAAAU
101
524-544
ATUUTAAGUGAAGUUACUUCUCU
742
522-544

1479521.1

AD-
AGAAGUAACUUCACUUAAAAU
101
524-544
ATUUTAAGUGAAGUUACUUCUCU
742
522-544

1479522.1

AD-
AAGUAACUUCACUUAAAAU
652
526-544
ATUUTAAGUGAAGUUACUUCU
743
524-544

1479523.1

AD-
AAGUAACUUCACUUAAAAU
652
526-544
ATUUTAAGUGAAGUUACUUCU
743
524-544

1479524.1

AD-
AGAACUAACUUCACUUAAAAU
653
524-544
AUUUTAAGUGAAGUUAGUUCUGG
744
522-544

1479525.1

AD-
AGAUGUAACUUCACUUAAAAU
654
524-544
AUUUTAAGUGAAGUUACAUCUGG
745
522-544

1479526.1

AD-
AGUAGUAACUUCACUUAAAAU
655
524-544
AUUUTAAGUGAAGUUACUACUGG
746
522-544

1479527.1

AD-
AUUUGCUAUGUUAGACGAUGU
115
155-175
ACAUCGTCUAACAUAGCAAAUCU
224
153-175

1479528.1

AD-
AUUUGCUAUGUUAGACGAUGU
115
155-175
ACAUCGUCUAACAUAGCAAAUCU
747
153-175

1479529.1

AD-
AUUUGCUAUGUUAGACGAUGA
656
155-175
UCAUCGTCUAACAUAGCAAAUCU
748
153-175

1479530.1

AD-
AUUUGCUAUGUUAGACGAUGA
656
155-175
UCAUCGUCUAACAUAGCAAAUCU
749
153-175

1479531.1

AD-
AUUUGCUAUGUUAGACGAUGA
656
155-175
UCAUCGTCUAACAUAGCAAAUCU
748
153-175

1479532.1

AD-
AUUUGCUAUGUUAGACGAUGA
656
155-175
UCAUCGUCUAACAUAGCAAAUCU
749
153-175

1479533.1

AD-
UUGCUAUGUUAGACGAUGU
657
157-175
ACAUCGTCUAACAUAGCAAGU
750
155-175

1479534.1

AD-
UUGCUAUGUUAGACGAUGU
657
157-175
ACAUCGUCUAACAUAGCAAGU
751
155-175

1479535.1

AD-
AUUUCCUAUGUUAGACGAUGU
658
155-175
ACAUCGUCUAACAUAGGAAAUCU
752
153-175

1479536.1

AD-
AUUAGCUAUGUUAGACGAUGU
659
155-175
ACAUCGUCUAACAUAGCUAAUCU
753
153-175

1479537.1

AD-
AUAUGCUAUGUUAGACGAUGU
660
155-175
ACAUCGUCUAACAUAGCAUAUCU
754
153-175

1479538.1

TABLE 8

Modified Sense and Antisense Strand Sequences of ANGPTL3 dsRNA Agents

SEQ

SEQ

SEQ

Duplex

ID

ID
mRNA
ID

Name
Sense Sequence 5′ to 3′
NO:
Antisense Sequence 5′ to 3′
NO:
Target Sequence
NO:

AD-
usgsuucaCfaAfUfUfaagcuccuuu
270
asAfsagdGa(G2p)cuuaauUfgUf
378
AAUGUUCACAAUUAAGCU
509

1331203.3
L96

gaacasusu

CCUUC

AD-
csascaauUfaAfGfCfuccuucuuuu
274
asAfsaagAfaggagcuUfaAfuugu
382
UUCACAAUUAAGCUCCUU
513

1331206.3
L96

gsasa

CUUUU

AD-
asasuuaaGfcUfCfCfuucuuuuuau
277
asUfsaaaAfagaaggaGfcUfuaau
385
ACAAUUAAGCUCCUUCUU
516

1331209.3
L96

usgsu

UUUAU

AD-
asasgcucCfuUfCfUfuuuuauuguu
25
asAfscaaUfaaaaagaAfgGfagcu
22
UUAAGCUCCUUCUUUUUA
520

1331212.3
L96

usasa

UUGUU

AD-
asgscuccUfuCfUfUfuuuauuguuu
281
asAfsacaAfuaaaaagAfaGfgagc
24
UAAGCUCCUUCUUUUUAU
521

1331213.3
L96

ususa

UGUUC

AD-
ususugauCfaGfUfCfuuuuuaugau
309
asUfscauAfaaaagacUfgAfucaa
416
UAUUUGAUCAGUCUUUUU
549

1331240.3
L96

asusa

AUGAU

AD-
ascsccagAfaGfUfAfacuucacuuu
331
asAfsaguGfaaguuacUfuCfuggg
438
ACACCCAGAAGUAACUUC
571

1331262.3
L96

usgsu

ACUUA

AD-
cscsagaaGfuAfAfCfuucacuuaaa
333
usUfsuadAg(Tgn)gaaguuAfcUfu
440
ACCCAGAAGUAACUUCAC
573

1331264.3
L96

cuggsgsu

UUAAA

AD-
csasgaagUfaAfCfUfucacuuaaaa
334
usUfsuudAa(G2p)ugaaguUfaCfu
441
CCCAGAAGUAACUUCACU
574

1331265.3
L96

ucugsgsg

UAAAA

AD-
asgsaaguAfaCfUfUfcacuuaaaau
335
asUfsuuuAfagugaagUfuAfcuucu
442
CCAGAAGUAACUUCACUU
575

1331266.3
L96

sgsg

AAAAC

AD-
asusuugcuaUfGfUfuagacgauguL96
349
asdCsaudCgdTcuaadCadTadGcaa
480
AGAUUUGCUAUGUUAGAC
589

1331329.3

auscsu

GAUGU

AD-
asasgcuccuUfCfUfuuuuauuguuL96
20
asdAscadAudAaaaadGaAfggagcu
825
UUAAGCUCCUUCUUUUUA
520

1479370.1

usasa

UUGUU

AD-
asasgcuccuUfCfUfuuuuauuguuL96
20
asdAscadAudAaaaadGadAgdGagc
826
UUAAGCUCCUUCUUUUUA
520

1479371.1

uusasa

UUGUU

AD-
asasgcuccuUfCfUfuuuuauuguuL96
20
asdAscadAudAaaaadGaAfggagcu
19
UUAAGCUCCUUCUUUUUA
520

1479372.1

usgsg

UUGUU

AD-
asasgcuccuUfCfUfuuuuauuguuL96
20
asdAscadAudAaaaadGadAgdGagc
827
UUAAGCUCCUUCUUUUUA
520

1479373.1

uusgsg

UUGUU

AD-
asasgcuccuUfCfUfuuuuauuguaL96
755
usdAscadAudAaaaadGaAfggagcu
828
UUAAGCUCCUUCUUUUUA
520

1479374.1

usgsg

UUGUU

AD-
asasgcuccuUfCfUfuuuuauuguaL96
755
usdAscadAudAaaaadGadAgdGagc
829
UUAAGCUCCUUCUUUUUA
520

1479375.1

uusgsg

UUGUU

AD-
asasgcuccuUfCfUfuuuuauuguuL96
20
asdAscadAudAaaaadGaAfggagcu
830
UUAAGCUCCUUCUUUUUA
520

1479376.1

uscsu

UUGUU

AD-
asasgcuccuUfCfUfuuuuauuguuL96
20
asdAscadAudAaaaadGadAgdGagc
831
UUAAGCUCCUUCUUUUUA
520

1479377.1

uuscsu

UUGUU

AD-
gscsuccuUfCfUfuuuuauuguuL96
756
asdAscadAudAaaaadGaAfggagcs
832
AAGCUCCUUCUUUUUAUU
977

1479378.1

usu

GUU

AD-
gscsuccuUfCfUfuuuuauuguuL96
756
asdAscadAudAaaaadGadAgdGagc
833
AAGCUCCUUCUUUUUAUU
977

1479379.1

susu

GUU

AD-
asasgcaccuUfCfUfuuuuauuguuL96
757
asdAscadAudAaaaadGaAfggugcu
834
UUAAGCUCCUUCUUUUUA
520

1479380.1

uscsu

UUGUU

AD-
asasgguccuUfCfUfuuuuauuguuL96
758
asdAscadAudAaaaadGaAfggaccu
835
UUAAGCUCCUUCUUUUUA
520

1479381.1

uscsu

UUGUU

AD-
asasccuccuUfCfUfuuuuauuguuL96
759
asdAscadAudAaaaadGaAfggaggu
836
UUAAGCUCCUUCUUUUUA
520

1479382.1

uscsu

UUGUU

AD-
asgscuccuuCfUfUfuuuauuguuuL96
760
asdAsacdAadTaaaadAgAfaggagc
837
UAAGCUCCUUCUUUUUAU
521

1479383.1

ususa

UGUUC

AD-
asgscuccuuCfUfUfuuuauuguuuL96
760
asdAsacdAadTaaaadAgdAadGgag
838
UAAGCUCCUUCUUUUUAU
521

1479384.1

cususa

UGUUC

AD-
asgscuccuuCfUfUfuuuauuguuuL96
760
asdAsacdAadTaaaadAgAfaggagc
839
UAAGCUCCUUCUUUUUAU
521

1479385.1

ususg

UGUUC

AD-
asgscuccuuCfUfUfuuuauuguuuL96
760
asdAsacdAadTaaaadAgdAadGgag
840
UAAGCUCCUUCUUUUUAU
521

1479386.1

cususg

UGUUC

AD-
asgscuccuuCfUfUfuuuauuguuaL96
761
usdAsacdAadTaaaadAgAfaggagc
841
UAAGCUCCUUCUUUUUAU
521

1479387.1

ususg

UGUUC

AD-
asgscuccuuCfUfUfuuuauuguuaL96
761
usdAsacdAadTaaaadAgdAadGgag
842
UAAGCUCCUUCUUUUUAU
521

1479388.1

cususg

UGUUC

AD-
asgscuccuuCfUfUfuuuauuguuuL96
760
asdAsacdAadTaaaadAgAfaggagc
843
UAAGCUCCUUCUUUUUAU
521

1479389.1

uscsu

UGUUC

AD-
asgscuccuuCfUfUfuuuauuguuuL96
760
asdAsacdAadTaaaadAgdAadGgag
844
UAAGCUCCUUCUUUUUAU
521

1479390.1

cuscsu

UGUUC

AD-
csusccuuCfUfUfuuuauuguuuL96
762
asdAsacdAadTaaaadAgAfaggags
845
AGCUCCUUCUUUUUAUUG
978

1479391.1

csu

UUC

AD-
csusccuuCfUfUfuuuauuguuuL96
762
asdAsacdAadTaaaadAgdAadGgag
846
AGCUCCUUCUUUUUAUUG
978

1479392.1

scsu

UUC

AD-
asgscugcuuCfUfUfuuuauuguuuL96
763
asdAsacdAadTaaaadAgAfagcagc
847
UAAGCUCCUUCUUUUUAU
521

1479393.1

uscsu

UGUUC

AD-
asgscaccuuCfUfUfuuuauuguuuL96
764
asdAsacdAadTaaaadAgAfaggugc
848
UAAGCUCCUUCUUUUUAU
521

1479394.1

uscsu

UGUUC

AD-
asgsguccuuCfUfUfuuuauuguuuL96
765
asdAsacdAadTaaaadAgAfaggucc
849
UAAGCUCCUUCUUUUUAU
521

1479395.1

uscsu

UGUUC

AD-
cscsagaaguAfAfCfuucacuuaaaL96
766
usUfsuadAg(Tgn)gaaguuAfcUfu
440
ACCCAGAAGUAACUUCAC
573

1479396.1

cuggsgsu

UUAAA

AD-
cscsagaaguAfAfCfuucacuuaaaL96
766
usdTsuadAg(Tgn)gaaguuAfcUfu
850
ACCCAGAAGUAACUUCAC
573

1479397.1

cuggsgsu

UUAAA

AD-
cscsagaaguAfAfCfuucacuuaaaL96
766
usUfsuadAg(Tgn)gaagdTuAfcuu
851
ACCCAGAAGUAACUUCAC
573

1479398.1

cuggsgsu

UUAAA

AD-
cscsagaaguAfAfCfuucacuuaaaL96
766
usUfsuadAg(Tgn)gaagdTudAcdT
852
ACCCAGAAGUAACUUCAC
573

1479399.1

ucuggsgsu

UUAAA

AD-
cscsagaaguAfAfCfuucacuuaaaL96
766
usdTsuadAg(Tgn)gaaguuAfcUfu
853
ACCCAGAAGUAACUUCAC
573

1479400.1

cuggscsu

UUAAA

AD-
cscsagaaguAfAfCfuucacuuaaaL96
766
usUfsuadAg(Tgn)gaagdTuAfcuu
854
ACCCAGAAGUAACUUCAC
573

1479401.1

cuggscsu

UUAAA

AD-
asgsaaguAfAfCfuucacuuaaaL96
767
usdTsuadAg(Tgn)gaaguuAfcUfu
855
CCAGAAGUAACUUCACUU
979

1479402.1

cusgsg

AAA

AD-
asgsaaguAfAfCfuucacuuaaaL96
767
usUfsuadAg(Tgn)gaagdTuAfcuu
856
CCAGAAGUAACUUCACUU
979

1479403.1

cusgsg

AAA

AD-
cscsagaaguAfAfCfuucacuuaaaL96
766
usdTsuadAg(Tgn)gaagdTuAfcuu
857
ACCCAGAAGUAACUUCAC
573

1479404.1

cuggsgsu

UUAAA

AD-
asgsaaguAfAfCfuucacuuaaaL96
767
usdTsuadAg(Tgn)gaagdTuAfcuu
858
CCAGAAGUAACUUCACUU
979

1479405.1

cusgsg

AAA

AD-
cscsagaagudAaCfuucacuuaaaL96
768
usUfsuadAg(Tgn)gaaguuAfcUfu
440
ACCCAGAAGUAACUUCAC
573

1479406.1

cuggsgsu

UUAAA

AD-
cscsagaagudAaCfUfucacuuaaaL96
769
usUfsuadAg(Tgn)gaaguuAfcUfu
440
ACCCAGAAGUAACUUCAC
573

1479407.1

cuggsgsu

UUAAA

AD-
cscsagaagudAaCfuucacuuaaaL96
768
usdTsuadAg(Tgn)gaagdTuAfcuu
857
ACCCAGAAGUAACUUCAC
573

1479408.1

cuggsgsu

UUAAA

AD-
cscsagaagudAaCfUfucacuuaaaL96
769
usdTsuadAg(Tgn)gaagdTuAfcuu
857
ACCCAGAAGUAACUUCAC
573

1479409.1

cuggsgsu

UUAAA

AD-
cscsagaagudAaCfuucacuuaaaL96
768
usdTsuadAg(U2p)gaagdTuAfcuu
859
ACCCAGAAGUAACUUCAC
573

1479410.1

cuggscsu

UUAAA

AD-
cscsagaagudAaCfUfucacuuaaaL96
769
usdTsuadAg(U2p)gaagdTuAfcuu
859
ACCCAGAAGUAACUUCAC
573

1479411.1

cuggscsu

UUAAA

AD-
cscsaguaguAfAfCfuucacuuaaaL96
770
usUfsuadAg(Tgn)gaaguuAfcUfa
860
ACCCAGAAGUAACUUCAC
573

1479412.1

cuggsgsu

UUAAA

AD-
cscsacaaguAfAfCfuucacuuaaaL96
771
usUfsuadAg(Tgn)gaaguuAfcUfu
861
ACCCAGAAGUAACUUCAC
573

1479413.1

guggsgsu

UUAAA

AD-
cscsugaaguAfAfCfuucacuuaaaL96
772
usUfsuadAg(Tgn)gaaguuAfcUfu
862
ACCCAGAAGUAACUUCAC
573

1479414.1

caggsgsu

UUAAA

AD-
usgsuucaCfaAfUfUfaagcuccuuu
270
asdAsagdGa(G2p)cuuaauUfgUfg
863
AAUGUUCACAAUUAAGCU
509

1479415.1
L96

aacasusu

CCUUC

AD-
usgsuucacaAfUfUfaagcuccuuuL96
773
asdAsagdGa(G2p)cuuadAuUfgug
864
AAUGUUCACAAUUAAGCU
509

1479416.1

aacasusu

CCUUC

AD-
usgsuucacaAfUfUfaagcuccuuuL96
773
asdAsagdGa(G2p)cuuadAuUfgUf
865
AAUGUUCACAAUUAAGCU
509

1479417.1

gaacasusu

CCUUC

AD-
usgsuucacaAfUfUfaagcuccuuuL96
773
asdAsagdGa(G2p)cuuadAudTgdT
866
AAUGUUCACAAUUAAGCU
509

1479418.1

gaacasusu

CCUUC

AD-
usgsuucacaAfUfUfaagcuccuuuL96
773
asdAsagdGa(G2p)cuuadAudTgdT
867
AAUGUUCACAAUUAAGCU
509

1479419.1

gaacascsu

CCUUC

AD-
usgsuucaCfaAfUfUfaagcuccuuu
270
asAfsagdGa(G2p)cuuaauUfgUfg
868
AAUGUUCACAAUUAAGCU
509

1479420.1
L96

aacasgsg

CCUUC

AD-
usgsuucaCfaAfUfUfaagcuccuuu
270
asdAsagdGa(G2p)cuuaauUfgUfg
869
AAUGUUCACAAUUAAGCU
509

1479421.1
L96

aacasgsg

CCUUC

AD-
usgsuucacaAfUfUfaagcuccuuuL96
773
asdAsagdGa(G2p)cuuadAuUfgug
870
AAUGUUCACAAUUAAGCU
509

1479422.1

aacasgsg

CCUUC

AD-
usgsuucaCfaAfUfUfaagcuccuuu
270
asAfsagdGa(G2p)cuuaauUfgUfg
871
UGUUCACAAUUAAGCUCC
980

1479423.1
L96

aascsg

UUC

AD-
usgsuucaCfaAfUfUfaagcuccuuu
270
asdAsagdGa(G2p)cuuaauUfgUfg
872
UGUUCACAAUUAAGCUCC
980

1479424.1
L96

aascsg

UUC

AD-
usgsuucacaAfUfUfaagcuccuuuL96
773
asdAsagdGa(G2p)cuuadAuUfgug
873
UGUUCACAAUUAAGCUCC
980

1479425.1

asacsg

UUC

AD-
usgsuugaCfaAfUfUfaagcuccuuu
774
asdAsagdGa(G2p)cuuaauUfgUfc
874
AAUGUUCACAAUUAAGCU
509

1479426.1
L96

aacasusu

CCUUC

AD-
usgsuacaCfaAfUfUfaagcuccuuu
775
asdAsagdGa(G2p)cuuaauUfgUfg
875
AAUGUUCACAAUUAAGCU
509

1479427.1
L96

uacasusu

CCUUC

AD-
usgsaucaCfaAfUfUfaagcuccuuu
776
asdAsagdGa(G2p)cuuaauUfgUfg
876
AAUGUUCACAAUUAAGCU
509

1479428.1
L96

uacasusu

CCUUC

AD-
csascaauuaAfGfCfuccuucuuuuL96
777
asdAsaadGadAggagdCuUfaauugu
877
UUCACAAUUAAGCUCCUU
513

1479429.1

gsasa

CUUUU

AD-
csascaauuaAfGfCfuccuucuuuuL96
777
asdAsaadGadAggagdCudTadAuug
878
UUCACAAUUAAGCUCCUU
513

1479430.1

ugsasa

CUUUU

AD-
csascaauuaAfGfCfuccuucuuuuL96
777
asdAsaadGadAggagdCuUfaauugu
879
UUCACAAUUAAGCUCCUU
513

1479431.1

gsgsg

CUUUU

AD-
csascaauuaAfGfCfuccuucuuuaL96
778
usdAsaadGadAggagdCuUfaauugu
880
UUCACAAUUAAGCUCCUU
513

1479432.1

gsgsg

CUUUU

AD-
csascaauuaAfGfCfuccuucuuuuL96
777
asdAsaadGadAggagdCudTadAuug
881
UUCACAAUUAAGCUCCUU
513

1479433.1

ugsgsg

CUUUU

AD-
csascaauuaAfGfCfuccuucuuuuL96
777
asdAsaadGadAggagdCuUfaauugu
882
UUCACAAUUAAGCUCCUU
513

1479434.1

gscsu

CUUUU

AD-
csascaauuaAfGfCfuccuucuuuaL96
778
usdAsaadGadAggagdCuUfaauugu
883
UUCACAAUUAAGCUCCUU
513

1479435.1

gscsu

CUUUU

AD-
csascaauuaAfGfCfuccuucuuuuL96
777
asdAsaadGadAggagdCudTadAuug
884
UUCACAAUUAAGCUCCUU
513

1479436.1

ugscsu

CUUUU

AD-
csasauuaAfGfCfuccuucuuuuL96
779
asdAsaadGadAggagdCuUfaauugs
885
CACAAUUAAGCUCCUUCU
981

1479437.1

usg

UUU

AD-
csasauuaAfGfCfuccuucuuuuL96
779
asdAsaadGadAggagdCudTadAuug
886
CACAAUUAAGCUCCUUCU
981

1479438.1

susg

UUU

AD-
csascauuuaAfGfCfuccuucuuuuL96
780
asdAsaadGadAggagdCuUfaaaugu
887
UUCACAAUUAAGCUCCUU
513

1479439.1

sgcsu

CUUUU

AD-
csascuauuaAfGfCfuccuucuuuuL96
781
asdAsaadGadAggagdCuUfaauagu
888
UUCACAAUUAAGCUCCUU
513

1479440.1

gscsu

CUUUU

AD-
csasgaauuaAfGfCfuccuucuuuuL96
782
asdAsaadGadAggagdCuUfaauucu
889
UUCACAAUUAAGCUCCUU
513

1479441.1

gscsu

CUUUU

AD-
csascaauuadAgCfuccuucuuuuL96
783
asdAsaadGadAggagdCuUfaauugu
882
UUCACAAUUAAGCUCCUU
513

1479442.1

gscsu

CUUUU

AD-
csascaauuadAgCfUfccuucuuuuL96
784
asdAsaadGadAggagdCuUfaauugu
882
UUCACAAUUAAGCUCCUU
513

1479443.1

gscsu

CUUUU

AD-
csascaauuaAfGfCfuccuucuuuuL96
777
asdAsaadGa(A2p)ggagdCuUfaAf
890
UUCACAAUUAAGCUCCUU
513

1479444.1

uugugscsu

CUUUU

AD-
asasuuaagcUfCfCfuucuuuuuauL96
785
asdTsaadAadAgaagdGaGfcuuaau
891
ACAAUUAAGCUCCUUCUU
516

1479445.1

sgusu

UUUAU

AD-
asasuuaagcUfCfCfuucuuuuuaaL96
786
usdTsaadAadAgaagdGaGfcuuaau
892
ACAAUUAAGCUCCUUCUU
516

1479446.1

usgsu

UUUAU

AD-
asasuuaagcUfCfCfuucuuuuuauL96
785
asdTsaadAadAgaagdGadGcdTuaa
893
ACAAUUAAGCUCCUUCUU
516

1479447.1

uusgsu

UUUAU

AD-
asasuuaagcUfCfCfuucuuuuuaaL96
786
usdTsaadAadAgaagdGadGcdTuaa
894
ACAAUUAAGCUCCUUCUU
516

1479448.1

uusgsu

UUUAU

AD-
asasuuaagcUfCfCfuucuuuuuauL96
785
asdTsaadAa(A2p)gaagdGaGfcuu
895
ACAAUUAAGCUCCUUCUU
516

1479449.1

aauusgsu

UUUAU

AD-
asasuuaagcUfCfCfuucuuuuuauL96
785
asdTsaadAa(A2p)gaagdGaGfcUf
896
ACAAUUAAGCUCCUUCUU
516

1479450.1

uaauusgsu

UUUAU

AD-
ususaagcUfCfCfuucuuuuuauL96
787
asdTsaadAadAgaagdGaGfcuuaas
897
AAUUAAGCUCCUUCUUUU
982

1479451.1

usu

UAU

AD-
ususaagcUfCfCfuucuuuuuauL96
787
asdTsaadAadAgaagdGadGcdTuaa
898
AAUUAAGCUCCUUCUUUU
982

1479452.1

susu

UAU

AD-
ususaagcUfCfCfuucuuuuuauL96
787
asdTsaadAa(A2p)gaagdGaGfcuu
899
AAUUAAGCUCCUUCUUUU
982

1479453.1

aasusu

UAU

AD-
ususaagcUfCfCfuucuuuuuauL96
787
asdTsaadAa(A2p)gaagdGadGcdT
900
AAUUAAGCUCCUUCUUUU
982

1479454.1

uaasusu

UAU

AD-
asasuuuagcUfCfCfuucuuuuuauL96
788
asdTsaadAadAgaagdGaGfcuaaau
901
ACAAUUAAGCUCCUUCUU
516

1479455.1

usgsu

UUUAU

AD-
asasuaaagcUfCfCfuucuuuuuauL96
789
asdTsaadAadAgaagdGaGfcuuuau
902
ACAAUUAAGCUCCUUCUU
516

1479456.1

usgsu

UUUAU

AD-
asasauaagcUfCfCfuucuuuuuauL96
790
asdTsaadAadAgaagdGaGfcuuauu
903
ACAAUUAAGCUCCUUCUU
516

1479457.1

usgsu

UUUAU

AD-
ususugauCfaGfUfCfuuuuuaugau
309
asUfscadTa(A2p)aaagacUfgAfu
904
UAUUUGAUCAGUCUUUUU
549

1479458.1
L96

caaasusg

AUGAU

AD-
ususugauCfaGfUfCfuuuuuaugaa
791
usUfscadTa(A2p)aaagacUfgAfu
905
UAUUUGAUCAGUCUUUUU
549

1479459.1
L96

acaasusg

AUGAU

AD-
ususugauCfaGfUfCfuuuuuaugau
309
asdTscadTa(A2p)aaagacUfgAfu
906
UAUUUGAUCAGUCUUUUU
549

1479460.1
L96

caaasusg

AUGAU

AD-
ususugauCfaGfUfCfuuuuuaugau
309
asdTscaua(A2p)aaagacUfgdAuc
907
UAUUUGAUCAGUCUUUUU
549

1479461.1
L96

aaasusg

AUGAU

AD-
ususugauCfaGfUfCfuuuuuaugau
309
asdTscadTa(A2p)aaagdAcUfgAf
908
UAUUUGAUCAGUCUUUUU
549

1479462.1
L96

ucaaasusg

AUGAU

AD-
ususugauCfaGfUfCfuuuuuaugaa
791
usdTscadTa(A2p)aaagdAcUfgAf
909
UAUUUGAUCAGUCUUUUU
549

1479463.1
L96

ucaaasusg

AUGAU

AD-
ususugauCfaGfUfCfuuuuuaugau
309
asdTscaua(A2p)aaagdAcUfgdAu
910
UAUUUGAUCAGUCUUUUU
549

1479464.1
L96

caaasusg

AUGAU

AD-
ususugauCfaGfUfCfuuuuuaugau
309
asdTscaua(A2p)aaagdAcdTgdAu
911
UAUUUGAUCAGUCUUUUU
549

1479465.1
L96

caasusg

AUGAU

AD-
ususugauCfaGfUfCfuuuuuaugau
309
asdTscadTa(A2p)aaagdAcUfgau
912
UAUUUGAUCAGUCUUUUU
549

1479466.1
L96

caaasusg

AUGAU

AD-
ususgauCfaGfUfCfuuuuuaugauL96
792
asdTscaua(A2p)aaagdAcUfgauc
913
AUUUGAUCAGUCUUUUUA
983

1479467.1

aascsu

UGAU

AD-
ususugaucadGuCfUfuuuuaugauL96
793
asdTscadTa(A2p)aaagdAcUfgAf
914
UAUUUGAUCAGUCUUUUU
549

1479468.1

ucaaascsu

AUGAU

AD-
ususugaucagUfCfUfuuuuaugauL96
794
asdTscadTa(A2p)aaagdAcUfgAf
914
UAUUUGAUCAGUCUUUUU
549

1479469.1

ucaaascsu

AUGAU

AD-
ususuguuCfaGfUfCfuuuuuaugau
795
asdTscadTa(A2p)aaagdAcUfgAf
915
UAUUUGAUCAGUCUUUUU
549

1479470.1
L96

acaaasusg

AUGAU

AD-
ususucauCfaGfUfCfuuuuuaugau
796
asdTscadTa(A2p)aaagdAcUfgAf
916
UAUUUGAUCAGUCUUUUU
549

1479471.1
L96

ugaaasusg

AUGAU

AD-
ususagauCfaGfUfCfuuuuuaugau
797
asdTscadTa(A2p)aaagdAcUfgAf
917
UAUUUGAUCAGUCUUUUU
549

1479472.1
L96

ucuaasusg

AUGAU

AD-
ususugaucaGfUfCfuuuuuaugauL96
798
asdTscadTadAaaagdAcUfgaucaa
918
UAUUUGAUCAGUCUUUUU
549

1479473.1

ascsu

AUGAU

AD-
csasgaagUfaAfCfUfucacuuaaaa
334
usdTsuudAa(G2p)ugaaguUfaCfu
919
CCCAGAAGUAACUUCACU
574

1479474.1
L96

ucugsgsg

UAAAA

AD-
csasgaagUfaAfCfUfucacuuaaaa
334
usdTsuudAa(G2p)ugaadGuUfaCf
920
CCCAGAAGUAACUUCACU
574

1479475.1
L96

uucugsgsg

UAAAA

AD-
csasgaagUfaAfCfUfucacuuaaaa
334
usdTsuudAa(G2p)ugaadGuUfacu
921
CCCAGAAGUAACUUCACU
574

1479476.1
L96

ucugsgsg

UAAAA

AD-
csasgaagUfaAfCfUfucacuuaaaa
334
usdTsuudAa(G2p)ugaadGudTadC
922
CCCAGAAGUAACUUCACU
574

1479477.1
L96

uucugsgsg

UAAAA

AD-
gsasagUfaAfCfUfucacuuaaaaL96
799
usdTsuudAa(G2p)ugaadGuUfacu
923
CAGAAGUAACUUCACUUA
984

1479478.1

ucsusg

AAA

AD-
csasgaagUfadAcfUfucacuuaaaa
800
usdTsuudAa(G2p)ugaadGuUfacu
921
CCCAGAAGUAACUUCACU
574

1479479.1
L96

ucugsgsg

UAAAA

AD-
csasgaagUfadAcUfucacuuaaaaL96
801
usdTsuudAa(G2p)ugaadGuUfacu
921
CCCAGAAGUAACUUCACU
574

1479480.1

ucugsgsg

UAAAA

AD-
csasgaaguadAcUfucacuuaaaaL96
802
usdTsuudAa(G2p)ugaadGuUfacu
921
CCCAGAAGUAACUUCACU
574

1479481.1

ucugsgsg

UAAAA

AD-
csasgaaguadAcUfUfcacuuaaaaL96
803
usdTsuudAa(G2p)ugaadGuUfacu
921
CCCAGAAGUAACUUCACU
574

1479482.1

ucugsgsg

UAAAA

AD-
csasgaaguaaCfUfUfcacuuaaaaL96
804
usdTsuudAa(G2p)ugaadGuUfacu
921
CCCAGAAGUAACUUCACU
574

1479483.1

ucugsgsg

UAAAA

AD-
csasgaagUfaAfCfUfucacuuaaaa
334
usdTsuudAa(G2p)ugaadGu(U2p)
924
CCCAGAAGUAACUUCACU
574

1479484.1
L96

aCfuucugsgsg

UAAAA

AD-
csasgaagUfaAfCfUfucacuuaaaa
334
usdTsuudAa(G2p)ugaadGuUf
925
CCCAGAAGUAACUUCACU
574

1479485.1
L96

(A2p)Cfuucugsgsg

UAAAA

AD-
csasgaagUfaAfCfUfucacuuaaaa
334
usdTsuudAa(G2p)ugaadGuUfa
926
CCCAGAAGUAACUUCACU
574

1479486.1
L96

(C2p)uucugsgsg

UAAAA

AD-
csasgaagUfaAfCfUfucacuuaaaa
334
usdTsuudAa(G2p)ugaadGuUfaCf
927
CCCAGAAGUAACUUCACU
574

1479487.1
L96

(U2p)ucugsgsg

UAAAA

AD-
csasgaaguaAfCfUfucacuuaaaaL96
805
usdTsuudAadGugaadGuUfacuucu
928
CCCAGAAGUAACUUCACU
574

1479488.1

gsgsg

UAAAA

AD-
ascsccagaaGfUfAfacuucacuuuL96
806
asAfsagdTg(Agn)aguuacUfuCfu
929
ACACCCAGAAGUAACUUC
571

1479489.1

gggusgsu

ACUUA

AD-
ascsccagaaGfUfAfacuucacuuuL96
806
asAfsagdTg(A2p)aguuacUfuCfu
930
ACACCCAGAAGUAACUUC
571

1479490.1

gggusgsu

ACUUA

AD-
ascsccagaaGfUfAfacuucacuuaL96
807
usAfsagdTg(Agn)aguuacUfuCfu
931
ACACCCAGAAGUAACUUC
571

1479491.1

gggusgsu

ACUUA

AD-
ascsccagaaGfUfAfacuucacuuaL96
807
usAfsagdTg(A2p)aguuacUfuCfu
932
ACACCCAGAAGUAACUUC
571

1479492.1

gggusgsu

ACUUA

AD-
ascsccagaaGfUfAfacuuuacuuuL96
808
asAfsagdTadAaguuacUfuCfuggg
933
ACACCCAGAAGUAACUUC
571

1479493.1

usgsu

ACUUA

AD-
ascsccagaaGfUfAfacuucacuuuL96
806
asdAsagdTg(Agn)aguuacUfuCfu
934
ACACCCAGAAGUAACUUC
571

1479494.1

gggusgsu

ACUUA

AD-
ascsccagaaGfUfAfacuucacuuuL96
806
asdAsagdTg(A2p)aguuacUfuCfu
935
ACACCCAGAAGUAACUUC
571

1479495.1

gggusgsu

ACUUA

AD-
ascsccagaaGfUfAfacuucacuuuL96
806
asdAsagdTg(Agn)aguuacUfuCfu
936
ACACCCAGAAGUAACUUC
571

1479496.1

ggguscsu

ACUUA

AD-
ascsccagaaGfUfAfacuucacuuuL96
806
asdAsagdTg(A2p)aguuacUfuCfu
937
ACACCCAGAAGUAACUUC
571

1479497.1

ggguscsu

ACUUA

AD-
ascsccagaaGfUfAfacuucacuuuL96
806
asAfsagdTg(A2p)aguuacUfuCfu
938
ACACCCAGAAGUAACUUC
571

1479498.1

ggguscsu

ACUUA

AD-
ascsccagaaGfUfAfacuucacuuuL96
806
asdAsagdTg(A2p)aguudAcUfuCf
939
ACACCCAGAAGUAACUUC
571

1479499.1

uggguscsu

ACUUA

AD-
cscsagaaGfUfAfacuucacuuuL96
809
asdAsagdTg(Agn)aguuacUfuCfu
940
ACCCAGAAGUAACUUCAC
985

1479500.1

ggsgsu

UUA

AD-
cscsagaaGfUfAfacuucacuuuL96
809
asdAsagdTg(A2p)aguuacUfuCfu
941
ACCCAGAAGUAACUUCAC
985

1479501.1

ggsgsu

UUA

AD-
cscsagaaGfUfAfacuucacuuuL96
809
asAfsagdTg(A2p)aguuacUfuCfu
942
ACCCAGAAGUAACUUCAC
985

1479502.1

ggsgsu

UUA

AD-
cscsagaaGfUfAfacuucacuuuL96
809
asdAsagdTg(A2p)aguudAcUfuCf
943
ACCCAGAAGUAACUUCAC
985

1479503.1

uggsgsu

UUA

AD-
ascsccugaaGfUfAfacuucacuuuL96
810
asdAsagdTg(A2p)aguuacUfuCfa
944
ACACCCAGAAGUAACUUC
571

1479504.1

gggusgsu

ACUUA

AD-
ascscgagaaGfUfAfacuucacuuuL96
811
asdAsagdTg(A2p)aguuacUfuCfu
945
ACACCCAGAAGUAACUUC
571

1479505.1

cggusgsu

ACUUA

AD-
ascsgcagaaGfUfAfacuucacuuuL96
812
asdAsagdTg(A2p)aguuacUfuCfu
946
ACACCCAGAAGUAACUUC
571

1479506.1

gcgusgsu

ACUUA

AD-
ascsccagaagUfAfAfcuucacuuuL96
813
asdAsagdTg(Agn)aguuacUfuCfu
934
ACACCCAGAAGUAACUUC
571

1479507.1

gggusgsu

ACUUA

AD-
ascsccagaagUfAfAfcuucacuuuL96
813
asdAsagdTg(A2p)aguuacUfuCfu
935
ACACCCAGAAGUAACUUC
571

1479508.1

gggusgsu

ACUUA

AD-
asgsaaguaaCfUfUfcacuuaaaauL96
814
asUfsuudTa(Agn)gugaagUfuAfc
947
CCAGAAGUAACUUCACUU
575

1479509.1

uucusgsg

AAAAC

AD-
asgsaaguaaCfUfUfcacuuaaaauL96
814
asUfsuudTa(A2p)gugaagUfuAfc
948
CCAGAAGUAACUUCACUU
575

1479510.1

uucusgsg

AAAAC

AD-
asgsaaguaaCfUfUfcacuuaaaauL96
814
asUfsuudTa(Agn)gugadAgUfuAf
949
CCAGAAGUAACUUCACUU
575

1479511.1

cuucusgsg

AAAAC

AD-
asgsaaguaaCfUfUfcacuuaaaauL96
814
asUfsuudTa(A2p)gugadAgUfuAf
950
CCAGAAGUAACUUCACUU
575

1479512.1

cuucusgsg

AAAAC

AD-
asgsaaguaaCfUfUfcacuuaaaaaL96
815
usUfsuudTa(Agn)gugadAgUfuAf
951
CCAGAAGUAACUUCACUU
575

1479513.1

cuucusgsg

AAAAC

AD-
asgsaaguaaCfUfUfcacuuaaaaaL96
815
usUfsuudTa(A2p)gugadAgUfuAf
952
CCAGAAGUAACUUCACUU
575

1479514.1

cuucusgsg

AAAAC

AD-
asgsaaguaaCfUfUfcacuuaaaauL96
814
asUfsuudTa(Agn)gugadAgUfuac
953
CCAGAAGUAACUUCACUU
575

1479515.1

uucusgsg

AAAAC

AD-
asgsaaguaaCfUfUfcacuuaaaauL96
814
asUfsuudTa(A2p)gugadAgUfuac
954
CCAGAAGUAACUUCACUU
575

1479516.1

uucusgsg

AAAAC

AD-
asgsaaguaaCfUfUfcacuuaaaauL96
814
asdTsuudTa(Agn)gugadAgUfuAf
955
CCAGAAGUAACUUCACUU
575

1479517.1

cuucusgsg

AAAAC

AD-
asgsaaguaaCfUfUfcacuuaaaauL96
814
asdTsuudTa(A2p)gugadAgUfuAf
956
CCAGAAGUAACUUCACUU
575

1479518.1

cuucusgsg

AAAAC

AD-
asgsaaguaaCfUfUfcacuuaaaauL96
814
asdTsuudTa(Agn)gugadAgUfuac
957
CCAGAAGUAACUUCACUU
575

1479519.1

uucusgsg

AAAAC

AD-
asgsaaguaaCfUfUfcacuuaaaauL96
814
asdTsuudTa(A2p)gugadAgUfuac
958
CCAGAAGUAACUUCACUU
575

1479520.1

uucusgsg

AAAAC

AD-
asgsaaguaaCfUfUfcacuuaaaauL96
814
asdTsuudTa(A2p)gugadAgUfuAf
959
CCAGAAGUAACUUCACUU
575

1479521.1

cuucuscsu

AAAAC

AD-
asgsaaguaaCfUfUfcacuuaaaauL96
814
asdTsuudTa(A2p)gugadAgUfuac
960
CCAGAAGUAACUUCACUU
575

1479522.1

uucuscsu

AAAAC

AD-
asasguaaCfUfUfcacuuaaaauL96
816
asdTsuudTa(A2p)gugadAgUfuAf
961
AGAAGUAACUUCACUUAA
986

1479523.1

ucuscsu

AAC

AD-
asasguaaCfUfUfcacuuaaaauL96
816
asdTsuudTa(A2p)gugadAgUfuac
962
AGAAGUAACUUCACUUAA
986

1479524.1

uuscsu

AAC

AD-
asgsaacuaaCfUfUfcacuuaaaauL96
817
asUfsuudTa(A2p)gugaagUfuAfg
963
CCAGAAGUAACUUCACUU
575

1479525.1

uucusgsg

AAAAC

AD-
asgsauguaaCfUfUfcacuuaaaauL96
818
asUfsuudTa(A2p)gugaagUfuAfc
964
CCAGAAGUAACUUCACUU
575

1479526.1

aucusgsg

AAAAC

AD-
asgsuaguaaCfUfUfcacuuaaaauL96
819
asUfsuudTa(A2p)gugaagUfuAfc
965
CCAGAAGUAACUUCACUU
575

1479527.1

aucusgsg

AAAAC

AD-
asusuugcuaUfGfUfuagacgauguL96
349
asdCsaudCg(Tgn)cuaadCaUfadG
966
AGAUUUGCUAUGUUAGAC
589

1479528.1

aacauscsu

GAUGU

AD-
asusuugcuaUfGfUfuagacgauguL96
349
asdCsaudCg(U2p)cuaadCaUfadG
967
AGAUUUGCUAUGUUAGAC
589

1479529.1

caaauscsu

GAUGU

AD-
asusuugcuaUfGfUfuagacgaugaL96
820
usdCsaudCg(Tgn)cuaadCaUfadG
968
AGAUUUGCUAUGUUAGAC
589

1479530.1

caaauscsu

GAUGU

AD-
asusuugcuaUfGfUfuagacgaugaL96
820
usdCsaudCg(U2p)cuaadCaUfadG
969
AGAUUUGCUAUGUUAGAC
589

1479531.1

caaauscsu

GAUGU

AD-
asusuugcuaUfGfUfuagacgaugaL96
820
usdCsaudCg(Tgn)cuaadCaUfagc
970
AGAUUUGCUAUGUUAGAC
589

1479532.1

aaauscsu

GAUGU

AD-
asusuugcuaUfGfUfuagacgaugaL96
820
usdCsaudCg(U2p)cuaadCaUfagc
971
AGAUUUGCUAUGUUAGAC
589

1479533.1

aaauscsu

GAUGU

AD-
ususgcuaUfGfUfuagacgauguL96
821
asdCsaudCg(Tgn)cuaadCaUfadG
972
AUUUGCUAUGUUAGACGA
26

1479534.1

acasgsu

UGU

AD-
ususgcuaUfGfUfuagacgauguL96
821
asdCsaudCg(U2p)cuaadCaUfadG
973
AUUUGCUAUGUUAGACGA
26

1479535.1

caasgsu

UGU

AD-
asusuuccuaUfGfUfuagacgauguL96
822
asdCsaudCg(U2p)cuaadCaUfadG
974
AGAUUUGCUAUGUUAGAC
589

1479536.1

agaauscsu

GAUGU

AD-
asusuagcuaUfGfUfuagacgauguL96
823
asdCsaudCg(U2p)cuaadCaUfadG
975
AGAUUUGCUAUGUUAGAC
589

1479537.1

cuaauscsu

GAUGU

AD-
asusaugcuaUfGfUfuagacgauguL96
824
asdCsaudCg(U2p)cuaadCaUfadG
976
AGAUUUGCUAUGUUAGAC
589

1479538.1

cauauscsu

GAUGU

TABLE 9

ANGPTL3 Dose Screen in Primary Cynomolgus Hepatocytes (PCH)

10 nM
1 nM
0.1 nM

% Avg

% Avg

% Avg

Message

Message

Message

Duplex
Remaining
STDEV
Remaining
STDEV
Remaining
STDEV

AD-1331203.3
21.83
3.88
37.26
10.35
63.40
6.85

AD-1331206.3
26.97
6.93
36.84
0.72
63.76
8.49

AD-1331209.3
29.11
6.54
47.11
9.54
69.87
10.35

AD-1331212.3
20.51
1.87
32.34
3.79
64.22
4.01

AD-1331213.3
24.52
6.06
54.62
13.41
79.48
4.89

AD-1331240.3
23.28
2.48
39.36
12.24
61.69
2.10

AD-1331262.3
21.78
4.54
36.65
10.43
34.32
6.45

AD-1331264.3
30.25
4.78
42.15
9.57
73.71
7.94

AD-1331265.3
15.48
6.76
23.56
9.61
58.07
11.35

AD-1331266.3
22.04
6.40
37.66
7.86
76.54
13.10

AD-1331329.3
27.51
4.89
48.91
13.92
80.66
18.31

AD-1479370.1
21.73
4.33
30.33
5.56
48.74
4.38

AD-1479371.1
31.70
5.00
45.03
9.50
75.21
6.98

AD-1479372.1
24.67
4.69
31.62
5.49
48.74
11.67

AD-1479373.1
24.70
5.31
42.70
11.47
55.73
7.91

AD-1479374.1
20.99
5.74
39.52
8.56
53.59
9.84

AD-1479375.1
34.71
4.39
42.32
8.36
68.22
7.34

AD-1479376.1
27.40
3.28
39.83
8.85
75.37
7.01

AD-1479377.1
23.02
6.24
28.41
4.55
46.53
3.65

AD-1479378.1
19.86
2.91
35.90
5.17
65.17
6.57

AD-1479379.1
40.95
9.09
45.69
7.59
91.98
9.04

AD-1479380.1
33.08
3.69
41.27
4.32
77.14
6.74

AD-1479381.1
59.79
5.80
58.68
11.10
97.26
18.01

AD-1479382.1
54.83
6.34
69.58
12.85
106.90
10.18

AD-1479383.1
26.82
7.80
39.42
5.78
66.74
13.93

AD-1479384.1
31.41
9.09
42.81
8.93
77.27
6.47

AD-1479385.1
23.53
2.60
42.30
6.40
63.42
5.36

AD-1479386.1
58.87
11.25
63.77
6.47
82.82
7.42

AD-1479387.1
28.69
6.25
40.57
7.31
66.99
5.01

AD-1479388.1
44.77
1.46
71.86
11.05
102.85
5.40

AD-1479389.1
33.00
3.97
59.97
7.53
76.18
7.92

AD-1479390.1
63.21
14.55
94.18
30.48
110.96
4.78

AD-1479391.1
19.40
2.17
32.29
10.49
48.57
6.14

AD-1479392.1
61.28
6.41
77.43
17.86
100.18
14.53

AD-1479393.1
96.38
5.44
123.77
19.35
131.27
5.92

AD-1479394.1
75.77
11.27
84.31
5.24
125.94
10.43

AD-1479395.1
84.00
3.40
110.51
15.20
135.40
22.27

AD-1479396.1
20.02
5.37
32.81
7.36
56.85
11.34

AD-1479397.1
13.38
2.73
26.07
1.29
42.37
9.09

AD-1479398.1
18.15
3.78
37.73
7.00
51.52
7.54

AD-1479399.1
26.26
3.82
66.97
14.01
76.11
13.57

AD-1479400.1
26.46
3.84
50.16
7.83
77.00
16.24

AD-1479401.1
14.67
3.25
36.91
7.56
60.75
9.50

AD-1479402.1
18.55
2.16
40.23
6.63
65.32
9.53

AD-1479403.1
18.00
1.15
38.70
3.77
58.14
12.26

AD-1479404.1
21.38
2.80
29.69
4.16
56.93
14.45

AD-1479405.1
15.85
4.03
28.15
5.44
44.64
8.56

AD-1479406.1
16.92
0.29
36.24
5.32
53.50
2.57

AD-1479407.1
23.54
1.76
21.01
4.97
56.23
8.47

AD-1479408.1
21.03
1.82
30.88
6.36
56.85
6.10

AD-1479409.1
22.92
3.73
44.89
5.55
68.09
6.93

AD-1479410.1
18.25
4.82
39.37
4.09
61.13
10.17

AD-1479411.1
14.08
2.22
42.44
1.98
47.58
10.60

AD-1479412.1
36.87
5.55
42.48
3.19
81.01
5.10

AD-1479413.1
36.52
7.54
37.35
7.69
64.91
4.50

AD-1479414.1
23.48
2.64
45.97
10.29
60.47
1.44

AD-1479415.1
25.78
3.27
42.28
8.67
67.23
8.22

AD-1479416.1
32.26
0.81
52.88
3.11
85.61
9.71

AD-1479417.1
25.89
4.12
57.24
10.15
73.76
12.58

AD-1479418.1
50.84
5.51
84.77
11.67
86.23
9.86

AD-1479419.1
81.24
13.71
86.77
18.63
109.03
3.82

AD-1479420.1
33.82
4.30
48.85
7.44
55.89
4.72

AD-1479421.1
27.81
2.72
55.22
13.15
71.11
7.85

AD-1479422.1
24.35
3.45
46.73
12.34
72.10
8.19

AD-1479423.1
38.85
8.70
69.75
11.36
94.64
10.27

AD-1479424.1
60.95
9.16
84.22
24.95
100.52
8.74

AD-1479425.1
49.93
5.03
81.50
3.59
106.39
17.05

AD-1479426.1
64.96
3.02
107.97
24.24
111.97
10.08

AD-1479427.1
53.66
9.36
49.75
1.44
83.24
4.12

AD-1479428.1
54.54
13.38
61.03
10.13
95.32
5.55

AD-1479429.1
28.06
0.11
34.65
13.04
68.26
6.60

AD-1479430.1
41.79
7.33
34.04
2.47
85.11
12.69

AD-1479431.1
41.03
5.73
40.66
14.93
79.67
8.18

AD-1479432.1
24.77
2.72
39.12
12.26
62.46
10.43

AD-1479433.1
22.76
4.25
39.21
7.40
55.17
1.73

AD-1479434.1
22.41
3.01
30.94
4.88
67.71
2.90

AD-1479435.1
46.22
2.94
37.66
6.83
70.31
12.03

AD-1479436.1
53.57
9.68
66.50
11.98
93.07
6.61

AD-1479437.1
30.05
2.19
31.48
7.94
81.65
10.22

AD-1479438.1
32.45
5.46
31.69
8.74
80.44
7.35

AD-1479439.1
31.32
4.75
42.83
8.67
75.05
12.99

AD-1479440.1
24.78
3.63
34.04
6.04
59.37
4.97

AD-1479441.1
19.12
1.68
24.28
6.41
56.31
11.28

AD-1479442.1
32.17
3.43
38.40
4.55
64.80
4.34

AD-1479443.1
30.40
1.97
41.56
10.74
78.97
13.24

AD-1479444.1
53.81
9.16
69.98
18.91
99.85
14.28

AD-1479445.1
35.46
6.89
45.54
8.33
71.44
7.16

AD-1479446.1
31.98
4.88
22.01
3.01
61.20
13.17

AD-1479447.1
24.59
1.80
21.52
2.02
59.10
3.71

AD-1479448.1
20.40
1.50
32.92
4.93
60.39
9.30

AD-1479449.1
38.49
4.54
34.93
4.00
73.51
6.96

AD-1479450.1
30.67
5.77
28.39
3.06
65.84
4.88

AD-1479451.1
32.03
1.24
54.77
8.19
66.14
6.03

AD-1479452.1
47.19
8.86
70.69
2.08
86.72
21.00

AD-1479453.1
62.14
2.67
67.53
3.34
113.26
3.76

AD-1479454.1
109.81
13.06
93.99
2.92
58.69
2.73

AD-1479455.1
32.58
10.08
39.20
10.59
42.16
4.54

AD-1479456.1
34.33
2.41
38.06
8.00
45.02
8.84

AD-1479457.1
26.03
8.91
33.26
9.15
51.76
4.91

AD-1479458.1
38.72
5.70
61.21
7.99
72.12
10.10

AD-1479459.1
31.06
2.30
46.84
10.36
64.49
8.60

AD-1479460.1
36.10
0.53
38.93
11.60
46.56
9.61

AD-1479461.1
49.69
14.23
64.11
10.16
64.82
10.62

AD-1479462.1
38.10
4.32
53.00
5.77
51.24
8.83

AD-1479463.1
29.29
3.76
41.94
8.30
61.26
10.42

AD-1479464.1
48.97
4.76
66.96
17.46
109.86
17.74

AD-1479465.1
98.84
16.78
105.30
11.34
113.42
18.73

AD-1479466.1
39.24
7.52
67.82
6.21
106.86
10.90

AD-1479467.1
65.56
13.36
89.24
24.01
128.50
14.14

AD-1479468.1
36.93
5.50
52.51
18.31
69.18
9.94

AD-1479469.1
57.21
6.51
86.69
11.17
69.71
10.74

AD-1479470.1
86.09
12.11
88.91
15.03
96.18
15.66

AD-1479471.1
64.25
8.99
70.62
9.85
119.81
12.25

AD-1479472.1
42.02
5.71
69.00
7.98
102.53
23.14

AD-1479473.1
24.01
6.34
60.89
3.70
79.05
6.27

AD-1479474.1
13.49
2.03
28.93
9.44
35.40
5.48

AD-1479475.1
20.47
1.73
42.26
8.24
30.02
8.45

AD-1479476.1
18.07
6.80
37.75
14.77
42.84
8.79

AD-1479477.1
27.36
6.67
54.67
11.39
79.19
18.42

AD-1479478.1
28.06
7.96
32.84
6.87
83.29
17.40

AD-1479479.1
26.54
6.18
48.54
10.73
83.40
6.36

AD-1479480.1
23.79
4.31
40.17
13.79
79.79
14.19

AD-1479481.1
19.44
4.33
34.39
10.89
39.32
7.47

AD-1479482.1
20.96
1.55
41.32
11.54
29.05
1.65

AD-1479483.1
21.13
3.90
38.58
7.09
48.12
8.51

AD-1479484.1
26.29
5.13
46.10
12.66
55.17
8.09

AD-1479485.1
36.56
8.06
47.42
4.42
68.70
5.47

AD-1479486.1
26.10
8.69
47.98
4.74
91.73
17.12

AD-1479487.1
27.49
7.14
57.39
4.76
83.07
12.31

AD-1479488.1
12.46
3.09
22.12
2.70
65.46
13.64

AD-1479489.1
23.50
4.20
43.78
3.19
26.93
2.48

AD-1479490.1
24.91
4.58
36.16
2.50
38.67
8.14

AD-1479491.1
17.96
0.44
37.69
7.51
52.46
14.94

AD-1479492.1
17.16
5.40
23.26
3.68
53.32
11.48

AD-1479493.1
39.85
5.04
43.16
14.17
103.09
8.75

AD-1479494.1
24.55
10.40
44.63
6.21
64.10
7.84

AD-1479495.1
26.79
9.37
45.44
7.49
68.61
12.47

AD-1479496.1
37.70
5.80
79.45
5.42
52.05
2.04

AD-1479497.1
19.94
2.51
55.28
9.15
67.55
13.60

AD-1479498.1
23.47
7.35
38.30
6.65
75.40
9.32

AD-1479499.1
22.56
4.30
50.37
6.18
103.58
26.12

AD-1479500.1
36.43
8.14
42.46
19.64
112.00
12.08

AD-1479501.1
19.57
5.58
39.48
13.76
65.35
5.54

AD-1479502.1
21.52
7.06
40.25
10.08
82.14
3.92

AD-1479503.1
25.61
4.21
35.97
9.20
42.53
6.68

AD-1479504.1
44.17
3.59
85.62
11.11
74.61
20.24

AD-1479505.1
35.41
6.70
67.31
11.33
90.56
25.07

AD-1479506.1
40.57
4.91
75.46
3.63
77.84
13.98

AD-1479507.1
36.24
1.16
57.87
11.93
90.58
15.11

AD-1479508.1
26.26
1.96
41.71
3.04
87.84
20.80

AD-1479509.1
36.83
3.05
61.90
4.66
98.42
19.40

AD-1479510.1
34.79
2.17
45.38
10.17
82.24
10.05

AD-1479511.1
35.10
6.24
49.37
11.18
37.46
9.73

AD-1479512.1
25.99
5.51
54.32
6.33
53.60
13.57

AD-1479513.1
21.56
6.48
25.88
15.98
73.48
16.15

AD-1479514.1
19.43
6.82
44.34
10.63
64.34
8.45

AD-1479515.1
25.18
8.67
39.57
16.86
85.87
8.35

AD-1479516.1
38.16
5.84
53.95
7.12
96.45
9.65

AD-1479517.1
39.56
10.21
51.49
8.41
59.11
9.25

AD-1479518.1
33.94
7.42
53.59
12.98
31.54
2.94

AD-1479519.1
43.12
8.26
63.00
10.67
64.42
9.27

AD-1479520.1
22.82
6.08
41.72
16.75
80.11
19.91

AD-1479521.1
26.02
2.29
48.99
9.22
91.48
14.66

AD-1479522.1
43.26
6.15
61.44
16.38
79.92
15.83

AD-1479523.1
44.07
3.24
66.18
5.97
103.15
9.97

AD-1479524.1
63.42
9.40
76.50
13.58
93.92
20.94

AD-1479525.1
61.13
7.14
74.69
10.00
55.51
5.76

AD-1479526.1
45.18
6.46
66.41
9.41
56.67
4.28

AD-1479527.1
39.53
5.39
55.03
9.70
55.04
2.46

AD-1479528.1
42.61
14.62
63.30
6.12
89.09
17.17

AD-1479529.1
40.15
6.52
55.13
6.97
91.58
18.95

AD-1479530.1
43.63
1.77
55.22
5.79
91.83
11.83

AD-1479531.1
35.71
4.54
43.24
7.42
64.00
12.70

AD-1479532.1
37.43
7.12
44.99
3.16
51.75
4.05

AD-1479533.1
31.71
5.48
49.18
5.98
54.17
7.90

AD-1479534.1
75.18
5.91
80.12
9.23
69.93
6.07

AD-1479535.1
43.87
2.79
53.58
7.92
44.33
9.04

AD-1479536.1
56.99
11.10
67.52
13.00
76.03
17.66

AD-1479537.1
43.81
2.50
57.35
9.20
71.02
15.35

AD-1479538.1
35.44
1.57
51.51
6.24
72.09
11.75

TABLE 10

ANGPTL3 Dose
10 nM
1 nM
0.1 nM

Screen in Hep3B
% Avg

% Avg

% Avg

Cells
Message

Message

Message

Duplex
Remaining
STDEV
Remaining
STDEV
Remaining
STDEV

AD-1331203.3
2.56
1.05
5.78
1.82
10.71
1.51

AD-1331206.3
1.59
0.49
3.68
1.19
19.15
7.31

AD-1331209.3
1.89
1.43
2.94
0.99
10.29
3.96

AD-1331212.3
0.82
0.21
2.92
1.20
12.51
3.50

AD-1331213.3
0.97
0.25
3.01
1.07
4.87
1.01

AD-1331240.3
2.30
0.82
2.72
1.01
9.26
2.42

AD-1331262.3
1.68
0.65
2.74
1.49
6.89
2.53

AD-1331264.3
1.26
0.68
2.09
0.53
4.45
0.98

AD-1331265.3
1.22
0.69
1.39
0.24
4.62
0.78

AD-1331266.3
1.45
0.45
2.81
1.69
8.40
3.51

AD-1331329.3
1.87
0.47
3.71
0.62
9.98
3.76

AD-1479370.1
0.70
0.26
1.70
0.37
6.01
2.25

AD-1479371.1
1.24
0.34
3.32
0.89
8.65
2.31

AD-1479372.1
0.74
0.32
2.21
0.66
7.22
1.47

AD-1479373.1
1.62
0.72
3.18
1.07
8.00
3.21

AD-1479374.1
0.82
0.55
1.90
0.84
3.94
1.09

AD-1479375.1
1.23
0.43
2.97
0.94
6.46
2.32

AD-1479376.1
0.71
0.47
0.98
0.40
1.63
0.98

AD-1479377.1
1.27
0.28
3.78
0.97
13.89
3.72

AD-1479378.1
1.27
0.25
3.99
1.54
5.86
0.67

AD-1479379.1
2.66
0.73
9.10
4.04
20.53
3.84

AD-1479380.1
1.87
0.74
7.68
4.32
20.84
7.70

AD-1479381.1
4.42
0.26
16.16
3.26
36.78
6.88

AD-1479382.1
4.57
0.62
13.52
5.37
32.46
5.88

AD-1479383.1
0.84
0.31
2.35
0.81
1.67
1.12

AD-1479384.1
1.93
0.64
5.83
2.83
14.73
4.19

AD-1479385.1
1.08
0.37
4.13
1.65
6.43
2.09

AD-1479386.1
2.83
0.83
8.74
4.58
19.64
9.39

AD-1479387.1
1.10
0.14
4.44
1.43
6.84
4.38

AD-1479388.1
2.99
0.86
10.08
3.07
29.02
7.17

AD-1479389.1
1.54
0.11
4.33
1.51
8.33
5.53

AD-1479390.1
10.13
3.41
16.53
6.45
23.79
9.14

AD-1479391.1
1.17
0.38
3.09
1.06
10.15
3.02

AD-1479392.1
7.63
1.83
31.21
15.94
57.54
10.66

AD-1479393.1
52.13
15.03
69.88
13.74
91.32
19.61

AD-1479394.1
9.00
2.71
22.63
2.67
51.95
6.90

AD-1479395.1
40.22
7.66
52.41
18.64
96.34
3.49

AD-1479396.1
1.07
0.46
1.70
1.35
6.63
6.58

AD-1479397.1
0.86
0.36
3.53
1.18
5.91
1.45

AD-1479398.1
1.50
0.90
6.42
3.46
10.99
3.66

AD-1479399.1
3.54
0.92
8.49
2.78
27.55
7.38

AD-1479400.1
1.11
0.24
3.20
0.78
12.77
7.00

AD-1479401.1
1.95
0.33
4.82
1.58
13.65
4.06

AD-1479402.1
1.34
0.38
3.79
0.76
5.90
2.65

AD-1479403.1
1.52
0.34
3.81
2.15
8.67
3.83

AD-1479404.1
1.39
0.75
2.32
1.87
5.86
2.43

AD-1479405.1
1.34
0.06
4.79
1.59
10.28
2.81

AD-1479406.1
1.23
0.43
7.02
3.49
14.07
1.53

AD-1479407.1
1.16
0.10
3.91
1.77
10.39
3.52

AD-1479408.1
1.49
0.35
4.94
0.91
11.23
2.72

AD-1479409.1
1.99
0.80
4.21
0.91
9.22
3.17

AD-1479410.1
1.42
0.58
3.36
1.67
9.71
0.44

AD-1479411.1
1.35
0.56
2.50
0.93
7.70
3.21

AD-1479412.1
3.89
2.46
13.62
4.70
28.28
8.42

AD-1479413.1
1.62
0.66
7.37
3.37
19.00
8.01

AD-1479414.1
1.40
0.28
4.70
2.02
9.41
5.26

AD-1479415.1
2.41
1.04
4.57
2.30
13.68
5.43

AD-1479416.1
2.20
0.48
4.53
2.94
24.63
9.63

AD-1479417.1
2.25
1.02
3.34
0.57
7.95
3.77

AD-1479418.1
39.69
14.09
45.94
2.87
48.92
7.24

AD-1479419.1
75.56
19.77
79.76
10.85
110.17
27.25

AD-1479420.1
2.52
1.06
8.41
3.93
18.16
10.80

AD-1479421.1
2.74
0.57
5.73
2.36
15.54
5.49

AD-1479422.1
2.10
0.48
5.58
2.03
18.31
3.85

AD-1479423.1
3.82
2.55
7.74
3.06
25.71
11.02

AD-1479424.1
4.02
1.23
9.16
2.94
37.90
13.00

AD-1479425.1
2.85
0.89
7.17
3.66
25.10
6.27

AD-1479426.1
55.96
15.59
61.93
8.78
49.65
5.04

AD-1479427.1
10.33
3.51
22.90
9.60
49.16
20.17

AD-1479428.1
9.77
2.51
25.64
11.07
56.36
12.52

AD-1479429.1
1.49
0.59
3.54
1.79
12.59
5.62

AD-1479430.1
1.62
0.43
4.61
1.88
9.64
4.08

AD-1479431.1
1.35
0.44
2.44
0.54
8.11
2.77

AD-1479432.1
1.62
0.72
2.38
1.34
6.91
2.49

AD-1479433.1
0.99
0.21
1.94
0.86
7.22
1.09

AD-1479434.1
0.90
0.25
5.97
2.64
12.11
5.31

AD-1479435.1
1.73
0.73
6.13
3.34
14.69
4.81

AD-1479436.1
1.05
0.20
3.67
0.65
11.24
2.31

AD-1479437.1
0.95
0.27
2.17
0.44
4.90
1.31

AD-1479438.1
1.42
0.49
1.92
0.28
6.34
1.69

AD-1479439.1
2.21
1.72
2.95
1.13
10.06
5.02

AD-1479440.1
0.97
0.44
4.16
2.40
5.58
2.58

AD-1479441.1
1.43
0.24
5.17
2.44
10.85
5.96

AD-1479442.1
1.71
0.82
7.03
2.96
15.78
1.59

AD-1479443.1
1.99
0.15
4.20
1.76
15.11
6.13

AD-1479444.1
3.76
2.20
9.85
1.92
33.56
2.89

AD-1479445.1
1.33
0.41
3.61
0.56
9.38
3.59

AD-1479446.1
0.83
0.13
2.52
0.88
5.05
3.97

AD-1479447.1
0.65
0.24
2.33
1.08
6.13
3.55

AD-1479448.1
1.00
0.37
2.35
0.92
3.72
2.25

AD-1479449.1
1.50
0.31
10.17
1.89
18.74
1.57

AD-1479450.1
1.21
0.36
5.21
2.18
10.41
5.80

AD-1479451.1
0.66
0.12
3.73
1.58
13.22
3.90

AD-1479452.1
2.08
0.55
9.13
2.38
22.72
0.97

AD-1479453.1
15.54
5.16
32.78
10.94
71.93
22.57

AD-1479454.1
65.02
10.00
91.33
19.38
90.24
26.68

AD-1479455.1
1.57
0.66
2.83
0.87
7.39
1.03

AD-1479456.1
2.22
0.41
2.75
0.92
6.08
2.03

AD-1479457.1
1.72
0.69
2.71
0.39
4.41
1.23

AD-1479458.1
1.95
0.95
2.25
0.58
9.40
1.30

AD-1479459.1
1.44
0.47
2.75
1.38
7.52
3.58

AD-1479460.1
1.25
0.79
1.62
0.62
3.19
1.13

AD-1479461.1
15.71
6.42
40.90
1.81
70.79
13.15

AD-1479462.1
2.69
0.63
5.07
1.15
14.25
1.23

AD-1479463.1
1.93
0.40
3.44
0.69
13.10
4.65

AD-1479464.1
21.21
2.94
37.83
9.54
55.70
10.96

AD-1479465.1
94.02
21.46
89.76
13.33
84.42
8.02

AD-1479466.1
2.97
0.43
5.33
0.78
20.98
3.01

AD-1479467.1
34.59
8.40
56.36
9.71
65.42
7.49

AD-1479468.1
3.55
1.69
6.16
2.61
23.62
6.69

AD-1479469.1
7.19
2.25
31.75
8.89
59.45
14.83

AD-1479470.1
34.57
7.26
71.66
16.04
77.20
20.04

AD-1479471.1
19.71
6.12
42.15
7.03
62.85
10.38

AD-1479472.1
3.25
0.90
8.58
1.59
22.27
2.50

AD-1479473.1
1.94
0.35
2.95
0.97
7.67
2.15

AD-1479474.1
0.72
0.16
0.91
0.41
1.81
0.86

AD-1479475.1
1.03
0.29
1.51
0.75
6.54
1.76

AD-1479476.1
1.69
0.23
2.37
0.53
6.27
1.89

AD-1479477.1
2.10
0.47
4.60
1.46
8.94
2.45

AD-1479478.1
1.41
0.53
2.68
0.61
5.84
1.48

AD-1479479.1
1.23
0.26
1.92
1.14
4.62
0.98

AD-1479480.1
1.13
0.18
1.77
0.21
5.83
0.97

AD-1479481.1
0.71
0.20
1.14
0.53
2.83
0.33

AD-1479482.1
1.17
0.57
1.42
0.61
4.95
3.07

AD-1479483.1
1.59
0.19
2.93
0.55
6.52
2.36

AD-1479484.1
1.95
0.62
5.28
0.79
16.09
4.36

AD-1479485.1
10.21
3.88
24.41
3.03
46.43
8.45

AD-1479486.1
1.26
0.18
3.37
1.25
9.94
2.95

AD-1479487.1
1.24
0.41
2.37
0.59
6.36
0.97

AD-1479488.1
0.94
0.36
1.17
0.17
2.68
0.88

AD-1479489.1
1.24
0.48
4.32
2.08
8.54
1.70

AD-1479490.1
1.48
0.43
3.10
1.01
12.12
3.82

AD-1479491.1
2.94
0.42
8.38
1.49
16.68
0.57

AD-1479492.1
2.73
0.80
5.36
2.91
16.03
2.29

AD-1479493.1
2.21
0.39
7.03
1.87
21.40
3.70

AD-1479494.1
2.24
0.67
5.00
1.88
17.67
5.78

AD-1479495.1
1.15
0.26
2.50
1.01
11.45
2.94

AD-1479496.1
3.36
1.10
9.57
2.48
21.08
7.08

AD-1479497.1
1.81
0.10
4.07
2.09
14.57
6.34

AD-1479498.1
2.36
0.60
3.43
1.71
12.93
4.00

AD-1479499.1
1.44
0.31
3.14
1.38
8.29
1.30

AD-1479500.1
2.29
0.42
5.32
2.50
17.09
5.09

AD-1479501.1
1.53
0.34
2.65
0.72
10.66
2.02

AD-1479502.1
1.11
0.23
3.36
1.32
10.09
3.35

AD-1479503.1
1.14
0.79
1.38
0.84
3.36
2.03

AD-1479504.1
2.25
0.35
8.68
2.33
21.53
8.29

AD-1479505.1
1.71
0.54
4.90
2.53
10.14
3.64

AD-1479506.1
2.09
0.75
4.57
1.13
12.90
1.93

AD-1479507.1
4.54
0.69
13.63
2.25
33.97
4.86

AD-1479508.1
1.82
0.53
6.13
0.67
23.73
4.03

AD-1479509.1
4.80
1.98
8.33
0.80
29.49
14.92

AD-1479510.1
0.58
0.21
1.25
0.52
3.52
0.80

AD-1479511.1
1.36
0.36
3.50
2.20
9.28
2.77

AD-1479512.1
1.11
0.44
2.19
0.76
6.64
2.72

AD-1479513.1
3.46
0.90
7.66
2.66
20.30
8.67

AD-1479514.1
1.35
0.42
2.47
1.68
5.16
2.20

AD-1479515.1
11.22
1.44
36.27
10.10
57.69
8.34

AD-1479516.1
2.03
0.53
4.16
0.78
17.23
8.59

AD-1479517.1
1.80
0.62
3.09
1.42
11.87
2.55

AD-1479518.1
0.76
0.24
2.07
0.76
4.62
1.33

AD-1479519.1
8.53
1.62
17.79
1.36
56.60
18.23

AD-1479520.1
2.94
0.56
4.64
2.17
15.83
5.06

AD-1479521.1
1.67
0.50
4.71
1.84
12.38
5.24

AD-1479522.1
6.66
2.45
19.95
1.02
42.74
9.16

AD-1479523.1
1.45
0.27
2.25
0.82
5.24
1.59

AD-1479524.1
3.72
1.08
5.93
2.08
24.05
11.86

AD-1479525.1
1.49
0.65
7.18
2.11
18.32
7.26

AD-1479526.1
2.83
0.37
6.65
1.60
21.57
10.68

AD-1479527.1
2.15
0.29
5.42
0.58
13.22
3.12

AD-1479528.1
1.50
0.31
4.55
0.92
11.97
0.58

AD-1479529.1
4.69
5.91
3.30
1.22
6.02
1.83

AD-1479530.1
1.82
0.62
3.38
1.07
9.22
1.73

AD-1479531.1
1.07
0.33
1.21
0.88
3.29
1.85

AD-1479532.1
1.03
0.14
2.26
1.22
8.37
2.27

AD-1479533.1
0.78
0.11
1.87
0.38
3.90
1.94

AD-1479534.1
3.57
1.37
5.74
1.72
19.59
8.15

AD-1479535.1
1.43
0.36
2.32
0.56
5.13
1.48

AD-1479536.1
1.40
0.38
4.19
0.79
11.84
0.61

AD-1479537.1
1.11
0.34
2.44
0.79
6.02
1.66

AD-1479538.1
0.75
0.11
1.46
0.32
4.69
1.79

Example 5: In Vivo Screening of dsRNA Duplexes in Mice

Duplexes of interest, identified from the above in vitro studies, were evaluated in vivo. In particular, mice were transduced with an AAV containing hANGPTL3 (full length human) at 2e11 viral particles per mouse. Four weeks post-transduction, mice were subcutaneously administered a single 3 mg/kg dose of a duplex of interest. At Days 7 and 14 post-dose, sera was collected and the level of hANGPTL3 protein was determined by ELISA (R&D Systems hANPTL3 ELISA, DANL30) The results of these analyses are provided in Table 11 below. An average of three mice were used per time point, and the percent of hANGPTL3 protein compared to samples from PBS control at Day 7 and Day 14 are represented in the Table 11.

TABLE 11

ANGPTL3 dsRNA screen in vivo

Average compared
Average compared

to PBS control
to PBS control

Day 7
Day 14

PBS
100
100

Naïve
99.77
69.34

AD-1331203.2
44.24
33.25

AD-1331206.2
15.05
7.72

AD-1331209.2
19.34
17.56

AD-1331212.2
11.85
17.54

AD-1331213.2
14.41
18.03

AD-1331329.2
29.39
30.07

AD-1331237.2
30.52
46.84

AD-1331238.2
31.11
66.36

AD-1331240.2
17.48
36.42

AD-1331244.2
22.35
75.83

AD-1331256.2
43.7
33.75

AD-1331262.2
30.91
47.3

AD-1331264.2
18.46
36.5

AD-1331265.2
15.2
48.17

AD-1331266.2
24.28
33.19

AD-1331316.2
56.1
58.06

AD-1331338.2
36.89
57.43

AD-74757.13
14.5
18.42

Example 6: SAR Analysis of Selected dsRNA Duplexes In Vivo

Structure-activity-relationship (SAR) analyses were also evaluated in vivo similarly as described above. Briefly, mice were transduced with an AAV containing hANGPTL3 at 2e11 viral particles per mouse. Two weeks post-transduction, mice were subcutaneously administered duplexes of interest, and sera were collected on Day 0 (day of dosing), Day 7, Day 14 and Day 28. hANGPTL3 protein levels were determined by ELISA, as described above. The results, presented as average percent compared to Day 0, are shown in Table 12 and Table 13.

TABLE 12

Structure-activity-relationship (SAR) of ANGPTL3

dsRNAs in vivo-Day 7 and 14 results

Avg Percent
Avg Percent

Change
Change

Treatment
Parent
Day 7
Day 14

PBS
n/a
152.8
151.2

Naïve
n/a
147.2
77.2

AD-1331212.4
parent
16.3
5.9

AD-1479372.2
AD-1331212.4
18
8.3

AD-1479374.2
AD-1331212.4
23.4
15.3

AD-1479378.2
AD-1331212.4
31.5
36.2

AD-1331213.4
parent
22.1
16.6

AD-1479385.2
AD-1331213.4
21.7
33.3

AD-1479391.2
AD-1331213.4
59.1
50

AD-1479397.2
AD-1331264
31.5
39.2

AD-1331206.4
parent
13.4
11.4

AD-1479440.2
AD-1331206.4
30.1
50.7

AD-1479460.2
AD-1331240
92.9
131.5

AD-1479481.2
AD-1331265
21.2
44.1

AD-1479482.2
AD-1331265
63.2
58.9

AD-1479489.2
AD-1331262
21.2
30.7

AD-1479511.2
AD-1331266
51.5
128.6

AD-1479533.2
AD-1331329
22.8
24.3

AD-74757.14
Benchmark
62.3
49.6

TABLE 13

Structure-activity-relationship (SAR) of

ANGPTL3 siRNAs in vivo-Day 28 results

Avg Percent
STDEV

Treatment
Parent
Change Day 28
Day 28

PBS
n/a
58.8
4.3

Naïve
n/a
66.7

AD-1331212.4
parent
7.5
2.7

AD-1479372.2
AD-1331212.4
22.2
2.1

AD-1479374.2
AD-1331212.4
26.2
7.3

AD-1479378.2
AD-1331212.4
51.2
15.1

AD-1331213.4
parent
14
2.3

AD-1479385.2
AD-1331213.4
59
14

AD-1479391.2
AD-1331213.4
77.3

AD-1479397.2
AD-1331264
56.2
21.3

AD-1331206.4
parent
20.2
3.2

AD-1479440.2
AD-1331206.4
71.2
6.4

AD-1479460.2
AD-1331240
80.1
24.7

AD-1479481.2
AD-1331265
44.3
11.6

AD-1479482.2
AD-1331265
71.6
18.4

AD-1479489.2
AD-1331262
119.6

AD-1479511.2
AD-1331266
90.5
22.1

AD-1479533.2
AD-1331329
24.4
8.4

AD-74757.14
Benchmark
16.7
11.4

Example 7: Effects of siRNA-GalNAC Conjugates in Non-Human Primate Studies

Lead candidates from the in vivo studies described above, AD-1331212, AD-1331213 and AD-1479372, were further investigated for their effectiveness in non-human primates. Specifically, a single dose of 3 mg/kg or 10 mg/kg of AD-1331212, AD-1331213 and AD-1479372 were subcutaneously administered to cynomolgous monkeys. Sera were collected from the animals every week, and the serum level of ANGPTL3 protein was determined by ELISA. The results, presented as percent change of ANGPTL3 compared to the level on dosing day (Day 0), are shown in FIG. 3.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments and methods described herein. Such equivalents are intended to be encompassed by the scope of the following claims.

Number	Name	Date	Kind
7935796	Lee et al.	May 2011	B2
9322018	Bettencourt et al.	Apr 2016	B2
9708607	Rajeev et al.	Jul 2017	B2
9771591	Bettencourt et al.	Sep 2017	B2
9796974	Rajeev et al.	Oct 2017	B2
10337010	Bettencourt et al.	Jul 2019	B2
10550390	Bettencourt et al.	Feb 2020	B2
10557139	Bettencourt et al.	Feb 2020	B2
10570393	Querbes et al.	Feb 2020	B2
11130953	Bettencourt et al.	Sep 2021	B2
20040259247	Tuschl et al.	Dec 2004	A1
20050246794	Khvorova et al.	Nov 2005	A1
20050255487	Khvorova et al.	Nov 2005	A1
20080177045	Lee et al.	Jul 2008	A1
20100010066	Fitzgerald et al.	Jan 2010	A1
20130023579	Crooke et al.	Jan 2013	A1
20140179768	Bettencourt et al.	Jun 2014	A1
20150315594	Prakash et al.	Nov 2015	A1
20170275626	Maier et al.	Sep 2017	A1
20170355994	Bettencourt et al.	Dec 2017	A1
20180008724	Rajeev et al.	Jan 2018	A1
20200140866	Bettencourt et al.	May 2020	A1
20200224201	Querbes et al.	Jul 2020	A1

Number	Date	Country
WO-2008073300	Jun 2008	WO
WO-2009073809	Jun 2009	WO
WO-2009134487	Nov 2009	WO
WO-2010036962	Apr 2010	WO
WO-2010048228	Apr 2010	WO
WO-2010068816	Jun 2010	WO
WO-2010144740	Dec 2010	WO
WO-2010148013	Dec 2010	WO
WO-2012177784	Dec 2012	WO
WO-2013074974	May 2013	WO
WO-2013165816	Nov 2013	WO
WO-2014182661	Nov 2014	WO
WO-2016028649	Feb 2016	WO
WO-2016168286	Oct 2016	WO

	Number	Date	Country
	63308668	Feb 2022	US
	63156476	Mar 2021	US

	Number	Date	Country
Parent	PCT/US2022/018630	Mar 2022	US
Child	17689034		US

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Abstract

Description

Claims

RELATED APPLICATIONS

US Referenced Citations (23)

Foreign Referenced Citations (14)

Non-Patent Literature Citations (35)

Related Publications (1)

Provisional Applications (2)

Continuations (1)

Entry
U.S. Appl. No. 14/132,999 U.S. Pat. No. 9,322,018, filed Dec. 18, 2013 Apr. 26, 2016, US 20140179768, Granted.
U.S. Appl. No. 15/068,912 U.S. Pat. No. 9,771,591, filed Mar. 14, 2016 Sep. 26, 2017, US 20160186180, Granted.
U.S. Appl. No. 15/683,999 U.S. Pat. No. 10,337,010, filed Aug. 23, 2017 Jul. 2, 2019, US 20170355994, Granted.
U.S. Appl. No. 16/411,261, filed May 14, 2019, US 20200140866, Allowed.
U.S. Appl. No. 16/443,998 U.S. Pat. No. 10,557,139, filed Jul. 18, 2019 Feb. 11, 2020, US 20190316137, Granted.
U.S. Appl. No. 16/444,021 U.S. Pat. No. 10,550,390, filed Jun. 18, 2019 Feb. 4, 2020, US 20190352645, Granted.
U.S. Appl. No. 17/089,854, filed Nov. 5, 2020, US 20210171954, Published.
U.S. Appl. No. 17/158,375 U.S. Pat. No. 11,130,953, filed Jan. 26, 2021 Sep. 28, 2021, U5-20210171955, Granted.
U.S. Appl. No. 17/531,885, filed Nov. 22, 2021, Allowed.
U.S. Appl. No. 17/531,888, filed Nov. 22, 2021, Allowed.
U.S. Appl. No. 17/531,900, filed Nov. 22, 2021, Allowed.
U.S. Appl. No. 17/531,913, filed Nov. 22, 2021, Pending.
U.S. Appl. No. 17/531,919, filed Nov. 22, 2021, Pending.
U.S. Appl. No. 17/531,921, filed Nov. 22, 2021, Pending.
U.S. Appl. No. 15/782,091 U.S. Pat. No. 10,570,393, filed Oct. 12, 2017 Feb. 25, 2020, US 20180087054, Granted.
U.S. Appl. No. 16/712,152, filed Dec. 12, 2019, US 20200224201, Allowed.
U.S. Appl. No. 17/517,733, filed Nov. 3, 2021, Pending.
International Preliminary Report on Patentability from PCT/US2012/043378, dated Jul. 29, 2013.
Gao et al., “Angiopoietin-like protein 3 regulates the motility and permeability of podocytes by alterning nephrin expression in vitro”, Biochemical and Biophysical Research Communications, 2010, pp. 31-36, vol. 399:1.
English translation of a Chinese Office Action and Chinese Search Report issued by the Chinese Intellectual Property Office dated Feb. 16, 2015.
Watts et al., “Gene silencing by siRNAs and antisense oligonucleotides in the laboratory and the clinic”, J Pathol 2012; 226: 365-379.
GaLNAc-siRNA with Enhanced Stabilization chemistry:ESC-GaLNAc-siRNA, Muthiah Manoharan TIDES, (Mar. 14, 2014). Retrieved from the Internet: URL: http://www.alnylam.com/web/assets/ALNY-ESC-GalNAc-siRNA-TIDES-May2014-Capella.pdf.
International Search Report and Written Opinion from PCT/US2016/027271 dated Sep. 8, 2016.
International Search Report and Written Opinion from PCT/US2012/043378, dated Dec. 17, 2012.
Reynolds et al., “Rational siRNA design for RNA interference,” Nature Biotechnology, vol. 22, pp. 326-330, 2004.
Ando et al, “A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice,” J. Lipid Res., vol. 44, pp. 1216-1223 (2003).
Vickers, T., et al., “Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents,” The Journal of Biological Chemistry, Feb. 28, 2003, pp. 7108-7118, vol. 278, No. 9.
Comparative In Vitro Studies cited in Notice of Opposition to European Patent No. EP 2 723 758 B1, dated Mar. 19, 2019.
The Dharmacon Story cited in Opposition to European Patent No. EP 2 723 758 B1, dated Feb. 17, 2021.
Comparative in vitro Studies on ANGPTL3 inhibition of the top 10 ANGPTL3 sequences disclosed in U.S. Patent Publication 2005/0255487 cited in Opposition to European Patent No. EP 2 723 758 B1, dated Feb. 17, 2021.
Ambion Product Information Sheet cited in Opposition to European Patent No. EP 2 723 758 B1 dated Feb. 17, 2021.
Dharmacon Press Release cited in Opposition to European Patent No. EP 2 723 758 B1 dated Feb. 17, 2021.
Excerpt from WO 2009-082817 cited in Opposition to European Patent No. EP 2 723 758 B1 dated Feb. 17, 2021.
Excerpt from WO 2008-011431 cited in Opposition to European Patent No. EP 2 723 758 B1 dated Feb. 17, 2021.
Excerpt from WO2007056861 cited in Opposition to European Patent No. EP 2 723 758 B1 dated Feb. 17, 2021.